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DNA Deoxyribonucleic acid 
DSB Double stranded breaks 
EGFR Epidermal growth factor receptor 
EORTC European Organisation for Research and Treatment of Cancer  
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Il-10 Interleukin-10 
IL-17 Interleukin-17 
IL-4 Interleukin-4 
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LHRH Luteinising Hormone Releasing Hormone 
LP Likely pathogenic  
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MAMS Multi-arm multi-stage 
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mCSPC  Metastatic castrate-sensitive prostate cancer  
MHC Major histocompatibility complex 
MI Myocardial infarction  
MRC Medical Research Council 
MRN complex  MRE11–RAD50–NBS1 complex  
MSI Microsatellite instability  
MSK-IMPACT Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer 
Targets  
NCI National Cancer Institute (USA) 
NEPC Neuroendocrine prostate cancer  
NF-κB Nuclear factor kappa B 
NGS Next-generation sequencing  
NHEJ Non-homologous end-joining  
NHEJ non-homologous end joining pathway  
NHS National Health Service 
NICE National Institute for Health and Care Excellence   
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NSAID Non-Steroidal Anti-inflammatory Drugs 
NSCLC  Non-small cell lung cancer  
NVALT Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose 
OR Odds Ratio 
ORR Overall response rate  
OS Overall Survival 
P   Pathogenic  
PARP poly ADP ribose polymerase  
PARPi poly ADP ribose polymerase inhibitors  
PBMC Peripheral blood mononuclear cells  
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PCSM Prostate cancer specific mortality 
PCWG Prostate Cancer Working Group  
PD-L1 Programme death-ligand 1   
PFS Progression-free survival 
PGE2 Prostaglandin E2 
PGE-M Major urinary metabolite of PGE2 (PGE-M) 
POR Pooled Odds Ratio 
PR Partial response 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
pRR pathological response rate 
PSA Prostate-Specific Antigen 
PTGS Prostaglandin endoperoxide synthetase  
RANK Receptor activator of nuclear factor kappa-Β  
RCT Randomised Controlled Trial  
REC Regional ethics committee 
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RECIST Response Evaluation Criteria In Solid Tumours 
Ref Reference 
RP Radical prostatectomy  
RR Relative risk  
RS Recurrence score  
RT  Radiotherapy  
RUO Research Use Only  
SMP2 Stratified Medicine Programme 2  
SNV Single Nucleotide variant  
SOC Standard of care 
SRE Skeletal related event  
SSB Single stranded breaks 
SToPCaP Systemic Treatment Options for Prostate Cancer; a collaborative meta-
analysis group  
STRATOSPHERE  STratification for RAtional Treatment-Oncomarker pairings of STAMPEDE 
Patients starting long –term Hormone treatment; a translational consortium 
conducting research in parallel with the STAMPEDE trial  
SU2C-PCF Stand-up to Cancer-Prostate Cancer Foundation; a funding initiative that has 
supported several large collaborative sequencing studies 
SWOG North American cancer cooperative group, formerly the Southwest Oncology 
Group 
t170 Illumina TruSight Tumour 170 Panel 
TCC Transitional cell carcinoma 
TCGA The Cancer Genome Atlas  
TGF-B Transforming growth factor beta 1  
TIL Tumour infiltrating lymphocytes 
TLR Toll like receptor  
TMG Trial management group  
TNF Tumour necrosis factor  
tNGS Targeted next-generation sequencing  
TP53BP1 Tumour-protein p53 binding protein 1  
TSC Trial steering committee 
TTP Time to progression  
UCL University College London  
VEGF Vascular endothelial growth factor 
VUS Variant of Unknown Significance  
WES Whole exome sequencing 
WGS Whole genome sequencing  
ZA Zoledronic acid  
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Gene list  
Abbreviation  Description  
ABRA1 BRCA1 A complex subunit  
AKT  Oncogene named after the viral oncogene v-AKT 
APC  Adenomatous polyposis coli  
ATM Ataxia telangiectasia mutated gene 
BARD1 BRCA1 associated RING domain 1 
BRAF v-Raf murine sarcoma viral oncogene homolog B 
BRCA1 BReast CAncer susceptibility gene -1 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 
CCND1 Cyclin D1 
CDK  Cyclin dependent kinases 
CDK12  Cyclin dependent kinase 12 
CHEK2 Checkpoint kinase 2 
CTNNB1 catenin beta-1 
ERG ETS-related gene 
ETS Erythroblast transformation-specific, a family of transcription factors 
ETV ETS translocation variants  
FANCA Fanconi anaemia, complementation group A  
FLI1 Friend leukaemia integration 1 transcription factor, also known as transcription 
factor ERGB, is a member of the ETS transcription factor family 
FOXA1 Forkhead box protein A1 
JNK c-Jun N-terminal kinases 
KLK3 kallikrein-3, gene encodes PSA  
MAPK mitogen-activated protein kinase  
MED12 Mediator complex subunit 12  
MLH1 mutL homolog 1  
MMR Mismatch repair genes  
MSH2 mutS homolog 2 
MSH6 mutS homolog 6 
mTOR Mammalian target of rapamycin 
NBN Nibrin 
NCOR1 Nuclear receptor co-repressor 1 
PALB2 Partner and localizer of BRCA2 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PTEN  Phosphatase and tensin homolog deleted on chromosome 10 
RAD51 RAD51 recombinase 
RAD51B RAD51 paralog B 
RAD51C RAD51 paralog C 
RAD51D RAD51 paralog D 
RAD54L RAD54L  
RAS1 Ras family GTPase  
RB1 Retinoblastoma 1, gene involved in cell cycle regulation  
RNF43 ring finger protein 43  
SPINK1 Serine protease inhibitor Kazal-type 1 
SPOP Speckle-Type POZ Protein  
TMPRSS2 Transmembrane protease, serine 2, an androgen regulated gene  
TP53 Tumour protein p53 
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List of clinical trials 
Abbreviation  Description  Registration number  
Add-Aspirin 
Phase 3 placebo controlled trial od adjuvant aspirin in 4 
cohorts: prostate, colorectal, breast and oesophageal  NCT02804815 
AFFIRM 
Phase 3 RCT of enzalutamide post chemotherapy in 
mCRPC  NCT00974311 
ALSYMPCA 
ALpharadin in SYMPtomatic Prostate Cancer, a phase 3 
RCT of radium-223 in mCRPC  NCT00699751 
APPROVe 
Adenomatous Polyp Prevention on Vioxx Trial - rofecoxib 
chemoprevention RCT  NCT00282386 
APRiCOT Apricoxib in Combination Oncology Treatment - Lung NCT00652340 
ARASENS 
Darolutamide in addition to ADT and docetaxel in 
metastatic castrate-sensitive prostate cancer NCT02799602 
ARCHES 
A phase 3 study of enzalutamide vs. placebo plus ADT in 
metastatic castrate-sensitive prostate cancer  NCT02677896 
CHAARTED 
Chemohormonal Therapy in Metastatic Hormone-
sensitive prostate cancer NCT02677896 
COU-AAA-301 Phase 3 RCT of abiraterone post chemotherapy in mCRPC  NCT00638690 
COU-AAA-302 Phase 3 RCT of abiraterone pre chemotherapy in mCRPC  NCT00887198 
CYCLUS 
CY-cyclooxygenase-2 inhibitor, Chemotherapy, LUng 
cancer, Survival (Clinical Trial)  NCT00300729 
ENGOT-
OV16/NOVA 
European Network for Gynaecological Oncological 
Trials/NOVA  NCT01847274 
ENZAMET 
Phase 3 trial of enzalutamide plus ADT versus ADT alone 
(+- docetaxel)  in metastatic castrate sensitive prostate 
cancer  NCT02446405 
FOCUS-4 
A molecularly stratified trial programme in colorectal 
cancer  
EUCTR2012-005111-
12-GB 
GECO GEmcitabine-COxib in NSCLC NCT00385606 
GETUG-15 
Phase 3 trial of ADT with or without docetaxel in 
metastatic castrate-sensitive prostate cancer  NCT00104715 
LATITUDE 
Phase 3 trial of abiraterone versus placebo in high-risk 
metastatic castrate-sensitive prostate cancer  NCT01715285 
Matrix  
National Lung Matrix Trial: Multi-drug Phase II Trial in 
Non-Small Cell Lung Cancer NCT02664935 
NCI-IMPACT 
NCI-Molecular Profiling-Based Assignment of Cancer 
Therapy, a molecularly targeted basket trial  NCT01827384 
NCI-MATCH  
NCI-Molecular Analysis for Therapy Choice, molecularly 
targeted basket trial NCT02465060 
PATCH  Prostate Adenocarcinoma TransCutaneous Hormones  NCT00303784 
PEACE-1 
Phase 3 trial of ADT +/- docetaxel +/- local RT +/- 
abiraterone for metastatic castrate-sensitive prostate 
cancer  NCT01957436 
PREVAIL Phase 3 RCT of enzalutamide pre chemotherapy in mCRPC  NCT01212991 
PROREPAIR-B  
A prospective cohort study of DNA repair defects in 
metastatic castrate resistant prostate cancer  NCT03075735 
RE-AKT 
A study of Enzalutamide in combination with AZD5363 in 
patients with mCRPC  NCT02525068 
RxRONDER Rx for Positive Node, Endocrine-Responsive Breast Cancer NCT01272037 
STAMPEDE 
Systemic Therapy in Advancing and Metastatic Prostate 
Cancer: Evaluation of Drug Efficacy  NCT00268476 
SWOG 9346  
Southwest Oncology Group trial 9346; phase 3 evaluation 
of intermittent versus continuous ADT in men with newly 
diagnosed castrate-sensitive metastatic prostate cancer NCT00002651 
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A phase 3 study of apalutamide plus ADT versus ADT in 
metastatic castrate-sensitive prostate cancer NCT02489318 
TOPARP Trial of PARP Inhibition in Prostate Cancer, a clinical trial   NCT01682772 
TRACERx 
TRAcking Non-small cell lung cancer Evolution Through 
Therapy (Rx) (TRACERx) NCT01888601 
TRITON2 
Trial of Rucaparib in ProsTate IndicatiONs; phase 2 non-
randomised trial  NCT02952534 
TRITON3 
Trial of Rucaparib in ProsTate IndicatiONs; phase 3 
randomised evaluation of rucaparib versus physician 
choice NCT02975934 
TROPIC 
Phase 3 trial of mitoxantrone and prednisolone versus 
cabazitaxel and prednisolone NCT00417079 
UKGPCS 
United Kingdom Genetic Prostate Cancer Study, a clinical 
trial   NCT01737242 
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Hypothesis 
Prostate cancer is a heterogeneous disease and men with metastatic castrate-sensitive 
prostate cancer (mCSPC) experience variable benefit from an increasing number of 
treatment options. Outcomes can be improved through moving away from a uniform 
approach and developing prognostic and predictive biomarkers to inform rational 
treatment selection.  
Research aim  
In this thesis I aim to develop a greater understanding of the results of the STAMPEDE 
clinical trial. I will explore how the data may inform treatment selection and consider how 
trials may adapt to evaluate molecularly-selected treatments.  
Objectives  
 To contextualise the celecoxib zoledronic acid (celecoxib-ZA) results in which the 
combination was synergistic in men with metastatic disease, despite no effect 
shown for either agent alone or in non-metastatic (M0) disease.  
 To evaluate PSA response and PSA nadir as prognostic biomarkers able to risk-
stratify patients when assessed after commencing ADT and completion of docetaxel 
respectively, to inform the use of additional therapies, such as docetaxel and 
abiraterone. 
 To assess the feasibility of performing targeted next-generation sequencing (tNGS) 
using formalin-fixed paraffin embedded (FFPE) prostate tumour samples as a 
means of implementing molecular stratification.   
 To explore the genetic profile of mCSPC and determine the prevalence of putative 
predictive biomarkers, specifically defects in genes involved in homologous 
recombination, to inform future trial designs of molecularly-selected therapies 
including poly ADP ribose polymerase inhibitors (PARPi).  
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Abstract  
The treatment paradigm for metastatic castrate sensitive prostate cancer (mCSPC) is 
changing. The results of the STAMPEDE trial show intensified systemic therapy with 
docetaxel or abiraterone added to androgen deprivation therapy (ADT) improves overall 
survival (OS). However treatment benefit and tolerance vary, therefore prognostic and 
predictive biomarkers are required to improve patient outcomes.   
Through performing a systematic review and meta-analysis I contextualised the intriguing 
celecoxib and zoledronic acid (celecoxib-ZA) results which showed a synergistic therapeutic 
effect that was only seen in metastatic disease. Secondly, I explored whether prostate-
specific antigen (PSA) response, assessed after commencing ADT, and PSA nadir assessed 
after docetaxel completion, are prognostic of OS. Through collaboration with industry 
partners, I assessed the feasibility of performing targeted next-generation sequencing 
(tNGS) using formalin-fixed paraffin embedded (FFPE) prostate tumour samples. I explored 
the genomic profile of mCSPC to determine the prevalence of putative predictive 
biomarkers to inform the evaluation of therapies such as poly ADP ribose 
polymerase inhibitors (PARPi).  
No other trials evaluating a cox-2 inhibitor with a bisphosphonate were identified. 
However, supported by pre-clinical data, an immunological mechanism mediated by γδ T 
cells is proposed to explain the observed synergy. This strengthens the need for future trials 
and informs parallel translational research.  PSA response can be used to risk-stratify 
patients shortly after commencing ADT and may be used to inform the use of docetaxel. 
High PSA nadir, assessed after completion of docetaxel identified patients at high risk of 
death where additional systemic therapies e.g. abiraterone, should be evaluated. The 
genomic study found 94% (108/115) of samples had ≥1 pathogenic mutation although 
mutation frequencies remain low and pathway aberrations often co-exist, necessitating 
hierarchical allocation if used to guide treatment. The prevalence of HRD is clinically 
significant (15%) however the screening burden is considerable, compounded by variable 
sample quality, compromising the sequencing success rate (64%).  
These data support the further evaluation of the combination of cox-2 inhibitors and 
bisphosphonates and the use of PSA-based outcomes in risk-stratification, whilst the 
genomic feasibility and prevalence data will  inform future trial designs incorporating 
molecular stratification.  
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Impact Statement  
The results of STAMPEDE show that celecoxib-ZA may significantly improve OS in men with 
mCSPC. However to influence clinical practice this surprising result would need to be 
supported by other evidence. Through undertaking a systematic review and meta-analysis I 
show that although there is currently a lack of supporting clinical data, pre-clinical data 
suggests an immunological hypothesis that may explain the observed synergistic 
therapeutic effect. Importantly, the proposed mechanism is not prostate cancer specific so 
may be relevant to other indications, for example metastatic breast or non-small cell lung 
cancer, potentially impacting future research priorities and patient outcomes across a 
range of cancers. I plan to disseminate these results through publication.  
Two PSA-based biomarkers, PSA response and PSA nadir, assessed in patients receiving ADT 
alone and ADT and docetaxel respectively, are shown to be prognostic of OS. Both 
assessments are at clinically meaningful time points when they may inform the use of 
additional systemic therapy. To date, PSA response has been evaluated in small historical 
cohorts in mCSPC or castrate-resistant disease therefore this result represents a significant 
increase in our understanding. Following validation, this finding may impact on patient 
outcome through improved risk stratification, for example enabling the toxicities of 
docetaxel to be avoided in patients identified to be at less risk of progression, who could 
receive ADT alone.  In a second analysis, PSA nadir >4ng/ml was associated with an 
increased risk of death despite docetaxel treatment. This finding adds to previous research 
that has shown this PSA threshold to be prognostic when assessed as an absolute value. 
The use of PSA nadir may impact future trial design through identifying a high-risk group in 
whom to evaluate additional systemic therapies, thus focusing research efforts on those 
patients with the greatest unmet clinical need. Additionally, these data may support future 
translational research, for example correlative analyses in the PSA response and PSA nadir 
cohorts may help identify predictors of relative ADT and docetaxel resistance respectively. I 
have presented these results to the STAMPEDE TMG and am preparing to disseminate 
further through presentation and publication.  
Knowledge of the genomic profile of mCSPC is significantly advanced by the results of the 
sequencing analysis, which represents the largest cohort of mCSPC patients to be 
sequenced to date. The impact of this work will, in the first instance, be on the design of 
the next generation of trials, but ultimately may affect patient care through informing the 
implementation of biomarker-directed therapies. The prevalence and feasibility data 
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continue to inform how best to evaluate PARPi and other molecularly targeted therapies 
within the STAMPEDE trial and once presented, will be informative for others. Our 
experience of using different sequencing providers, technical protocols and data 
interpretation is also relevant to the future conduct of such trials. Through successfully 
leveraging industry support this project helped establish the required infrastructure for 
sample collection. The feasibility data obtained helped secure funding to support the 
STRATOSPHERE consortium, which continues to coordinate biomarker-focused research 
conducted in parallel to STAMPEDE, generating much needed data necessary to inform 
rational treatment selection in this setting.   
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Chapter 1 Introduction 
1.1 Clinical overview   
In the UK alone, each year over 45,000 men are diagnosed with prostate cancer (PCa) and 
there are over 11,000  prostate-cancer related deaths 1.  PCa has been described as “a 
heterogeneous disease that affects a heterogeneous population” 2.  One of the challenges 
in the management is appropriate risk-stratification, enabling informed treatment 
selection, balancing potential treatment benefit against the unavoidable costs and risks of 
toxicity. For the majority, PCa is a localised disease for which effective treatment strategies 
include radical treatment with radiotherapy (RT) or surgery, or active surveillance; all of 
which have been shown to offer excellent long-term outcomes3. However, around 10-15% 
of men will present with metastatic disease for which treatment is currently palliative and 
outcomes remain poor4-6. Numerous clinical trials are evaluating intensified therapeutic 
strategies for the management of metastatic prostate cancer, see Table 1 and I will focus 
on this, the highest-risk group.  
1.1.1 Systemic treatment of metastatic prostate cancer 
PCa is hormonally driven as recognised by Huggins and Hodges who provided the first 
clinical evidence of the effectiveness of castration in the 1940s7. To this day, androgen 
deprivation therapy (ADT), typically achieved through the use of gonadotropin hormone 
releasing analogues, remains the cornerstone of the systemic management to which all 
subsequent therapies are added. Even if patients present with metastatic disease, over 90% 
will respond to ADT, however resistance is inevitable. Disease progression despite castrate 
levels of testosterone is termed castrate-resistant prostate cancer (CRPC) and is fatal in the 
vast majority; see Figure 1. for an overview of the natural history of metastatic prostate 
cancer. It is in the setting of mCRPC that the effectiveness of adding additional therapies to 
ADT was first demonstrated. There are now six treatments licenced for the management of 
mCRPC, all shown to improve overall survival (OS) when given with ADT; docetaxel, 
abiraterone, enzalutamide, cabazitaxel, radium-223 and Sipuleucel-T8-15. All may be given 
sequentially with ADT, yet despite the varying therapeutic mechanism of actions, all are 
used in unselected populations due to the lack of predictive biomarkers, see Table 2.  
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Figure 1: Overview of systemic therapies for metastatic prostate cancer  
(adapted from Lorente et al.16) 
 
All six systemic therapies shown to be effective in mCRPC may be added sequentially to ADT which, 
until recently, was the only treatment for metastatic castrate-sensitive disease. Treatments licenced 
based on demonstrated survival gains include two taxane chemotherapy agents, docetaxel and 
cabazitaxel; two novel-AR targeted treatments abiraterone and enzalutamide, an alpha-emitting 
radio-pharmaceutical Radium-223 and Sipuleucel-T, an autologous dendritic vaccine.   
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Table 1: Ongoing phase III trials of systemic therapy given in addition to ADT in mCSPC 
Target Agent Trial 
acronym  
Registration  Patient 
group 
Treatment 
details 
Primary 
outcome 
measure(s) 
Status  
AR Apalutamide TITAN  
 
NCT02489318 mCSPC 
(bone) 
 
 ADT + Apalutamide 
 ADT+ Placebo 
rPFS 
OS 
Recruiting  
Accrual target: 1000 
Est report date: Nov 2022 
AR Abiraterone PEACE-1 NCT01957436 mCSPC  ADT (+/- docetaxel) 
 ADT (+/- docetaxel) +  abiraterone + pred  
 ADT (+/- docetaxel) +/- RT 
 ADT (+/- docetaxel) + RT + abiraterone + pred 
OS (5.5yr) 
PFS 
Recruiting   
Target accrual: 916 
Est report date: Oct 2023 
AR Enzalutamide 
+ 
Abiraterone 
STAMPEDE  NCT00268476 mCSPC  ADT 
 ADT + Abiraterone +Enzalutamide  
OS In follow up 
Accrued: 1976 
Est report date: 2020 
AR Enzalutamide ENZAMET NCT02446405 mCSPC  ADT (+/- docetaxel) 
 ADT (+/- docetaxel) +Enzalutamide 
OS In follow up   
Target accrual: 1100 
Est report date: Dec 2020  
AR Daralutamide ARASENS NCT02799602 mCSPC  ADT + docetaxel + Daralutamide  
 ADT + docetaxel + placebo 
OS Recruiting 
Target accrual: 1300 
Est report date: Aug 2022 
AR Enzalutamide ARCHES NCT02677896 mCSPC  ADT (+/- docetaxel) + Enzalutamide  
 ADT (+/- docetaxel) + placebo 
rPFS Recruiting  
Target accrual: 1100 
Est report date: Dec 2023 
Non-
AR 
Metformin STAMPEDE  NCT00268476 mCSPC  ADT (+/- docetaxel) 
 ADT (+/-docetaxel) + metformin  
OS  Recruiting 
Target accrual: 1800 
Est report date: 2025 
Key: ADT, Androgen deprivation therapy; AR, Androgen receptor; Est, estimated; OS, overall survival; rPFS, radiological progression free survival; RT, radiotherapy; Pred, 
Prednisolone; PFS, progression free survival. 
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Table 2: Treatments shown to improve survival in mCRPC 
 
 
 Treatment  Trial  Year  Comparator Median survival benefit 
(months) 
Hazard ratio  
 
Docetaxel  TAX 327
8
 2004 Mitoxantrone 2.9 (19.2 vs. 16.3) HR 0.76 (0.62-0.94) 
Sipuleucel-T IMPACT
15
 2010 Placebo  4.1 (25.8 vs. 21.7) HR 0.78 (0.61-0.98) 
Post-docetaxel   Cabazitaxel TROPIC
13
 
 
2010 Mitoxantrone 2.4 (15.1 vs. 12.7) HR 0.70 (0.59-0.83) 
Abiraterone COU-AAA-301
10
 
 
2011 Placebo 4.6 (15.8 vs. 11.2) HR 0.81 (0.70-0.93) 
Enzalutamide AFFIRM
11
 
 
2012 Placebo 4.8 (18.4 vs. 13.6) HR 0.63 (0.53-0.75) 
Radium-223 ALSYMPCA
14
 
 
2013 Placebo 3.6 (14.9 vs. 11.3) HR 0.70 (0.55-0.88) 
Pre-docetaxel  Abiraterone 
 
COU-AAA-302
9,17
 2013 Placebo 4.4 (34.7 vs. 30.3) HR 0.65 (0.54-0.77) 
Enzalutamide 
 
PREVAIL
12,18
 2014 Placebo 2.2 (32.4 vs. 30.2) HR 0.77 (0.67-0.88) 
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1.1.2 Changes in up-front systemic therapy  
Between 2015 and 2016 the results of three trials provided level 1 evidence that the 
greatest absolute benefit of docetaxel and abiraterone, both known to be effective in 
mCRPC, may be gained when given in the castrate-sensitive setting, see Figure 219-21. The 
addition of docetaxel to ADT was shown to improve survival in metastatic castrate-sensitive 
prostate cancer (mCSPC) by two randomised controlled trials (RCT), CHAARTED 
(Chemohormonal Therapy in Metastatic Hormone-sensitive prostate cancer) and 
STAMPEDE (Systemic Therapy in Advancing and Metastatic Prostate Cancer: Evaluation). 
Both contributed to a meta-analysis (STOpCaP) which combined aggregate data from 3206 
patients with mCSPC demonstrating docetaxel to improve survival by 23%, Hazard Ratio 
(HR) 0.77; 95% CI 0.68-0.87, p<0.0001) and 4-year survival rate by  9% (range 5-14%).20-22 
These data have changed practice, supported within the UK by a NICE evidence summary 
and NHS England who recommend that docetaxel is considered for all suitable men with 
mCSPC.23,24  
The addition of abiraterone to ADT has also been shown to improve survival and disease 
control rates in the randomised comparison of abiraterone conducted within STAMPEDE 
and the co-published LATITUDE trial, a placebo-controlled RCT in an overlapping population 
of high-risk mCSPC19,25. Both trials demonstrated highly significant improvements in survival 
and disease control rates, which, when combined in a meta-analysis, estimate abiraterone 
to reduce the risk of death by 38% (HR 0.62; 0.53-0.71; p=0.55x10-10); translating into a 14% 
improvement in 3 year survival rates. Although disease control definitions differ slightly, the 
effect on clinical or radiological progression free survival (rPFS) was also highly significant 
(HR = 0.45, 95% CI = 0.40-0.51, p = 0.66 × 10-36)26. Therefore, for the first time in over 60 
years, the management of mCSPC has been updated and may now include the addition of 
abiraterone or docetaxel to ADT, see Figure 2.  
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Figure 2: Updated systemic therapeutic options for metastatic prostate cancer 
(adapted from Lorente et al.16) 
 
Upfront use of abiraterone or docetaxel given in addition to ADT in the castrate-sensitive setting is 
the first change to the systemic treatment of metastatic castrate-sensitive prostate cancer in over 60 
years.  
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There are now three potential standard of care (SOC) treatment strategies for men 
presenting with mCSPC; ADT+docetaxel, or ADT+abiraterone, or in those patients unwilling 
or unable to receive either, ADT alone. However, the observed degree of clinical benefit is 
variable, see Table 320.  Potential benefit must be weighed up against the risk of treatment-
related toxicity; often a complex assessment in the predominantly elderly, co-morbid 
population affected by prostate cancer. Here, trial data likely underestimates risk as 
variability in treatment tolerance can be expected to be greater in non-clinical trial 
populations who differ in performance status, age and co-morbid burden. This is supported 
by emerging data from “real-world” use of docetaxel in the hormone-naïve setting, where 
the reported frequency of neutropenic sepsis is 20% compared with 2-15% in trial 
populations20,21,27-29. In addition, abiraterone and docetaxel have different therapeutic 
mechanisms of action, leading to the hypothesis that differences in prostate cancer biology 
may predict differential treatment effects. 
Table 3: Metastatic survival outcomes in STAMPEDE docetaxel comparison 
 ADT ADT + Docetaxel 
5-year survival  39% 50% 
Median OS 42 months 60 months 
Calculated IQR 68 months 
(23 – 91 months) 
 
76 months 
(27-103 months) 
 
Key: IQR Interquartile range, OS overall survival  
NB: At the time of the primary analysis of the STAMPEDE abiraterone comparison the median OS is 
unreported. There is insufficient follow up to report 5 year survival.  
 
1.2 Molecular basis of prostate cancer  
Improvements in the understanding of the molecular basis of PCa have revealed genetic 
diversity that may help explain the observed clinical variability. The Cancer Genome Atlas 
(TCGA) has comprehensively profiled treatment-naïve non-metastatic (M0) prostate 
cancers through sequencing prostatectomy samples. Their findings have demonstrated 
copy number alterations, recurrent somatic point mutations and oncogenic structural DNA 
rearrangements, termed chromoplexy, are all common genomic feature of M0 disease30,31. 
Overall, the most frequent alterations, occurring in 40-60%, are fusions of androgen-
regulated promoters such as transmembrane protease, serine 2 (TMPRSS2) with 
erythroblast transformation-specific (ETS) transcription factors such as ERG, ETV1 and 
ETV430,32. Other fusions are observed, although less frequently, such as those involving B-
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Raf proto-oncogene (BRAF) and the Ras family GTPase (RAS), identified in 1-2%30,33. 
Sequencing the whole genome enables large chromosomal deletions or amplifications to be 
detected, termed somatic copy number alterations (CNA). These frequently occur and 
commonly affected regions include chromosome 8, spanning the proto-oncogene c-myc 
and chromosome 10 affecting phosphatase and tensin homolog deleted on chromosome 10 
(PTEN)30. Recurrent somatic mutations are also observed; the most frequently affected 
gene is Speckle-Type POZ Protein (SPOP), mutated in 6-13% of primary prostate cancers 
and mutually exclusive with ETS-fusions34. Other frequently mutated genes include the 
androgen receptor associated gene Forkhead Box A1 (FOXA1), tumour protein p53 (TP53) 
and chromatin modifiers such as Chromodomain-helicase-DNA-binding protein 1 (CHD1)30, 
see Figure 3. 
The genomic profile of metastatic PCa has been studied most in the setting of advanced or 
fatal CRPC, with the majority of data coming from trial cohorts enrolled in precision 
medicine initiatives or rapid autopsy programmes30,31,34-39. When compared with M0 
treatment naïve disease, both the mutational burden and copy number burden is 
increased33. The accumulating genetic aberrations correlate with tumour progression and 
likely further drive intra-patient heterogeneity. There is a relative paucity of sequencing 
data acquired in men presenting with mCSPC. The MSK-IMPACT cohort included the most 
cases (n=140), however possibly reflecting differences in PSA screening practices in the US, 
half of cases were being treated for relapsed disease having originally presented with 
localised disease which was previously radically treated33. In contrast, over 90% of men 
enrolled with mCSPC in STAMPEDE present with de novo metastatic disease. It has been 
suggested that the biology of this aggressive high-risk phenotype may be more similar to 
mCRPC than the more indolent localised disease profiled through sequencing 
prostatectomy cohorts. To test this hypothesis, genomic data acquired from men with de 
novo metastatic disease is required and this is a pre-requisite to evaluating potential 
molecularly-selected treatments in this setting.  
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Figure 3: Frequent mutations occurring in prostate cancer  
 
Frequent mutations occurring in prostate cancer: Several somatic (acquired) mutations are 
recognised affecting multiple pathways. In metastatic castrate resistant disease, the most frequently 
mutated gene is the androgen receptor (AR), aberrant in up to 70%, consistent with the emergence 
of androgen-independent AR-transcriptional activity, a well-recognised feature of progression to 
CRPC
39
. At the pathway level, PI3K, DNA repair, cell cycle and Wnt pathway aberration are all 
observed and are more frequent in mCRPC compared with localised, treatment-naïve prostate 
cancer
33
. Activation of the PI3K pathway is seen in around 50%, which may occur through biallelic 
loss of PTEN or activating mutations, fusions or copy number amplification of PI3K subunits or AKT. 
Dysregulation of the cell-cycle pathway is predicted in around 20% of mCRPC as a result of RB1 loss, 
or amplification of CDK kinases including CCND1, CDK4. Whilst mutations and copy number loss of 
genes involved in DNA repair, specifically homologous recombination, has been shown to occur in 
between 15-23% of mCRPC; affected genes include BRCA2, CDK12, FANCA, Rad51 paralogues and 
ATM
39,40
. 
 
Key: AR, Androgen receptor;  ATM, Ataxia telangiectasia mutated gene; BRAF, v-Raf murine sarcoma 
viral oncogene homolog B; BRCA2, BReast CAncer susceptibility gene 2; CDK, Cyclin dependent 
kinases; CCND1, Cyclin D1; CDK4, cyclin dependent kinase 4; CDK12, cyclin dependent kinase 12; 
CRPC, Castrate-resistant prostate cancer; DNA, Deoxyribonucleic acid; NCOR1, Nuclear receptor co-
repressor 1; PI3K, Phosphatidylinositol-4,5-bisphosphate 3-kinase; PTEN, phosphatase and tensin 
homolog deleted on chromosome 10; RB1, Retinoblastoma 1. 
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1.3 STAMPEDE clinical trial  
1.3.1 Trial design  
STAMPEDE is a large ongoing RCT evaluating therapeutic strategies for the management of 
men with high-risk localised or mCSPC (www.stampedetrial.org). The trial employs a multi-
arm multi-stage (MAMS) platform design: multi-arm because many treatment approaches 
can be tested simultaneously, and multi-stage because pre-specified interim analyses can 
be used to stop recruitment early to arms showing insufficient evidence of activity41. Data 
from all stages is included in the final analysis of efficacy, powered on the primary 
outcome; OS. The trial opened in 2005 with five comparisons evaluating the efficacy of 
adding therapies to ADT, the then SOC (Figure 4). The additional treatments assessed were 
docetaxel chemotherapy, the bisphosphonate zoledronic acid (ZA) and celecoxib, a cox-2 
inhibitor. These three treatments were evaluated alone and in combination, to give a total 
of 5 research arms (B-F); since referred to as the original comparisons. One of the 
advantages of the MAMS platform design is that new research arms can be incorporated 
within a single protocol, utilising the established trial infrastructure and thus enabling rapid 
activation of recruitment to new research questions42. Since the start of the trial, a number 
of new research arms have been added to STAMPEDE to evaluate: abiraterone (arm G); 
prostate RT for patients with newly-diagnosed metastatic disease (arm H); enzalutamide 
given in combination with abiraterone (arm J); metformin (arm K), an anti-diabetic 
medication and transdermal oestradiol (arm L), as an alternative approach to ADT. To date 
over 10,000 men have enrolled and the STAMEPDE trial remains the largest ever RCT in this 
disease setting.   
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Figure 4: STAMPEDE overview: arms open to recruitment over time (2005-current) 
 
STAMPEDE Trial overview: The STAMPEDE trial uses a MAMS design to conduct multiple randomised comparisons between research arms and a shared control arm (A). 
Research arms B-F are referred to as the original comparisons and together with research arm G have reported the primary analysis. Comparisons made between 
contemporaneous A, H and J are yet to be reported. The dashed line highlights the latest research arm to be added into the platform, arm L activated in June 2017. 
As of May 2018 the current recruiting arms are A, K and L.
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1.3.2 Summary of STAMPEDE results to date  
Docetaxel-containing comparisons (research arms A-C, A-E)  
The primary analyses of the original comparisons are published. As summarised in Section 
1.1.2 the docetaxel results have contributed to a change in the SOC, supported by data 
from the CHAARTED trial21. The STAMPEDE docetaxel comparison (control and arm C) was 
comprised of 1,776 men with either high-risk locally advanced disease (~40%) or metastatic 
disease (~60%) and demonstrated that the addition of docetaxel improved survival by 22%, 
with a 10 month improvement in median survival from 71 to 81 months; HR 0.78; (95%CI 
0.66- 0.93) p=0.006.  No evidence of heterogeneity was seen by metastatic status, however 
survival data is more mature in the poor-prognostic metastatic subgroup (n=1086) in whom 
the addition of docetaxel was shown to result in a 15 month improvement in median 
survival (45 to 60 months). Although survival data remains immature in the M0 subgroup, a 
significant improvement in failure-free survival (FFS) is observed; FFS is defined as the first 
of radiological, clinical or PSA progression or death from PCa (HR 0·60, 95% CI 0·45–0·80; 
p=0·283 × 10 -³). Again, no heterogeneity in treatment effect is observed by metastatic 
status and the effect on FFS in the metastatic subgroup is consistent (HR 0·61, 95% CI 0·53–
0·71; p=0·283 × 10-¹⁰). Docetaxel was also evaluated in addition with ZA (comparison of 
control arm with research arm E). The addition of ZA was not shown to confer any 
additional benefit in FFS or survival over docetaxel, consistent with the results of the ZA 
comparison, which showed no benefit20. See Table 4 for a summary of all trial data 
evaluating docetaxel in CSPC. 
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Table 4: Summary of survival data from trials evaluating docetaxel in mCSPC  
Trial acronym Patient 
group  
Randomised 
comparison (n)  
Treatment detail  Summary of efficacy data (OS)  
GETUG-15
27
 mCSPC 385  ADT 
 ADT + docetaxel (up to 9 cycles)  
Median OS 58.9 (95%CI 50.8-69.1) vs. 54.2m (95%CI 42.2-NR) 
HR 1.01 (95%CI 0.75-1.36) p=0.955 
CHAARTED
21
 mCSPC 790 
 
 
High-volume M1 
n=513 
 ADT 
 ADT + docetaxel (up to 6 cycles) 
Overall  
Median OS 57.6m vs. 44.0m; HR 0.61 (95%CI 0.47-0.80) p<0.001 
 
High-volume M1 subgroup 
Median OS 49.2m vs. 32.2m; HR 0.60; 95% CI 0.45-0.81; p<0.001 
STAMPEDE
20
  mCSPC 
and  
high-risk 
M0 CSPC  
 
Total 1776  
 
 
M1 subgroup  
n=1086 
 ADT 
 ADT + docetaxel+ prednisolone 
(up to 6 cycles) 
Overall  
Median OS 81m (IQR 41-NR) vs 71m (IQR 32-NR) 
HR 0.78 (95%CI 0.66-0.93) p=0.006 
 
M1 subgroup  
Median OS 60m (IQR 27-103) vs. 45m (IQR 23-91);  
HR 0.76 (95%CI 0.62-0.92) p=0.005 
STOpCaP meta-
analysis
22
  
mCSPC 
and  
high-risk 
M0 CSPC  
 
M1 n=3206 
 
M0 n=3978  
 ADT 
 ADT + docetaxel (6-9 cycles) +/- 
prednisolone 
M1 subgroup  
HR 0.77 (95% CI 0.68-0.87) p<0.0001) 
Improvement in 4-year survival rates 40-49% (range 5-14%) 
 
M0 
HR 0.87 (95% CI 0.69-1.09) p=0.218 
 
Summary of docetaxel efficacy data: Both GETUG-15 and CHAARTED trials restricted recruitment to patients with M1 disease. CHAARTED performed a subgroup analysis by 
disease volume; high-volume M1 was defined by the presence of visceral metastases or four or more bone lesions with ≥1 outside the spine or pelvis. Only STAMPEDE 
recruited men with M1 or high-risk M0 disease.  
 
Key: ADT, androgen deprivation therapy; CSPC, castrate-sensitive prostate cancer; HR, Hazard ratio for overall survival; m, months;  M0,non-metastatic; M1, metastatic; OS, 
overall survival.  
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Celecoxib-containing comparisons (research arms A-D, A-F) 
In contrast to the docetaxel data, the results of the celecoxib-containing comparisons are 
intriguing and hypothesis generating rather than practice changing43. As afforded by the 
MAMS trial design, STAMPEDE has evaluated celecoxib alone (arm D) and in combination 
with ZA (arm F). In total, 1,245 men enrolled between October 2005 and April 2011 were 
randomised 2:1:1 to receive SOC (ADT+/- pelvic radiotherapy), or SOC + celecoxib or SOC + 
celecoxib + ZA. Celecoxib treatment was given orally 400mg BD for 1 year; ZA was given 
monthly for a total of 2 years using a standard dose of 4mg. Of note, the duration of 
celecoxib was reduced from 2 years to 1 year following regulatory advice sought by the 
STAMPEDE Trial Management Group (TMG), prompted by the withdrawal of the cox-2 
inhibitor rofecoxib. In 2011, recruitment was halted to both the celecoxib-containing 
research arms due to insufficient activity demonstrated for the intermediate outcome of 
FFS (pre-defined target HR 0.92).44 Lifelong follow-up continued and survival data was 
presented shortly after the reporting of the primary efficacy analyses of the remaining 
original comparisons to which recruitment had continued. Overall, no survival benefit is 
shown for either celecoxib, ZA, or the combination. However, in a pre-planned subgroup in 
men with M1 at presentation (n=567) the combination of celecoxib-ZA is shown to improve 
survival by 22% (HR=0·78, 0·62-0·98; p=0·033)20,44. This is despite no effect being shown in 
this subgroup when either treatment is given alone, see Table 5. 
 
Table 5: Results of the STAMPEDE celecoxib-containing comparisons  
Patient 
group 
Comparison made between arm A (control) and the following research arms 
 
Research arm D Research arm E Research arm F 
ADT + celecoxib43 
 
ADT + ZA20 ADT + celecoxib + ZA43 
M1 & 
high-risk 
M0  
 
No benefit  
HR 0.98  
(95% CI 0.80-1.20) 
P = 0.847 
No benefit  
HR 0·94 
 (95% CI 0·79–1·11) 
p=0·450 
No benefit  
HR 0.86  
(95% CI 0.70-1.05)  
P =0.130 
 
M1 
subgroup 
 
No benefit  
HR, 0.94  
(95% CI 0.75-1.18)  
P = 0.602 
No benefit  
HR 0.93 
(95% CI 0·77–1·11) 
p=0·416 
Survival benefit observed  
HR 0.78  
(95% CI 0.62-0.98)  
p=0.033) 
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Abiraterone comparison (research arms A-G) 
The results of the STAMPEDE abiraterone comparison also show improved outcome with an 
intensified upfront treatment strategy.  1917 men with high-risk M0 or metastatic castrate-
sensitive prostate cancer were randomised 1:1 to receive ADT or ADT + abiraterone 
1000mg BD + prednisolone 5mg daily. Treatment duration was dependent on disease stage 
and treatment intention. For patients with M0 disease receiving radical prostate RT, 
abiraterone was to continue for 2 years or until progression, whichever came first. For all 
others, abiraterone was to continue until progression, defined as a PSA rise, symptomatic 
or radiological or another treatment for progressive disease was started. In keeping with 
the approach adopted by the two pivotal trials in CRPC (COU-AAA-301 and COU-AAA-302), 
abiraterone could continue until all three types of progression had occurred, if judged by 
the treating clinician to be in the patients’ best interest 9,10. 
Overall, the use of abiraterone with ADT + prednisolone improved the time to treatment 
failure by 71% and OS by 37%, compared with ADT alone. The treatment effect was 
consistent in both metastatic and M0 subgroups; although survival data remains immature 
in the latter.  Within the metastatic subgroup the estimated survival effect is HR 0.61 (95% 
CI 0.49-0.75), with an even larger effect observed on FFS; HR 0.29 (0.25-0.34); p 0.38 x10-
61). These data are consistent with the results of the LATITUDE trial which demonstrated a 
comparable OS improvement: HR 0.62 (0.51-0.76) p<0.001) and both contributed to a 
meta-analysis (STOpCaP), see Table 6 25,26.  
There have been two recent analyses which attempt to address the question of which 
treatment, abiraterone or docetaxel can achieve the greatest survival improvement. A 
network meta-analysis using aggregate data would suggest superior survival gains with 
abiraterone (HR = 0.61, 95% CI 0.51-0.76) over docetaxel (HR = 0.74, 95% CI 0.65-0.85)45. 
However an opportunistic direct comparison is possible within STAMPEDE due to the 
overlap in the accrual to both docetaxel and abiraterone containing comparisons between 
November 2011 and March 2013. In contrast, this provides no strong evidence for a survival 
advantage with one treatment compared with the other. However, measures of disease 
control rates such as FFS and PFS which excludes PSA-driven failure, all favour 
abiraterone46. The latter result provides strong evidence that abiraterone given in the 
castrate-sensitive state successfully delays the progression to CRPC, but the failure of this 
to translate into a survival advantage over docetaxel may reflect the negative impact 
abiraterone use may have on access and response to second-line therapies. For example, 
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currently within the UK, prior abiraterone is a contraindication to accessing funding to 
enzalutamide in CRPC due to evidence of cross-resistance47. In summary, there is no strong 
evidence that either docetaxel or abiraterone is superior based on this direct comparison; 
the underpowered comparison of prostate cancer specific survival would suggest they are 
equivalent HR 1.02 (0·70-1·49); as such, both remain SOC options. Therefore the challenge 
now facing clinicians, patients and healthcare funders is to determine which individuals are 
most likely to benefit from each treatment strategy.  
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Table 6: Summary of abiraterone efficacy data in mCSPC   
 
Summary of abiraterone efficacy data: STAMPEDE recruits both M1 and M0 CSPC. The treatment duration is up to 2 years or progression in patients with M0 disease who 
receive radical RT. Otherwise, treatment was planned to continue until all three types of progression (PSA, symptomatic and radiological) occurred, or second-line 
treatment was started. LATITUDE recruited an overlapping population defined as high-risk mCSPC by the presence of 2 out of 3: Gleason ≥8, at least 3 bone lesions and the 
presence of measurable visceral disease. 
 
Key: ADT, androgen deprivation therapy; HR, Hazard ratio; HNPC, Hormone-naïve prostate cancer; M0, non-metastatic; M1, metastatic; OS, overall survival 
Trial acronym Patient group  Randomised 
comparison (n)  
Treatment detail  Summary of efficacy data (95% CI)   
STAMPEDE M1 and high-risk 
M0 CSPC 
1917 randomised 1:1 
 
(M0 915; M1 1002) 
 ADT 
 ADT + abiraterone + prednisolone   
 
Overall:  
 OS HR 0.63 (0.52-0.76); p<0.001 
 Improvement in 3-yr survival from 76% to 83% 
 
By metastatic subgroups: 
 M1: OS 0.61 (0.49-0.75), FFS 0.31 (0.26-0.37) 
 M0: OS 0.75 (0.48-1.18), FFS 0.21 (0.15-0.31) 
 
LATITUDE  
 
 
Metastatic CSPC 
(high-risk)  
1199 randomised 1:1  ADT + dual placebo 
 ADT + abiraterone + prednisolone   
Overall (Dual primary endpoints): 
 OS HR 0.62 (0.51-0.76) p<0.001 
 rPFS  HR 0.47 (0.39-0.55) p<0.001 
STOpCaP 
meta-
analysis
22
  
Metastatic CSPC  2201  ADT +/-placebo 
 ADT + abiraterone + prednisolone   
Overall:  
 Overall survival HR: 0.62 (0.53-0.71); p=0.55 x10-10 
 Improvement in 3 year survival from 55% to 69% 
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1.4 Identified research priorities 
Acquiring data that can inform treatment selection in mCSPC is now a priority to ensure the 
recent evidence of benefit shown for intensified treatment strategies translates to the best 
individual outcome. This is the concept of personalised medicine, an area where prostate 
cancer has lagged behind other solid tumour types. Factors likely contributing to this 
include the predominance of the AR pathways and the almost universal initial response to 
ADT. The development of predictive genomic biomarkers is also made more challenging by 
tumour tissue availability, typically limited to small prostate core biopsies, whilst the 
predominance of bone metastases means sampling metastatic disease is technically 
difficult, requiring specific protocols if sufficient concentration of high quality DNA are to be 
obtained48. Added to this is the lack of validated intermediate clinical endpoints, meaning 
that prognostic and predictive questions are reliant on analyses of OS, increasing the cost 
and time of data acquisition. However, in anticipation that the trend will continue for the 
greatest absolute benefit of effective treatments to be seen when used at first 
presentation, the need for improved tools to risk-stratify, prognosticate and predict 
treatment response and/or toxicity is only set to increase.  
Personalised medicine approaches may improve outcome through identifying patients who 
have a differential treatment response and providing these groups are not overlapping, 
outcomes in the group overall will improve as a result of optimised treatment. Whilst at a 
societal level, through reduced use of therapies in populations predicted to benefit least, 
this approach offers a more efficient allocation of healthcare resource. Paired to the 
concept of personalised medicine, is the term biomarker, used to define a measurable 
characteristic that is an indicator of a process, be it biological, pathogenic or response to a 
therapeutic intervention49. The implementation of a personalised approach is reliant on 
biomarkers to identify and characterise patient groups in whom specific treatment 
strategies should be evaluated. In this thesis I will explore how the development of 
biomarkers in the setting of mCSPC can be best achieved through analyses of existing and 
future data collected as part of the STAMPEDE trial.  
1.5 How can STAMPEDE data inform treatment selection? 
Biomarker development can be facilitated through additional analyses conducted in parallel 
or as part of clinical trial protocols. As described in the Cancer Research UK (CRUK) 
prognostic and predictive biomarker roadmap, see Figure 5, correlative analyses using 
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biological samples obtained from clinical trial cohorts provide multiple opportunities to 
support biomarker development50. These include enabling retrospective analyses of 
biomarker status correlated with clinical outcome and testing of hypotheses to explain 
heterogeneity in treatment response. Samples may also be used to optimise biomarker 
assays, or estimate prevalence in the population of interest. Access to sample collections 
and correlative clinical data is a valuable resource which can support external validation. 
Finally, the clinical utility of validated biomarkers can be confirmed through protocols in 
which biomarker status defines randomisation or patients are randomised to the strategy 
of biomarker-directed therapy vs. non biomarker-directed treatment.  
All participants joining the STAMPEDE trial have been asked to consent to donate remaining 
diagnostic tissue e.g. formalin-fixed paraffin embedded (FFPE) prostate core biopsies for 
use in separate ethically approved translational protocols. As mature outcome data is now 
known for several randomised comparisons, correlative retrospective analyses are possible. 
As an adaptive trial platform, the protocol can also be amended to address biomarker-
driven questions, acquiring prospective data to evaluate this approach.  
1.5.1 Seek support and understanding of variable treatment effects 
The results of the celecoxib-containing comparisons provide evidence of unexpected 
heterogeneity in treatment effect. An additive effect for the combination of celecoxib-ZA is 
observed, selectively beneficial in men with metastatic disease. The results are clinically 
significant with a 22% improvement in OS and evidence of good tolerability; the proportion 
of patients reporting a Common Terminology Criteria for Adverse Events version 3.0 
(CTCAE) toxicity grade ≥3 was comparable in all groups: control-SOC alone (36%), SOC + 
celecoxib (33%) and SOC + celecoxib + ZA (32%). The magnitude of benefit is similar to that 
observed for docetaxel; however in contrast, these data have not translated into a change 
in practice. This is likely due to the lack of supporting clinical data and uncertainty around 
the mechanism of action sufficient to explain the additive effect observed between 
celecoxib-ZA and why this should be selective to metastatic disease.  
One approach to biomarker identification is through seeking to identify and understand 
heterogeneity in therapeutic responses. This strategy may enable characterisation of a 
subpopulation who may benefit from a particular treatment. Further investigation, 
particularly involving molecular characterisation, may in turn reveal distinct mechanisms of 
response and support biomarker development. This is the rationale behind the study of 
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exceptional responders supported by several precision medicine intiatives51. Furthermore 
there are several examples of targeted therapeutic strategies, initially evaluated in 
unselected populations but now licenced in biomarker-defined groups, characterised 
through parallel translational research, such as cetuximab in Kirsten rat sarcoma viral 
oncogene homolog (KRAS) wild-type colorectal cancer or epidermal growth factor receptor 
(EGFR) inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC)52-54. I will seek to 
contextualise and understand the results of the celecoxib-ZA comparison and explore 
biological hypotheses to explain the observed selective effect in mCSPC. 
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Figure 5: Cancer Research UK Biomarker Roadmap 
 
 
Cancer Research UK Biomarker Roadmap: Outlines the multiple ways in which clinical trials can support biomarker 
development through assay refinement, retrospective biomarker-clinical outcome correlation studies, prospective analyses 
and qualification studies whereby biomarker status determine eligibility for randomisation. Clinical trials using adaptive 
protocols may support multiple stages.  
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1.5.2 Improved risk-stratification  
As PCa predominantly affects older men, treatment paradigms emphasise the need to 
balance relative life expectancy with the risk of lethal disease55.  Over half of men with 
newly diagnosed PCa are aged 70 years and over and almost all have co-morbidities that 
can be anticipated to impact on treatment tolerance to some degree1,55 Accurate 
identification of high-risk cancers may provide the justification for intensified therapeutic 
strategies and ensure optimal use without compromising quality of life through risking 
unnecessary toxicity. Prognostic biomarkers may aid this assessment and inform clinical 
trial design, through identifying patient subgroups with a similar risk profile in whom to 
evaluate a specific treatment strategy56. Through characterising prognostic biomarkers, 
insights into the biological basis of heterogeneity in outcome may also be gained. The 
increasing number of available therapies means the need for improved prognostic tools 
continues to grow.  
Through using PSA measurements collected as part of the STAMPEDE protocol I will 
evaluate two proposed on treatment biomarkers with the aim of improving risk 
stratification pre and post docetaxel use in the castrate-sensitive setting. PSA response is 
proposed as an early prognostic indicator able to assess initial ADT response, with the 
magnitude of response hypothesised to correlate with improved survival outcome. This can 
be used to identify patients at low risk in whom the toxicities of docetaxel may be avoided. 
Secondly, I will evaluate if PSA nadir, defined as the lowest PSA on treatment is prognostic 
of survival when assessed on completion of docetaxel. It is hypothesised that high PSA 
nadir, shown to be prognostic in mCSPC treated with ADT alone, may identify a high-risk 
group in whom further intensified treatment strategies should be considered. Several 
ongoing trials are evaluating the combination of ADT + docetaxel + AR-targeted therapy 
such as abiraterone or enzalutamide (see Table ). Whilst it is yet to be shown if the benefits 
of docetaxel and abiraterone will prove additive, many anticipate that this further 
intensified treatment strategy will be more effective. However, given the associated 
additional cost and toxicity, it is unlikely that this will be considered suitable for all, 
emphasising the role of improved risk-stratification at this time point.  
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1.5.3 Identify potential predictors of response   
The knowledge of the genomic landscape of PCa has increased rapidly within the last 
decade due to advances in high-throughput sequencing technologies. This provides both 
the means and the rationale to evaluate molecularly-selected treatment strategies within a 
subset of patients characterised by a putative predictive biomarker.  
The results of the Trial of PARP inhibition in Prostate Cancer (TOPARP) study provide proof-
of-concept of this approach in mCRPC. This phase 2 trial recruited 50 heavily pre-treated 
patients with mCRPC; all had received docetaxel, 49/50 had received abiraterone or 
enzalutamide and over half had received cabazitaxel. Olaparib, a PARP inhibitor (PARPi), 
was shown to be selectively active in mCRPC with defects in genes involved in homologous 
recombination DNA repair pathway. Biomarker assessment involved targeted next-
generation sequencing (tNGS) of mandated fresh tumour biopsies, obtained prior to trial 
entry. Response was defined using a composite endpoint that included any of the following: 
radiological response, according to Response Evaluation Criteria In Solid Tumours (RECIST) 
criteria; PSA reduction ≥50%, or confirmed circulating tumour cell (CTC) count conversion 
from ≥5 per 7.5ml to <5 per 7.5ml. Overall, responses were seen in 88% (14/16 cases) of 
cases associated with detectable homologous recombination deficiency (HRD). The median 
duration of treatment was 9 months with 4/16 patients continuing olaparib for more than 
12 months. Crucially, only 6% (2/33) patients defined as biomarker negative responded, 
suggesting a high specificity of the tNGS panel57. 
This evidence of selective clinical benefit provides the motivation to profile mCSPC, aiming 
to determine if HRD is present at the first presentation of metastatic disease, thus providing 
a rationale to evaluate PARPi in this setting. As has been seen to date, the greatest absolute 
impact on outcome may be seen when effective treatments are used earlier and it is 
hypothesised that this may be particularly relevant to therapeutic strategies that seek to 
exploit defective mechanisms of DNA repair. The presence of which can be expected to 
drive genomic instability and the development of genetic heterogeneity, the latter can 
thwart targeted medicine approaches due to the risk of co-existing sub-clonal mutations 
that may confer treatment resistance58,59.  
The adaptive STAMPEDE platform has been shown to be amenable to evaluating questions 
in a subset of the broader eligible population, the best example of this being the 
assessment of prostate RT in men with newly diagnosed metastatic disease. 2061 patients 
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were recruited between January 2013 and September 2016 to this comparison, made 
between patients allocated to research arm H and comparable controls. Accrual was 
sustained alongside other questions that addressed treatments relevant to the broader 
population of metastatic and high-risk M0 disease. One of the perceived challenges of 
addressing biomarker-selected questions is the anticipated low prevalence, leading to a 
high screening burden. Therefore it is proposed that the most efficient route to evaluation 
may be to further amend the STAMPEDE trial; allowing recruitment to both biomarker-
selected and unselected comparisons within one inclusive platform protocol. 
There are several recognised challenges when considering the implementation of a 
biomarker-selected randomised comparison in this setting. Firstly, in keeping with the 
pragmatic approach that has helped ensure the STAMPEDE trial can successfully recruit at 
both academic and district general hospitals, the aim would be to avoid additional tumour 
sampling. Therefore implementation of prospective biomarker screening would rely on 
rapid retrieval and centralised testing of remaining diagnostic tissue, typically prostate core 
biopsies stored as FFPE blocks. Through undertaking a retrospective analysis of clinically 
representative samples, I will assess the test performance and thus the feasibility of this 
approach. I will also aim to pilot several of the operational changes required, including 
establishing collaborations with a biorepository and sequencing laboratories, as well as 
testing new processes to track samples and securely transfer genetic data. Finally, I will aim 
to estimate the prevalence of HRD in mCSPC, as this determines the number needed to 
screen, accrual rate and trial duration so is considered the most important parameter when 
evaluating the feasibility of this approach and defining the optimum trial design. 
1.6 Summary of research objectives  
In this thesis I will aim to improve outcomes for patients with mCSPC through a deeper 
understanding of the results generated from STAMPEDE so far and through genomic 
profiling aiming to evaluate if it is feasible to evaluate upfront PARP inhibition in this 
disease setting.  
First, I will seek to contextualise and understand the selective beneficial effect of the 
combination of celecoxib-ZA through undertaking a systematic review and, where possible, 
a meta-analysis aiming to evaluate if there is external clinical data to support the observed 
clinical efficacy. In addition, relevant clinical and pre-clinical data will be reviewed with the 
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aim of generating biological hypotheses that may explain the observed additive effect of 
this therapeutic combination, and why this should be selective to metastatic disease.  
Secondly, I will explore the relationship between PSA and OS aiming to evaluate two PSA-
based outcomes as potential prognostic biomarkers capable of risk-stratifying patients and 
informing treatment selection in the castrate-sensitive setting.  I will explore if the 
magnitude of early PSA response on ADT is associated with survival, testing the hypothesis 
that a large PSA response may identify a good prognostic subgroup. Secondly, I will 
evaluate the relationship between PSA nadir on docetaxel and OS as a proposed on 
treatment biomarker that may be able to identify patients that remain at high-risk in whom 
intensified therapeutic strategies in the castrate-sensitive setting should be evaluated.    
Finally, through collaboration with industry partners, I will assess the feasibility of 
implementing prospective molecular biomarker screening within STAMPEDE in order to 
identify a population hypothesised to benefit from PARP inhibition. Through additional 
exploratory analysis of the sequencing data I will aim to explore the broader genomic 
profiles to better understand whether future genomic biomarker-treatment pairings may 
be evaluated through further adaptation of the STAMPEDE trial platform.  
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Chapter 2 Contextualising the STAMPEDE celecoxib and zoledronic 
acid results  
2.1 Introduction 
The aim of this systematic review and meta-analysis is to contextualise the results of the 
STAMPEDE celecoxib-containing comparisons. Overall, no survival benefit was seen for 
either celecoxib, ZA, or the combination. However, in a pre-planned subgroup analysis in 
men with metastatic disease at presentation (n=567) the combination of celecoxib-ZA is 
shown to improve survival by 22% (HR=0·78, 0·62-0·98; p=0·033)18,40. This clinically and 
statistically significant finding is consistent with a heterogeneity in treatment effect 
according to baseline metastatic status (p=0.072). Furthermore, no evidence of benefit was 
observed when either celecoxib or ZA were added alone, consistent with an additive effect 
for the combination, see Table 5.  
In 2003 when the STAMPEDE trial was in development, cox-2 inhibitors were novel agents 
under evaluation in multiple indications. However by the time of data reporting in 2016, 
the perception and use of cox-2 inhibitors was very different and this result was 
unexpected. Despite the relative survival gain being comparable with the practice changing 
results of the docetaxel comparison, see Table 5, Figure 6 and Figure 7, these data are 
hypothesis generating as opposed to practice changing, largely due to the absence of 
supporting data. I will determine if this intriguing finding has been identified in any other 
clinical data and explore hypotheses seeking to understand it further.   
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Figure 6: Survival in metastatic subgroup in docetaxel comparison 
 
 
Figure 7: Survival in metastatic subgroup in celecoxib-ZA comparison 
 
 
Figure 6 shows the difference in overall survival between men (n=1089) with metastatic castrate-
sensitive prostate cancer randomised between control ADT alone and ADT + docetaxel; HR 0.76 
(95%CI 0.62-0.92) p=0.005. Figure 7 shows the difference in overall survival between men (n=567) 
with metastatic castrate-sensitive prostate cancer randomised between control (ADT alone) and 
celecoxib + zoledronic acid; HR 0.78 (95% CI 0.62-0.98) p=0.033). 
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2.1.1 Rationale to evaluate cox-2 inhibitors as anti-cancer agents 
Cox-2 inhibitors are non-steroidal anti-inflammatory drugs (NSAID) developed initially as 
analgesics. NSAIDs all act to inhibit the cyclooxygenase (cox) enzyme family, also known as 
prostaglandin endoperoxide synthetase (PTGS), reducing the production of prostaglandins, 
prostacyclin and thromboxanes, which mediate signal-transduction pathways modulating 
cellular growth, adhesion and proliferation60. Cox-1 is widely expressed in normal tissue and 
is thought to have a “housekeeping” role, which includes mediating prostaglandin 
synthesis, necessary in gastric cytoprotection and platelet aggregation. Cox-2, whilst 
constitutively expressed in some tissues, including the vascular endothelium, is 
predominantly induced in response to inflammatory, injury and malignancy61. Most NSAIDs 
are non-selective; however celecoxib is an example of a selective inhibitor of cox-2, 
developed with the aim of avoiding the gastrointestinal toxicities, attributed to cox-1 
inhibition.  
Up-regulation of the cox-pathway is associated with the development or progression of 
cancers including colon, lung, breast, prostate, bladder and oesophageal62. For example, 
PCa is associated with a 3.4 fold increase in mean cox-2 levels relative to surrounding 
normal tissue, and overall cox-2 overexpression is detected in 83%63. Cox-2 overexpression 
results in increased prostaglandin synthesis, which itself is associated with more advanced 
disease64. Consistent with this, administration of prostaglandins to prostate cancer cells 
significantly increases cellular proliferation and increases cox-2 expression. The therapeutic 
relevance of this is supported by in vivo evidence that shows selective cox-2 inhibition 
suppresses tumour growth through induction of apoptosis and inhibition of angiogenesis 
through the down-regulation of endothelial growth factors65. 
Aspirin is a non-selective cox-inhibitor, also proposed as a re-purposed anti-cancer therapy. 
In contrast to other NSAIDs, aspirin is an irreversible cox-1 inhibitor, but due to its short 
half-life and extensive first pass metabolism, is unlikely to exert a systemic effect on the 
cox-pathway. Instead, aspirin exerts its predominant therapeutic effect on mature 
platelets, which contain cox-1 but as they lack a nucleus, are unable to resynthesize cox 
enzymes and so are vulnerable to irreversible cox inhibition66. Reduced platelet aggregation 
is one proposed mechanism through which aspirin may exert an anti-cancer activity, 
supported by the evidence demonstrating platelets  facilitate metastatic spread67. 
However, distinct to cox-2 selective inhibition, aspirin is also proposed to modify the host 
environment through non cox-dependent pathways that include inhibition of angiogenesis, 
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promoting apoptosis and modification of pathways that promote cancer growth, such as 
nuclear factor-kappa B (NF-κB) and tumour necrosis factor (TNF) signalling68.  
Pre-clinical data 
The therapeutic mechanism of NSAIDs in carcinogenesis is proposed to involve alteration of 
apoptosis, angiogenesis and immune function68,69. Pre-clinical evidence of anti-cancer 
activity has been demonstrated in multiple tumour types including colorectal (CRC), breast 
and non-small cell lung cancers (NSCLC) thus providing a rationale to review clinical data 
from a range of cancers when seeking to contextualise the STAMPEDE results70-72,73. 
In CRC, malignant transformation is associated with cox-2 overexpression, detectable in 
40% of adenomatous colonic polyps and increasing to 80% of CRC74. Pre-clinical and clinical 
data acquired in familial adenomatous polyposis (FAP), an inherited cancer-predisposition 
syndrome, demonstrates NSAID treatment restores apoptotic mechanisms and blocks 
tumour formation. Whilst cox-2 inhibition in pre-clinical models of CRC ameliorates tumour 
stimulated angiogenesis and neovascularization, providing a further therapeutic mechanism 
of anti-cancer effect69,74-77.   
Pre-clinical evidence obtained in PCa models suggests several proposed mechanisms of 
anti-cancer effect. Cox-2 has been shown to promote cellular invasion and metastases via 
activation of matriptase, a matrix degrading protease. In turn, matriptase expression has 
been shown to correlate with poor PCa outcome78. In a model of CRPC characterised by 
cox-2 overexpression, cox-2 inhibition was shown to supress matripatase-induced cell 
migration by 80% and invasion by 95%79. Multiple lines of evidence support celecoxib 
exerting a pro-apoptotic effect, all suggest that this effect is in part dependent on cox-2 
expression 80-83. Mechanisms differ, but include via inhibition of AKT phosphorylation or via 
TNF signalling pathway81,82.  
Pre-clinical data suggests aspirin and NSAIDs may exert an anti-cancer effect via separate 
mechanisms, therefore should be considered separately and may be expected to benefit 
different tumour types and settings. Aspirin is proposed to exert an anti-metastatic effect 
via the inhibition of platelet function. Platelets may promote cancer development and 
metastatic spread through facilitating cancer cell adhesion and transmigration; enabling 
evasion of immunosurveillance by adhering and protecting circulating cancer cells from 
natural killer cells, and altering the tumour microenvironment via transforming growth 
factor beta 1 (TGF-B) and NF-κB pathways to promote metastatic invasion84,85.  In addition, 
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it has been proposed that aspirin, via inhibition of cox-1 may indirectly suppress the 
induction of cox-2 in distant nucleated cells within the tumour cells or microenvironment86. 
This suggested inter-play between cox-1 and cox-2 is supported by the demonstration that 
inhibition of  either results in tumorigenesis in rodent models and provides an explanation 
for the clinical data suggesting low-dose aspirin, though insufficient to exert systemic cox-
inhibition, may have an anti-cancer effect87. For these reasons, when seeking supporting 
data for the celecoxib-ZA results, I will focus on data acquired with selective cox-2 inhibitors 
only.  
Clinical data 
Epidemiological data suggests NSAID use is associated with reduced PCa incidence, 
especially aspirin which is the most frequently studied association, see Table 7. In a 
systematic meta-analysis, data was pooled from 10 case-control and 14 cohort studies, 
including a total of 24,230 PCa cases in NSAID exposed populations. The results suggest 
NSAID use is associated with reduced PCa risk; Pooled Odds Ratio (POR) 0.89; 95% CI; 0.73-
1.09; p=0.26. This trend was confirmed in non-aspirin NSAID exposed populations (POR 
0.90; 95% CI 0.80-1.01, p=0.087) but only reached statistical significance in the largest 
population (17 studies) exposed to aspirin (POR 0.83; 95% CI 0.77-0.89, p<0.001)88. Included 
trials were heterogeneous; study design, outcomes and NSAID exposure all varied, limiting 
the ability to inform as to the impact of NSAID dose or duration.  
Some of the strongest clinical evidence for an anti-cancer effect of NSAIDS is observed with 
aspirin, acquired through secondary meta-analyses of cancer incidence amongst 
participants in vascular prevention trials. In a meta-analysis of 17285 participants in 5 RCTs, 
a reduced incidence of metastatic cancer was observed in those randomised to aspirin (HR 
0.64; 0.47-0.84, p<0.001) and a strong trend toward a reduction in PCa deaths, evident 
after 5-years follow-up (HR 0.52; 0.20-1.34)89. Consistent with this, retrospective review of 
aspirin use has shown an association with improved outcomes following radical treatment 
in three cohorts, with the greatest benefit observed in men with high-risk localised disease. 
In a review of 2051 men on surveillance following radical PCa treatment aspirin non-use 
was associated with earlier biochemical failure on multivariable analysis (aspirin non-use 
OR 2.05; 95%CI 1.33-3.17; p=0.0012)90. In a second cohort of 5955 men treated for localised 
PCa whilst also receiving anti-coagulation therapy, aspirin, as opposed to other anti-
coagulants, was associated with a significantly lower risk of prostate cancer specific 
mortality (PCSM) after a median follow up of 70 months (3% vs. 8%; p=<0.1). Multivariable 
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analysis confirmed aspirin use was independently associated with a lower risk of PCSM 
(adjusted HR 0.43; 95% CI, 0.21- 0.87; P=.02) and was associated with a reduced risk of 
disease recurrence and the development of bone metastases. In the largest cohort study 
which included 8427 men, a significant reduction in PCSM was seen in those with high-risk 
features (≥T3 or Gleason score ≥8) PCSM (HR = 0.60; 95% CI, 0.37 to 0.97)91. Together these 
data support the need for randomised trials to evaluate aspirin as an adjuvant anti-cancer 
treatment.  
 
Table 7: Epidemiological data assessing effect of NSAID and PCa incidence/outcome  
Reference n Setting Results 
Mahmud 2010 
et al
88
   
n=24,230 
(total) 
All stages 
of PCa  
 Aspirin use (17 studies)  
OR=0.83 (0.77-0.89; p<0.001)  
 Non-aspirin NSAID use (12 studies)  
OR=0.90 (95% CI 0.80-1.01; p=0.087) 
Zaorsky et al. 
2012
90
 
n=2,051 M0 post 
radical RT  
 Aspirin non-user associated with shorter 
biochemical failure free survival time  
OR 2.05 (95% CI 1.33-3.17) 
CaPSURE study  
Choe et al. 
2012
91
 
n=5,995 M0 post 
radical 
treatment  
 Aspirin use associated with improved prostate 
cancer-specific mortality 
HR 0.43 (95% CI 0.21-0.87) 
Jacobs et al. 
2014
92
 
n=7,118 High risk 
M0 
 Retrospective review of aspirin use suggested 
associated with improved PCa mortality  
HR 0.60 (95% CI 0.37-0.97) 
Rothwell et al
89
   n=17,285 All stages 
of PCa 
 Aspirin use associated with reduced risk of death 
due to PCa 
OR 0.34 (95% CI 0.12-0.99) p=0.049 
  
Downer et al
93
  
Physicians 
Health Study 
n=22,071 All stages 
of PCa 
 Current and past regular aspirin use associated 
with lower risk of lethal PCa(HR 0.68; 95% CI 
0.52-0.89)  
 Post cancer diagnosis aspirin use was associated 
with improved survival post diagnosis HR 0.72 
95%; CI 0.61-0.90 
 
The Add-Aspirin trial (NCT02804815) is a phase III placebo controlled RCT which will provide 
much needed randomised prospective data to address the question of whether adjuvant 
aspirin, given at a dose of 100mg or 300mg for at least 5 years, can improve rates of disease 
recurrence and survival. This trial will aim to recruit 2120 men with intermediate or high-
risk localised PCa and is designed to detect an 8% improvement in biochemical disease free-
survival. Recruitment is ongoing to this, and three parallel cohorts which include radically 
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treated colorectal, gastro-oesophageal and breast cancer, with combined analyses of 
survival also planned94.   
 
2.1.2 Impact of external safety data 
The acquisition of clinical data evaluating cox-2 inhibitors as anti-cancer agents has been 
hampered by concerns regarding cardiovascular toxicity. Although cox-2 inhibitors were 
originally developed with the aim of achieving an improved toxicity profile, in 2002 
rofecoxib was withdrawn in response to data demonstrating an increased risk of 
cardiovascular events95. This prompted numerous trials evaluating cox-2 inhibitors to close 
early due to poor accrual, see Table 8 for three such examples in PCa. 
 
Table 8: Cox-2 inhibitor trials in PCa that closed early in response to external safety data 
Trial ID  Patient 
Group 
Treatment  Outcomes Sample size and trial status 
NCT00136487 
 
Biochemical 
relapse post 
radical 
treatment   
 
Celecoxib or 
Placebo 
PSA 
doubling 
time 
Design: Placebo controlled phase 
II/III 
Accrual: 85 (target unknown)  
Recruitment period: Oct-2002- Sept 
2006 
Status: Terminated early in response 
to external safety data  
Conclusion: Primary objective not 
met but PSA velocity decreased 
96
 
NCT00073970 Biochemical 
relapse post 
radical 
treatment   
 
Celecoxib  PSA 
response  
Design: Single arm phase II 
Accrual: 37 (target 100) 
Recruitment period: Apr-2003 – Jan 
2006 
Status: Terminated early in response 
to external safety data  
Note: Results not published  
NCT01220973 Biochemical 
relapse post 
radical 
treatment   
 
Celecoxib + 
atorvastatin 
PSA 
response 
Design: Single arm phase II 
Accrual: 27 (target unknown) 
Open: Feb-2009 
Status: Terminated early; results not 
published 
Date summarised from www.clinicaltrials.gov 
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Evidence of increased cardiovascular risk  
Evidence of increased cardiovascular risk was shown for rofecoxib in two chemoprevention 
trials. The Adenomatous Polyp Prevention on Vioxx Trial (APPROVe) randomised 2586 
patients with a history of colorectal adenomas to receive 3 years of treatment with 
rofecoxib or placebo. The trial was halted due to an increase in thrombotic cardiovascular 
events, predominantly myocardial infarctions (MI) and ischaemic strokes, in the rofecoxib-
treated group. Although the absolute risk was small, the corresponding relative risk (RR) is 
clinically significant when considering the setting: the evaluation of a preventative 
treatment in an otherwise healthy population. 46 confirmed thrombotic events occurred in 
the treatment group compared with 22 in the placebo group, corresponding RR 1.92; 1.19-
3.11; (p=0.008); which, when adjusted for time on follow-up, represents a difference of 
1.50 events vs 0.78 events per 100 patients years95. This prompted a review of 
accumulating safety data in a second trial, Adenoma Prevention with Celecoxib in which 
2035 patients were randomised 1:1:1 to receive placebo, celecoxib 200mg BD or celecoxib 
400mg BD. Blinded review of all deaths and non-fatal cardiovascular adverse events 
demonstrated a dose-related increase in cardiovascular-related mortality for celecoxib. The 
annual incidence of death from cardiovascular causes was 3.4 per 1000 in the placebo 
group, increasing to 7.8 per 1000 and 11.4 per 1000 in the 200mg and 400mg celecoxib 
treatment groups respectively97. 
These data fuelled the concern that this was a class effect of selective cox-2 inhibitors, 
hypothesised to be due to an imbalance between prothrombotic and anti-thrombotic 
eicosanoids resulting from the lack of cox-1 inhibition. Selective cox-2 inhibition reduces 
the production of prostacyclin, but without affecting the Cox-1 dependent synthesis of 
thromboxane A2, a promoter of platelet aggregation and vasoconstriction. Cox-2 
expression is increased in the presence of endothelial injury and therefore suppression of 
cox-2 dependent prostaglandin I2 and the resulting pro-thrombotic imbalance may be most 
clinically apparent in those with the highest intrinsic risk of atheromatous cardiovascular 
disease98. The latter providing a rationale for the observation that greatest increased 
relative risk was seen in patients with a history of cardiovascular disease99,100. Although the 
clinical data for increased cardiovascular risk for cox-2 inhibitors other than rofecoxib was 
inconsistent, significant concern remained and many trials closed early101,102.  
In 2017, a meta-analysis has shown that the assumption that cox-2 selectivity confers 
increased cardiovascular risk cannot be supported, instead demonstrating this to be specific 
56 
 
to rofecoxib103. In total, 26 RCTs or prospective cohort studies evaluating NSAIDs in a range 
of disease settings were identified where cardiovascular outcome data was also included. 
This represents a total of 228,391 patients, of which 65,341 were exposed to celecoxib. 
Comparisons were made between cox-2 inhibitors, non-selective NSAIDs or placebo groups, 
depending on the trial design. The meta-analysis used the primary outcome of MI, stroke or 
cardiovascular death, or any combination of these. The findings demonstrate that the 
adverse cardiovascular events may not be based on the cox-2 selectivity of NSAIDs, as 
rofecoxib appears to be the only NSAID to confer increased cardiovascular risk. When 
compared to placebo, rofecoxib was associated with an increase in cardiovascular events: 
OR 1.572; 95% CI 1.123-2.201; p=0.008. When rofecoxib is removed from the cox-2 
inhibitor group no difference in cardiovascular outcome is observed, consistent with this 
single agent skewing the data. The results of this meta-analysis are reassuring when 
considering the clinical relevance of the STAMPEDE celecoxib-ZA results.  Yet the impact the 
toxicity data had at the time cannot be reversed, influencing the perceived role of celecoxib 
in this setting and delaying data acquisition. 
 
2.1.3 Rationale for evaluating in combination with zoledronic acid  
ZA is a bisphosphonate shown to have anti-cancer effects in models selected due to the 
predominance of metastatic bone involvement e.g. breast, prostate and lung cancer. 
Bisphosphonates bind preferentially to bone where they are ingested by osteoclasts leading 
to inhibition of bone reabsorption and osteoclast apoptosis104. The strength of evidence of 
anti-cancer effect is greatest for the second generation nitrogen-containing compounds, 
such as ZA. Studies using PCa cells lines demonstrate ZA inhibits prostate tumour cell 
adhesion, migration and invasion suggesting it may act to prevent metastatic spread105-107. 
In addition to direct anti-tumour cell effects, ZA is proposed to have an immune modulatory 
function via stimulating γ𝛿 T cells108. This T cell subpopulation is capable of exerting an anti-
tumour response through the recognition of phosphoantigens overexpressed in some 
cancer cells. ZA treatment has been shown to stimulate γ𝛿 T cell expansion and function in 
PCa patients108. However, this is not PCa specific as breast cancer cells are also more 
vulnerable to γ𝛿 T cell mediated cell death following ZA treatment108,109. Therefore this 
represents a further proposed mechanism by which ZA may control cancer cell progression 
and may be relevant when considering the observed additive effect observed when given in 
combination with celecoxib. 
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ZA was evaluated alone and in combination with celecoxib within STAMPEDE, hypothesised 
to improve FFS and OS. In 2002, ZA was licenced for use in mCRPC having been shown to 
prolong the time to first skeletal-related event (SRE), a composite outcome measure used 
to describe the major complications of metastatic bone involvement: pathological fracture, 
spinal cord compression, or pain or impending fracture, necessitating radiotherapy or 
surgery110. SREs are a major cause of significant health and economic burden and can lead 
to severe pain, reduced quality of life, disability and increased risk of death111.   The use of 
ZA was shown to reduce the risk of an SRE (RR 0.64 (95% CI 0.49-0.85)112. Prior to 
STAMPEDE opening, the MRC PR05 trial reported a survival improvement with sodium 
clodronate in mCSPC and a second trial (PR04) was underway in M0 disease. Intriguingly, 
updated survival data from PR05 reported in 2009 also suggest a selective beneficial effect 
metastatic castrate-sensitive disease, (HR 0.77; 95% CI 0.60-0.98; p=0.032)113. No evidence 
of benefit was ultimately seen in the M0 population in PR04 (HR 1.12; CI 0.89-1.42; p=0.94). 
However despite evidence of benefit with this first generation bisphosphonate, these data 
did not impact practice and cannot be supported by the results of the STAMPEDE ZA 
comparison (HR 0·94; 95% CI 0·79–1·11; p=0·450). A STOpCaP meta-analysis identified 
seven RCTs evaluating bisphosphonates in mCSPC and showed that when PR05 was 
excluded there was no evidence of benefit and specifically, there was no evidence that ZA 
improved OS (HR 0.94; 0.83-1.07; p=0.323)22.  
 
Bisphosphonate use  
Current guidance recommends ZA is considered for men with metastatic prostate cancer at 
high risk of SREs, although  NICE guidance states use should be restricted to symptomatic 
groups in whom other treatments, including analgesics and palliative radiotherapy have 
failed114,115. The recent demonstration that a 12-weekly schedule is non-inferior to 4-weekly 
is expected to support the cost-effectiveness argument and mean that this continues to be 
a useful adjunct in the management of metastatic disease116,117. Guidance for use in other 
tumour sites varies,  reflecting the varying strength of evidence of benefit110. When seeking 
to contextualise the celecoxib-ZA results, studies evaluating cox-2 inhibitors as treatments 
for metastatic breast, prostate or NSCLC were considered suitable for inclusion. The 
rationale being that bisphosphonates were introduced in these indications during the time 
period in which cox-2 inhibitors were under evaluation within clinical trials.  
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Bisphosphonates were recommended for use in patients with metastatic breast cancer as 
early as 1999118.  This was based on accumulating evidence published between 1993 and 
1998 demonstrating they were beneficial adjuncts to chemotherapy, prolonging the time to 
first SRE and reducing the number overall119. In 2000, the American Association of Clinical 
Oncology (ASCO) guidance recommended bisphosphonates may be used in addition to SOC 
for women symptomatic from metastatic bone disease based on the evidence they reduced 
SREs120.  
The introduction of bisphosphonates as part of the SOC treatment for NSCLC was later. In 
2003, ZA was shown to reduce the risk of SREs by 31% (HR 0.693; p=0.003) in a placebo-
controlled RCT of 773 patients, including 224 with NSCLC121. This led to both the American 
and European Society of Medical Oncology (ESMO) guidance supporting use from 2008 and 
2009 respectively122,123. It is therefore anticipated that a proportion of NSCLC trials 
identified may have permitted bisphosphonate use as part of protocol therapy so be able to 
provide data relevant to contextualising the celecoxib-ZA combination. 
In summary, the evaluation of both celecoxib and ZA was supported by pre-clinical, 
epidemiological and clinical data. STAMPEDE aimed to assess the impact on OS of adding 
both, alone or in combination, in the setting of high-risk M0 or mCSPC . The rationale for 
the combination was that the differing proposed mechanisms of action may be 
complementary and deserved evaluation as a novel combined approach. Results show that 
the treatment combination was well tolerated with no excess in cardiovascular toxicity 
when celecoxib was given for the planned maximum duration of 1 year. This is further 
supported by the recently published meta-analysis which did not find evidence of increased 
cardiovascular risk associated with celecoxib103. Within the metastatic subgroup, the 
estimated treatment effect of celecoxib-ZA is clinically and statistically significant (HR 0.78; 
95%CI 0.62-0.98) and comparable with that shown for the addition of docetaxel (HR 0.76; 
95%CI 0.62-0.92), which has changed practice20,23,24. As a well-tolerated generic drug 
combination, this therapeutic strategy could be provided in both middle and high income 
countries and therefore has the potential to impact on global PCa outcomes. However 
importantly, in contrast to docetaxel, there is no known external clinical data supporting 
the activity of this combination. Additionally, the biological rationale for the observed 
selective and additive effect is poorly understood.  
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2.1.4 Research aims  
In this chapter I will aim to address the following research question and objectives:  
Research question 
 Can the STAMPEDE result demonstrating a clinically significant improvement in 
survival with the combination of celecoxib-ZA be supported by external clinical 
data?  
  
Objectives 
 To undertake a systematic review and meta-analysis of relevant clinical data  
 To explore pre-clinical data to generate hypotheses as to the therapeutic 
mechanism of  action that is selective to metastatic disease 
 
 
2.2 Methods  
Methods for this systematic review and meta-analysis were described in a prospectively 
registered protocol available online (PROSPERO registration: CRD42016041743), available 
via www.crd.york.ac.uk/prospero and in Appendix D. This review was conducted and 
reported in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) guidelines124.   
2.2.1 Search strategy 
Electronic searches of databases (Medline, Embase, and Cochrane Central Register of 
Controlled Trials), clinical trial registries (clinicaltrials.gov) and conference proceedings 
(ASCO and ESMO) were undertaken. All sources were searched from 1996 (when selective 
cox-2 inhibitors were first clinically evaluated) until 15-May-2017, except conference 
proceedings which were limited to 2004, when electronic records exist. For details refer to 
protocol in Appendix D. Bibliographies of full reports and review articles were searched in 
order to identify further potential eligible studies. All trials are summarised in Table 9. 
2.2.2 Outcomes 
The primary outcome was PFS defined as the time from randomisation to the first evidence 
of symptomatic or radiological progression or death. The secondary outcomes were OS, 
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defined as the time from randomisation to death from any cause; disease-free survival 
(DFS), defined as the length of time following completion of treatment during which there 
are no signs or symptoms of cancer recurrence and overall response rate (ORR), defined as 
the proportion of patients with documented partial (PR) or complete radiological (CR) 
response according to RECIST criteria125. Further secondary outcomes were cardiovascular 
outcomes, where available. Translational outcomes were also recorded to support 
discussion of potential therapeutic mechanisms of action.  
2.2.3 Study selection  
All identified studies were assessed for eligibility and where insufficient outcome data was 
available, additional data was requested from the authors. Where multiple publications had 
arisen from a single study the most recent was selected. Articles were grouped according to 
cancer histology and setting e.g. neo-adjuvant, adjuvant or metastatic.  
2.2.4 Eligibility criteria  
Phase II and III RCTs were eligible if evaluating selective cox-2 inhibitors as cancer therapies. 
All trials were required to be controlled with the comparator group receiving SOC or 
placebo. Cox-2 inhibitors could be given alone or in combination with additional research 
treatments, or the current SOC. Searches were conducted with no restriction on language 
however data extraction relied on sufficient information in English. All identified studies 
evaluating cox-2 inhibitors as treatments for metastatic cancer, containing sufficient 
outcome data for PFS, OS or RR were eligible for inclusion in the meta-analysis. Exclusion 
criteria included trials evaluating unselective cox-2 inhibitors e.g. aspirin; primary 
chemopreventive trials, or trials with active control arms e.g. cox-2 inhibitor vs. cox-2 
inhibitor + experimental agent.  
Modified eligibility criteria  
As initial searches failed to identify any RCTs evaluating the combination of a cox-2 inhibitor 
and bisphosphonates, the eligibility criteria were broadened by removing the 
bisphosphonate search terms to include RCT evaluating cox-2 inhibitors. In order to seek 
relevant data to contextualise the results of the STAMEPDE, meta-analyses were limited to 
metastatic solid organ cancers, with the primary focus of interest being cancers where bone 
metastases are common and bisphosphonates may have been given; prostate, NSCLC and 
breast cancer.  
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2.2.5 Data items and collection  
The following data items were extracted using a standardised pre-designed format from all 
eligible studies:  
1. Trial design - including phase, number of treatment arms, comparator, outcomes 
2. Trial conduct - including accrual target and period, participating countries and 
where trials terminated early, the reason for discontinuation. 
3. Participants’ details - including cancer type and treatment setting 
4. Intervention -  specific cox-2 inhibitor, dose and duration  
5. Outcomes – included PFS, OS, RR, cardiovascular and translational outcomes  
Methodological quality was assessed using the Cochrane Collaboration tool for assessing 
the risk of bias126. Information was extracted on the method of randomisation sequence 
generation, allocation concealment, blinding, completeness of outcome data and whether 
all outcomes were reported or available; results of this assessment are summarised in 
Figure 10- Figure 12. 
Additional data collection of bisphosphonate use 
Protocols for trials in metastatic NSCLC and breast cancer were searched for electronically, 
and requested from all corresponding authors to determine if bisphosphonates were 
allowed as protocol permitted SOC. Relevant clinical guidance was also reviewed.  
2.2.6 Statistical analysis  
I undertook all statistical analyses supported by the meta-analysis group at MRC CTU at 
UCL. HR and associated statistics (95% confidence interval, p value and sample size) were 
extracted from all study reports. Where unavailable, authors were contacted and if 
necessary, estimations were made from the Kaplan-Meier curves or other available 
summary statistics using published methods127-129. 
Where sufficient data were available PFS, OS or RR a meta-analysis was conducted in which 
HRs were combined across the trials using a fixed-effect model (Mantel-Haenzsel). The 
appropriateness of this model, which assumes no statistical heterogeneity, was assessed 
using the I² statistic and χ² test. In the case of significant heterogeneity, a random-effect 
model was used to assess the robustness of the results to the choice of model130. 
Probability values were two-sided, with p<0.05 considered statistically significant. Analyses 
were performed in Review Manager Version 5.3.    
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2.3 Results  
2.3.1 Study selection  
Initial searches failed to identify any other studies using the original search criteria that 
combined both cox-2 search terms and bisphosphonate search terms. All eligible studies 
were references to the STAMPEDE trial. There was no randomised data evaluating the 
combination in any other cancer setting, see  
Figure 8. 
 
Figure 8: PRISMA diagram  
Using the modified inclusion criteria 555 study reports were screened and 50 eligible 
studies identified, see Figure 9.  Reasons for exclusion included non-randomised design, 
pre-clinical studies and trials evaluating cox-2 inhibitors as chemopreventive agents or for 
symptom control. One study was excluded as it included an active control arm, another 
which enrolled patients with different types of cancer was excluded as it was not possible 
63 
 
to extract sufficient data for each type individually. 16/50 studies contained sufficient data 
for PFS, RR and/or OS. 
Figure 9: PRISMA diagram using modified search criteria  
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Table 9: Summary of trials identified   
Site   Total no 
 trials  
Split by disease setting Split by outcome 
Tr
an
sl
at
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n
al
 
o
u
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o
m
e
 o
n
ly
   Total no of 
trials in M1 
setting with 
efficacy data 
Notes 
N
e
o
-
ad
ju
va
n
t 
A
d
ju
va
n
t 
M
e
ta
st
at
ic
 
P
FS
 
O
S 
R
R
 
NSCLC 14 0 0 14 9 8 6 1 10 5 authors contacted  
Unpublished data provided for one study 
Breast 12 7 4 2 2 1 2 2 2 3 authors contacted, no response 
Prostate 4 2 1 1 1 1 0 2 1 All trials excluding STAMPEDE designed with PSA 
or pathological endpoints 
Colorectal 9 2 2 5 2 3 5 1 4 3 authors contacted  
Meta-analysis includes published and 
unpublished data available on clinicaltrials.gov 
HBP  2 0 0 2 0 0 0 0 0 Both trials in hepatocellular carcinoma 
Gastro-
oesophageal 
4 3 0 1 1 0 1 0 0 Only one article available in English  
Urothelial 3 2 1 0 0 0 0 1 0  
Gynae 2 0 0 2 1 1 0 0 1  
Key: NSCLC Non-small cell lung cancer, HBP Hepato-Pancreato-Biliary, Gynae Gynaecological, PFS progression free survival, OS overall survival, RR response rate, tumour 
types of interest highlighted by red shading  
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2.3.2 Study characteristics 
No trials evaluating cox-2 inhibitors in combination with bisphosphonates were identified.  
Therefore all trials identified using the modified search criteria (n=50) were evaluating cox-
2 inhibitors given alone, or in combination with SOC. The majority of eligible studies 
recruited patients with NSCLC (n=14), breast cancer (n=12) or CRC (n=9). STAMPEDE was 
the only identified trial in metastatic prostate cancer. Other tumour types included gastro-
oesophageal (n=4), hepatocellular carcinoma (n=2), urothelial (n=3) and gynaecological 
(n=2); see Table 9. 
Trial conduct 
All eligible trials were controlled; the comparator group receiving placebo (n = 25) or SOC, 
which included observation in adjuvant trials. All trials were conducted between 2000 and 
2016, with the majority of trials recruiting between 2002 and 2011. 13/50 trials closed early 
or failed to reach the target accrual including two trials which discontinued due to early 
concerns about toxicity.  
A neo-adjuvant study prior to radical prostatectomy reported by Flamiatos et al closed to 
recruitment following a post-operative MI occurring in a patient receiving celecoxib, see 
A1: Table 67: Summary of ineligible PCa trials131. Additionally, a factorial study in CRC 
reported by Kohne et al which compared capecitabine and irinotecan (CAPIRI) and 5-
fluorouracil/folinic acid/irinotecan (FOLFIRI), with a second randomisation between 
celecoxib or placebo, also closed early due to excess toxicity associated with CAPIRI. 
Increased neutropenic infection, thromboembolic events (predominantly pulmonary 
emboli) and diarrhoea were observed when CAPIRI was combined with placebo or 
celecoxib, see Table 13132.  
External safety data was cited in four trials that discontinued early, see Table 8 and Table 
1096,133-135. One trial in NSCLC closed due to poor accrual136 and the evaluation of rofecoxib 
in NSCLC was terminated following its withdrawal, see Table 10137.  
Disease setting  
In NSCLC all trials were in the metastatic setting, see Table 10 and Table 11.  In breast 
cancer, the majority of trials were in the neo-adjuvant setting with cox-2 inhibitors given 
prior to surgery and assessed using pathological response rate (pRR). Four were adjuvant 
trials assessing improvements in DFS, see Table 64 and Table 65 in Appendix A1. Only two 
breast cancer trials were in the metastatic setting of interest; see Table 12. Out of 9 CRC 
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trials, five were in metastatic disease, however as bone metastases are infrequent, this was 
not defined as a tumour site of interest, see Table 13. The remaining 4 CRC trials were split 
between neo-adjuvant and adjuvant settings; see Table 66 in Appendix A1. 3 out of 4 
studies in gastro-oesophageal cancer were in the neo-adjuvant setting, one enrolled 
patients with metastatic disease and only one study in gynaecological cancer included 
patients with metastatic disease. 
Treatment exposure  
The most common cox-2 treatment was celecoxib (44/50 studies); rofecoxib was given in 4 
studies, whilst two evaluated etorcoxib or apricoxib. Treatment exposure varied by tumour 
site, disease setting and was shortened due to premature trial closure in 6 studies96,133-
135,137. The most frequent per-protocol dose of celecoxib was 400mg BD.  
Metastatic CRC: In all trials cox-2 inhibitor treatment was planned to be given until 
progression however 2/4 trials terminated early limiting treatment exposure, see Table 13.  
Metastatic NSCLC: In 4/14 trials the maximum duration of cox-2 treatment was capped at 
between 1 to 3 years. In the GECO trial, rofecoxib was evaluated in metastatic NSCLC 
however exposure was curtailed when the drug withdrawn137. Of the 118 patient treated 
with rofecoxib, the median treatment duration was 14 weeks (0-64), 33 patients received 
treatment for more than 6 months and only one received >1 year137.   
Breast cancer: The majority of trials were in the neo-adjuvant setting or adjuvant setting 
and the typical treatment duration was 3-6 months or 2 years respectively. In the largest 
study in advanced breast cancer the treatment exposure was limited following trial 
termination after 127 of the planned 342 were enrolled. At this point 85 patients were still 
receiving treatment, all of whom were stopped, limiting the median duration of treatment 
to 5.8 months133. In PCa the planned neo-adjuvant treatment duration was between 4-6 
weeks and the maximum treatment duration in the adjuvant or metastatic setting was 
capped at 1 year, a change prompted by external safety data.   
Outcomes  
In total, sufficient PFS data was obtained for 16 studies. When limiting to the trials in the 
metastatic tumour sites of interest, this includes 9 studies in NSCLC (1894 participants) and 
2 studies in breast cancer (257 participants). OS data were available for 14 studies; 8 
studies in metastatic NSCLC (1824 participants). In total, ORR data was available in 6 
studies, including 7 in metastatic NSCLC (1512 participants) and 2 in metastatic breast 
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cancer (234 participants). Although of less relevance due to the lack of frequent bone 
metastases, sufficient data for PFS, OS and ORR was obtainable for 298, 515 and 683 
participants respectively with metastatic CRC through the meta-analyses of 4 studies.  
Cardiovascular data was only reported in two trials. The only trial to suggest increased 
toxicity was reported by Groen et al. which randomised 561 patients with metastatic NSCLC 
to SOC chemotherapy with celecoxib or placebo. A greater absolute number of 
cardiovascular events were observed in celecoxib-treated patients; events included 
pulmonary embolism, pericardial effusion, atrial fibrillation, hypertension and an arterial 
thrombus. It should be noted that numbers were small (6 versus 3) and this difference was 
not statistically significant (p=0.50)138.  A second trial closed early due to increased toxicity 
reported by Fuchs et al attributed to CAPIRI chemotherapy, which was being compared 
with FOLFIRI, with celecoxib or placebo in a factorial design. 7 treatment-exacerbated 
deaths occurred, however importantly this excess toxicity was attributed to the 
chemotherapy regime (CAPIRI). 4 fatal events occurred in patients receiving CAPIRI+ 
placebo, and 2 in CAPIRI + celecoxib, with 2 in FOLFIRI and celecoxib. The reported 
treatment related toxicities were gastrointestinal, neutropenic infections or 
thromboembolic events. These resulted in recruitment being halted after 85 of the planned 
629 patients were accrued132. 
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Table 10: Summary of eligible NSCLC trials -1 
Key: CYCLUS, CY-cyclooxygenase-2 inhibitor; Chemotherapy, LUng cancer, Survival; GECO, GEmcitabine-COxib in NSCLC; NVALT, Nederlandse Vereniging van Artsen voor 
Longziekten en Tuberculose; NR, Not reported; NK, Not known.  
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Lilenbaum et 
al. 2006
136
   
 
Metastatic   
2nd line 
Full USA 2002 
to 
2003 
133 
(432) 
Phase II  
Factorial 
SOC chemo vs. non-
standard chemo  
+/- cox-2 inhibitor 
Celecoxib 400mg BD 
until progression 
  NR  Discontinued 
due to poor 
accrual 
De Ruysscher 
et al.2007
139
  
 
Locally 
advanced/ 
metastatic  
Full  Holland 2003 to 
2004 
42 
(102) 
Phase II SOC RT + cox-2 
inhibitor  
SOC RT + placebo   
 
Celecoxib 400mg BD 
until progression or 
max 2yrs 
   Yes Did not reach 
target accrual 
Gridelli et al. 
2007 
GECO
137
  
Metastatic 
1st line   
Full Italy  2003 to 
2004 
400 
(229) 
Phase III 
Factorial 
SOC chemo vs. non-
standard chemo  
+/- cox-2 inhibitor 
Rofecoxib 50mg OD 
until progression 
    Cox-2 
comparisons 
terminated 
early  
Zhou et al.  
2007
140
 
Metastatic   
1st line 
Abs China NK 65  
(NK) 
Phase II 
 
SOC chemo +cox-2 
inhibitor 
SOC chemo  
Celecoxib 400mg BD  NR NR NR  Completed  
Insufficient 
data 
Koch et al.  
2011  
CYCLUS
141
 
Metastatic   
1st line 
Full Sweden 2003 
to 
2006 
316 
(760) 
Phase III  
 
SOC chemo +cox-2 
inhibitor 
SOC chemo +placebo 
Celecoxib 400mg BD 
until progression or 
max 1yrs 
    Completed, 
failed to reach 
target accrual  
Groen et al. 
2011 
NVALT-4
138
 
Metastatic  
1
st
 line   
Full Holland 2003 to 
2007 
561 
(NK)  
Phase III SOC chemo + cox-2 
inhibitor 
SOC chemo +placebo 
Celecoxib 400mg BD 
until progression or 
max 3yrs 
    Completed 
 
CYC 
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Table 11: Summary of eligible NSCLC trials -2  
Key: NR, Not reported   
P
u
b
lic
at
io
n
 
Se
tt
in
g 
  
A
rt
ic
le
 t
yp
e
 
Accrual Trial design Treatment Outcomes Trial status 
C
o
u
n
tr
y 
D
at
e
 
To
ta
l a
cc
ru
al
 
(t
ar
ge
t)
 
P
h
as
e
 
Comparison Cox-2 dose & 
duration 
P
FS
 
O
S 
R
R
 
N
o
n
-
p
u
b
lis
h
e
d
 
d
at
a 
 
Gitlitz et 
al. 
2014
142
 
Metastatic   
1st line 
Full USA NK 120 
(NK) 
Phase II Erlotinib + cox-2 
inhibitor 
Erlotinib + placebo  
Apricoxib 400mg 
OD 
     Completed 
Reckamp 
et al. 
2015
143
 
 
Metastatic 
2
nd
 line  
Full USA 2007 to 
2011 
107 
(NK) 
Phase II Erlotinib +  cox-2 
inhibitor 
Erlotinib + placebo  
Celecoxib 600mg 
BD given until 
progression or max 
1year 
    Completed  
Edelman 
et al. 
2015
144
 
 
Metastatic 
2
nd
 line 
Full USA  UK 72 
(NK) 
Phase II  SOC Chemo +  cox-2 
inhibitor 
SOC Chemo   
Apricoxib 400mg 
OD 
 NR NR  Completed  
 
Edelman 
et 
al.2017
145
 
Metastatic  
1
st
 line  
Full USA 2010-
2013 
312 
(322) 
Phase II  SOC Chemo +  cox-2 
inhibitor 
SOC Chemo + placebo 
Celecoxib 400mg 
BD until 
progression 
  NR Pre-
publication 
data 
provided  
Completed  
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Table 12: Summary of eligible metastatic breast cancer trials  
Key: NR, Not reported 
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Dirix et al. 
2008
146
 
Metastatic  Full Multi-
national 
2002 111  
(100) 
Phase II  Exemestane 
Exemestane + cox-2 
inhibitor 
Celecoxib 400mg BD 
 
 NR  Yes: no 
addition
al data 
Completed  
Falandry 
et al.2009 
GINECO 
study  
 
Metastatic  
 
Full France 2003 to 
2004 
157  
(342) 
Phase III Aromatase inhibitor  
+ placebo 
Aromatase inhibitor 
+ cox-2 inhibitor  
Celecoxib 400mg BD    NR  Yes: no 
response 
Terminated 
early 
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Table 13: Summary of trials in metastatic colorectal cancer  
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Jin et 
al.2011
147
 
Metastatic  Full China 2005 to 
2008 
90  Phase II SOC Chemo + cox-2  
SOC Chemo  
Celecoxib 
400mg for min 
8 weeks 
NR NR    
Fuchs et 
al.2007
134
 
Metastatic 
1
st
 line 
Registry 
results 
summary 
only  
 
North 
America & 
Australasia  
2003 to 
2004 
430 Factorial 
phase III 
1
st
 randomisation 
Chemo 1  
Chemo 2  
Chemo 3 
2
nd
 randomisation 
cox-2  
placebo 
Celecoxib 
400mg BD 
   Yes: no 
response  
Terminated 
early due to 
external 
safety 
concerns 
Kohne et 
al.2008
132
 
Metastatic  Full EORTC 
group 
2003 to 
2004 
85 
(6290) 
Factorial 
phase III 
1
st
 randomisation 
Chemo 1  
Chemo 2  
2
nd
 randomisation 
cox-2  
placebo 
Celecoxib 
400mg BD 
   Yes: no 
response 
Terminated 
early 
 
Maiello et 
al.2006 
GOIM
148
  
Locally 
advanced or 
metastatic 
Full Italy 2003 to 
2004 
81 Phase II SOC chemo + cox-2 
SOC chemo 
Celecoxib 
400mg BD 
NR NR  Yes: no 
response 
Completed 
Key: TTP, Time to progression; PFS, progression free survival; OS, overall survival; RR, response rate; NR, Not reported. 
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2.3.3 Risk of bias  
The risk of bias within studies was evaluated using the Cochrane assessment tool and the 
consensus assessment is summarised in Figure 10-Figure 12. 
NSCLC  
The overall assessment of the nine NSCLC study reports was that there was a low risk of 
bias; however three potential sources were identified, judged likely to affect a total of four 
trials. The two unblinded trials were vulnerable to detection bias in outcomes of PFS and 
ORR, both relying upon investigator assessment with neither study reporting centralised or 
blinded review136,137. The CYCLUS (CY-cyclooxygenase-2 inhibitor, Chemotherapy, LUng 
cancer) reported by Koch et al excluded three ineligible patients from the efficacy analysis 
however the impact of potential attrition was judged to be small in a randomised 
population of 312 patients141. One trial were found to be at risk of selection bias due to 
inadequate detail of sequence generation and allocation concealment and baseline 
characteristics appear slightly imbalanced, reported by De Ruysscher et al. 139.  
Breast cancer 
Both studies are judged to be at potential risk of attrition and detection bias. Although 
balanced by group, Direx et al .report only 100/111 (90%) of randomised patients were 
assessable for RR and TTP, exclusion reasons included failure to start treatment and 
treatment duration of <4 weeks146. In addition, the lack of blinding risks performance and 
detection bias in a trial where the primary endpoint was rate of clinical benefit based on 
radiological assessment, which although based on RECIST, was not otherwise blinded to 
treatment allocation. Despite terminating early, the second trial reported by Falandry et al. 
was judged to have less risk of bias, apart from potential attrition bias for ORR as only 85% 
were assessable for this outcome133.  
Colorectal cancer  
All four studies are judged to be at some risk of bias; 3 studies are open label and therefore 
at risk of performance and detection bias of RR which was based on unblinded investigator 
assessment132,147,148. One study report was limited to information available on 
clinicaltrials.gov which lacks detail on randomisation and baseline characteristics meaning 
the risk of selection bias is unclear. In the same study, the higher number of withdrawals on 
the placebo arm and lack of detail on blinding means the risk of potential performance bias 
is also uncertain134.  
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Figure 10: Cochrane risk of bias summary (NSCLC trials)  
 
Key 
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Figure 11: Cochrane risk of bias summary (Breast cancer trials)  
 
 
Figure 12: Cochrane risk of bias summary (CRC trials)  
 
 
Key 
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2.3.4 Additional data on bisphosphonate use 
Additional data regarding bisphosphonate use was sought for all studies in metastatic 
NSCLC and breast cancer. It was possible to contact 10 out of 11 authors and 6 responded 
see Table 14- Table 16. Overall, bisphosphonate use is judged unlikely in 3 trials, possible in 
5 trials (all of which recruited in the USA, reflecting local guidance confirmed by two 
authors) and unknown in 2 trials. Two authors confirmed Dutch practice at the time would 
not have included bisphosphonates. Few trials collected data on concomitant medications; 
however the GECO trial team confirmed bisphosphonates were not listed for any of their 
participants. Neither author was able to provide additional details for the two breast cancer 
trials. Where it was recommended, clinical guidance suggested bisphosphonates were 
considered for symptomatic patients only; therefore overall it appears bisphosphonate use 
was uncommon.  
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Table 14: Bisphosphonate use in NSCLC trials -1 
Key: n/a, Not Applicable; NK, Not Known. 
 
Study Setting Country Accrual 
period 
Contacted  Responded Response details Relevant Clinical 
Guidance  
Bisphosphate Co-
administration  
Lilenbaum et al. 
2006
136
   
 
Metastatic   
2nd line 
USA 2002 to 
2003 
  Bisphosphonates may have been 
used according to clinical guidance 
at the time; concurrent use not 
collected by the trial  
Recommended in 
ASCO guidance since 
2003 
Possible 
De Ruysscher et 
al.2007
139
  
 
Locally 
advanced/ 
metastatic 
Stage II-III 
Holland 2003 to 
2004 
  Confirmed bisphosphonates not 
used as SOC at the time 
 Not used  
Gridelli et al. 
2007 
GECO
137
  
Metastatic 
1st line   
Italy  2003 to 
2004 
  Whilst permitted by the protocol, 
trial statistician confirmed not 
recorded as a supportive 
medication for any trial 
participants therefore unlikely  
Recommended in 
ESMO guidance since 
2009 
Unlikely  
Zhou et al.  
2007
140
 
Metastatic   
1st line 
China NK X n/a n/a NK Unknown  
Koch et al.  
2011  
CYCLUS
141
 
Metastatic   
1st line 
Sweden 2003 to 
2006 
 X n/a  Unknown  
Groen et al. 
2011 
NVALT-4
138
 
Metastatic  
1st line   
Holland 2003 to 
2007 
  Confirmed bisphosphonates not 
used as SOC at the time 
 Not used  
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Table 15: Bisphosphonate use in metastatic NSCLC trials -2  
Key: n/a, Not Applicable; NK, Not Known. 
 
Table 16: Bisphosphonate use in metastatic breast cancer  
Study Setting Country Accrual 
period 
Contacted  Responded Response details Relevant Clinical 
Guidance  
Bisphosphate Co-
administration 
Gitlitz et al. 
2014
142
 
Metastatic   
1st line 
USA 2002 to 
2003 
 X n/a 
 
 
Recommended in 
ASCO guidance since 
2003 
 
 
Possible 
Reckamp et al. 
2015
143
 
 
Metastatic 
2
nd
 line  
USA 2003 to 
2004 
  Confirmed, allowed as part of SOC  Likely 
Edelman et al. 
2015
144
 
 
Metastatic 
2
nd
 line 
USA 2003 to 
2004 
 X n/a Possible 
Edelman et 
al.2017
145
 
 
Metastatic  
1
st
 line  
USA NK  X n/a Possible 
Study Setting Country Accrual period Contacted  Responded Response details Bisphosphate Co-
administration 
Dirix et al. 
2008
146
 
Metastatic 
breast cancer   
Multi-
national 
2002   No further data available Possible 
Falandry et al.2009
133
 
GINECO study  
 
Metastatic  
Breast cancer  
France 2003 to 
2004 
 X  Likely 
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2.3.5 Synthesis of results  
Sufficient data was obtained to undertake a meta-analysis two disease settings, metastatic 
NSCLC and metastatic breast cancer, using the outcomes PFS, OS and ORR.  
NSCLC  
Overall, the addition of a cox-2 inhibitor did not significantly improve PFS in metastatic 
NSCLC (HR 0.97, CI 0.87-1.09). This is based on data extracted from 9 trials (1895 patients), 
representing 86% of all those randomised to the eligible trials identified. This is 96% of 
randomised patients with locally advanced or metastatic disease; the disease setting of 
most relevance to contextualising the STAMPEDE data and where PFS is a valid endpoint. 
All studies evaluated cox-2 inhibitors in addition to SOC however therapeutic regimes 
varied, including different chemotherapies or tyrosine kinase inhibitor e.g. erlotinib. Studies 
also differed in treatment setting and disease stage (locally advanced and/or metastatic), 
however despite this, was no evidence of significant statistical heterogeneity between trials 
(I2 0%; p=0.62). 
8 trials assessed OS, compromising 1584 patients, equivalent to 72% of all randomised 
patients. There is no evidence that cox-2 inhibitors improve OS (HR 0.98, CI 0.88 – 1.10) and 
again heterogeneity was not detected (I2 0%; p=0.77). ORR was reported in 7 trials 
comprising 1366 patients which represents 62% of all those randomised. On this outcome 
alone, where HR>1.0 favour the experimental group, the addition of celecoxib is shown to 
be beneficial (HR 1.32, CI 1.05-1.66). Heterogeneity remains low, justifying the 
appropriateness of the fixed effect model (I2 =15%; p=0.02); see Figure 13 - Figure 15. 
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Figure 13: PFS outcome in metastatic NSCLC (primary outcome)  
 
 
Figure 14: OS outcome in metastatic NSCLC (secondary outcome)  
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Figure 15: ORR outcome in metastatic NSCLC (secondary outcome) 
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Breast cancer 
Sufficient data was only available for two studies in metastatic breast cancer, compromising 
268 patients133,146. No benefit in PFS was observed (HR 0.98; 95% CI 0.76- 1.26) or ORR (HR 
1.21; 95% CI 0.65-2.25). There was insufficient data to undertake a meta-analysis of OS. No 
statistical heterogeneity was detected for either PFS (I2=0%; p=0.85) or ORR ((I2=0%; 
p=0.55), see Figure 16 and Figure 17. Both authors were contacted but no additional 
information was provided therefore the use of bisphosphonates is unclear. 
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Figure 16: PFS outcome in metastatic breast cancer (primary outcome)  
 
 
 
Figure 17: ORR in metastatic breast cancer (secondary outcome)  
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Colorectal cancer  
Sufficient data was available to permit meta-analysis of metastatic CRC studies, however 
this is the least relevant as metastatic bone involvement is rare132,134. No PFS benefit was 
shown in the two studies where this outcome was assessed, compromising 515 patients 
(HR 1.04; CI 0.85-1.26). The same RCT assessed OS and similarly no benefit is seen (HR 1.05; 
CI 0.84-1.31). No significant heterogeneity was detected between these two studies. Data 
from all four studies was obtained for ORR (683 patients) and results demonstrate no 
benefit (HR 0.65; 0.48-0.88) however there was variation detected (I2=89%; p=0.005). When 
the random effects model was applied the result remains consistent, favouring control over 
experimental groups (HR 0.49; CI 0.14-1.66)132,134,147,148, see Figure 18 - Figure 20. 
Prostate and other cancer types 
There were no additional eligible trials identified other than STAMPEDE therefore it was not 
possible to undertake a meta-analysis. There were also insufficient data to warrant meta-
analysis of other outcomes in other cancer types.  
 
Spacer 
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Figure 18: PFS in metastatic CRC (primary outcome)  
 
 
Figure 19: OS in metastatic CRC (secondary outcome)  
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Figure 20: ORR in metastatic CRC (secondary outcome)  
 
 
  
86 
 
2.3.6 Review of additional translational analyses  
Two RCTs assessed cox-2 overexpression as a predictive and prognostic biomarker in 
metastatic NSCLC however evidence remains inconclusive. In a retrospective analysis of the 
NVALT-4 study cohort, cox-2 expression was shown to be prognostic of PFS and OS in a 
univariate, but not multivariate analysis. Analyses of predictive effect were inconclusive and 
likely underpowered as suitable tissue was only available for 167 (31%)138. The CALGB 
30801 study reported by Edelman et al. 2017 evaluated apricoxib in advanced NSCLC 
enriched for cox-2 overexpression; randomisation was stratified by cox-2 index but again, 
concluded no evidence of predictive or prognostic effect for either the dichotomised or 
continuous variable145.  
A second approach to biomarker stratification to predict sensitivity to cox-2 inhibition is 
through measuring the major urinary metabolite of PGE2 (PGE-M) which, when raised may 
be considered a measure of cox-2 activity. Non-randomised phase II data suggests a large 
PGE-M decline in patients receiving cox-2 inhibitors may predict therapeutic sensitivity and 
has been shown to associate with improved survival149. This has been evaluated in two 
RCTs; the first randomised 109 patients; 89 provided urinary samples for additional analysis 
with the largest PFS improvement observed in those with high baseline urinary PGE-M. In 
the unselected population the median PFS improved from 3.5 to 5.4 months (HR 0.82; 
p=0.33); in the subgroup with high baseline urinary PGE-M this was prolonged from 2.2 
months to 5.4 months (HR 0.67; p=0.15)143. The second RCT (APRiCOT-L) evaluated this as a 
tool for biomarker-selection, restricting eligibility to those patients exhibiting >50% decline 
in urinary PGE-M assessed following a run-in period of 5 days apricoxib treatment, however 
the trial failed to show a benefit for the cox-2 containing experimental arm142.  
Trials evaluating translational outcomes can help elucidate therapeutic mechanisms of 
action, however when studied in relatively small trials, results have been inconsistent. Two 
neo-adjuvant trials in breast cancer assessed pre and post-treatment cancer tissue and 
evaluated gene expression and Ki-67 status, as a marker of cellular proliferation. Gene 
expression data (n=37) demonstrate upregulation of genes functionally involved in 
extracellular matrix organisation, wound response, cell adhesion and biological adhesion 
together with receptor activator of nuclear factor kappa-Β (RANK) signalling150. The impact 
on proliferation-associated genes was reflected in a significant reduction in Ki-67 in 
celecoxib-treated cases whilst the recruitment of tumour-infiltrating leukocytes to cancer 
tissue also supports the functional significance of the gene expression data. However the 
87 
 
second study (n=120) found no significant change in Ki-67 observed between the celecoxib 
and placebo groups, despite a longer duration of neo-adjuvant treatment (6 weeks).  
Two PCa trials reported translational outcomes, but neither study elucidated a therapeutic 
mechanism of action for celecoxib given alone in the neo-adjuvant setting. In a randomised 
cohort of 64 men, celecoxib was not shown to be associated with significant changes in any 
of the biomarkers of proliferation, apoptosis or angiogenesis after 4-6 weeks of neo-
adjuvant treatment. Tissue penetration also appeared poor, the mean concentration of 
celecoxib within prostate tissue was 0.16umol/L; approximately 50 times lower than 
maximal plasma concentrations151. In a second study of a similar design, examination of 
prostatectomy samples revealed no statistically significant difference in markers of 
apoptosis or prostaglandin levels; although this study is limited due to low accrual (28 of 
planned 44 patients) as the trial closed early due to safety concerns131.  
Translational data in other cancer types is limited to two studies in metastatic CRC and 
urothelial cancer. In a placebo-controlled RCT of 44 patients undergoing liver resection for 
metastatic colorectal pre-operative rofecoxib was shown to reduce microvascular density 
but had no significant impact on markers of apoptosis or proliferation as determined by 
immunohistochemistry (IHC)152. The only study to evidence a biological correlate for 
therapeutic benefit was a small placebo-controlled RCT (n=26) with high-grade invasive 
transitional cell carcinoma (TCC). Pre-operative celecoxib was associated with increased 
apoptosis and decreased tumour cell expression of Vascular endothelial growth factor 
(VEGF) consistent with anti-cancer effects of 2-3 weeks neo-adjuvant therapy153.  
 
2.3.7 Ongoing trials of interest  
Several ongoing trials were identified registered on www.clinicaltrials.gov including four 
trials evaluating the combination of cox-2 inhibitors with immunomodulatory agents, 
summarised in Table 17. 
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Table 17: Ongoing trials of cox-2 inhibitors and immunomodulatory agents  
Trial ID  Patient Group Treatment  Outcomes Sample size and trial status 
NCT02268825 
 
 
Advanced 
metastatic GI 
cancers 
Pembrolizumab + 
FOLFOX6 + 
Celecoxib  
Safety  Design: Phase I 
Accrual: 39 (target NK) 
Status: In follow-up  
Timelines: Est completion 
Jan- 2020 
NCT02615574 
 
Metastatic CRC  Type-1 Polarized 
dendritic cell 
(aDC1)  
+ interferon-a2b  
+ rintatolimod  
+ celecoxib 
 
OS 
 
 
Design: Single arm phase II 
Accrual: 44 (target NK) 
Status: Not yet open  
 
NCT03026140 
(NICHE Trial)  
Neo-adjuvant 
treatment for 
localised CRC 
Nivolumab + 
Ipiliumab  
 
Nivolumab + 
Ipiliumab + 
celecoxib  
Safety & Toxicity  
 
Secondary: 
Translational, 
relapse-free 
survival  
Design: Randomised phase II 
Accrual: Ongoing  (target 60) 
Open: Feb-2017 
Status: Recruiting  
NCT01545141 Neo-adjuvant 
treatment for 
advanced  CRC 
suitable for 
surgery  
 Celecoxib + 
rintatolimod 
 
(control: 
observation)  
Change in tumour 
infiltrating CD8+ 
cells 
Design: Randomised phase I/II 
Accrual: Ongoing  (target 50) 
Status: Recruiting 
Timelines: Est completion 
Dec-2020 
NCT02432378 Recurrent 
ovarian cancer, 
palliative 
Cisplatin + 
Celecoxib + 
Dendritic cell 
vaccine 
Change in tumour 
infiltrating CD8+ 
cells in peritoneal 
fluid  
Design: Randomised phase I/II 
Accrual: Ongoing  (target 40) 
Status: Recruiting 
Timelines: Est completion 
Dec-2020 
Summarised from www.clinicaltrials.gov who define completion as completion of data collection for 
the primary outcome i.e. last patient last visit.
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2.4 Discussion  
2.4.1 Summary of evidence 
These analyses have not found any supporting clinical data for the findings of the celecoxib-
ZA comparison evaluated within STAMPEDE. No other trials were identified investigating 
the combination of a cox-2 inhibitor with a bisphosphonate, even in extended searches 
including non-randomised trials. Data in PCa is very limited; STAMPEDE is the only RCT to 
have evaluated cox-2 inhibitors in mCSPC. Two trials identified in overlapping populations 
both terminated early, emphasising the impact of initial concerns regarding toxicity, which 
have since been shown not to be relevant to celecoxib. Therefore relevant clinical data is 
restricted to metastatic NSCLC or breast cancer as pre-defined disease settings of interest 
due to the predominance of bone involvement.  
The addition of cox-2 inhibitors are not shown to benefit either indication. The level of 
evidence is greatest in metastatic NSCLC where data capture was high, the risk of bias was 
judged to be low and the treatment exposure was least affected by trial termination. Whilst 
no benefit is seen in PFS or OS, meta-analysis of the secondary outcome ORR is consistent 
with benefit and it is notable that results from the only trial confirmed to permit 
bisphosphonate treatment as part of per-protocol SOC, are suggestive of benefit143.  
Sufficient data was also identified to permit analyses in metastatic CRC. If, as hypothesised, 
the selective beneficial effect observed in the STAMPEDE data is due to synergy of 
bisphosphonates and a cox-2 inhibitor in the presence of metastatic bone involvement, we 
would not expect to observe benefit in CRC where bone involvement is rare and 
bisphosphonates are not used. No effect is seen on PFS, ORR or OS, with the consistency in 
effect with survival outcomes reassuring given the risk of bias identified in the three 
unblinded trials which relied upon investigator assessment of progression and response. 
Whilst this finding is therefore consistent with the hypothesis, the absence of benefit may 
also reflect the limited treatment exposure. Trials in CRC were most frequently terminated 
early, likely reflecting that evidence suggesting increased cardiovascular risk arose in CRC 
prevention trials.  
The impact of cardiovascular toxicity concerns has been considerable. It has limited the 
acquisition of clinical data through curtailing recruitment, shortening treatment durations, 
increasing attrition bias through lack of reported survival data and increasing the risk of 
trials remaining unreported. Only 1 of the 9 terminated trials was evaluating rofecoxib, all 
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of the remaining were investigating celecoxib, reflecting that the cardiovascular toxicities 
were considered a class effect at the time, although this has been recently been 
disproved103.  
2.4.2 Limitations 
The limitations of this meta-analysis include the uncertainty surrounding bisphosphonate 
use. Despite efforts to review study protocols including contacting authors, given the length 
of time since the trials were conducted, data remains incomplete. Based on the knowledge 
available, concurrent use of bisphosphonates appears uncommon. This limits the relevance 
of these data, but does not undermine the rationale for the original systematic review.  
The planned focus was on trials in metastatic cancer, specifically including tumour types 
where metastatic bone involvement is frequent. However, the trial populations were 
heterogeneous and often grouped as locally advanced and metastatic disease, rarely giving 
exact proportions of patients with metastatic bone involvement; again limiting the known 
relevance of each trial cohort. Trials evaluating cox-2 inhibitors are at risk of having 
remained unpublished following the withdrawal of rofecoxib as investigators/sponsors may 
have deprioritised dissemination of results taking the view that safety concerns would 
prevent results impacting on practice. I have sought to limit the impact of this reporting 
bias by including review of clinical trial registries. However as highlighted by the two 
unpublished studies, registry data is more restricted and may be insufficient to permit 
further meta-analyses.   
A further limitation is that cox-2 inhibitor treatment duration was limited in the majority of 
studies. Insufficient data is available to permit further analyses but pre-clinical data 
suggests the effect of cox-2 inhibitors to be dose dependent so shortened treatment 
durations may reduce the ability of individual trials or meta-analyses to reliably evaluate 
clinical response154.  
2.4.3 Exploring potential therapeutic mechanisms of action  
Through inclusion of trials with translational outcomes or biomarker-defined sub-analyses, I 
sought to develop a better understanding of the celecoxib-ZA results.  Several studies have 
sought to evaluate Cox-2 expression as a putative biomarker but neither prognostic or 
predictive effects have consistently been shown138,144,145. Furthermore, the lack of 
correlation between Cox-2 overexpression and urinary PGE-M undermines the functional 
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relevance of these proposed biomarkers of prostaglandin synthesis144,155. Of the two 
approaches, there is more supportive data for the measurement PGE-M, a urinary 
metabolite of PGE2. Two trials have evaluated raised urinary PGE-M as a biomarker 
predictive of sensitivity to cox-2 inhibitors. However  in both, apricoxib was given in 
addition to erlotinib but prior to the routine assessment of epidermal growth factor 
receptor (EGFR) status, which was only measured for 79% and 29% respectively. As the 
proportion of EGFR mutant patients on the control and experimental arm is not known this 
represents an important potential confounder. The APRiCOT-L trial evaluated decline in 
urinary PGEM hypothesised to identify a population of patients with advanced NSCLC 
sensitive to cox-2 inhibitors144. Results failed to show any survival benefit for the addition of 
apricoxib, however this enrichment strategy may have been undermined by uncertainly as 
to the most suitable cut-off value142,149. Therefore, neither cox-2 expression or urinary PGE 
appear to have clear clinical utility or provide explanation for the heterogeneity observed 
by metastatic status. 
One hypothesis, suggested by recent pre-clinical data is that the combination of celecoxib-
ZA interact to promote an anti-cancer immunological effect with the metastatic tumour 
microenvironment. Prostaglandin E2 has an immunological function, facilitating Th1 cell 
differentiation. Therefore, through inhibiting PGE2, celecoxib promotes a Th1-cytokine 
response, characterised by interferon-gamma (IFN-γ) and interleukin-2 (IL2) release156,157. 
ZA inhibits enzymes in the mevalonate pathway of lipid synthesis, promoting the 
accumulation of isopentenyl pyrophosphate (IPP), an intermediary in this pathway and a 
stimulator of a specific subset of regulatory T cells, γ𝛿 T cells158,159. This T cell subpopulation 
can be activated by non-MHC (major histocompatibility complex) restricted antigen 
presentation. This enables tumour cells to act as antigen presenting cells promoting an 
adaptive anti-cancer effect, whilst  γ𝛿 T cells toll-like receptors (TLR) mean an innate 
response can also be triggered160. This, together with their high cytokine production ability 
is proposed to explain the anti-cancer effect of γ𝛿 T cells, observed in vitro and in vivo. 
However, clinical evidence of anti-cancer effects of γ𝛿 T cells has been contradictory with 
response rates ranging between 20% and 57%. This may be explained by the in vitro 
observation that different subtypes of γ𝛿 T cells have both pro and anti-cancer effects161.  
Recent data have highlighted the importance of the cytokine balance and 
microenvironment in determining γ𝛿 T subtype differentiation, leading to the speculation 
that this could be the mechanism by which celecoxib and ZA interact.  In support of this, in 
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an in vivo model of wound healing, celecoxib has been shown to reduce the production of 
interleukin-17 (IL-17), recognised to be an important trigger of immunosuppression and 
differentiation to the pro-cancerous γ𝛿 T subtype (δ1 γδ T cells)162,163. Furthermore, the 
selective effect in men with metastatic disease supports a therapeutic interaction with 
tumour microenvironment. Therefore, when celecoxib triggered Th1-priming and cytokine 
release is combined with IPP stimulated γ𝛿 T cell function, it is speculated that this 
treatment combination may promote this T cell subset to differentiate to have anti-cancer 
potential within the context of the metastatic microenvironment. All cox-2 inhibitors are 
likely capable of some degree of immuno-modulation. Paracoxib has been shown to 
ameliorate the immunosuppressive post-operative changes with reduced elevations in IL-2, 
IFY-y and IL-17 and suppression of interleukin-4 (IL-4), interleukin 10 (IL-10) and TGF-B164. It 
is noted that consistent with this a number of novel combination trials have been 
registered including several assessing the combination of celecoxib with immuno-
modulatory agents, see Table 17. 
2.4.4 Future work  
Future work should aim to provide mechanistic data that can strengthen the STAMPEDE 
results and support further clinical evaluation. The immunological hypothesis presented 
could be tested within a small randomised phase II trial with a parallel translational study 
examining gamma delta T cell isolated from sampling peripheral mononuclear blood cells 
(PMBCs). Future clinical evaluation should aim to both validate the STAMPEDE result and 
ensure it can be applied within the current treatment paradigm. Having been shown to be a 
well-tolerated treatment, celecoxib-ZA may be considered as alternative to the addition of 
docetaxel. However, once accessible abiraterone is likely to become the standard-of-care 
for a large proportion of those not offered chemotherapy. A MAMS approach could 
efficiently acquire confirmatory data whilst concurrently obtaining updated data 
incorporating abiraterone. This could be addressed within STAMPEDE through the addition 
of 4 new arms, allowing two separate comparisons (shown as 1a and 1b in Figure 21). This 
design can be modelled based on the FFS effect size shown in the celecoxib-zoledronic acid 
M1 sub-group (HR 0.77) and median FFS observed in the M1 sub-group in the abiraterone 
comparison. The celecoxib-ZA comparison would reach the interim FFS analysis first and 
continued recruitment to the much longer, larger and more costly abiraterone containing 
comparison would be dependent on this result being consistent with the original 
STAMPEDE result.  As well as ensuring these data are relevant to the current SOC, this 
approach may have additional patient benefit. For example the addition of a 
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bisphosphonate may reduce the fracture risk associated with prolonged androgen 
deprivation and exacerbated by abiraterone and prednisolone.   
Figure 21: Proposed MAMS trial design to further evaluate celecoxib + ZA 
 
Men with metastatic CSPC not suitable or who decline docetaxel would be eligible to be randomised 
1:1:1:1. The original STAMPEDE comparison would be replicated with the co-recruitment to a longer 
abiraterone containing comparison being dependent on a similar FFS signal being shown. 
 
Key: Abi, abiraterone; ADT, androgen deprivation therapy; FFS, failure free survival; pred, 
prednisolone; OS, overall survival; SOC, standard-of-care; M1, metastatic; ZA zoledronic acid.  
 
 
2.5 Conclusions 
The results of these analyses have been unable to identify external clinical data reporting 
similar activity for the combination of cox-2 inhibitor and bisphosphonate.  Further clinical 
evaluation of this treatment strategy is warranted given the degree of clinical benefit. The 
treatment combination was well tolerated and a recent meta-analysis has confirmed that 
celecoxib does not confer increased cardiovascular risk, so this should not be perceived as a 
barrier to further evaluation. Future clinical trials should focus on patients with metastatic 
disease with bone involvement. Through parallel translational programmes the potential 
biological hypotheses for synergy such as immunomodulation and impact on the metastatic 
niche, particularly at the site of bone metastases, could be explored. Only through 
improved understanding of the mechanism of treatment heterogeneity will it be possible to 
determine the scope of patient benefit, which may yet be shown to be relevant to other 
metastatic disease settings.  
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Chapter 3 Prostate-specific antigen kinetics as prognostic 
biomarkers  
3.1 Introduction  
PSA is an enzyme and a member of the kallikrein-related peptidase family165.  Clinically, it 
has been used since the 1980's having been shown to have a role in the detection, risk-
stratification and monitoring of prostate cancer166. PSA is secreted by epithelial cells within 
the prostate gland and functions to liquefy the seminal fluid167. In health, PSA is retained 
within the prostate gland and blood levels remain low. Prostatic disease, both benign and 
malignant, can cause a rise a circulatory levels, with the highest levels seen in prostate 
cancer, thought to be due to a disruption of the tissue architecture166. The promoter region 
of kallikrein-3 (KLK3), the gene encoding PSA, is androgen responsive meaning PSA 
transcription is androgen dependent165. Therefore ADT initially causes a rapid PSA decline 
due to both tumour regression and suppression of PSA transcription167. The clinical utility of 
PSA as a marker of disease burden is therefore greatest in the castrate-sensitive setting 
when AR-dependent pathways are the predominant drivers of disease168.  
The relationship between early PSA response and OS will be explored as a potential on 
treatment biomarker that may provide early indication of risk, able to guide the use the 
intensified treatment strategies for mCSPC. PSA response will be defined as the 
proportionate change, expressed as a percentage of the baseline value, consistent with the 
Prostate Cancer Working Group (PCWG) criteria169.  Previous analyses conducted in small 
mCSPC cohorts (n=57, 73) have demonstrated large PSA responses to ADT; 80% of patients 
experience a PSA response of >80% and around half will have a PSA response of >90%170,171. 
Retrospective analyses have shown that the magnitude of PSA response positively 
correlates with time to progression to CRPC170-172. Conversely, persistent PSA elevation 3 
months after initiating ADT is associated with rapid progression171. The majority of these 
analyses are small with relatively short follow-up so lack power to detect survival 
difference, instead relying on time to treatment failure, often measured by PSA change. 
However as the definition of PSA progression is linked to PSA response, OS is judged the 
most robust outcome to determine prognostic impact. To date, the only setting where PSA 
response has been shown to associate with survival differences is mCRPC. Early PSA 
responses assessed 4 weeks after initiating abiraterone or enzalutamide have been shown 
to associate with OS and rPFS in multivariable models adjusted for other known prognostic 
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factors173-177. Analysis within STAMPEDE provides an opportunity to assess this in a large, 
sufficiently powered mCSPC cohort with mature OS data. 
It is hypothesised that the prognostic value of PSA may be greatest in the castrate-sensitive 
setting. This is suggested by the assessment of surrogacy of PSA outcomes in mCRPC. On 
treatment prognostic biomarkers may be evaluated as surrogate endpoints, able to provide 
an early indication of treatment effect. The Prentice criteria requires the surrogate to be in 
the causal disease pathway and to capture the net treatment effect178. Abiraterone, an AR-
targeted treatment, exerts an anti-cancer effect via a PSA-dependent pathway, supporting 
the evaluation of PSA kinetics as potential surrogates of response. In a statistical modelling 
analysis that pooled data from COU-301 and COU-302, two phase III trials of abiraterone in 
mCRPC post and pre-chemotherapy respectively, measures of PSA kinetics were used to 
construct a model shown to be predictive of survival173. For chemo-naïve patients, the 
effect of abiraterone on survival was no longer significant having adjusted for PSA kinetics 
fulfilling the Prentice criteria. The value of PSA outcomes was shown to be less in more 
advanced mCRPC, consistent with the molecular data demonstrating the progressive 
involvement of aberrant-AR and non-AR pathways 179.  For example, in an adjusted analysis, 
maximum PSA decline (%) was significantly associated with treatment effect in chemo-
naïve patients; HR 1.38 (95% CI 1.08-1.75) p=0.01, but not chemotherapy pre-treated 
patients, HR 1.09 (95%CI 0.92-1.31) p=0.30173. Together, these data suggest that PSA 
outcomes are likely to best capture treatment effects in early disease, when PSA-
dependent pathways are the most dominant drivers of disease progression and support the 
evaluation of PSA kinetics as prognostic biomarkers in the castrate-sensitive setting.  
Absolute PSA levels obtained several months post-treatment have been shown to be 
prognostic in mCSPC treated with ADT+/- docetaxel in two secondary analyses within 
clinical trial cohorts180,181. Hussain et al. reported that absolute PSA assessed after a 
minimum of 7 months ADT was inversely associated with overall survival. The SWOG 9346 
trial assessed whether survival is equivalent with intermittent versus continuous ADT. Men 
with mCSPC with a presenting PSA of ≥5ng/ml were eligible for registration prior to 
commencing ADT. Late registration was permissible in those who had commenced ADT 
within the previous ≤6 months (~30% of those registered). Following 7 months induction 
ADT those achieving a PSA ≤4ng/mL were eligible for randomisation to intermittent or 
continuous treatment. All registered participants were followed up for survival (n=1345). In 
a multivariable risk model that included performance status, Gleason score, bone pain and 
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PSA at study entry, patients with a PSA ≤4ng/ml but >0.2ng/ml at completion of induction 
were at less than one third the risk of death of those with a PSA>4ng/mL (HR 0.30; 0.24-
0.38; p<0.0001). Comparative median survival times were 44 months and 13 months 
respectively. However, patients with a PSA <0.2ng/ml were shown to have the best 
prognosis, with less than one fifth the risk of death of those with a PSA>4ng/ml (HR 0.17; 
0.13-0.21; p<0.0001) and median survival 75 months181, see Table 18. 
Absolute PSA has also been shown to be prognostic of OS in a similar secondary landmark 
analysis of the CHAARTED trial180. This trial randomised 790 men with mCSPC to receive 
ADT or ADT+docetaxel. 719 patients were eligible for this analysis; inclusion criteria 
included PSA measurement 7 months post starting ADT and sufficient follow-up data to at 
least this point. In a multivariable model, adjusting for treatment allocation, absolute PSA 
level was shown to be prognostic and results were highly consistent with those observed in 
the SWOG 9347 registrational cohort who were treated with ADT alone. The investigators 
used three categories of PSA response: 7 month PSA level <4ng/ml but >0.2ng/ml was 
associated with a 67% reduction in risk of death compared with a PSA>4ng/ml (HR 0.33; 
0.23-0.47, p<0.001). However, the best prognosis was observed in the 7 month PSA 
<0.2ng/ml group; (HR 0.18; 0.12-0.28, p<0.001). A similar trend in unadjusted median 
survival times was observed within each treatment group (ADT alone n=361) and ADT + 
docetaxel (n=358), but the analysis lacked sufficient power required for a multivariable 
adjusted analysis by treatment group, see Table 18. 
Table 18: Summary of analyses of absolute PSA value within the CHAARTED and SWOG 
9346 clinical trials  
Landmark 
PSA value 
SWOG 9346181 CHAARTED180 
Treatment: ADT Treatment: ADT +/- docetaxel 
n Median OS  Adjusted 
HR (95% CI)  
n Median OS  Adjusted 
HR (95% CI)  
       
≤0.2ng/ml 602 
(45%) 
75 months  
(95% CI 62-91) 
HR 0.17  
(0.13-0.21) 
266 
(37%) 
60 months  
(95% CI 46-73) 
HR 0.18  
(0.12-0.28) 
>0.2 ≤4ng/ml 360 
(28%) 
44 months  
(95% CI 39-55) 
HR 0.30  
(0.24-0.38) 
214 
(30%)  
52 months  
(95% CI 40-69) 
HR 0.33  
(0.23-0.47)  
>4ng/ml 383 
(28%) 
13 months  
 (95% CI 11-16) 
 HR 1.0  
(reference) 
 
239 
(33%) 
22 months 
(95% CI 20-27) 
HR 1.0  
(reference) 
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As opposed to using a pre-specified ‘landmark reading’, PSA nadir (defined as the lowest 
PSA measurement on treatment) has also been proposed as an on treatment biomarker, 
and shown to be prognostic of survival in ADT-treated mCRPC. The best evidence for this 
comes from analyses of the STAMPEDE control group. The trial protocol requires PSA 
measurements 6 weekly until 6 months post randomisation, from which the nadir value is 
calculated, defined as the lowest value reported during this time period. In an analysis 
(n=917) of men with mCSPC allocated to receive ADT alone between 2005 and 2013, PSA 
nadir≥4ng/ml was associated with an increased risk of death compared with those 
achieving PSA nadir< 4ng/ml (HR 2.43; 1.85-3.19, p<0.001)182. This confirms the association 
previously demonstrated in smaller cohorts and retrospective reviews, where PSA nadir has 
been shown to be prognostic of improved PFS, with similar trends observed in 
survival172,183,184.  
As yet, PSA nadir defined in this way has not been examined in patients receiving the 
updated SOC, ADT + docetaxel. Given the observed variability in survival outcomes (see 
Table 3) there is a need to identify patients who remain at high-risk of poor survival 
outcomes despite docetaxel. PSA nadir is a potential on treatment biomarker that could 
reflect response to ADT+ docetaxel and provide prognostic information at a clinically 
meaningful landmark which correlates with docetaxel completion. This could be used to 
identify a population in whom to evaluate additional strategies within a clinical trial. In the 
future, should the combination of ADT + docetaxel + AR-targeted therapy be shown to be 
beneficial (currently under evaluation in several trials including PEACE-1 and ENZAMET, see 
Table 1, this potential biomarker could be used to risk-stratify and identify a population in 
whom the additional toxicity and costs may be justified.   
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3.1.1 Research aims  
In this chapter I will address the following: 
Research questions 
 Is the magnitude of PSA response prognostic of OS? 
 Is PSA nadir assessed following completion of docetaxel prognostic of OS? 
 
Hypotheses  
 A large PSA response may identify a good prognostic hormone-sensitive subgroup 
in whom the toxicities of additional treatments may be avoided 
 A high PSA nadir assessed following completion of docetaxel may identify a high-
risk subgroup in whom additional therapies should be evaluated 
 
3.2 Methods 
Both research questions can be addressed through analyses of participants with metastatic 
disease at trial entry allocated to the STAMPEDE docetaxel-containing randomisations. In 
total, 1451 metastatic patients were randomised to the control group (arm A) or one of the 
docetaxel-containing treatment groups (arm C or arm E). As the addition of ZA to docetaxel 
did not impact on survival, patients allocated to either arm C or E will be combined20. This 
accounts for the allocation ratio (2:1:1:1:1:1) and means control and docetaxel groups are 
of equal size; 724 metastatic control (ADT alone) and 727 metastatic patients allocated to 
receive ADT + docetaxel, see Figure 4 for an overview of research arms. This analysis will 
focus on the patients with metastatic disease as the population of interest in this thesis. 
STAMPEDE also recruits high-risk M0 however, as absolute PSA level may reflect disease 
burden separate analyses of PSA-outcomes would be required in this disease setting as 
prognostic PSA thresholds may differ. 
A data release request was approved by the STAMPEDE Trial Management Group (TMG) 
and Trial Steering Committee (TSC) allowing access to the published dataset used for 
primary analysis of the docetaxel-containing comparisons, see Appendix E. This includes 
data collected from participants randomised between October 2005 and March 2013 
allocated to control or research arm C or E. The data were frozen on May 13th 2015. 
Baseline data included patient demographics, disease stage, metastatic distribution, date of 
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diagnosis and date of randomisation were provided, in addition to all PSA values obtained 
according to the protocol until 24 weeks post randomisation (6, 12, 24 weeks and the 
calculated nadir value). Outcome data for both OS and FFS were also obtained.  
3.2.1 Outcome measures 
The trial protocol defines OS as the time from randomisation to death from any cause and 
FFS as the time from randomisation to evidence of at least one of the following: 
biochemical failure, disease progression, or death from PCa. The protocol definition of 
biochemical failure is a relative assessment made between the pre-treatment PSA and PSA 
nadir. Biochemical failure is defined as immediate (PSA nadir >50% the pre-treatment PSA), 
or when the PSA reaches >50% above the nadir, or if the nadir value is <4ng/ml, when the 
PSA reaches >50% nadir and is above 4ng/ml, whichever is greater. As FFS is predominantly 
driven by biochemical failure, OS is preferred over FFS as the outcome for prognostic 
analyses of PSA kinetics, as the latter is confounded due to the definition of FFS being 
linked to pre-treatment and nadir PSA values; see Figure 22.  
Figure 22: STAMPEDE trial definition of biochemical failure (illustrative examples) 
 
PSA outcome definitions: 
 PSA response is defined for the purposes of this analysis as the percentage fall in 
PSA from the pre-treatment value to the first post-ADT value obtained by the 
protocol (6-weeks post randomisation).  
PSA response (%) = (pre-treatment PSA-week 6 PSA/ pre-treatment PSA) x 100 
100 
 
 PSA nadir is as defined by the STAMPEDE protocol, the lowest PSA value reported 
in the first 24 weeks post randomisation.  
 
3.2.2 Statistical approach 
I undertook all statistical analyses supported by Matthew Nankivell and Matthew Sydes, 
statisticians at the MRC CTU at UCL. Analyses were performed using Stata version 15.0 
(StataCorp LP, College Station, TX, USA) using standard survival-analysis methods; Kaplan-
Meier estimates were used to produce survival curves. In all analyses multivariable models 
for both outcomes OS and FFS were built to include all pre-defined subgroups, including all 
those shown to be prognostic in a cohort analysis of the STAMPEDE control arm182. A p 
value was calculated using the likelihood ratio to assess the impact of the variable in the 
survival model. All baseline characteristics that were statistically significant at the 5% level 
were included in the multivariable model. The PSA outcome measures were added to each 
separate baseline model for OS and FFS outcomes in an adjusted Cox regression analysis.  
3.2.2.1 Analysis of PSA response  
Population of interest 
Initially, I planned to assess PSA response shortly after commencing ADT in patients 
randomised to the control and docetaxel-treated groups in order to explore if the 
magnitude of benefit from chemotherapy differed according to PSA response. 
Unfortunately, a lack of comparable PSA data prevented this from being possible as the 
STAMPEDE protocol does not collect PSA at the time of randomisation; the 6-week post 
randomisation value is the first post ADT PSA value collected. The vast majority of 
participants allocated to receive docetaxel had commenced treatment prior to this 
landmark; the median time to starting was 2.4 (IQR 1.4-3.7) weeks and by 6-weeks, over 
50% had received 2 cycles. Therefore the impact of PSA response was explored separately 
in the groups allocated to receive ADT alone (control) and ADT+docetaxel, with the latter 
being of primary relevance to the main hypothesis. In addition, the following two criteria 
were required to be eligible for inclusion:  
 Metastatic disease at randomisation  
 PSA data available pre-treatment and 6-weeks post randomisation to permit 
calculation of PSA response 
101 
 
Survival analyses   
For the analysis of PSA response a landmark approach was used at 6-weeks post 
randomisation, from which both time-to-event outcomes were timed, reflecting the time 
point at which PSA response was assessed. The distribution of PSA response was assessed 
in the eligible population and the impact of the categorised variable explored in a 
multivariable Cox model to allow the calculation of an adjusted HR incorporating all other 
prognostic factors that remained statistically significant at the 5% level. 
Exploring PSA response threshold values  
A threshold value that identifies a good prognostic subgroup in patients who have been 
exposed to ADT was sought. Calculation of a concordance index (c-index) was used to 
measure the predictive discrimination of each threshold value. The c-index estimates the 
probability of concordance between predicted and observed responses, calculated by 
considering all pairs of patients where at least one has experienced the event (in this case 
death). Where the predicted survival time is longer for the patient with a longer observed 
survival time the pair are judged concordant and vice versa. A value 1.0 is perfect 
discrimination whereas 0.5 indicates no predictive discrimination of patients with different 
outcomes. The Harrell-C index will be calculated and the threshold with the highest 
discriminating value used when categorising PSA response185,186.   
Sensitivity analyses   
A sensitivity analysis excluded patients with a low presenting PSA. The rationale was that 
those patients with metastatic disease who present with a low PSA may be considered not 
to have the biomarker of interest (PSA), impacting on the prognostic significance of a 
relative PSA change. The cut-off value of less than 15ng/ml was pre-specified as this was 
judged sufficiently atypical at presentation of metastatic disease.  
 
3.2.2.2 Analysis of PSA nadir  
Population of interest  
The population relevant to this analysis are those allocated to receive docetaxel in research 
arms C or E, limited to the per-protocol population. This excludes 12% who did not report 
starting docetaxel; reasons included treatment refusal, patient choice and trial 
withdrawal20. The population is limited to those who can still be described as castrate-
sensitive at 24-weeks post randomisation, the timing of the landmark analysis i.e. have not 
yet reported a FFS event (biochemical, radiological or clinical progression). The rationale 
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being that if progression to CRPC has already occurred additional treatment with any one of 
the multiple, licenced options currently available will likely be initiated reducing the need 
for an additional prognostic biomarker. Where there is current uncertainty and a greater 
need to risk-stratify is in the management of metastatic castrate-sensitive disease, the 
selected population of interest. Additionally, initiation of second-line treatment may affect 
the PSA nadir value which may no longer be considered reflective of response to first-line 
therapy. Therefore the selection criteria for this analysis can be summarised as: 
 Metastatic at randomisation 
 Allocated to a docetaxel-containing research arm (C or E)  
 Commenced docetaxel treatment (per-protocol population) 
 Sufficient PSA data to calculate nadir value  
 No reported FFS event prior to 24 weeks post randomisation   
Threshold values  
The distribution of PSA nadir was explored employing categorisation as previously 
described in the literature180-182. Additional threshold values were also explored and 
assessed visually through plotting Kaplan-Meier graphs. 
Survival analyses  
For the analysis of PSA nadir a landmark of 24 weeks post randomisation was used and all 
time-to-event outcomes were adjusted to account for this. Similarly, a multivariable model 
considering the same baseline factors was built for the primary outcome of OS. Prognostic 
significance was assessed using the likelihood ratio and results considered statistically 
significant at the 5% level. 
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3.3 Results  
3.3.1 Patient cohorts for analysis of PSA response 
The cohort selection is shown in Figure 23. Of 724 metastatic patients allocated to the 
control arm within the docetaxel comparison, 677 (94%) were eligible for inclusion in this 
analysis. 47 were excluded due to missing PSA data at 6-weeks. The median duration of 
ADT prior to the assessment of PSA response was 12.3 weeks (IQR 9.1-15.0). Comparison 
with the metastatic intention-to-treat population (ITT) revealed a similar distribution of 
baseline characteristics, suggesting the analysis population were representative, see Table 
19. The median follow-up for the analysis population was 29 months post landmark 
(6-weeks post randomisation). 
The impact of PSA response was explored separately in the docetaxel-treated cohort, see 
Figure 24. Of 727 metastatic patients allocated to receive ADT+docetaxel, 626 were eligible 
for inclusion (86% of ITT). 63 were excluded as docetaxel was never reportedly started, 
week-6 PSA was missing in a further 34 and duration of prior ADT was missing for one 
patient.  
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Figure 23: Patient selection for analysis of PSA response-1 
 
 
Patients with metastatic (M1) disease at trial entry who were allocated to receive ADT alone were included if week-6 PSA was 
recorded. To be comparable, patients with M1 disease allocated to receive docetaxel had be in the subsequent per-protocol 
population (i.e. commence treatment) but may not have started it by the landmark when early PSA response was to be assessed. 
Only 33 patients (5% of ITT) met these criteria, limiting this analysis to those allocated to receive ADT alone. 
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Figure 24: Patient selection for analysis of PSA response-2 
 
 
In a separate analysis, the impact of early PSA response was explored in the M1 patients allocated to receive docetaxel accepting 
that as docetaxel treatment had started in the majority, this population is not comparable with the ADT alone treated group. 636 
patients were eligible for this analysis; 34 were excluded due to missing week-6 PSA measurements and 63 did not report 
commencing docetaxel. Reasons for not starting included: refusal, trial withdrawal and clinician decision and in one case, disease 
progression.  
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Table 19: Comparative baseline characteristics in the PSA response cohort (ADT alone) 
Baseline 
characteristics 
Metastatic  ITT PSA response  ADT alone 
treated cohort 
Excluded 
 n=724  n=677  n=47   
Tumour stage  
≤T2 90 (12%) 85 (13%) 5 (11%) 
T3 404 (56%) 380 (56%) 24 (51%) 
T4 163 (23%) 154 (23%) 9 (19%) 
Tx 67 (9%) 58 (9%) 9 (19%) 
Nodal stage  
N0 242 (33%) 228 (34%) 14 (30%) 
N+ 416 (57%) 387 (57%) 29 (62%) 
Nx 66 (9%) 62 (9%) 4 (9%) 
Metastatic distribution  
Bone only  454 (63%) 428 (63%) 26 (55%) 
Distant nodes only 63 (9%) 56 (8%) 7 (15%) 
Bone & nodes or other   207 (29%) 193 (29%) 14 (30%) 
Gleason sum score 
≤ 7 156 (22%) 148 (22%) 8 (17%) 
≥ 8 476 (66%) 445 (66%) 31 (66%) 
Unknown  92 (13%) 84 (12%) 8 (17%) 
Age 
≤55  70 (10%) 9 (19%) 9 (19%) 
55-59  104 (14%) 8 (17%) 8 (17%) 
60-64 146 (20%) 11 (23%) 11 (23%) 
65-69 187 (26%) 6 (13%) 6 (13%) 
70-74 134 (19%) 10 (22%) 10 (21%) 
≥ 75 83 (11%) 3 (6%) 3 (6%) 
Performance status 
0 521 (72%) 495 (73%) 26 (55%) 
1 or 2 203 (28%) 182 (27%) 21 (45%) 
Presenting PSA  
(ng/ml) 
   
≤20 125 (17%) 116 (17%) 9 (19%) 
21-50  121 (17%) 112 (17%) 9 (19%) 
51-100  114 (16%) 108 (16%) 6 (13%) 
101-250 143 (20%) 140 (21%) 3 (6%) 
>250 221 (31%) 201 (30%) 20 (43%) 
Duration of ADT prior to 6-week assessment of PSA response  
≤6 weeks 44 (6%) 43 (6%) 1 (2%) 
≤10 weeks 196 (27%) 183 (27%) 13 (28%) 
≤14 weeks  238 (33%) 222 (33%) 16 (34%) 
≤18 weeks 239 (33%) 224 (33%) 15 (32%) 
≤20 weeks 6 (1%) 5 (1%) 1 (2%) 
>20 weeks 1 (0.1%)  0 (0%) 1 (2%) 
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3.3.2 PSA response in ADT alone group  
Distribution  
The median PSA response 6-weeks post randomisation, equivalent to 12.3 weeks (IQR 9.1-
15.0) post-initiation of ADT, was 97% (IQR 91-99%). A PSA response of >50% was reported 
in 95% of the cohort, whilst only 13% reported a PSA response of <80%. Failure to respond 
(6-week PSA value>pre-treatment value) was reported in 2 cases within the population with 
sufficient PSA data to be eligible for inclusion.  
Baseline survival model -1  
The prognostic significance of seven baseline characteristics was evaluated in a cox 
regression survival model: tumour and nodal stage, metastatic distribution, Gleason score, 
presenting PSA, age and performance status at randomisation and prior duration of ADT. 
These were selected based on the published literature demonstrating prognostic 
significance in an analysis with the M1 subgroup allocated to the STAMPEDE control arm 
(n=917)182. Models with and without each variable were compared using the likelihood-
ratio test. As shown in Table 21 metastatic distribution, Gleason sum score, baseline age, 
performance status were statistically significant at the 5% level.  
Baseline survival model -2  
As shown in Table 20, the groups defined by PSA response significantly differed in two 
ways, patients with a PSA response <80% were more likely to have a poorer baseline 
performance status and patients with a PSA response ≥99% had a lower absolute PSA value 
at the landmark (6-weeks post randomisation). Therefore a second survival model was 
fitted, in which presenting PSA was removed and week 6 PSA was considered instead. This 
is because the two variables were shown not to be independent of each other. In this 
second baseline model metastatic distribution, Gleason sum score, baseline age, 
performance status and week-6 PSA were shown to remain statistically significant, see 
Table 22. A separate model for FFS was fitted using the same approach. The same four 
prognostic characteristics remained statistically significant, see Appendix A3: Table 68. 
Defining groups based on identified threshold value 
The c-stat was calculated aiming to split the group into three categories defined by PSA 
response. The lowest threshold was set and the c-stat was calculated for a range of upper 
values, adjusting for the baseline characteristics within the baseline survival model (2), see 
Graph 1. Concordance was highest when PSA response was categorised as low (<80%) 
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moderate (90-99%) and high ≥99%. The impact of setting different lower thresholds was 
explored; see A2: Figure 38 - A2: Figure 40.    
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Table 20: Baseline characteristics by PSA response category 
 
  
  PSA response 
≥99% 
PSA response 
80 -98% 
PSA response 
<80% 
P* 
 n=188 (28%) n=398 (59%) n=91 (13%)  
Tumour stage   
≤T2 27 (14%) 45 (11%) 13 (14%) 0.3811 
T3 91 (48%) 241 (61%) 48 (58%) 
T4 49 (26%) 84 (21%) 21 (23%) 
Tx 21 (11%) 28 (7%) 9 (10%) 
Nodal stage   
N0 70 (37%) 129 (32%) 29 (32%) 0.7488 
N+ 98 (52%) 236 (59%) 53 (58%) 
Nx 20 (11%) 33 (8%) 9 (10%) 
Metastatic distribution   
Bone only  128 (68%) 240 (60%) 60 (66%) 0.2728 
Distant nodes only 10 (5%) 40 (10%) 6 (7%) 
Bone & nodes or 
other   
50 (27%) 118 (30%) 25 (27%) 
Gleason sum score  
≤ 7 49 (26%) 83 (21%) 16 (18%) 0.9290 
≥ 8 108 (57%) 271 (68%) 66 (73%) 
Unknown  31 (16%) 44 (11%) 9 (10%) 
Age   
≤55 14 (7%) 32 (8%) 15 (16%) 0.1683 
55-59 20 (11%) 64 (16%) 12 (13%) 
60-64 36 (19%) 86 (22%) 13 (14%) 
65-69* 58 (31%) 98 (25%) 25 (27%) 
70-74 33 (18%) 76 (19%) 15 (16%) 
≥75 27 (14%) 42 (11%) 11 (12%) 
Performance status  
0  141 (75%) 299 (75%) 55 (60%) 0.0137 
1 or 2 47 (25%) 99 (25%) 36 (40%) 
Duration of ADT prior to week-6 assessment of PSA response   
≤6 weeks 8 (4%) 29 (7%) 6 (7%) 0.3255 
≤10 weeks 50 (27%) 111 (28%) 22 (24%) 
≤14 weeks *** 62 (33%) 130 (33%) 30 (33%) 
≤18 weeks 65 (35%) 127 (32%) 32 (35%) 
≤20 weeks 3 (2%) 1 (0.3%) 1 (1%) 
PSA at landmark (6-weeks post randomisation)  
<0.5 ng/ml 77 (41%) 37 (9%) 1 (1%) 0.0001 
≥0.5 to <2.5 ng/ml 70 (37%) 153 (38%) 5 (5%) 
≥2.5 to <10 ng/ml 27 (14%) 111 (28%) 16 (18%) 
≥10 to <50  ng/ml 13 (7%) 62 (16%) 28 (31%) 
≥50  ng/ml 1 (0.5%) 35 (9%) 41 (45%) 
* Kruskal Wallis test of difference by group; bold indicates result statistically significant at 5% level  
* Contains median age in all groups (65 years if PSA response ≥99% or <80%, 66 years if PSA 80-90%)  
** Median value prior ADT 12 weeks  
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Table 21: Baseline multivariable OS model for PSA response analysis (model 1)   
Characteristic  Overall survival 
  Category description n Events 
  
Multivariable  p-value* 
T stage  ≤T2 85 32 0.90 (0.61-1.32)   
  
  
0.5569 
T3 380 176 1.0 
T4 154 74 1.10 (0.84-1.45) 
Tx 58 35 1.24 (0.85-1.83) 
Nodal stage  N0 228 100 1.0   
  
0.8475 
N+ 387 184 1.09 (0.82-1.44) 
Nx 62 33 1.04 (0.70-1.59) 
Metastatic 
distribution  
Bone only  428 205 3.01 (1.64-5.54)   
  
<0.0001 Distant nodal only  56 11 1.0 
Bone & nodal or other  193 101 3.47 (1.85- 6.52) 
Gleason sum 
score  
≤ 7 148 51 1.0   
  
0.0005 
≥ 8 445 217 1.95 (1.43-2.68) 
Unknown  84 49 1.93 (1.25- 2.97) 
Age  ≤55  61 38 2.15 (1.45-3.19)   
  
  
  
  
0.0002 
55-59  96 56 1.56 (1.10-2.21) 
60-64 135 65 1.08 (0.77-1.51) 
65-69** 181 78 1.0 
70-74 124 44 0.81 (0.55-1.17) 
≥ 75 80 36 1.11 (0.74-1.65) 
Performance 
status   
0 495 207 1.0   
<0.0001 1 or 2 182 110 1.88 (1.49-2.38) 
Duration of 
prior ADT 
(weeks)  
Continuous  - - 0.99 (0.96-1.02)  0.5538 
Ln presenting 
PSA 
Continuous - - 1.01 (0.95-1.08) 0.7168 
*For variable in overall survival model, statistically significant at 5% level shown in bold 
** Median age 65 years  
 
  
111 
 
Table 22: Baseline multivariable OS model for PSA response analysis (model 2)   
Characteristic Overall survival  
  Category 
description 
n Events 
  
Multivariable  p-value* 
 
Tumour stage  ≤T2 85 32 0.96 (0.64-1.41)   
  
  
0.8945 
T3 380 176 1.0 
T4 154 74 1.06 (0.81-1.39) 
Tx 58 35 1.13 (0.77-1.66) 
Nodal stage  N0 228 100 1.0   
  
0.8673 
N+ 387 184 1.07 (0.81-1.41) 
Nx 62 33 0.98 (0.66-1.46) 
Metastatic 
distribution  
Bone only  428 205 2.98 (1.62- 5.49)   
  
<0.0001 
Distant nodal only  56 11 1.0 
Bone & nodal or 
other  
193 101 3.10 (1.65- 5.83) 
Gleason sum 
score  
≤ 7 148 51 1.0   
  
0.0003 
≥ 8 445 217 1.83 (1.34-2.51) 
Unknown  84 49 1.44 (0.96- 2.18) 
Age  ≤55  61 38 1.65 (1.11-2.46)   
  
  
  
  
0.0125 
55-59  96 56 1.40 (0.99-2.00) 
60-64 135 65 1.10 (0.80-1.53) 
65-69** 181 78 1.0 
70-74 124 44 0.78 (0.53-1.13) 
≥ 75 80 36 1.19 (0.80-1.78) 
Performance 
status 
0 495 207 1.0   
<0.0001 1 or 2 182 110 1.75 (1.38-2.21) 
Duration of 
prior ADT 
(weeks)  
Continuous  - - 0.99 (0.96-1.02)  0.4482 
Ln week 6 
PSA***  
Continuous - - 1.24 (1.17-1.32) <0.0001 
*For variable in overall survival model, statistically significant at 5% level shown in bold 
** Median age 65 years  
*** Natural logarithmic transformation  
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Graph 1: PSA response threshold value in ADT alone group (concordance statistic)  
 
Harroll’s C-statistic was calculated for a range of threshold values and the highest predictive 
discriminatory value was observed for PSA response ≥99% (marker). This calculation was made using 
a lower threshold value of <80% which was observed to result in the highest level of concordance for 
the upper value. See Appendix A for calculations using alternative lower thresholds 85% and 90%.   
 
 
3.3.3 Impact of PSA response on overall survival  
The magnitude of PSA response was shown to be associated with improved OS (p<0.0001). 
When categorised, a PSA response ≥99% was associated with a reduced risk of death, with 
73% 3 year survival compared with 61% if the PSA response was 80-98% and 23% if the PSA 
response <80%, see Graph 2. In the multivariable analysis this remained statistically 
significant using model 1, adjusting for metastatic distribution, baseline performance 
status, age and Gleason score; see Table 23. However, when absolute PSA was also 
adjusted for in model 2, the additional prognostic effect of PSA response was less, 
consistent with both the relative change and absolute PSA value being clinically significant, 
see Table 24.  
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Graph 2: Overall survival by PSA response in ADT alone group  
 
 
 
Table 23: Summary survival statistics (model-1) 
 
 
 
 
 
  *HR adjusted for metastatic distribution, baseline performance status, age and Gleason score. 
 
 
Table 24: Summary survival statistics (model-2)  
PSA response   n Events  *Adjusted HR  
(95%CI) 
Median OS 
(m) (95% CI) 
3yr OS   P value  
≥99% 188 69 0.66 (0.50-0.88) 58 (46-66) 73% <0.0001 
80-98% 398 180 1.0 (reference)  45 (40-54) 61% 
<80% 91 68 2.94 (2.20-3.93) 21 (14-23)  23% 
 
 
 
 
 
PSA response   n Events  *Adjusted HR  
(95%CI) 
Median OS 
(m) (95% CI) 
3yr OS   P value  
≥99% 188 69 0.79 (0.59-1.07) 58 (46-66) 73% <0.0001 
80-98% 398 180 1.0 (reference)  45 (40-54) 61% 
<80% 91 68 2.23 (1.61-3.08) 21 (14-23)  23% 
 
  
* HR adjusted for metastatic distribution, Gleason score, baseline age and performances status 
and absolute PSA at landmark (week-6 PSA). Median OS and survival rates timed from landmark 
6-weeks after randomisation which equates to 12 weeks (median) post initiation of ADT 
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Sensitivity analysis  
Consistency of effect was observed in the sensitivity analysis in which 12% of patients 
presenting with metastatic disease and PSA <15ng/ml were excluded. Results show patients 
with a PSA response of ≥99% have improved 3 year survival rates compared with those with 
moderate or low PSA responses. However, in the multivariable analysis the estimated 
prognostic improvements is less, and when adjusted for absolute PSA value this is not 
statistically different to the moderate PSA response group; HR 0.83; (95% CI 0.60-1.15) 
p<0.0015, see Graph 3 and Table 25. As shown in Table 26, as anticipated, those with a low 
presenting PSA are less likely to experience a large PSA response, therefore the sensitivity 
analysis proportionately excludes most patients from the PSA response <80% category.  
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Graph 3: Overall survival by PSA response group in sensitivity population  
 
Table 25: Summary of PSA response and survival outcome in sensitivity analysis  
PSA response n Events  Adjusted HR*  
(95% CI) 
Median OS (m) 
(95%CI) 
3yr OS  P value 
≥99% 179 67 0.83 (0.60-1.15) 55 (46-66) 73% 0.0015 
80-98% 345 160 1.0 (reference)  42 (39-53) 61% 
<80% 75 55 1.92 (1.33-2.77) 20 (14-23)  20% 
* Adjusted for metastatic distribution, baseline performance status, age, Gleason score and absolute 
PSA at landmark (week-6 PSA) 
 
 
 
Table 26: Comparative population included in sensitivity analysis   
PSA response Primary analysis Sensitivity analysis Proportion excluded 
(% primary analysis population) 
≥99% 188 179 9(5%) 
80-98% 398 345 53 (13%) 
<80% 91 75 16 (18%) 
Totals  677 599 78 (12%) 
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3.3.4 Impact of PSA response on failure-free survival in ADT alone group  
In a multivariable model adjusted for metastatic distribution, Gleason score, week-6 PSA 
and age and performance status, PSA response was shown to be prognostic of FFS 
(p<0.0024). 2-year FFS was 60%, 49% and 24% if the PSA response was ≥99%, 80-98% or 
<80% respectively. 
Graph 4: Failure free survival by PSA response category 
 
Table 27: Summary of PSA response and failure-free survival  
 
*HR adjusted for metastatic distribution, week-6 PSA, and baseline age and performance status. 
Median FFS timed from landmark (6-weeks post randomisation)   
 
 
PSA response  n Events *Adjusted HR (95%CI) Median FFS (m) 
(95% CI) 
2 yr 
FFS  
 P 
value 
≥99% 188 132 HR 0.81 (0.60-1.10) NR (40 - NR) 60% 0.0024 
80-98% 398 327 HR 1.0 (reference) 21 (13 - 40) 49% 
<80% 91 86 HR 1.85 (1.28-2.67) 3 (2 - 8) 24% 
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3.3.5 Impact of PSA response in ADT+docetaxel treated group  
Distribution  
The median PSA response 6-weeks post randomisation was 98% (IQR 94-.0 – 99.5%). The 
median absolute value was 1.6ng/ml (IQR 0.4-6.2ng/ml). Only eight patients had not 
experienced a PSA response. The Kruskal-Wallis test showed that both PSA response 
(p=0.0001) and absolute week-6 PSA (p=0.0001) were statistically significantly different 
between ADT alone and ADT+docetaxel treatment groups.  
Table 28: Comparative PSA distribution by treatment group   
 ADT alone ADT+docetaxel p value  
 
PSA response (%)  97% (91.1-99.1) 98.1 (IQR 94-.0 – 99.5) 0.0001 
Absolute PSA at 
landmark (ng/ml) 
2.4 (0.7-11) 1.6 (IQR 0.4-6.2) 0.0001 
*Kruskal-Wallis test of difference, statistical significant values at 5% shown in bold  
 
 
Baseline survival model  
A baseline survival model was constructed and metastatic distribution, nodal stage, 
Gleason sum score, duration of prior ADT, week-6 PSA and performance stage at 
randomisation were all statistically significant at the 5% level, so included in the 
multivariable analysis, see A4: Table 69. 
Threshold value  
The observed relationship between PSA response and OS was different when compared 
with the ADT alone treated group. In a multivariable cox-regression model the concordance 
indices for a range of threshold PSA response values was consistently lower with the 
highest observed value around 67.5%, see Graph 5. 
Taken together these results suggest the impact of docetaxel treatment had impacted PSA; 
the predictive discrimination value of this outcome is less, with no clear threshold value 
shown to have potential clinical utility. Therefore further analyses were not conducted.  
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Graph 5: PSA response threshold value in ADT+docetaxel group (concordance statistic)  
 
  Harroll’s C-statistic was calculated for a range of threshold values. The highest predictive 
discriminatory value was only 67.5%, this is less than observed in the ADT alone treated group 
(78%) suggesting the prognostic impact of PSA response assessed at this time point is less in 
patients treated with ADT+docetaxel.  
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3.4 Patient cohort for analysis of PSA nadir assessed following completion 
of docetaxel  
612 of the 727 (84%) metastatic ITT population allocated to receive docetaxel were eligible 
for inclusion in this analysis, see Figure 25. The most common reason for exclusion was not 
commencing docetaxel; 9% of metastatic patients did not report starting. Other reasons foe 
exclusion included a reported FFS event (i.e. PSA, symptomatic or radiological disease 
progression) prior to 24-weeks landmark. Only one additional case was excluded due to 
insufficient PSA data.  
As shown in Table 29, the population excluded from the analysis had a slightly different 
metastatic distribution and more patients with a poor performance status, however 
otherwise the analysis population were comparable with the ITT population.  All but one 
patient had completed docetaxel by 24-weeks post randomisation; 89% received ≥5 of the 
6 planned cycles. Toxicity was the most frequent reason for early treatment stopping (71%).  
3.4.1 Comparative baseline characteristics by PSA nadir category   
The clinical characteristics of the groups categorised by PSA nadir are shown in Table 31. 
PSA nadir >4ng/ml was associated with a higher presenting PSA, worse baseline 
performance status and a higher proportion of unknown Gleason score which may be 
explained by a histological diagnosis made from a metastatic sample.  
3.4.2 PSA nadir 
Within the docetaxel-treated population eligible for inclusion in analysis the median PSA 
nadir was 0.6ng/ml (IQR 0.2-2). In the comparable ADT alone treated population, median 
PSA nadir was 0.9ng/ml (IQR 0.3-2.9), see Table 30 for distribution by category. The 
addition of docetaxel was associated with an increased proportion of patients achieving a 
PSA nadir of <0.2ng/ml (21% vs. 14%). 
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Figure 25: Patient selection for analysis of PSA nadir 
 
 
The prognostic impact of PSA was explored in the patient group allocated to receive docetaxel who reported starting treatment and 
had not reported (or been censored) a failure-free survival event prior to the landmark. In total, 612 patients with metastatic 
disease (M1) at trial entry allocated to receive docetaxel met the inclusion criteria (84% of the ITT) as shown by the red circle. 
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Table 29: Comparative baseline characteristics in docetaxel treated cohort  
Characteristic  
  
Population  
ITT (%) Analysis Excluded 
  n=727 n=612 n=115 
Tumour stage  
≤T2 97 (13%) 82 (13%) 15 (13%) 
T3 391 (54%) 336 (55%) 55 (48%) 
T4 165 (23%) 135 (22%) 30 (26%) 
Tx 74 (10%) 59 (10%) 15 (13%) 
Nodal stage  
N0 236 (33%) 207 (34%) 29 (25%) 
N+ 423 (58%) 347 (57%) 76 (66%) 
Nx 68 (9%) 58 (9%) 10 (9%) 
Metastatic distribution  
Bone only  447 (61%) 390 (64%) 57 (50%) 
Distant nodal 79 (11%) 67 (11%) 12 (10%) 
Bone & distant nodes, or 
other metastatic site  
201 (28%) 155 (25%) 46 (40%) 
Gleason sum score 
≤ 7 131 (18%) 114 (19%) 17 (15%) 
≥ 8 499 (67%) 423 (69%) 76 (66%) 
Unknown  97 (13%) 75 (12%) 22 (19%) 
Age 
≤55  61 (8%) 53 (7%) 8 (7%) 
55-59  98 (13%) 82 (13%) 16 (14%) 
60-64 169 (23%) 138 (23%) 31 (27%) 
65-69 192 (26%) 169 (28%) 23 (20%) 
70-74 138 (19%) 116 (19%) 22 (19%) 
≥ 75 69 (9%) 54 (9%) 15 (13%) 
Performance status  
0 533 (73%) 453 (74%) 80 (70%) 
1 or 2 194 (27%) 159 (26%) 35 (30%) 
Presenting PSA  (ng/ml) 
<18.6 108 (15%) 93 (15%) 15 (13%) 
18.6 – 46.4  105 (14%) 90 (15%) 15 (13%) 
46.5 – 94.2  143 (20%) 120 (20%) 23 (20%) 
94.3 – 277.2 150 (21%) 124 (20%) 26 (23%) 
>278 221 (30%) 185 (30%) 36 (31%) 
 
Table 30: Frequency within PSA nadir categories   
PSA category  Metastatic ITT Analysis population 
ADT+ docetaxel ADT-alone 
≤0.2ng/ml 210 (14%) 131 (21%) 71 (14%) 
>0.2  - ≤4ng/ml 818 (56%) 385 (63%) 341 (67%) 
>4mg 423 (29%) 96 (16%) 98 (19%) 
 
  
122 
 
Table 31: Comparative baseline characteristics by PSA nadir category  
 
Baseline 
characteristic 
PSA nadir 
≤0.2ng/ml 
PSA nadir 
 >0.2 ≤4ng/ml 
PSA nadir  
>4ng/ml 
P value* 
 n= 131 (21%) n=385 (63%) n=96 (16%)  
Tumour stage   
≤T2 16 (12%) 53 (14%) 13 (14%) 0.066 
T3 71 (54%) 221 (57%) 44 (46%) 
T4 37 (28%) 72 (19%) 26 (27%) 
Tx 7 (5%) 39 (10%) 13 (14%) 
Nodal stage   
N0 42 (32%) 132 (34%) 33 (34%) 0.834 
N+ 79 (60%) 216 (56%) 52 (54%) 
Nx 10 (8%) 37 (10%) 11 (11%) 
Metastatic distribution   
Bone only  80 (61%) 249 (65%) 61 (64%) 0.171 
Distant nodes only 19 (15%) 43 (11%) 5 (5%) 
Bone & nodes or 
other   
32 (24%) 93 (24%) 30 (31%) 
Gleason sum score  
≤ 7 31 (24%) 72 (19%) 11 (11%) <0.001 
≥ 8 93 (71%) 271 (70%) 59 (61%) 
Unknown  7 (5%) 42 (11%) 26 (27%) 
Age  
≤55  11 (8%) 35 (9%) 7 (7%) 0.5752 
55-59  14 (11%) 56 (15%) 12 (13%) 
60-64 27 (21%) 84 (22%) 27 (28%) 
65-69** 40 (31%) 105 (27%) 24 (25%) 
70-74 25 (19%) 72 (19%) 19 (20%) 
≥ 75 14 (11%) 33 (9%) 7 (7%) 
Performance status  
0 107 (82%) 281 (73%) 65 (68%) 0.042 
1 or 2 24 (18%) 104 (27%) 31 (32%) 
Presenting PSA  
(ng/ml) 
    
≤20 48 (37%) 56 (15%) 1 (1%) 0.0001 
21-50  27 (21%) 67 (17%) 3 (3%) 
51-100  21 (16%) 85 (22%) 12 (13%) 
101-250 18 (14%) 70 (18%) 10 (10%) 
>250 17 (31%) 107 (28%) 70 (73%) 
Duration of ADT prior to randomisation   
0 weeks*** 4 (3%) 20 (5%) 5 (5%) 0.0666 
≤2 weeks 23 (19%) 43 (11%) 9 (9%) 
≤4 weeks  19 (15%) 54 (14%) 8 (8%) 
≤6 weeks 23 (18%) 65 (17%) 16 (17%) 
≤8 weeks  24 (18%) 57 (15%) 24 (25%) 
≤10 weeks 18 (14%)  74 (19%) 12 (13%) 
≤12 weeks 17 (13%) 67 (17%) 22 (21%) 
≤14 weeks 1 (1%) 4 (1%) 0 (0%) 
*Kruskal-Wallis test of difference by group; statistically significant at 5% level shown in bold 
** Contains median age 
*** Started within 7 days post randomisation 
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3.4.3 Baseline survival model for analysis of PSA nadir  
All baseline characteristics were evaluated in a multivariable model and those that 
remained significant at the 5% level included in the baseline survival model: metastatic 
distribution, Gleason sum score, baseline performance status and duration of prior ADT, 
see Table 32. 
Table 32: Baseline multivariable survival model (PSA nadir)  
Characteristic Overall survival 
  Category description n Events  Multivariable  p-value* 
T stage  ≤T2 82 29 0.90 (0.61-1.32)   
  
  
0.9341 
T3 335 116 1.0 
T4 135 55 1.10 (0.84-1.45) 
Tx 59 29 1.24 (0.85-1.83) 
Nodal stage  N0 207 70 1.0   
  
0.0686 
N+ 346 131 1.45 (1.04-2.02) 
Nx 58 28 1.38 (0.89-2.14) 
Metastatic 
distribution  
Bone only  390 149 1.87 (1.07- 3.26)   
  
0.0191 
Distant nodal only  66 14 1.0 
Bone & nodal or other  155 66 2.17 (1.21-3.88) 
Gleason sum 
score  
≤ 7 113 33 1.0   
  
0.0286 
≥ 8 423 157 1.54 (1.06-2.25) 
Unknown  75 39 1.81 (1.14-2.89) 
Age  ≤55  53 20 0.85 (0.51-1.42)   
  
  
  
  
0.3929 
55-59  82 35 1.13 (0.74-1.74) 
60-64 138 49 0.86 (0.59-1.27) 
65-69
a
 168 57 1.0 
70-74 116 50 1.11 (0.75-1.64) 
≥ 75 54 18 0.68 (0.40-1.17) 
Performance 
status  
0 453 155 1.0   
0.0178 1 or 2 159 74 1.40 (1.06-1.85) 
Duration ADT 
prior to 
randomisation  
0 week
b
 29 15   
  
  
  
1.05 (1.02-1.09) 
  
  
  
  
0.0048 
≤2 weeks 77 26 
≤4 weeks 81 24 
≤6 weeks  104 35 
≤8 weeks 105 42 
≤10 weeks 104 41 
≤12 weeks 106 44 
≤14 weeks 5 2 
Presenting PSA
c
 - 611 229 0.98 (0.90-1.07)  0.7111 
 
  
a
 Median age 65yrs 
b
 All patients who were yet to start ADT prior to randomisation, commenced within 7 days  
c
 Natural Logarithmic transformation  
*For variable in overall survival model, values statistically significant at 5% level shown in bold 
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3.4.4 Impact of PSA nadir on overall survival   
Median survival from the 24-week landmark was significantly longer in patients who 
achieved a PSA nadir <0.2ng/ml, median survival 85 months (95% CI 59-NR) compared with 
those that did not; median survival 53 months (95% CI 49-60) if PSA nadir >0.2<4ng/ml, and 
42 months (95% CI 34-64) if PSA nadir>4ng/ml. This difference was highly statistically 
significant in a multivariable analysis, see Table 33 and Graph 6. 
Graph 6: Differential survival by categorised PSA nadir in docetaxel treated cohort       
:  
Table 33: Summary of survival statistics (PSA nadir)  
*Adjusted for metastatic distribution, Gleason score, baseline performance status and duration of 
prior ADT 
  
PSA nadir  n Events Median (95%CI) 3-yr OS  *Adjusted HR (95%CI) P value 
≤0.2ng/ml 131 29 85 months  (59 – NR)  82% 1.0 (reference)  0.0001 
>0.2  - 4ng/ml 384 154 53 months  (49 – 60)  68% 1.99 (1.34-2.98)  
>4ng/ml 96 46 42 months  (34 - 64) 58% 2.64 (1.64 – 4.26)  
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3.4.5 Exploring additional threshold values  
Three PSA thresholds previously shown to be prognostic when used as nadir and absolute 
values in ADT-treated cohorts were evaluated in this population, receiving the updated SOC 
ADT + docetaxel180-182. In addition, three further PSA threshold values shown to be 
prognostic in smaller ADT-treated cohorts were evaluated187-189. Thresholds of 1ng/ml and 
2ng/ml were explored aiming to further differentiate within the 63% of the cohort who 
achieved a PSA nadir of between 0.2ng/ml and 4ng/ml. However neither of these values 
appeared to have additional prognostic significance, as shown by the overlapping survival 
curves (Graph 7, Graph 8). It was hypothesised that PSA nadir >10ng/ml may identify a very 
poor prognostic group, as has previously been seen in ADT-treated cohorts187. This 
threshold value identified a group with lower a 3 year survival rate (53%) however the 
effect was inconsistent over time and the estimated median survival time was the same as 
for the PSA nadir 4-10ng/ml category. Distinguishing if these groups have significantly 
different outcomes is limited by the relatively small numbers in each (n 49, 47), see Graph 
9. 
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Graph 7: Differential survival by  PSA nadir  (threshold 1ng/ml)   
 
 
Table 34: Summary of survival by PSA nadir category (additional threshold 1ng/ml) 
 
 
 
 
 
 
 
 
 
*Adjusted for metastatic distribution, Gleason score, baseline performance status and duration of prior ADT 
 
PSA nadir 
category 
n Events Median (95%CI) 3 year 
OS  
*Adjusted HR 
(95%CI) 
P value 
≤0.2ng/ml 131 29 85 months  (59 - NR)  82% 1.0 (reference)   0.0003 
>0.2 to ≤1ng/ml 256 97 54  months (45 – 59)  68% 1.91 (1.25-2.91)  
>1 to ≤4ng/ml 129 57 53 months (45 - 68) 68% 2.15 (1.37 – 3.37)  
>4ng/ml 96 46 42 months (34-64) 58% 2.64 (1.64-4.26) 
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Graph 8: Differential survival by  PSA nadir  (threshold 2ng/ml)   
 
 
Table 35: Summary of survival by PSA nadir category (additional threshold 2ng/ml) 
PSA nadir 
category 
n Events Median (95%CI) 3 year 
OS 
*Adjusted HR 
(95%CI) 
P value 
≤0.2ng/ml 131 29 85 months  (59 - NR)  82% 1.0 (reference)   0.0003 
>0.2 to ≤2ng/ml 332 135 52  months (46 – 59)  68% 2.03 (1.36 - 3.05)  
>2 to ≤4ng/ml 52 19 70 months (49 - NR) 67% 1.76 (0.98 – 3.15)  
>4ng/ml 96 46 42 months (34 - 64) 58% 2.65 (1.64 – 4.27) 
*Adjusted for metastatic distribution, Gleason score, baseline performance status and duration of prior ADT 
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Graph 9: Differential survival by  PSA nadir  (threshold >10ng/ml)   
 
 
Table 36: Summary of survival by PSA nadir category (additional threshold >10ng/ml) 
PSA nadir 
category 
n Events Median (95%CI) 3 year 
OS 
*Adjusted HR 
(95%CI) 
P value 
≤0.2ng/ml 131 29 85 months (59 - NR)  82% 1.0 (reference)   0.0002 
>0.2 to ≤4ng/ml 385 154 53  months (49 – 60)  68% 1.99 (1.33-2.97)  
>4 to ≤10ng/ml 49 21 41 months (34 - NR) 63% 2.31 (1.30 –4.11)  
>10ng/ml 47 25 42 months (20 - 64) 53% 3.01 (1.74-5.21) 
 
*Adjusted for metastatic distribution, Gleason score, baseline performance status and duration of 
prior ADT 
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3.4.6 Relationship between PSA nadir and failure-free survival 
As the STAMPEDE protocol definition of FFS is related to the PSA nadir value this outcome 
was considered less robust, as it may be biased and over-estimate the prognostic 
importance of a high PSA nadir. However FFS continues to have clinical value as an early 
intermediate outcome and therefore was explored as a secondary outcome, accepting this 
limitation. A baseline multivariable model was constructed. Baseline age, duration of ADT 
prior to randomisation and presenting PSA were all statistically significant and therefore 
included in the adjusted analysis. PSA nadir continued to be strongly prognostic in this 
model see Table 37 and Graph 10. The baseline survival model is shown in A5: Table 70. 
Graph 10: FFS by PSA nadir in docetaxel-treated cohort  
 
Table 37: FFS survival by PSA nadir category  
* Timed from landmark (24-weeks post randomisation)  
**Adjusted for metastatic distribution, Gleason score, baseline performance status and duration of prior ADT 
PSA nadir  n Events Median (95%CI) 1-yr FFS * **Adjusted HR 
(95%CI) 
P value 
≤0.2ng/ml 131 64 33 months  (30 – 50)  81% 1.0 (reference)   <0.0001 
>0.2- 4ng/ml 385 272 17 months  (14 – 21)  59% 1.83 (1.38-2.41)  
>4ng/ml 96 83 9 months  (6 - 11) 38% 2.97 (2.07 – 4.24)  
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3.4.7 Relationship between PSA nadir and survival in ADT alone group  
A secondary analysis of PSA nadir and overall survival was performed in the STAMPEDE 
control group who received ADT alone until progression to CRPC (n=510, see Figure 25). 
This allows comparison with other published analyses that have explored PSA nadir and 
absolute PSA decline in ADT alone treated groups180,181,187,190. The median duration of ADT 
prior to the landmark was 30 weeks (IQR 27-33). At the 24 week landmark, 27% of patients 
allocated to the control group had already reported a FFS event. These patients were 
excluded because if second-line treatment had been started for progressive disease the 
nadir value may no longer be reflective of response to ADT alone. Additionally, these 
patients no longer fulfilled the definition of CSPC. Consistent with an aggressive clinical 
course, the excluded population had a higher disease burden, with more widespread 
metastatic distribution, higher tumour stage and a higher likelihood of pelvic nodal 
involvement, see Table 38. 
In the population who were progression-free at 24-weeks post randomisation (around 30 
weeks post ADT initiation) there is no good evidence that PSA nadir was associated with 
overall survival, see Graph 11. Although a similar trend was observed, in a multivariable 
model adjusted for metastatic distribution, Gleason score, baseline age and performance 
status, PSA nadir did not remain statistically significant (p 0.1462), see Table 40. 
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Table 38: Baseline characteristics (ADT alone treated population)  
  
Baseline 
characteristic 
Metastatic ITT Eligible for PSA 
nadir analysis 
Excluded 
 n=724  n=510  n=214 
Tumour stage  
≤T2 90 (12%) 70 (14%) 20 (9%) 
T3 404 (56%) 297 (58%) 107 (50%) 
T4 163 (23%) 106 (21%) 57 (27%) 
Tx 67 (9%) 37 (7%) 30 (14%) 
Nodal stage  
N0 242 (33%) 170 (33%) 72 (34%) 
N+ 416 (57%) 293 (57%) 123 (57%) 
Nx 66 (9%) 47 (9%) 19 (9%) 
Metastatic distribution  
Bone only  454 (63%) 319 (63%) 135 63%) 
Distant nodes only 63 (9%) 54 (11%) 9 (4%) 
Bone & nodes or other   207 (29%) 137 (27%) 70 (33%) 
Gleason sum score 
≤ 7 156 (22%) 119 (23%) 37 (17%) 
≥ 8 476 (66%) 335 (66%) 141 (66%) 
Unknown  92 (13%) 56 (11%) 36 (17%) 
Age 
≤55  70 (10%) 39 (8%) 31 (14%) 
55-59  104 (14%) 70 (14%) 34 (16%) 
60-64 146 (20%) 100 (20%) 46 (22%) 
65-69
a
 
187 (26%) 141 (28%) 46 (22%) 
70-74 134 (19%) 100 (20%) 34 (16%) 
≥ 75 83 (11%) 60 (12%) 23 (11%) 
Performance status  
0 521 (72%) 391 (77%) 130 (61%) 
1 or 2 203 (28%) 119 (23%) 84 (39%) 
Presenting PSA  
(ng/ml) 
   
≤20 125 (17%) 101 (20%) 23 (11%) 
21-50  121 (17%) 94 (18%) 27 (13%) 
51-100  114 (16%) 84 (16%) 30 (14%) 
101-250 143 (20%) 104 (20%) 39 (18%) 
>250 221 (31%) 126 (25%) 95 (44%) 
Duration of ADT prior to randomisation  
0
b
  44 (6%) 37 (7%) 7 (2%) 
≤2 weeks 88 (12%) 65 (13%) 23 (11%) 
≤4 weeks  108 (12%) 80 (16%) 28 (13%) 
≤6 weeks 109 (33%) 68 (13%) 41 (19%) 
≤8 weeks
 
129 (18%) 91 (18%) 38 (18%) 
≤10 weeks 114 (16%)  84 (16%) 30 (14%) 
≤12 weeks 125 (17%) 80 (16%) 45 (21%) 
≤14 weeks 7 (1%) 5 (1%) 3 (1%) 
a
 Median age 65yrs, 
b
 All patients who were yet to start ADT prior to randomisation, commenced within 7 days  
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Table 39: Multivariable baseline survival model (ADT alone treated population)  
 
  
Characteristic Overall survival 
  Category description n Events 
  
Multivariable  p-value* 
T stage  ≤T2 80 20 0.78 (0.48-1.28)   
  
  
0.6003 
T3 297 113 1.0 
T4 106 41 1.06 (0.74-1.53) 
Tx 37 18 1.21 (0.72-2.04) 
Nodal stage  N0 170 58 1.0   
  
0.7760 
N+ 293 114 1.14 (0.79-1.64) 
Nx 47 20 1..06 (0.63-1.80) 
Metastatic 
distribution  
Bone only  319 128 2.97 (1.55-5.68)   
0.0005 Distant nodal only  54 10 1.0 
Bone & nodal or other  137 54 2.97 (1.49-5.90) 
Gleason sum 
score  
≤ 7 119 31 1.0   
  
0.0010 
≥ 8 335 139 1.95 (1.31-2.90) 
Unknown  56 22 1.53 (0.88-2.67) 
Age  ≤55  39 23 2.58 (1.54-4.31)   
  
  
  
  
0.0027 
55-59  70 33 1.73 (1.10-2.73) 
60-64 100 40 1.27 (0.83-1.95) 
65-69
a
 141 44 1.0 
70-74 100 31 1.06 (0.67-1.68) 
≥ 75 60 21 1.21 (0.72-2.05) 
Performance 
status 
0 391 138 1.0   
0.0110 1 or 2 119 54 1.53 (1.11-2.10) 
Duration ADT 
prior to 
randomisation  
0 week
b
 37 14   
  
  
  
0.99 (0.95-1.03) 
  
  
  
  
0.5508 
≤2 weeks 65 25 
≤4 weeks 80 37 
≤6 weeks  68 29 
≤8 weeks 91 26 
≤10 weeks 84 31 
≤12 weeks 80 28 
≤14 weeks 5 2 
Ln presenting 
PSA
c
 
-   0.97 (0.88-1.06)  0.4411 
a
 Median age 65yrs 
b
 All patients who were yet to start ADT prior to randomisation, commenced within 7 days  
c
 Natural Logarithmic transformation  
*For variable in overall survival model, values that are statistically significant at 5% level shown in bold 
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Graph 11: Differential survival by PSA nadir in patients receiving ADT alone 
 
Table 40: Summary of survival by PSA nadir in patients receiving ADT alone 
PSA nadir 
category 
n Events Median (95%CI) 3 year 
OS 
*Adjusted HR 
(95%CI) 
P value 
≤0.2ng/ml 71 19 55 months (45- NR)  74% 1.0 (reference)   0.1462   
>0.2 to ≤4ng/ml 341 129 53  months (42 – 63)  65% 1.14 (0.70-1.87)  
>4ng/ml 98 44 45 months (37 - 52) 63% 1.59 (0.92-2.75)  
*Adjusted for metastatic distribution, Gleason score, baseline performance status and duration of 
prior ADT 
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Comparative survival analyses  
These results do not show PSA nadir assessed around 30 weeks after commencing ADT is 
prognostic of OS. This contrasts with the findings of other similar analysis conducted within 
the SWOG 9346 and CHAARTED trial cohorts. As reported by Hussain et al. and Harshman 
et al. respectively, these data would suggest that when the same PSA threshold values 
(<0.2ng/ml, 0.2-4ng/ml, >4ng/ml) are assessed as absolute values at a landmark, they are 
prognostic of clinically significant survival differences in men with mCRPC treated with ADT 
+/- docetaxel180,181. 
However, the approach adopted by these investigators differs in two ways, the population 
and the definition of the PSA outcome. Firstly, all participants were included regardless of 
whether disease progression had occurred by the landmark assessment of PSA. Secondly, 
the PSA outcome is an absolute value assessed at a single point in time.  In order to 
contextualise these data, I undertook a further exploratory analysis to assess the impact of 
defining the population differently, specifically including the subgroup experiencing early 
progressive disease. 
To highlight the impact of this differing approach, Graph 13 demonstrates the relative 
prognosis of the group in whom disease progression was reported within the first 24 weeks 
post randomisation (around 30 weeks after commencing ADT). As summarised in Table 42, 
these results demonstrate that this group have a distinct and very poor prognosis; median 
survival from the 24 week landmark was 17 months (95% CI 14- 19 months). This is 
equivalent to a median survival time of 2 years from the point of starting ADT. In an 
adjusted multivariable analysis this group were at 3 times greater risk of death compared 
with the group with a PSA nadir >4ng/ml but who reached the 24 week landmark 
progression-free; HR 3.10 (95% CI 2.18-4.40); p<0.0001. As shown in Table 43, progression 
prior to 24 weeks was associated with younger age, higher disease burden, higher 
presenting PSA and a poorer baseline performance status.  
Graph 12 and Table 41 summarise the results where all participants are categorised based 
on the recorded nadir value, but without excluding those in whom an FFS event (e.g. PSA 
progression) has been reported prior to the landmark. In keeping with the approach 
adopted in the analyses of the CHAARTED and SWOG 9346 cohorts, all patients 
experiencing disease progression were grouped in the PSA nadir >4ng/ml category180,181.  
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Graph 12: OS by PSA nadir including patients experiencing early progression (ADT alone) 
 
Table 41: Summary of OS including patients experiencing early progression (ADT alone) 
PSA nadir 
category 
n Events Median (95%CI) 3 year 
OS  
*Adjusted HR 
(95% CI)  
P value 
≤0.2ng/ml 71 19 55 months (45 - NR)  74%  0.30 (0.19-0.49) <0.0001 
>0.2 to ≤4ng/ml 341 129 53  months (42 – 63)  65% 0.36 (0.29-0.46) 
>4ng/ml 301 199 21 months (19 - 28) 36% 1.0 (reference)  
*Adjusted for metastatic distribution, Gleason score, baseline performance status and duration of 
prior ADT 
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Graph 13: OS by PSA nadir highlighting distinct clinical course of patients experiencing 
early progression (ADT alone)  
 
 
Table 42: Summary survival statistics including patients experiencing early progression  
Category n Events Median (95%CI) 3 year 
OS  
*Adjusted HR 
(95%CI) 
P value 
Disease progression reported 
prior to 24 week landmark 
198 150 17 months  
(14-19) 
20% 3.10 (2.18-4.40)  <0.0001 
PSA nadir 
category  
≤0.2ng/ml 72 20 55 months  
(45 - NR)  
74% 0.63 (0.36-1.08) 
>0.2 to 4ng/ml 342 129 53  months  
(42 – 63)  
65% 0.75 (0.29-0.46) 
>4ng/ml 99 45 45 months  
(37 - 52) 
63% 1.0 (reference)  
*Adjusted for metastatic distribution, Gleason score, baseline performance status and duration of 
prior ADT 
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Table 43: Comparative baseline characteristics (including progression <24 weeks)  
 
 PSA nadir 
≤0.2ng/ml 
PSA nadir  
>0.2 ≤4ng/ml 
PSA nadir 
>4ng/ml 
Progressed 
prior to 24 
weeks 
P value*  
 n=72 (10%) n=342 (48%) n=99 (14%) n=198 (28%)  
Tumour stage 
≤T2 14 (19%) 47 (14%) 11 (11%) 16 (8%)  
T3 40 (56%) 201 (59%) 56 (57%) 103 (52%) 
T4 12 (17%) 73 (21%) 22 (22%) 52 (26%) 
Tx 6 (8%) 21 (6%) 10 (10%) 27 (14%) 
Nodal stage   
N0 28 (39%) 117 (34%) 26 (26%) 70 (35%) 0.542 
N+ 39 (54%) 196 (57%) 60 (61%) 111 (56%) 
Nx 5 (7%) 29 (8%) 13 (13%) 17 (9%) 
Metastatic distribution   
Bone only  47 (65%) 218 (64%) 55 (56%) 128 (65%) 0.015 
Distant nodes only 8 (11%) 35 (10%) 11 (11%) 6 (3%) 
Bone & nodes or 
other   
17 (24%) 89 (26%) 33 (33%) 64 (32%) 
Gleason sum score  
≤ 7 21 (29%) 78 (23%) 21 (21%) 33 (17%) 0.013 
≥ 8 44 (61%) 234 (68%) 59 (60%) 132 (67%) 
Unknown  7 (10%) 30 (9%) 19 (19%) 33 (17%) 
Age  
≤55  3 (4%) 26 (8%) 10 (10%) 29 (15%) 0.0028 
55-59  3 (4%) 50 (15%) 17 (17%) 32 (16%) 
60-64 13 (18%) 74 (22%) 13 (13%) 43 (22%) 
65-69 
a
 
26 (36%)* 87 (25%)* 29 (29%)* 43 (22%) 
70-74 16 (22%) 65 (19%) 21 (21%) 29 (15%) 
≥ 75 11 (15%) 40 (12%) 9 (9%) 22 (11%) 
Performance status  
0 55 (76%) 265 (77%) 73 (74%) 123 (62%) 0.002 
1 or 2 17 (24%) 77 (23%) 26 (26%) 75 (38%) 
Presenting PSA  (ng/ml)  
≤20ng/ml 30 (42%) 71 (21%) 1 (1%) 20 (10%) 0.0001 
21-50ng/ml  17 (24%) 75 (22%) 3 (3%) 23 (12%) 
51-100ng/ml  7 (10%) 65 (19%) 12 (13%) 30 (15%) 
101-250ng/ml 5 (7%) 66 (19%) 33 (33%) 38 (19%) 
>250ng/ml 13 (18%) 65 (19%) 50 (51%) 87 (44%) 
Duration of ADT prior to randomisation   
0 
b
  5 (7%) 28 (8%) 4 (4%) 6 (3%) 0.067 
≤2 weeks 10 (14%) 41 (12%) 14 (14%) 21 (11%) 
≤4 weeks  12 (17%) 53 (16%) 17 (17%) 24 (12%) 
≤6 weeks 6 (8%) 49 (14%) 13 (13%) 39 (20%) 
≤8 weeks 14 (19%) 59 (17%) 18 (18%) 36 (18%) 
≤10 weeks 12 (17%) 57 (17%) 15 (15%) 29 (15%) 
≤12 weeks 11 (15%) 53 (16%) 17 (17%) 42 (21%) 
≤14 weeks 2 (3%) 2 (1%) 1 (1%) 1 (1%) 
a
 Median age 65yrs, 
b
 All patients who were yet to start ADT prior to randomisation, commenced within 7 days  
*Kruskal Wallis test for difference, values statistically significant at 5% level shown in bold 
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3.5 Discussion  
The addition of docetaxel chemotherapy to ADT is now recommended for all men 
presenting with metastatic castrate-sensitive prostate cancer who are judged fit enough. 
However in the predominantly elderly co-morbid population affected by PCa this can be a 
complex assessment of the relative risks and benefits24,191. Emerging data describing “real-
world” use of docetaxel suggests whilst similar PFS gains are observed, toxicity is increased 
compared with that observed in trial populations. In particular, a higher incidence of febrile 
neutropenia is observed; 17-20% compared with 12% reported by the STAMPEDE trial28,29. 
In a recently reported small non-trial cohort of 103 patients receiving docetaxel for mCSPC, 
34% were hospitalised and 2% died within 30 days of receiving chemotherapy28. The risk of 
febrile neutropenia is suggested to be inversely related to time between starting ADT and 
docetaxel; the OR of febrile neutropenia is 9.75 (95% CI 1.2-77.7; p 0.032) if docetaxel is 
started ≤19 days after starting ADT, but if 60-79 days have elapsed the OR is reduced to 
1.86 (0.28-12.16). Although the number of events are small, these preliminary data suggest 
that a strategy of initiating ADT and waiting to assessing PSA response before deciding on 
docetaxel use may be beneficial. Through an additional analysis of the metastatic subgroup 
within the STAMPEDE control arm, I sought to test the hypothesis that the magnitude of 
PSA response assessed around 12 weeks (IQR 9.1-15.0) after commencing ADT would be 
prognostic of OS and therefore improve risk-stratification in this disease setting.  
PSA responses to ADT were large (median 97%; IQR 91-95%) and 95% experienced a 
response of >50%. This is comparable with previous cohorts of newly diagnosed metastatic 
castrate-resistant disease; in a retrospective review of 982 patients 91% were reported to 
experience a ≥50% PSA response to ADT alone192. This consistently high response rate 
contrasts with those observed in mCRPC cohorts, where PSA responses of ≥30% and ≥50% 
are frequently reported and may be included in composite assessments of benefit in the 
castrate-resistant setting. The PCWG classifies PSA response as an “activity estimating 
endpoint” but has not recommended thresholds specific to the castrate-sensitive setting. 
This may simply reflect that, until recently, this patient group uniformly received ADT alone, 
meaning there was little clinical need to assess activity169.  
The magnitude of PSA response was shown to associate with improved OS in patients 
receiving ADT alone (p<0.0001). To be applicable to clinical practice, prognostic categories 
must be defined. As there were no established thresholds I sought to define these within 
this cohort. A PSA response of ≥99% was found to have the greatest predictive 
139 
 
discrimination of differences in OS. 3 year survival was 73% compared with 61% if the PSA 
response was 80-99%, equivalent to a 13 month difference in median OS times. However, 
in a multivariable analysis, the statistical significance of PSA response was reduced in the 
model that included absolute PSA value at the landmark, suggesting with both the relative 
and absolute PSA reduction may be significant.  
PSA responses of <80% were fortunately rare occurring in 13% but were associated with 
significantly worse survival outcome; median survival of 21 months compared with 45 
months if a PSA response of 80-98% was observed. In the multivariable analysis, a PSA 
response of <80% was associated with almost a 3-fold increase in the risk of death (HR 2.94; 
2.20-3.93, p<0.0001). Again, data acquired in mCRPC cohorts supports this trend although 
the magnitude of difference is smaller, consistent with the hypothesis that the prognostic 
effect of PSA is greatest in the castrate-sensitive setting, when AR-responsive PSA 
transcription would be most reflective of therapeutic response173,174. Together these data 
suggest that PSA response assessed around 12 weeks post initiation of ADT in men with 
mCSPC can provide additional prognostic information that may be clinically useful when 
considering the use of first-line docetaxel.  
Strengths of this analysis include the availability of prospectively collected PSA data for 93% 
of the STAMPEDE cohort, thus avoiding the bias that retrospective analyses may risk 
through systematic differences in those with and without available PSA data. Other 
strengths include the completeness of the data and length of follow-up.  However, the 
median age of this cohort was 65 years (at least 10 years younger than the average clinic 
population) and all patients recruited to STAMPEDE during this period had to be considered 
fit for chemotherapy. Therefore, whilst prognostic factors can be explored within this 
cohort, external validation in groups more representative of clinic populations would be 
important in confirming their utility in risk-stratification and informing the decision as to 
whether to give docetaxel. Other ongoing trials in this setting such as PATCH 
(NCT00303784) may be useful sources of external validation. The population enrolled in 
PATCH to date have been older and fewer patients are receiving SOC docetaxel (~50% 
compared with ~90% in STAMPEDE) suggesting that this is more typical of a population in 
whom additional risk-stratification could be useful. 
A limitation of this analysis is that the timing of PSA data collection does not allow us to 
explore the interaction of PSA response with subsequent docetaxel use, as PSA at 
randomisation is not collected within the STAMPEDE protocol, so we lack comparative 
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baseline PSA data. The median observed survival time in the group who experienced a PSA 
response of ≥99% following ADT alone is 58 months (IQR 46-66), which is closer to the 
estimated median observed for the docetaxel treated metastatic subgroup than it is the 
ADT alone metastatic subgroup20. However, what is unclear is where the groups defined by 
PSA response lie in the wide variation in survival times observed for both treatment 
strategies. Within the randomised docetaxel comparison the median survival observed was 
45 months (IQR 23-91) for mCSPC treated with ADT alone, and 60 months (IQR 27-103) in 
the group allocated to receive ADT + docetaxel. Analysis of comparable pre-treatment PSA 
data within a randomised cohort is required to determine whether the magnitude of 
benefit for docetaxel differs within the risk categories identified in this analysis. This 
information would be required to support not using docetaxel in selected patients with a 
PSA response ≥99%, as although the results of the analysis show this group to have a 
comparatively good outcome relative to those achieving smaller PSA responses, the 
potential survival gain of additional docetaxel is not known. 
The second objective of this analysis was to assess whether PSA nadir assessed following 
completion of SOC docetaxel is prognostic of survival outcome. This second on treatment 
biomarker is proposed to have potential clinical utility in identifying a subgroup who remain 
at high-risk of death despite docetaxel, in whom additional intensified treatment strategies 
could be evaluated. Results showed that the failure to achieve a PSA nadir of <4ng/ml was 
associated with significantly worse survival outcome, with 3 year survival rates of 58% 
compared with 82% if PSA nadir reached <0.2ng/ml; HR 2.64 (95% CI 1.64-4.26) p<0.0001. 
21% of patients treated with ADT + docetaxel achieved a PSA nadir <0.2ng/ml and 
docetaxel use increased the likelihood of this. Recently reported results from the 
CHAARTED trial180 also demonstrate that docetaxel use is associated with improved PSA 
response, however the approach to this analysis differs in the PSA measurement, 
assessment timing and the patient population, see Table 44. 
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Table 44: Comparison of main trial cohorts in which PSA has been evaluated 
 SWOG 9346 
 
CHAARTED 
 
STAMPEDE 
Population 
 
 n=1345  
 Treatment: ADT 
alone 
 
 
 n=719  
 Randomised to 
receive ADT + 
docetaxel or ADT 
alone 
 n=612  
 Treatment: ADT + 
docetaxel  
 
  
Inclusion 
criteria  
 PSA ≥5ng/ml  ≥7 months FU after 
ADT initiation 
 7-month post ADT 
PSA 
 Sufficient PSA data 
 No FFS event prior to 
landmark 
PSA 
measurement  
Absolute PSA  
level at 6 and 7 months 
post registration 
Absolute PSA  
level  7 months post 
initiation of ADT 
PSA nadir 
lowest PSA reported at 
any time point within 
first 24 weeks post 
randomisation 
ADT prior to 
assessment 
of PSA nadir  
Maximum 13 months  
 Late registration 
group (~30%) 
received ≤6 months 
pre-registration 
 All received  7 
months post 
registration  
Maximum 7 months  
 ADT could start ≥4 
months prior to 
randomisation but 
landmark set 7 
months post 
initiation of ADT 
regardless of when 
this started  
Maximum 9 months 
 ADT can start ≥12 
weeks prior to 
randomisation  
 PSA assessed 24 
weeks post 
randomisation  
 
The PSA measurement assessed in the STAMPEDE cohort was PSA nadir, defined as the 
lowest PSA reported in the first 24 weeks on trial. Given that up to 12 weeks ADT is 
permitted prior to randomisation, this equates to an assessment of response that may 
occur from randomisation up until 36 weeks/8 months after starting ADT; the median time 
point in this cohort was around 30 weeks. This landmark corresponds to when docetaxel 
has been completed, typically within the previous 6 weeks.  In contrast, the approach 
adopted in the CHAARTED analysis was a snapshot assessment of PSA 7-months post 
starting ADT. This absolute PSA value measured at one point in time has the advantage that 
it is easily replicated outside of trial setting; however it is unclear whether docetaxel was 
complete and therefore whether this PSA value is reflective of full response. Data in ADT 
alone treated cohorts have suggested the median time to nadir is 8-9 months183,187,190 so 
these measurements are unlikely to be directly comparable. When both absolute 6-month 
PSA and PSA nadir were assessed in a cohort of 286 men with mCSPC, only PSA nadir 
remained significant on the multivariable analysis, suggesting that, as is seen with measures 
such as PSA doubling time, kinetic measures of PSA may be more informative than 
assessments made at a single point in time166,190. 
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A further difference between my approach to this analysis and that adopted within the 
CHAARTED cohort is how the eligible population is defined. One of the strengths of the 
STAMPEDE cohort is its large size that permits investigation of PSA nadir in the group 
receiving ADT and docetaxel (n=612). In addition, only those who reached the landmark 
progression-free, such that they fulfilled the definition of CSPC were included.  This allowed 
me to address the question of whether PSA nadir could be used as a prognostic biomarker 
in docetaxel-treated patients capable of identifying a population in whom to evaluate 
intensified CSPC treatment. The rationale being that patients who experience disease 
progression prior to this landmark have declared themselves as having poor prognostic 
disease and will likely commence treatment for CRPC and therefore have less need for 
further risk-stratification. In contrast, CHAARTED randomised a total of 790 patients and 
grouped both ADT and ADT + docetaxel treated patients together for the analysis of PSA 
response, stratifying for treatment allocation. All patients were categorised according to 
the absolute 7-month PSA measurement and patients experiencing prior progression were 
included in >4ng/ml group. Therefore, the CHAARTED population may be considered more 
heterogeneous, containing patients fulfilling the definition of castrate-sensitive, but also 
castrate-resistant disease and who have received different first treatments. Significantly, 
the PSA >4ng/mL group was used as the reference group in the multivariable analysis (i.e. 
the group that contains early patients with early CRPC) likely increasing the differences 
observed in prognosis. 
Within my analysis, the results of the group allocated to receive ADT alone highlight that 
progression within around 30 weeks (range 24-36) of starting ADT is associated with a 
distinctly poor prognosis. A failure-free survival time of <24 weeks was observed in 28% 
patients receiving ADT alone and was associated with a very poor outcome; 3 year survival 
rate of 20% and median survival 17 months (95% CI 14-19), considerably worse than the 
group overall (45 months). This group was characterised as younger, with a high disease 
burden, higher presenting PSA and worse baseline performance status. The proportion of 
early treatment failures on ADT is considerable higher in STAMPEDE compared with the 
CHAARTED or SWOG 9346 cohorts180,181. This may be explained by the longer duration of 
ADT prior to the landmark analysis in STAMPEDE, together with the likelihood that the 
other trials selected patients with an improved response to ADT. In contrast to STAMPEDE, 
the CHAARTED protocol explicitly excluded patients showing signs of progression, whilst the 
SWOG 9346 induction phase specifically aimed to identify ADT-responsive cases suitable for 
randomisation to intermittent therapy180,181.  
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 Although the methods differ, the results of this analysis and that conducted within the 
CHAARTED trial cohort both demonstrate that patients receiving ADT + docetaxel who 
experience poor PSA response, either defined by PSA nadir or absolute value assessed 7-
months after starting ADT, are at high-risk of early death. These data support the need to 
evaluate additional treatment strategies in these groups. Flaig et al. recently reported a 
small phase 2 study which recruited 41 patients who had a poor response to ADT, defined 
as a 7-month PSA >4ng/ml and evaluated whether the addition of abiraterone increased 
the proportion of patients subsequently achieving a PSA level <0.2ng/ml within 12 months. 
Although the pre-specified threshold of 20% (requiring 6 patients of the target 38 to 
achieve primary outcome) was not met, 5 patient (12%) did subsequently achieve a PSA 
<0.2ng/ml and a further 8 (20%) achieve a PSA <4ng/ml193.   
3.5.1 Future work  
Future validation of these data is possible within the STAMPEDE dataset. The PSA response 
finding in ADT treated patients may be validated within participants allocated to any of the 
trial arms where an improvement in FFS or OS has not been observed e.g. non-overlapping 
controls to other comparisons, or those allocated to the celecoxib or zoledronic acid single 
agent arms. However, validation using other clinical trial datasets is challenging whilst PSA 
based outcomes are non-standardised and therefore protocol specific. Based on these data, 
the STAMPEDE protocol has been revised (version 19.0) to include collection of PSA at 
randomisation. This will permit analyses of PSA response (albeit at a slightly earlier time 
point) in randomised cohorts including testing for treatment interaction to address whether 
treatment effect varies within each prognostic risk category, for example through stratified 
randomisation and sub-group analyses. PSA nadir continues to be collected for all 
STAMPEDE participants and therefore subsequent analyses could explore if this is 
prognostic in groups receiving alternative therapies e.g. abiraterone. The prior hypothesis 
would be that as abiraterone is an AR-targeted therapy, PSA is more likely to capture 
treatment effect and therefore the prognostic impact may be even greater, such that it may 
be appropriate to asses surrogacy if prognostic effect is confirmed. Taken together, these 
data would support the further examination of PSA based outcomes as pragmatic, readily 
available biomarkers that may be able to inform treatment decisions if prognostic effect is 
validated.  
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3.6 Conclusions  
Both the magnitude of PSA response and PSA nadir are shown to associate with survival 
differences within the STAMPEDE cohort. PSA response assessed around 12 weeks after 
ADT initiation was shown to associate with survival differences, suggesting that this could 
be an early indicator of risk of death, clinically useful in considering whether to intensify 
treatment to include docetaxel or abiraterone in addition to ADT. Alone, the discriminatory 
value of the biomarker is reduced in a survival model adjusted for absolute PSA value at the 
landmark. Future evaluation in a larger cohort would enable this potential interaction to be 
explored further. PSA nadir, previously shown to be prognostic of survival in patients within 
the STAMPEDE control arm receiving ADT-alone, was shown to remain so in patients 
receiving ADT + docetaxel, the updated SOC182.  These data would support further 
investigation and prospective validation of both these on treatment biomarkers. 
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Chapter 4 Genomic profiling in metastatic castrate-sensitive 
prostate cancer: a feasibility and prevalence study  
4.1 Introduction  
4.1.1 Background  
Due to recent technological advances it is now possible to genetically profile cancers, 
paving the way for rational treatment selection based on identified oncogenic drivers. DNA 
sequencing was first described in the 1970's by Sanger et al, who described a biochemical 
process that mirrors natural DNA synthesis194. Briefly, DNA fragments are amplified by 
polymerase chain reaction (PCR) and then sequenced through the addition of 
deoxynucleotides. Dideoxynucleotides, chain elongating inhibitors of DNA polymerase are 
added, generating DNA fragments of different sizes that can be separated by capillary 
electrophoresis, allowing the complementary base sequence to be interpreted. Through 
automating and developing this process further it was possible to complete the Human 
Genome Project in 2003 and introduce DNA sequencing as a clinical diagnostic tool. 
Next-generation sequencing (NGS) follows the same principles, but is a more fully 
automated process that allows millions of sequencing reactions to occur in parallel, hence 
its alternative name, massively parallel sequencing or high-throughput sequencing195. 
Sophisticated sequencing machines automate DNA amplification and then independently 
sequence each copy of the DNA fragment simultaneously, providing multiple reads of each 
fragment. This enables huge amounts of genomic data to be acquired in less time and cost. 
It is through this approach that it has been possible to sequence cancer genomes.  
Cancer has been described as a disease of the genome, characterised by the presence of 
multiple mutational clones, driven by the accumulation of genomic changes that provide a 
selective advantage within the tumour environment196. The cancer genome will reflect the 
germline genomic profile of the individual in which the cancer has arisen and, somatic 
mutations, defined as acquired changes that are unique to the cancer cell. Paired 
examination of germline DNA is therefore recommended to correctly distinguish germline 
from somatic changes197. Processes through which somatic mutations may arise include 
exogenous or endogenous mutagen exposures or defective DNA repair198.  
Sequencing studies have revealed the considerable genetic diversity observed in tumours 
arising from the same primary sites in different individuals (intertumoural heterogeneity) 
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and within tumours (intratumoural heterogeneity)199. Somatic mutations may occur early in 
tumorigenesis, such that they are present in all tumour cells; referred to as clonal or 
truncal, subsequent somatic mutations are observed to develop and may follow a branched 
pattern of evolution, such that multiple sub-clones may co-exist, accelerating genetic 
variability200,201. Within this genomically diverse and dynamic environment, some mutations 
will be considered drivers of disease, capable of promoting tumour growth and others less 
so, referred to as passengers 202,203. In PCa both spatial and temporal heterogeneity is 
observed, with different clonal populations present in different metastatic sites and 
changes observed over time in response to treatment-related pressures35.   
Added to this complexity, tumour samples e.g. prostate core biopsies, typically contain 
both cancerous and non-cancerous cells in varying proportions (referred to as tumour 
purity), this means that the DNA sequenced will contain germline variants present in the 
individual, together with a selection of somatic variants contained in the clones and sub-
clones in the cancer cells captured by the biopsy. One of the advantages of NGS is that, 
providing each DNA segment is sequenced and read to a sufficient depth, it is sufficiently 
sensitive to detect sub-clonal mutations195. Complex computational methods that 
incorporate the number of reads, the copy number and proportion of tumour vs. normal 
cells, aim to infer clonal from sub-clonal mutations, although the functional and clinical 
significance of sub-clonal mutations is currently less clear204.  
Interpretation of this huge and complex data requires bioinformatic and genetic expertise. 
Data interpretation relies on a validated process of data processing that is referred to as the 
bioinformatic pipeline. These analysis algorithms function to impose filters to adhere to 
pre-defined quality standards and to ensure results are robust and reproducible205. Most 
bioinformatic pipelines will involve three key steps206; alignment of the sequencing data 
against the reference human genome in order to detect variants from ‘normal’. Secondly, 
an assessment of the read quality to determine if the sequencing depth, that is the number 
of times a DNA segment has been read, is sufficient to be confident in distinguishing a 
sequencing error from a true variant.  Thirdly, annotation of functional significance i.e. 
what is the likelihood that the variant detected is pathological? When processing cancer 
samples some pipelines will also include a comparison with the individual’s germline DNA in 
order to confidently distinguish somatic from germline variants. The assessment of 
functional significance is informed by the type of mutation e.g. frameshift or stop-gain 
variants are more likely to result in a protein change, and therefore be significant. However, 
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reflecting that this is a rapidly developing field where knowledge is in constant flux, many 
pipelines will be linked with databases that collate published data describing cancer related 
somatic changes, such as the Catalogue of Somatic Mutations in Cancer (COSMIC), 
(http://cancer.sanger.ac.uk/cosmic) maintained by the Wellcome Sanger Institute207. 
Figure 26: Overview of Next-generation Sequencing   
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4.1.2 Genomic data obtained in prostate cancer cohorts  
Increasingly complex and sophisticated integrated analyses have enabled comprehensive 
molecular profiling of tumour and patient tissue at the genomic, transcriptomic, proteomic 
and epigenetic level. Several, multi-academic collaborations such as that funded as part of 
the Stand Up To Cancer-Prostate Cancer Foundation (SU2C-PCF) translational programme, 
have been successfully undertaken33,39. These demonstrate that large-scale efforts to 
molecularly profile PCa cohorts are both feasible and informative; see Table 45 for 
summary of characteristics of the cohorts profiled to date.  
Sampling  
Initially, sequencing studies utilised surgical prostatectomy samples, preferably fresh frozen 
as the optimal sample type to ensure sufficient amounts of high quality nucleic acid30,31,34,38.  
However, in order to profile patients with more extensive disease who are unsuitable for 
radical surgical treatment it was necessary to broaden this approach. Warm-autopsy 
studies permit multiple metastatic sites to be sampled, exploring the genetic changes 
observed in fatal mCRPC and illuminating the complex ways in which sub-clones compete 
and seed metastatic sites31,35,36. The development of patient-derived xenograph models 
from fatal mCRPC samples has further supported the investigation of recurrent genomic 
features including mutational burden and sub-clonal architecture208. As sequencing 
technology has improved, the required amount of extracted nucleic acid has decreased and 
this has enabled the study of patients with mCRPC, enrolled in protocols mandating fresh 
frozen metastatic biopsies39,57. However, whilst fresh frozen samples remain the gold 
standard for nucleic acid preservation, cost means that this is not routine clinical practice 
and recent efforts have focused on optimising nucleic acid extraction and NGS protocols for 
formalin-fixed material. The MSK-IMPACT cohort study provides the best example to date 
of where FFPE material has been used to sequence 451 patients using routinely available 
clinical samples, including prostate core biopsy material40. Optimising this approach will be 
important to determine if molecularly-directed therapies can be successfully implemented 
into existing routine PCa clinical pathways. 
Sequencing approaches  
NGS approaches have ranged from whole genome sequencing (WGS) to whole exome 
sequencing (WES), the latter are limited to the ~1% coding regions of the genome that 
include the majority of cancer related somatic changes198. These approaches can support 
discovery and unbiased profiling; alternatively, targeted assays (tNGS) that amplify and 
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sequence specific regions allow profiling of genes of prior interest e.g. those commonly 
mutated in cancer. In addition, through the collection of paired normal tissue e.g. whole 
blood or buccal saliva swabs, it is possible to sequence germline DNA to determine the 
prevalence of inherited aberrations in known cancer susceptibility genes such as Breast 
Cancer susceptibility gene 2 (BRCA2)209,210.  
Population characteristics  
The majority of cohorts profiled to date have had either localised operable PCa or advanced 
heavily pre-treated or fatal mCRPC. There is relatively little evidence obtained from men 
with metastatic castrate-sensitive prostate cancer. It is hypothesised that the biology of de 
novo metastatic disease may be more similar to mCRPC than localised disease suitable for 
prostatectomy. This assumes that the somatic changes observed in mCRPC are not all in 
response to treatment-exerted selection pressures, but may occur as early events in 
tumorigenesis so may be present earlier, at first presentation of metastatic 
castrate-sensitive disease. These genetic features may correlate with aggressive disease, 
consistent with a de novo metastatic presentation and progression to CPRC. In the following 
sections I will summarise the published prevalence data focusing on the studies that have 
included men with metastatic disease, accepting that, with the exception of the MSK-
IMPACT cohort, all sampled patients had advanced or fatal mCRPC. 
Prevalence data  
AR pathway aberrations are seen in 50-70% of mCRPC and include amplification or 
mutation of AR itself or associated genes such as FOXA1, an AR-associated transcription 
factor or NCOR1/2 and a negative regulator of AR33,35,39,40. These somatic mutations are 
thought to occur as a result of ADT exerted treatment pressure and signal the molecular 
transition to the castrate-resistant state179. Activation of the Phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K)-AKT pathway is seen in around a quarter of primary prostate 
cancers and up to half of mCRPC38,39,211. PI3K activation phosphorylates and activates AKT, 
itself negatively regulated by the tumour suppressor PTEN. AKT mediates the 
phosphorylation and activation of mTOR complex 1, a regulator of protein translation, 
synthesis, angiogenesis and cell cycle progression212. Dysregulation of this pathway occurs 
in multiple tumour types and can occur through several mechanisms; in PCa the most 
common mechanism is through PTEN loss or truncating mutations. However mutations, 
amplification and activating fusions involving PI3K subunits or AKT are also observed33,39,40. 
PTEN loss is associated with ERG rearrangement and in multi-regional sampling of 
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metastatic disease aberrations in ERG are consistent but PTEN loss demonstrates spatial 
discordance, suggesting PTEN loss is sub-clonal and may occur as a ‘second hit' following 
ERG rearrangement31,213,214.  
The tumour suppressor gene TP53 regulates the transcription of numerous downstream 
target genes involved in cell cycle arrest, DNA repair and apoptosis and thus when p53 
activity is lost, cells lose the ability to control their growth and death215.  After AR and the 
ETS family, mutations in TP53 are the third most common somatic point mutation identified 
in metastatic prostate cohorts, occurring in 40-53%30,36,39. Analysis of matched archival and 
metastatic tissue has demonstrated TP53 mutations to be concordant and present in all 
cancer cells, consistent with this being an early clonal driver mutation40. Cell cycle 
dysregulation may also occur as a result of aberrations within the cyclin/cyclin dependent 
kinase (CDK)/retinoblastoma (RB) axis, a critical modulator of cell cycle entry 202.  RB1 loss is 
present in up to 20% of mCRPC and has been associated with neuroendocrine prostate 
cancer (NEPC), an aggressive subtype rarely identified in the hormone-naïve setting but 
present in up to 25% of lethal mCRPC 216. Additionally, aberrations in cyclin-dependent 
kinases (CDKs) such as CDK4, CDKN2A/B and CDKN1B have been identified in 4-10% 39,40.  
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Table 45: Published cohorts: approach to sequencing and sampling 
Reference Cohort details 
M
0
 
n
H
N
P
C
 
m
C
R
P
C
 Sequencing Sampling 
Barbieri et 
al.201234 
M0 CSPC suitable for prostatectomy 112  - WES  Frozen tumour blocks sampled at RP and matched normal  
TCGA 201530 Predominant low-intermediate risk M0 CSPC 333  - WES & WGS  Frozen tumour blocks sampled at RP and matched normal 
Baca et al.201431 Predominantly M0 CSPC suitable for RP; two M1 
patients with NEPC 
55  2 
 
WGS  Frozen or FFPE tumour blocks sampled at RP and matched 
normal. 2 lymph node metastases (NEPE) 
Taylor et 
al.201030 
Mixed cohort but predominantly M0 CSPC 181  37 Transcriptomic & CNA 
Exome sequencing (n=80)  
181 sampled at RP with matched normal. Additional 37 
metastatic samples   
Beltran et 
al.201337 
Mixed cohort including: M0, mCSPC and mCRPC 
including 18 with NEPC 
16 4 25  tNGS  FFPE samples: archival RP and prostate core biopsies 
Grasso et 
al.201236 
Fatal mCRPC (rapid autopsy programme) and  
M0 HNPC suitable for prostatectomy 
11  50 WES Fatal mCRPC sampled at rapid autopsy   
RP from M0 subgroup  
Cheng et 
al.2016217 
Selected due to unusual clinical course, suspected 
clinical predisposition e.g. family history  
29  13 tNGS Fresh or archival  FFPE samples (27 archival primary 
samples, 14 M1 tumour and 2 salvage RP samples 
Kumar et 
al.201635 
Fatal mCRPC sampled at rapid autopsy   63 WES and gene expression  Multiple metastatic samples obtained at rapid autopsy 
Robinson et 
al.201539 
Participants in mCRPC trials at academic centres -  150 WES Fresh frozen metastatic samples  
Mateo et 
al.201557 
mCRPC eligible for olaparib trial (TOPARP-A) 
(also analysed as part of Robinson et al
39
) 
-  50 tNGS  (DNA repair panel)  Fresh frozen metastatic tumour biopsies 
 
Pritchard et 
al.2016210 
Seven cohorts  participating in clinical trials, 
autopsy or precision medicine programmes  
  692 tNGS (DNA repair panel) Germline assessment using whole blood, buffy coat or 
buccal sampling. 
Hussain et 
al.2017218 
Sporadic mCRPC eligible for abiraterone +/- 
veliparib clinical trial  
-  80 tNGS (DNA repair panel) Fresh frozen metastatic biopsies  
Castro et 
al.2017219 
Sporadic mCRPC eligible for PROREPAIR-B  -  419 tNGS ( DNA repair panel) Germline only 
Abida et al.201740 Prospective profiling of pts attending MSK  103 135 211 tNGS  FFPE samples and blood for germline analysis  
Key: CNA, copy number alteration; CSPC, Castrate-sensitive prostate cancer; FFPE, formalin-fixed paraffin embedded; RP, radical prostatectomy; M0, non-metastatic; mCSPC, 
metastatic castrate-sensitive prostate cancer; MSK, Memorial Sloan Kettering; NEPC, neuroendocrine prostate cancer; tNGS, targeted next-generation sequencing; TOPARP, Trial of 
Trial of PARP Inhibition in Prostate Cancer; WES whole exome sequencing, WGS, Whole Genome Sequencing. 
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The maintenance of DNA integrity is a crucial cellular function, which when impaired within 
cancer cells contributes to genomic instability, thus promoting the acquisition of further 
oncogenic mutations220. Of the numerous genes involved in DNA repair, BRCA1  and BRCA2 
are the most widely studied and, together with Ataxia telangiectasia mutated gene (ATM), 
Partner and localizer of BRCA2 (PALB2), Rad51, Rad52, Checkpoint kinase 2 (CHEK2) and 
Fanconi anaemia, complementation group A (FANCA) are components in the homologous 
recombination pathway221-223. The SU2C-PCF collaboration collated exome data from 1013 
prostate cancers (including 680 primary and 333 metastatic tumours) and demonstrated 
10% of primary and 27% of metastatic PCa harboured mutations in DNA repair genes33. 
Consistent with this relative prevalence, when comparing primary and mCRPC samples 
BRCA2 was one of several genes to demonstrate significant enrichment40. This can be 
explained in one of two ways; somatic BRCA2 loss-of-function occurring as a result of 
treatment-related pressure as a molecular feature of CRPC, or alternatively as BRCA2 
mutations are associated with more aggressive disease, CRPC cohorts are enriched for this 
genetic subtype224,225. Evidence from matched archival and metastatic tissue would favour 
the latter explanation as somatic BRCA2 mutations were all concordant, suggesting that this 
occurred early in tumorigenesis40. Comparative frequencies of non-BRCA HRD aberrations 
have not been reported. However, when the incidence of somatic mutations is compared 
between mCSPC and mCRPC, all are more prevalent in mCRPC (ATM 7% vs. 10%; FANCA 3% 
vs 7%, and CDK12 6% vs. 11%), suggesting these potentially occur later in tumorigenesis40.  
Microsatellite instability (MSI) is a phenotypic consequence of impaired DNA repair 
resulting in genetic hypermutation. MSI is associated with mutated mismatch repair genes 
(MMR) such as mutS homolog 2 (MSH2) and mutS homolog 6 (MSH6). MSI has been 
reported in 3-12% of mCRPC cohorts and preliminary data suggests an association with 
ductal adenocarcinoma, a rare non-PSA secreting subtype with distinct histopathological 
features and an aggressive clinical course226. This is suggested by an analysis of 9 cases of 
ductal carcinoma sampled at rapid autopsy where 4 had evidence of MSI227. Examination of 
paired normal tissue confirmed somatic mutations in DNA mismatch repair genes, although 
in contrast with colorectal and endometrial cancer, epigenetic silencing was not observed, 
instead complex structural rearrangements in MSH2 and MSH6 occurred with resultant 
protein loss confirmed by IHC. Multi-regional sampling confirmed MSI was present in all 
metastatic sites, and concordance was also shown in the two cases where paired archival 
and metastatic samples were available228.   
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Other less frequent somatic alterations include those affecting the Wnt-B Catenin pathway, 
aberrant in 15-20% with mutations identified in adenomatous polyposis coli (APC), catenin 
beta-1 (CTNNB1) and ring finger protein 43 (RNF43)39,40. Mutations within the RAS-RAF-
MAPK pathway are observed in 3-5% and include mutations in BRAF, KRAS, RAF1 and 
mitogen-activated protein kinase 1 (MAP2K1). Additionally, mutations in chromatin 
modifiers are seen in 2-12% with the highest frequencies observed in ETS-negative mCRPC; 
genes involved include mixed-lineage leukemia-3 (MLL3 also known as KMT2C) and 
CHD133,39,40.  
In summary, the most common aberrant pathway mutations in metastatic prostate cohorts 
that are likely to be relevant to de novo metastatic disease are TP53, PTEN-PI3K-AKT and 
DNA repair. Of these, only DNA repair deficiency is currently thought to be therapeutically 
‘actionable’ and therefore this remains the largest group for which there is a strong 
rationale to investigate a molecular-directed therapeutic strategy. We hypothesised that 
the prevalence of HRD in mCSPC would be less than observed in mCRPC, but more than 
observed in M0 disease.  
 
4.1.3 Rationale for therapeutically targeting DNA repair deficiency 
DNA damage may lead to single strand breaks (SSB), double stranded breaks (DSB) or base 
modification229. SSB are common and may arise from exogenous factors such as reactive 
oxygen species; or endogenous factors such as base excision repair (BER) of damaged bases 
that may occur as a result of DNA topoisomerase 1 activity230. DNA repair may occur by 
several mechanisms; SSB are predominantly repaired by BER and to a lesser extent, 
nucleotide excision and DNA mismatch repair. BER is reliant on the PARP family of enzymes, 
which are essential for efficient DNA repair231.  If left unrepaired, SSB become DSB during 
cellular replication. DSB are highly unstable and can induce mutagenesis or cell death 
therefore highly organised mechanisms of DNA repair are required; the most accurate and 
efficient of these is homologous recombination which competes with the error prone non-
homologous end joining pathway (NHEJ)230. 
Homologous recombination repair is initiated via the recruitment of ATM which senses 
DSBs and promotes the formation of the MRN complex, containing MRE11, Rad50 and 
NBS1. ATM then plays a key role in phosphorylating substrates including BRCA1, or 
alternatively tumour-protein p53 binding protein 1 (TP53BP1) if NHEJ is being used. Which 
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pathway is selected depends in part on cyclin dependent kinases such as CDK12, which 
when active, favour BRCA1 activation232. Activated BRCA1 interacts with BRCA2 and PALB2, 
and together they promote Rad51 and replication protein A to initiate DNA repair. DNA is 
repaired using the homologous region of the sister chromatin as the replicative template, 
helping to avoid the errors of competing NHEJ pathway229. Homologous recombination is a 
complex, highly accurate pathway that involves many genes. The exact contribution of each 
gene is incompletely understood and there is likely to be some degree of redundancy. Loss 
of function of any of the genes critical to homologous recombination is predicted to result 
in HRD leading to a reliance on alternative, less efficient mechanisms of DNA repair such as 
BER, which are all PARP dependent, thus providing the rationale for therapeutic PARP 
inhibition in HRD cancers233,234.  
 
 Figure 27: Synthetic lethality  
 
Synthetic lethality: exploiting deficiencies in DNA repair: Single-stranded DNA breaks (SSB) can be 
repaired using base end repair (BER) and homologous recombination. Repair of double stranded 
DNA breaks (DSB) requires homologous recombination. Homologous recombination deficient (HRD) 
cancer cells are sensitive to PARP inhibition which leads to accumulating DNA damage and selective 
cancer cell death 
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Table 46: Selected genes involved in Homologous recombination      
Gene Name Function  
ATM Ataxia Telangiectasia-mutated  Encodes ATM , a protein kinase that senses DNA damage and phosphorylates key substrates involved 
in DNA repair including BRCA1, checkpoint kinase CHK2 and other checkpoint proteins 235,236 
BARD1 BRCA1  associated RING domain 1 The BARD1 protein binds to and interacts with BRCA1237 
BRCA1 BReast CAncer susceptibility gene -1 Encodes, BRCA1 a nuclear phosphoprotein that assists in 5’ to 3’ resection of DSBs and loading of 
Rad51238  
BRCA2 BReast CAncer susceptibility gene -2 Encodes BRCA2 which regulates the activity of Rad51 by binding to the site of DNA damage and 
encasing it in a protein sheath, the first step in the DNA repair process238 
BRIP1 BRCA1 interacting protein C-terminal 
helicase 1 
The BRIP1 protein interacts and forms a complex with BRCA1239  
CDK12 Cyclin dependent kinase 1 Regulates expression of BRCA1 and other genes involved in DNA repair240 
CHEK2 Checkpoint kinase 2 A checkpoint protein which halts cell cycle progression in response to DNA damage and also interacts 
and phosphorylates BRCA1241 
NBN Nibrin Nibrin (protein product of NBN gene) forms a complex with MRE11A and Rad50  (MRN complex) that 
interacts with the ATM gene242 
PALB2 Partner and localizer of BRCA2  PALB2 recruits BRCA2 and Rad51 to the site of DNA breaks243 
Rad51 Rad51 recombinase Interacts with BRCA2 and BRCA1; in turn activation is controlled by BRCA2, loss of this control is 
thought to be key event in genomic instability and tumourigenesis244 
Rad51B Rad51 paralog B Member of the Rad51 protein family, Rad51B forms a stable heterodimer with Rad51C and helps 
sense DNA damage245 
Rad51C Rad51 paralog C Forms a sub-complex Rad51B:Rad51C (part of BCDX2) which facilitates phosphorylation of the 
checkpoint kinase CHEK2 leading to cell cycle arrest and homologous recombination activation246 
Rad51D Rad51 paralog D Part of the Rad51 paralog protein complex BCDX2, assists with Rad51 stabilization 247  
Rad54L Rad54L  Binds to double-stranded DNA and facilitates homologous recombination repair248 
Key: BCDX2, Rad51B-Rad51C-Rad51D-XRCC2 Complex
156 
 
4.1.4 Evidence of predictive effect  
Of the many genes involved in homologous recombination, BRCA1 and BRCA2 have been 
the most studied. Data obtained in ovarian, breast and prostate cancer demonstrate that 
BRCA1 and BRCA2 mutations have the strongest evidence of predictive effect to PARP 
inhibition57,249-252. Clinical evidence that genetic faults in non-BRCA HRD genes have the 
same predictive effect has not been directly sought in ovarian and breast cancer. However, 
the therapeutic relevance of HRD arising from mutations in non-BRCA HRD genes has been 
shown in the study of platinum responses in ovarian cancer253. In a study of 390 patients 
with advanced ovarian cancer, germline or somatic mutations in one or more of 13 HRD 
genes (BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK1, CHEK2, ABRA1, MRE11A, NBN, PALB2, 
Rad51C and Rad51D) was associated with platinum sensitivity (p=0.0002). As platinum is a 
DNA-damaging chemotherapy HRD tumours are predicted to exhibit similar therapeutic 
sensitivity. This therefore may be considered indirect evidence that HRD arising due to 
mutations in genes other than BRCA1 or BRCA2 are therapeutically relevant.  
ATM loss is predicted to result in PARPi sensitivity reflecting its important role in 
homologous recombination repair, see Table 46. As ATM mutations are relatively rare in 
ovarian cancer there is limited clinical evidence in this setting, however recent in vitro data 
in ATM-mutant colorectal cancer demonstrates PARP sensitivity254. Pre-clinical data has also 
shown NBN, Rad51, CHK2 and PALB2 mutations all to predict PARP sensitivity in vitro255-260. 
Preliminary clinical evidence for activity in the broader HRD group in PCa is also provided by 
the TOPARP trial, a phase 2 study of olaparib in mCRPC. Responses were observed in 4/6 
patients with an ATM mutation, 2/3 with FANCA mutation, 1/2 with CHEK2 mutation, 2/2 
PALB2 mutation, 1/1 NBN mutation; although it should be noted that both patients who 
had a FANCA and CHEK2 mutation also had a BRCA1 or BRCA2 mutation57.  
In summary, mechanistically the presence of HRD occurring through germline or somatic 
mutation in a relevant gene predicts synthetic lethality with PARP inhibition. Homologous 
recombination is a complex, multi-gene pathway and the functional significance of 
individual mutations within known genes remains incomplete. It is also possible that known 
genes involved in homologous recombination interact with other genes and pathways, 
meaning that additional genetic aberrations may impact on homologous recombination, or 
redundancy may rescue this function in the presence of mutations predicted to be 
significant.  The strongest evidence of a predictive effect is currently seen for BRCA1 and 
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BRCA2 as these have been predominantly used as biomarkers in the clinical evaluation of 
PARPi to date, summarised in the sections below.  
 
4.1.5 Initial evaluation of PARP inhibitors in ovarian and breast cancer    
Ovarian data  
The clinical activity of PARP inhibition was first shown in BRCA-associated ovarian and 
breast cancer. Olaparib, rucaparib and niraparib have all received regulatory approval for 
use in platinum-sensitive ovarian cancer. Olaparib was the first to be licenced in BRCA-
mutated (BRCA-m) platinum-sensitive ovarian cancer based on the results of Study 19, 
which showed a significant improvement in PFS, 8.4 months vs. 4.8 months (HR 0.35 95% CI 
0.24-0.49)261. A subsequent retrospective analysis demonstrated the largest benefit in 
BRCA-m arising as a germline or somatic loss262.  BRCA status was assessable in 254/265 
patients and the mutational prevalence was 51%. The treatment effect in the BRCA-m 
subgroup was HR 0.12 (95% CI 0.10-0.31), compared with BRCA-wild-type (BRCA-WT); HR 
0.54; (95% CI 0.34-0.85). 
It is hypothesised that observed benefit in BRCA-WT cases may be explained by functional 
HRD occurring due to epigenetic silencing of BRCA1 or BRCA2 or inactivation of other genes 
involved in homologous recombination263. In support of this, distinct mutational signatures 
associated with BRCA1 and BRCA2 mutations are also observed in BRCA-WT samples and 
developed as biomarkers of “BRCA-ness” or HRD198. These algorithms assess genomic 
features of instability as a marker of HRD, including loss-of-heterozygosity (LOH)264, 
telomeric allelic imbalance265 and large-scale state transitions266. Foundation Medicine 
provides an assessment of LOH as part of Foundation One, whilst Myriad Genetics have 
incorporated all three into their commercialised assay myChoice®. Both niraparib and 
rucaparib have been evaluated in trials designed to evaluate these biomarkers of HRD, 
building upon the broader benefit suggested in Study-19, although as HRD is defined 
differently in all trials, these data are not directly comparable. An ongoing non-randomised 
phase II trial will also evaluate olaparib in four cohorts aiming to explore this further; 
germline BRCA (gBRCA) mutant, somatic BRCAm and gBRCA-WT, HRD positive as defined by 
myChoice and a further HRD negative cohort (NCT02983799). 
Rucaparib is approved as a treatment and maintenance therapy for BRCA-m (germline or 
somatic) platinum-sensitive ovarian cancer. Evidence of activity in the relapsed setting was 
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shown by the results of the ARIEL2 study. This open-label phase 2 trial enrolled 206 patients 
and assessed PFS within three cohorts evaluating different biomarker enrichment 
strategies: BRCA mutant (n=40), BRCA-WT and high LOH (n=83), and BRCA WT and LOH low 
(n=71); it was not possible to determine LOH status in 12 cases.  PFS was 12.8 months (95% 
CI 9.0-14.7) in the BRCA-m subgroup, 5.7 months (95% CI 5.3-7.6) in the high-LOH group 
and 5.2 months (95% CI 3.6-5.5) in the LOH low subgroup. ARIEL 4 is an ongoing post-
registrational confirmatory study in this setting. ARIEL-3 demonstrated that rucaparib is 
also beneficial in the maintenance setting. This placebo controlled phase 3 RCT enrolled 
564 patients analysed in three cohorts using a stepdown approach: BRCA-m (n=196); high-
LOH, which may include BRCA mutant, (n=354), and the entire ITT i.e. molecularly 
unselected. Consistent with previous results, the largest benefit was observed in the BRCA-
m group, HR 0.23 (95% CI 0.16-0.34) p<0.0001. A significant improvement in PFS was also 
shown in the high LOH subgroup; HR 0.32 (95% CI 0.24-0.42) p<0.0001. When the BRCA-m 
group are excluded (as they overlap with high-LOH and may be driving this effect) we 
continue to observe benefit in the BRCA-WT group, consistent with the results of Study-19. 
However when the treatment effect is examined in the BRCA-WT group the predictive 
ability of LOH appears less clear; BRCA-WT LOH-high (HR 0.55; 95% CI 0.35-0.89) p=0.0135 
and BRCA-WT-LOH-low (HR 0.47; 95% CI 0.31-0.71) p=0.0003. Therefore the utility of LOH 
remains uncertain, importantly threshold values continue to require refinement, and are 
yet to be validated outside of ovarian cancer267.   
Niraparib is the only PARPi to receive approval for non-BRCA mutated, platinum-sensitive 
ovarian cancer, based on the results of the NOVA trial268. In total 553 patients were 
enrolled and split into two efficacy populations based on the results of gBRCA testing; 
gBRCA mutant (n=203) and non-gBRCA mutant (n=350). Significant PFS benefit was shown 
in both gBRCA mutant, HR 0.27 (95% CI 0.17-0.41) p<0.01 and non-gBRCA-mutant cancers; 
HR 0.38 (95% CI 0.24-0.59) p<0.01, supporting the regulatory approval in an unselected 
population. Further exploratory subgroup analyses were performed and confirm that 
germline and somatic BRCA1 or BRCA2 mutations appear to confer the same predictive 
effect, gBRCA-mutant HR 0.27 (95% CI 0.17-0.41) and somatic BRCA-mutant 0.27 (95% CI 
0.08-0.90). Prior to the primary analysis a protocol amendment required submission of 
tumour samples for HRD analysis, assessed using myChoice®, classifying non gBRCA-mutant 
cases as HRD positive and negative and again, benefit was observed in HRD negative cases: 
HR 0.58 (95% CI 0.36-0.92) p<0.01. 
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Breast Cancer data 
PARPi have also been shown to be active in BRCA-m metastatic breast cancer, with two 
large positive phase III trials reported in 2017. The OlympiAD trial randomised 302 patients 
with gBRCA-mutant, HER-ve metastatic breast cancer to receive olaparib or physicians 
choice therapy252. Blinded central review of rPFS was required given the open-label design 
and demonstrated a significant improvement; 7.0 vs. 4.2 months (HR 0.58; 0.43-0.80) 
p<0.001. This led to regulatory approval of both olaparib in this indication, and a 
companion diagnostic, Myriad Genetic BRCA Analysis Companion diagnostic. The recently 
reported EMBRACA trial has also shown a comparable PFS gain with talazoparib in BRCA-m 
metastatic breast cancer; 5.6 months vs. 8.6 months (HR 0.54; 0.41-0.71, p<0.0001)269.  
4.1.6 Rationale for PARP inhibitors in prostate cancer  
A proportion of prostate cancers are associated with gBRCAm; for men ≤65 years BRCA2 
mutations confer a 8.6 fold increased risk and BRCA1 a 3.4 fold increased lifetime risk of 
developing prostate cancer270,271. The demonstration that BRCA2 deficient cells are 
selectively sensitive to PARPi provided the rationale to include PCa in the range of BRCA-
associated cancers eligible for the early phase PARPi trials272,273. AR activity has been shown 
to be linked with DNA repair. PARP1 is recruited to sites of AR activity where it regulates 
transcriptional function274. AR signalling has been shown to promote homologous 
recombination through facilitating MRN foci formation and ATM activation275. Therefore 
ADT can be expected to inhibit homologous recombination, requiring a shift to other less 
efficient and PARP-dependent mechanisms of DNA repair. It is proposed that this may 
explain the observed synergy between ADT and RT, another DNA damaging therapy which 
induces DSBs276. The same mechanism is thought to explain the in vitro and in vivo synergy 
of bicalutamide or enzalutamide with olaparib, and the demonstration that “lead in” with 
enzalutamide followed by PARPi suppressed HRD gene expression and promoted DNA 
damage-induced cancer cell death in vivo prostate cancer models275,277. Together, these 
data provide a strong pre-clinical rationale for the evaluation of PARPi in addition to ADT in 
PCa.  
Early phase trials that sought to evaluate PARPi in gBRCA-m cohorts provided the first 
evidence of activity in BRCA-m prostate cancer. In a phase I trial eight patients with BRCA-m 
mCRPC were treated with olaparib and RECIST responses were observed in half250. In a 
second phase I trial, 3/60 patients enrolled had BRCA-m mCRPC, and biochemical, clinical or 
radiological responses were all seen. A durable treatment response was observed in one 
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BRCA2 mutant case, who remained on treatment for over a year having experienced a PSA 
response of >50% associated with resolution of bone metastases249. Supported by these 
data, several phase 2 trials were initiated in prostate cancer, as summarised in Figure 28, 
Figure 29 and Figure 30.  
Figure 28: Olaparib: summary of ongoing evaluation in prostate cancer 
 
When seeking to identify the subpopulation of PCa hypothesised to benefit most from 
PARPi, several differences exist in comparison to other BRCA-associated cancers that have 
led to a different biomarker enrichment approach. Firstly, platinum sensitivity may be 
considered a clinical biomarker likely to correlate with PARPi sensitivity, as a subsequent 
DNA-damaging therapy seeking to exploit the same biological vulnerability. Platinum 
sensitivity has been incorporated into all selection strategies for PARPi trials in ovarian 
cancer, and used as a surrogate for HRD sensitivity when developing biomarkers of HRD265.  
However, as platinum is not a standard treatment for PCa it cannot be used in the same 
way. Secondly, the observed prevalence of BRCA1 and BRCA2 mutations in ovarian cancer is 
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33-51%, much higher than in PCa. These differences help explain the adaptive 2-stage 
approach to biomarker selection adopted in TOPARP, a phase II evaluation of olaparib in 
mCRPC. Initially, an unselected population were recruited (n=50) to part A, all of whom 
underwent biomarker assessment using mandated fresh frozen biopsies obtained prior to 
trial entry. Biomarker assessment was not limited to BRCA1 or BRCA2; instead a tNGS panel 
including 12 genes involved in homologous recombination was assessed. 33% of those 
enrolled were defined as biomarker positive based on a deleterious mutation in one or 
more HRD genes. High specificity was demonstrated for this approach. 14/16 biomarker 
positive patients responded, compared with 2 out of 33 biomarker negative patient. As 
detailed in Section 4.1.4, the strongest evidence of predictive effect was in BRCA2, BRCA1 
and ATM, in total 13/16 patient responded. Lack of response was observed where 
monoallelic deletions were present supporting the observations of others that biallelic loss 
is required to be functionally relevant57,278. This biomarker strategy has informed the design 
of the TOPARP-B trial which aims to recruit 88 participants with HRD-mCRPC 
(NCT01682772) and has influenced several other ongoing phase II trials.  
Figure 29: Rucaparib: summary of ongoing evaluation in prostate cancer 
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The TRITON programme aims to evaluate rucaparib in HRD deficient mCRPC. TRITON 2 is 
enrolling three cohorts in order to evaluate activity in the BRCA1, BRCA2, ATM subset, as 
the group with the highest prior evidence of predictive effect. Additionally, preliminary 
evidence for activity in a broader group defined by predicted pathogenic mutations in one 
of 15 HRD genes listed in Table 46 is also being sought in cohort C, see Figure 29. A phase II 
trial evaluating niraparib in a broader HRD-group of mCRPC, defined using a company 
specific assay has been initiated and results are awaited (NCT02854436).  
Figure 30: Niraparib: summary of evaluation in PCa 
 
In addition, PARPi are being evaluated in combination with checkpoint inhibitors or second-
generation AR-targeted agents. The combination of PARPi and immune checkpoint 
inhibition is supported by the observation that HRD tumours are associated with increased 
tumour infiltrating lymphocytes (TILs) and may exhibit an immunosuppressive phenotype, 
characterised by upregulation of Programmed death-ligand 1 (PD-L1) expression279. This has 
been observed when comparing immune cell marker expression in ovarian cancer, which is 
higher in BRCA-m compared with BRCA-WT tumours280. Similarly, BRCA1 associated triple 
negative breast cancers have increased TILs and overall mutational burden compared with 
BRCA1-WT tumours279. The suggestion that this subset may benefit from checkpoint 
inhibition is further supported by the demonstration that BRCA2 mutations correlate with 
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responses to anti-PD-1 agents in melanoma281. The recent demonstration of synergy 
between AR signalling and HRD provides a rationale to investigate the combination with 
second-generation AR-targeted agents275,277. Should this combination be shown to be safe, 
this strategy could also be evaluated in the castrate-sensitive setting as abiraterone has 
recently been shown to be an alternative SOC to docetaxel. See Appendix G AB: Table 78 - 
AB: Table 80 for full list of PARPi trials in PCa. 
In summary, whilst the clinical data in metastatic breast cancer is limited to gBRCA-mutant 
cases, there is clear evidence of a broader effect in ovarian cancer. We consistently observe 
the greatest benefit in BRCA-m cancers, and germline and somatic mutations appear 
functionally similar and to confer a similar predictive effect268,282. Within ovarian cancer, 
non-BRCA mutated cancers may also be effectively treated by PARPi but the clinical utility 
of biomarkers of HRD is yet to be convincingly shown, and as such regulatory approval 
within this biomarker-defined group has not been achieved. In comparison with other 
BRCA-associated cancers, hereditary PCa is rare meaning biomarker strategies that are 
limited to germline mutations are expected to fail to identify the entire population 
hypothesised to benefit. This means tumour-based assessments that capture both somatic 
and germline mutations are preferable. The evidence from TOPARP supports a tNGS 
approach that includes several of the genes known to be involved in homologous 
recombination. Finally, the biomarker strategies adopted in the pivotal trials have relied 
upon collaboration between pharmaceutical companies and commercial sequencing 
providers and several companion diagnostics have been approved as a result. Whilst 
regulatory assessment of predictive biomarkers may be expected to ensure high-quality 
standards are met, this pattern of joint regulatory submission of drug and companion 
diagnostic adds complexity to trial design and data use. From the perspective of an 
academic-led trial, such partnerships necessitate collaborations with multiple industry 
partners and can mean the sequencing data is commercially sensitive. Lastly, when 
considering how best to evaluate PARPi in prostate cancer, the commercialisation of 
biomarkers of HRD will likely mean that this population is defined differently across 
different trials which may risk delaying regulatory approval in this expanded indication, if 
shown to be effective.  
  
164 
 
4.1.7 Evaluating PARP inhibitors: trial design considerations 
When considering how best to design and implement a randomised evaluation of a PARPi in 
mCSPC, biomarker prevalence was identified as the key factor in determining feasibility and 
the optimal approach. Prevalence impacts on the number needed to screen, accrual rate, 
recruitment duration and required number of participating screening sites. When 
addressing this question within a MAMS platform, the prevalence also determines the likely 
impact on the accrual and generalisability of other co-recruiting comparisons. When 
modelling the scenarios within STAMPEDE several trial designs were modelled and based 
on current recruitment rates, the minimum feasible prevalence was estimated at 10%, as 
shown in Figure 31 and Figure 32. 
Part of the rationale to investigate molecularly-selected PCa treatments in the first-line 
setting is the proximity to the time of diagnostic sampling. Although, to avoid repeat 
sampling, as required in many other CRPC trial protocols, it is necessary to demonstrate 
that the residual diagnostic FFPE tumour tissue yields sufficient DNA required for tNGS. Test 
failure rates inflate screening numbers and are therefore an important component in the 
feasibility assessment. Obtaining data in representative clinical samples was identified as a 
second aim that could be addressed through analyses of retrospectively collected samples 
from existing STAMPEDE participants with metastatic disease at trial entry.  
Biomarker–selected trials that limit recruitment to one molecularly-defined cohort risk high 
screen failure rates which may negatively impact on participant and investigator 
enthusiasm, whilst incurring high screening costs. This was part of the rationale to embed 
this question within the STAMPEDE study, aiming to have an inclusive trial platform in 
which all participants may be eligible for randomisation, regardless of biomarker status. To 
be eligible to join the transdermal comparison or the metformin comparison participants 
must be randomised within 8 or 14 weeks of starting anti-androgens respectively. This 
therefore means the turnaround time for biomarker analysis becomes a critical rate limiting 
step and an important consideration in defining the duration of ADT permitted before 
biomarker screening. In turn, the eligibility criteria need to be workable within the current 
clinical pathway if the required screening accrual is to be achieved. Currently the vast 
majority of patients commence ADT before being approached about STAMPEDE trial 
participation and most have received around 6-9 weeks ADT exposure prior to 
randomisation; this means biomarker-screening needs to be completed within 4 weeks. 
165 
 
Piloting this process and testing out the necessary infrastructure required to implement this 
was recognised as an important part of the feasibility assessment. 
Another design consideration relates to the prognostic impact of the biomarker as this 
determines whether it is valid to use the single control group within a MAMS platform. 
Data obtained from two large PCa cohort studies has shown gBRCA-m are associated with a 
more aggressive clinical course suggesting that a separate control arm may be needed to 
distinguish prognostic from predictive effect. In an analysis of 2019 patients with PCa 
enrolled in either the United Kingdom Genetic Prostate Cancer Study (UKGPCS) or 
Epidemiological Study of BRCA1/2 mutations Carriers (EMBRASE), gBRCA1-m or gBRCA2-m 
were shown to be independently prognostic of cancer-specific survival (HR 1.8; 95% CI 1.1-
3.5; p=0.015)224. Recent analyses have suggested that germline defects in ATM may confer 
a similar negative prognostic effect. In a retrospective case-case study of 313 patients with 
lethal PCa and 486 patients with low-risk localised prostate cancer, germline DNA analysis 
demonstrated a significantly higher incidence of BRCA1, BRCA2 or ATM mutations in those 
who died of their disease. Survival analyses in the entire cohort adjusted for race, age, PSA 
and Gleason score at presentation demonstrated the presence of a germline aberration in 
one or more of these three genes was an independent predictor of lethal PCa (HR 2.13; 95% 
CI 1.24-3.66; p0.004) 283. Further support for this is provided by the retrospective review 
conducted as part of the PRO-REPAIR cohort study, which showed gBRCA2-m were 
associated with earlier progression to CRPC and shorter prostate cancer-specific survival209.  
Evidence for the prognostic significance of aberrations in other HRD genes is more limited. 
A published international collaboration reported outcomes in 390 patients with metastatic 
prostate cancer who had undergone germline analysis as part of various clinical trials or 
precision medicine initiatives. 60 were found to have germline aberrations in BRCA2, 
BRCA1, ATM, CHEK2, PALB2 or Rad51D.  The median survival from time of 
castrate-resistance was comparable in the gHRD-mutated group 3.0 years (IQR 2.4-5.6) vs. 
the gHRD-non mutated group 3.2 (1.7-5.5 years). Although likely underpowered, in a 
multivariable analysis adjusted for other known prognostic factors, the presence of 
germline HRD mutation was not shown to be statistically significant: adjusted HR 0.93; 95% 
CI 0.63-1.37; p=0.72)284. Within the PRO-REPAIR study 9.1% were found to have germline 
HRD, however the prognostic effect appeared driven by the BRCA2-m subset (3.3%)209. On 
the basis of these data that suggest germline aberrations in BRCA1/2 and ATM are 
negatively prognostic, and in the absence of data to elucidate the prognostic impact of 
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somatic aberrations, the proposal is that PARPi randomisations should be compared against 
a separate biomarker positive control arm to enable predictive and prognostic impact to be 
distinguished.  
There are two clear advantages of evaluating biomarker-selected comparisons within an 
adaptive trial platform. Firstly, biomarker specificity can be tested through opening a 
randomised comparison within an unselected group. Where initial evidence for predictive 
effect is judged sufficient to support an enrichment strategy, this assessment may be 
undertaken once activity has been demonstrated at a pre-planned analysis of futility. Early 
stopping rules may be useful in the unselected population i.e. through defining different 
futility parameters. The need to undertake this assessment should be driven by data 
external to the trial, for example evidence that PARPi may benefit a broader group.  
Secondly, as exemplified by other biomarker-stratified trial platforms such as FOCUS-4 and 
the National Lung Matrix Trial (Matrix), efficiencies can be gained through utilising the 
trials’ infrastructure to address multiple biomarker-selected questions. These can be 
addressed through one centralised cost-efficient biomarker-assessment and multiple 
pharmaceutical collaborations can help reduce the cost of screening.  However the 
feasibility and design implications of this strategy depend on the overlap between 
biomarker-defined subgroups. As has been shown to be the case in colorectal and lung 
cancer, sub-clonal putative aberrations may co-exist leading to uncertainty as to which 
therapy should be selected and requiring hierarchical systems to be established. 
Furthermore, HRD cancer may be hypothesised to acquire and tolerate other genetic 
aberrations at a higher frequency, increasingly the likelihood of overlap. Comprehensive 
genomic profiling within this disease setting is required to known if it is feasible to address 
multiple biomarker-selected comparisons within one protocol.  
In summary, analysis of clinically representative samples from men with mCSPC enrolled in 
STAMPEDE can provide valuable genomic profiling data, assess the feasibility of addressing 
molecular biomarker-treatment pairings in this disease setting and inform how these could 
potentially be evaluated within a MAMS trial platform in the future.  
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Figure 31: Provisional trial design – biomarker prevalence 14%  
 
Figure 32: Provisional trial design – biomarker prevalence 10%  
 
 
  
Provisional trial designs: The minimum biomarker prevalence required to achieve a efficacy 
analysis within around 10 years is 10% (allowing for a test failure rate of up to 25%). These 
projected scenarios are based on 100 patients joining STAMPEDE per month, 65% of patient 
having metastatic disease at trial entry and 80% of these accessing screening. Therefore 52 
patients per month are eligible for screening. Given these parameters the total number 
needed to screen is 5772 and the recruitment duration is 9 years. If the prevalence if 14%, 
the accrual period is reduced to 6.75 years and the efficacy analysis is projected within 8.5 
years. The total estimated required sample size is around 420 patients, targeting a survival 
difference of HR 0.65.  
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4.1.8 Research aims 
In this chapter I will describe a feasibility and prevalence study undertaken to address the 
following three research questions:  
1. Is it feasible to molecularly profile mCSPC through analysing remaining FFPE 
diagnostic tissue using tNGS assays? 
2. What is the prevalence of HRD in mCSPC? 
3. What is the prevalence of other putative actionable mutations and how do these 
groups overlap?  
 
4.2 Methods  
This study was undertaken through retrieving remaining diagnostic PCa samples stored as 
FFPE tumour blocks from a selection of NHS sites, in collaboration with the Wales Cancer 
Bank (WCB), the trial designated biobank. Funding was provided by Clovis Oncology who 
supported the costs of sequencing and provided a grant to the MRC CTU at UCL to support 
sample retrieval. Two analyses were performed in collaboration with two different 
commercial sequencing providers. Foundation Medicine (FM) sequenced all samples in 
analysis one and Almac Diagnostics (Almac) sequenced all samples in analysis two.  
All STAMPEDE participants recruited since 2006 have been asked to consent to the use of 
remaining diagnostic PCa tissue in additional analyses. These projects require separate 
ethical approval and review by the trial oversight groups. I wrote a translational protocol 
that described these analyses and obtained ethical approval from the West Midlands REC 
(16/WM/0188), see Appendix F Biomarker Development Protocol and Appendix G 
Confirmation of ethical approval. This project was also approved by the STAMPEDE 
Biological Research Group, a subgroup of the TMG. 
4.2.1 Sample collection  
Although described in the STAMPEDE protocol since 2006, sample retrieval had not been 
initiated, necessitating establishment of new processes, collaborations and contractual 
relationships. I coordinated a call for collaborators to select two trial biobanks. WCB, one of 
the two selected, received all samples contributing to these analyses. I contacted NHS sites 
to update site contracts to permit material transfer and reimbursement. Through querying 
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the trial databases, I generated sample lists which were sent with site guidance in order to 
request the required samples.  
4.2.2 Sample selection  
Sampling was limited to participants randomised since November 2011 to ensure that 
prevalence estimates were generalisable to all metastatic patients. Prior to this date a 
histological diagnosis was not required by the STAMPEDE protocol in cases of clinically 
metastatic disease with bone involvement and PSA>100ng/mL. Sample requests were sent 
to the randomising site and the most tumour rich FFPE tumour blocks containing the PCa 
samples obtained prior to randomisation were requested i.e. pre-treatment. 
The key selection criteria were: 
 Metastatic disease at trial entry  
 Consented to gift remaining tumour samples 
 Randomised from November 2011 onwards at a site participating in sample 
retrieval  
Pathology review was undertaken by a single uro-pathologist (Dr David Griffiths) who 
assessed tumour content based on a representative Haemotoxylin and Eosin (H&E) stained 
slide prepared at the WCB if not provided by the site. For analysis two, conducted in 
collaboration with Almac, an H&E slide was marked with the estimated tumour content. In 
both analyses, samples with an estimated tumour content of >20% were submitted for 
sequencing.  
4.2.3 Nucleic acid extraction and sequencing  
Sequencing analysis was undertaken by two commercial providers. Analysis one was 
conducted as an extension of an existing collaboration between Clovis Oncology and 
Foundation Medicine (FM) who supported biomarker screening for the ARIEL programme 
and subsequent successful FDA submission. Reflecting this rapidly developing technological 
area and considering the logistics and cost implications of using a provider based in the US, 
preliminary data was acquired using a second UK-based provider, Almac. Both providers 
undertook nucleic acid extraction and sequencing using a tNGS panel.  
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Analysis One: FoundationOne® provided by Foundation Medicine  
FoundationOne® (F1) is a clinically accredited tNGS-based test available from FM, a 
commercial laboratory which is Clinical Laboratory Improvement Amendments (CLIA) 
certified and College of American Pathologists (CAP) accredited.  F1 has been 
commercialised as a comprehensive cancer genome profiling suitable for all solid 
tumours285. The F1 assay has been validated in FFPE samples where the requirements are: 
surface areas of ≥25mm2, nucleated cellularity of ≥80% or ≥30,000 cells and tumour 
content ≥20%. Library preparation is performed from DNA extracted from unstained FFPE 
sections and requires a minimum of 50ng dsDNA. The selected areas of interest are 
amplified by hybridization capture using biotinylated DNA oligonucleotides complementary 
to 315 exons of cancer-related genes and selected introns where cancer related 
rearrangements frequently occur. Sequencing is performed using the Illumina HiSeq 
platform. The typical median coverage is 500X; with >100X at >99% of exons. Four classes 
of somatic genomic alterations are reported: base substitutions, insertions and deletions 
(also termed indels), copy number alterations and rearrangements. 
The published validation and experience from the first 2221 sequenced samples (mixed 
solid tumours) reported >99% positive predictive value where the threshold of ≥20% of 
nucleated cells are tumour derived was met. As part of the validation the concordance with 
aberrations detected by fluorescent in-situ hybridisation (FISH) or IHC was assessed; this 
included 25 PCa samples with AR-amplification and 22 PCa samples with PTEN deletion; 
concordance was 100% and 95% respectively. See A7: Figure 41 in Appendix A for the list of 
326 genes covered by F1. 
Analysis Two: Ilumina TruSight Tumour T170 Panel provided by Almac Diagnostics   
Illumina TruSight Tumour 170 (t170) Panel is a tNGS assay, provided by Illumina and 
analytically validated by Almac, a commercial provider of companion diagnostics.  The t170 
has been developed to target both RNA and DNA extracted from FFPE tumour samples. 
Parallel DNA and RNA library preparation occurs, each requiring 40ng DNA/RNA input. The 
assay detects base substitutions, insertions and deletions, fusions and splice variants.  This 
project was conducted whilst Almac were providing this as a RUO assay. Analytical 
validation was ongoing and as such the assay underwent refinement during the conduct of 
the project. Almac aim to commercialise the t170 as a CLIA compliant assay for prospective 
use in clinical trials of molecularly-directed therapies, with pharmaceutical companies 
providing a list of mutations of interest that will be used to define eligibility. Almac 
incorporate this into the analysis algorithm and report a proportion of the t170 assay 
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according to the agreed parameters required for the trial. Almac has successfully 
collaborated with several other clinical trials, including the European Organisation for the 
Research and Treatment of Cancer (EORTC) SPECTRA programme (Screening Patients for 
Effective Clinical Trial Access), a pan-European network that aims to support numerous 
precision medicine trials. See A7: Figure 42 in Appendix A for the list of 170 genes 
sequenced as part of the t170. However in contrast to F1, only the proportion of pre-
specified genes relevant to the eligibility call are reported, in this case 14 genes involved in 
homologous recombination. These were defined by Clovis, the pharmaceutical partner and 
manufacturer of rucaparib, informed by pre-clinical and clinical data.   
4.2.4 Assay comparison  
Comparison of sequencing methods  
Details of the sequencing methods are shown Appendix A6. Notable differences include 
dual DNA and RNA extraction performed by Almac who also routinely macrodissect all 
samples, aiming to enrich tumour content. Both providers use Illumina sequencing 
platforms, however the hybrid capture and amplification differ and the comparable 
coverage at positions relevant to HRD eligibility calls is not known. F1 is a broader assay 
covering over 300 genes and has been validated to detect copy number alternations. T170 
covers 170 genes but excludes intronic regions, which prevents the detection of intronic 
deletions or intragenic splice site variants that occur across exonic-intronic regions. 
Additionally, the t170 cannot reliably detect copy number alterations as these failed to 
meet with pre-defined analytical validation criteria. Also, splice variants, which are called 
from the RNA component in the t170 assay, are yet to be analytically validated so can only 
be reported on a RUO basis.  
Concordance assessment 
20 samples were analysed by both providers in order to assess concordance. Samples 
underwent DNA extraction by FM and initial sequencing using the F1 assay. Remaining DNA 
was then transferred to Almac who performed sequencing using the t170 assay. This 
allowed comparison of the DNA component of both assays across the 126 genes covered by 
both, see Appendix 7 for detailed gene lists. 
4.2.5 Site pathology survey  
All 15 hospital sites contributing samples to analysis one were surveyed to assess pathology 
practices. Research teams were requested to obtain pathology input when providing 
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answers to the nine questions listed in Box 1. The responses were compared with FM’s 
optimum sample processing guidance, see Appendix H. 
Box 1: Pathology questionnaire 
 
1. What fixative solution is used?    
2. What is the minimum fixation time for prostate biopsies?  
3. What is the maximum fixation time?   
4. Do you process on a Saturday?   
5. Are Friday samples in fixative until Monday?  
6. Do you use microwave processing?  
7. Do you use xylene free processing?  
8. For prostate biopsies, do you use a ‘routine’ overnight cycle or do you have a 
specific biopsy processing cycle?   
9. If you have a specific biopsy cycle, what is the cycle length? 
 
4.2.6 Biomarker-screening pilot  
I designed and wrote an amendment to the STAMPEDE protocol in order to pilot 
prospective biomarker-screening at a selection of hospital sites, see Appendix C for links to 
online protocol. This will assess the feasibility of enrolment based on HRD, defined as a 
pathogenic mutation in one or more of 14 HRD genes.  This will pilot rapid sample retrieval 
from a range of sites (district general and large tertiary referral centres) and provide 
preliminary data on turnaround time. Data from other ongoing STAMPEDE sub-studies has 
demonstrated that it is feasible to sequence nucleic acid extracted from saliva, FFPE and 
Streck tubes™ from which circulating tumour DNA (ctDNA) can be isolated. All three 
sampling approaches will be evaluated as a means to prospective genomic characterisation, 
with comparative results anticipated in summer 2018. Accruing germline data is presented 
obtained through saliva sampling analysed by Color Genomics as a preliminary indication of 
germline prevalence in this population. See A7: Figure 43 in Appendix A7 for the list of 
genes covered by this germline assay.  
4.2.7 Correlative clinical information and data interpretation 
Baseline clinical information collected at randomisation was obtained for all participants 
sampled and the comparable randomised population during the time period (November 
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2011 to May 2017). Baseline data included all prognostic characteristics such as disease 
stage, baseline age and performance status, Gleason sum score and presenting PSA.  When 
comparing groups, the Kruskal Wallis non-parametric test was used and a p value <0.05 was 
considered statistically significant. I performed all analyses using STATA version 15.0 
(StataCorp LP, College Station, TX, USA) and additional data management and analysis was 
undertaken in Microsoft Excel 2010. Supported by Fiona Ingleby, statistician at the MRC 
CTU at UCL, I generated Venn diagrams to visualise overlap between molecularly defined 
subsets. Publically available genomic dataset available via cBioPortal 
(http://www.cbioportal.org) an online resource hosted by Memorial Sloan Kettering Cancer 
Centre (MSK) were interrogated in order to contextualise these data with other published 
sequencing studies.  
 
4.3 Results  
4.3.1 Population characteristics  
Samples from 187 patients, randomised to 1 of 7 research arms between July 2010 and 
April 2017 were submitted for sequencing as part of analysis one. See Appendix A8: Table 
73 for all 15 contributing sites and Appendix A9: Table 75 for the distribution of 
participants by allocated trial arm.  
Samples from 100 patients randomised to 1 of 3 arms open between Jul-2014 and May-
2017 were submitted for sequencing as part of analysis two. These samples were collected 
from 28 sites; see Appendix A8: Table 74 for a site list. Appendix A9: Table 76 shows the 
distribution by allocated trial arm. 
Both sampled populations were representative of the population enrolled into the 
STAMPEDE trial. As shown in Table 47 and Table 48, both are comparable with the 
intention-to-treat (ITT) population, defined as all patients randomised into STAMPEDE 
during the respective time period. No difference in baseline characteristics were noted 
between the participants in whom sequencing failed compared with those for whom data 
was successfully obtained. Therefore the missing sequencing data is assumed to be missing 
at random.  
The patient population identified to have an HRD cancer did not appear significantly 
different when compared with the total sampled population. There was little evidence to 
174 
 
support a prior hypothesis that HRD cancers may be more prevalent in younger men. 
Instead, a borderline statistically significant trend was observed for HRD cancers to be 
observed in older men (Kruskal Wallis test p=0.0421), see Table 49. 
 
Table 47: Comparative baseline characteristics (Analysis One: F1)  
* Comparative ITT population had metastatic disease (M1) at trial entry, randomised during the 
same time period at the 15 sites who contributed samples to this analysis  
 
 
  
Baseline Characteristics  Comparative 
ITT* 
Sampled 
population  
Sequenced  Test failed   
    N=1043  n=187 n=115 n=72 
Age  Median  68 years 69 years 70 years 67 years 
Range  40-86 years 44-85 years 44-85 56-80 
Presenting 
PSA  
(ng/ml  
Median  97  129 90 149 
IQR   31-338 27-421 17-400 51-455 
T stage ≤T2 130 (12%) 13 (7%) 9 (8%) 4 (5%) 
T3 590 (57%) 103 (55%) 62 (54%) 41 (57%) 
T4 257 (25%) 59 (32%) 35 (30%) 24 (33%) 
Tx 66 (6%) 12 (6%) 9 (8%) 3 (4%) 
Nodal state N0 373 (36%) 72 (38%) 35 (30%) 37 (51%) 
N1 602 (58%) 103 (55%) 72 (63%) 31 (43%) 
Nx 68 (7%) 12 (6%) 8 (7%) 4 (6%) 
Disease 
category 
De novo M1 1005 (96%) 183 (98%) 112 (97%) 71 (99%) 
Relapsed M1 38 (4%) 4 (2%) 3 (3%) 1 (1%) 
Metastatic 
distribution 
Bone only 694 (67%) 127 (68%) 73 (63%) 54 (75%) 
Distant node 
only 
104 (10%) 16 (9%) 12 (10%) 4 (6%) 
Bone & nodal 
or other 
245 (23%) 44 (24%) 30 (26%) 14 (19%) 
Gleason ≤7 200 (19%) 41 (22%) 20 (17%) 21 (29%) 
8-10 778 (75%) 139 (74%) 91 (79%) 48 (67%) 
Unknown 65 (6%) 7 (4%) 4 (3%) 3 (4%) 
Performance 
status 
0 757 (73%) 138 (74%) 80 (70%) 58 (81%) 
1-2 286 (27%) 48 (26%) 35 (30%) 14 (19%) 
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 Table 48: Comparative baseline characteristics (Analysis two: t170)  
* Comparative ITT population had metastatic disease (M1) at trial entry, randomised during the 
same time period at the 28 sites who contributed samples to this analysis.   
 
 
  
Baseline Characteristics  Comparative 
ITT* 
Sampled 
population  
Sequenced  Test failed 
  n=773 n=100 n=77 n=23 
    
Age  Median  68 years 67 years 68 years 66 years 
Range  37-87 years 45- 85 years 50-85 years (61-71 years)  
Presenting PSA  
(ng/ml  
Median  101  112  97 131  
IQR   29-347 43-335 42-372 47-312 
T stage ≤T2 74 (10%)  14 (14%)  10 (13%) 4 (17%) 
T3 447 (58%) 60 (60%)  46 (60%) 14 (61%) 
T4 175 (23%) 20 (20%)  17 (22%) 3 (13%) 
Tx 77 (10% 6 (6%) 4 (5%) 2 (9%) 
Nodal state N0 256 (33%) 32 (32%) 27 (35%) 5 (22%) 
N1 479 (62%) 61 (61%) 45 (58%) 16 (70%) 
Nx 38 (5%) 7 (7%) 5 (6%) 2 (9%) 
Disease 
category 
De novo M1 747 (97%) 100 (100%) 77 (100%) 23 (100%) 
Relapsed M1 26 (3%) 0  0  0 
Metastatic 
distribution 
Bone only 498 (64%) 65 (65%) 47 (61%) 18 (78%) 
Distant node 
only 
86 (11%) 11 (11%) 9 (12%) 2 (9%) 
Bone & nodal 
or other 
189 (24%) 24 (24%) 21 (27%) 3 (13%) 
Gleason ≤7 132 (17%) 9 (9%) 8 (10%) 1 (4%) 
8-10 537 (69%) 84 (84%) 62 (81%) 22 (96%) 
Unknown 104 (13%) 7 (7%) 7 (9%) 0 
Performance 
status 
0 538 (70%) 70 (70%) 56 (73%) 14 (61%) 
1-2 235 (30%) 30 (30%) 21 (27%) 9 (39%) 
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Table 49: Characterising the biomarker-positive (HRD) subgroup 
* p value for Kruskal Wallis test for differences between groups, values statistically significant at 5% 
level shown in bold 
  
Baseline Characteristics  Total 
Sampled 
population  
HRD   Biomarker 
negative 
Biomarker 
unknown  
p value*  
 n=287 n=28 n=164 n=95  
Age  Median  68 years 70 years 69 years 67 years 0.0421 
Range  44- 85 years 52-82 years  44-85 years  45-80 years  
Presenting 
PSA  
(ng/ml  
Median  126  138 90 148 0.1461 
IQR   35-400 56- 1179 23-384 48-435 
T stage ≤T2 27 (9%)  2 (7%) 17 (10%)  8 (8%)  0.9730 
T3 163 (57%)  16 (57%)  92 (56%) 55 (58%) 
T4 79 (28%)  9 (32%) 43 (26%) 27 (28%) 
Tx 18 (6%) 1 (4%) 12 (7%) 5 (5%) 
Nodal state N0 104 (36%) 6 (21%) 56 (34%) 42 (44%) 0.0711 
N1 164 (57%) 19 (68%) 98 (60%) 47 (47%) 
Nx 19 (7%) 3 (11%) 10 (6%) 6 (6%) 
Disease 
category 
De novo M1 283 (99%) 28 (100%)  161 (98%) 94 (99%) 0.7044 
Relapsed M1 4 (1%) 0  3 (2%) 1 (1%) 
Metastatic 
distribution 
Bone only 192 (67%) 17 (61%)  103 (63%) 72 (76%) 0.0770  
Distant node 
only 
27 (9%) 0  21 (13%) 6 (6%) 
Bone & nodal or 
other 
68 (24%) 11 (39%) 40 (24%) 17 (18%) 
Gleason ≤7 50 (17%) 5 (18%) 23 (14%) 22 (28%) 0.0950 
8-10 223 (78%) 18 (64%) 135 (82%) 70 (74%) 
Unknown 14 (5%) 5 (18%) 6 (4%) 3 (3%) 
Performance 
status 
0 208 (72%) 19 (68%) 117 (71%) 72 (76%) 0.6298 
1-2 79 (28%) 9 (32%) 47 (29%) 23 (24%) 
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4.3.2 Feasibility data 
Overall, 192 out of 287 samples (67%) were successfully sequenced. The sequencing 
success rate was 61% and 77% in analysis one and two respectively. In seven cases 
sequenced as part of analysis two the minimum DNA concentration of 3.3ng/µL was just 
missed. In 5/7 cases results could be reported, although with reduced confidence and copy 
number alterations were not reliable. The most frequent reason for failure in both analyses 
was inadequate concentration of sufficiently high quality DNA, resulting in quality control 
(QC) failure post DNA extraction.  
Figure 33: Sequencing success rate  
 
Site variability  
As shown in Table 50, the sequencing success rate also varied by hospital site. In total, 
samples from 287 patients randomised at 35 sites were included, with between 1-47 
patients sampled per site. Sequencing success rates are judged preliminary where <5 
patients had been sampled (highlighted in grey). In the 9 sites where >10 patients have 
been sampled the sequencing success rate ranges from 21-100%.  
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Table 50: Sequencing success by site (both analyses combined)  
Site name  
Site  
number 
Number of cases 
sampled per site 
Successfully  
sequenced 
Success  
rate (%) 
Velindre, Cardiff 2 47 36 77% 
Singleton, Swansea 11 38 17 45% 
Stepping Hill, Stockport 41 21 6 29% 
Royal United Hosp Bath  72 19 4 21% 
Ipswich 39 15 14 93% 
Broomfield Hosp 32 13 13 100% 
Huddersfield 40 13 10 77% 
Royal Devon & Exeter 7 13 11 85% 
Torbay DGH 20 11 11 100% 
Bristol 24 9 6 67% 
Pilgrim Hosp 114 7 5 71% 
Raigmore Hosp 57 7 6 86% 
York Hosp 133 7 2 29% 
Burnley General Hosp 59 6 6 100% 
Guy's Hosp, London 13 6 5 83% 
Barnet General Hosp 115 5 3 60% 
Darlington Memorial Hosp 53 5 2 40% 
Lister Hosp 55 5 0 0% 
Lincoln County Hosp 113 4 4 100% 
Royal Albert Edward Infirmary 65 4 3 75% 
Royal Bolton Hosp 56 4 2 50% 
Musgrove Park Hosp 51 3 2 67% 
Royal Bournemouth Hosp 22 3 2 67% 
University College Hosp 38 3 3 100% 
Weston General Hosp 112 3 2 67% 
King's Mill  102 2 2 100% 
North Middlesex Hosp 46 2 2 100% 
Queen Alexandra, Portsmouth 75 2 1 50% 
Southend University Hosp 31 2 1 50% 
Worthing Hosp 43 2 2 100% 
Essex County Hosp 124 1 0 0% 
Hereford 42 1 0 0% 
James Cook University Hosp 28 1 1 100% 
Southampton General Hosp 17 1 1 100% 
Yeovil District Hosp 128 1 1 100% 
 
 
Exploring pre-analytical variables  
The site variability was higher than anticipated and so in order to explore potential 
explanations for this a survey of fixation protocols was conducted, comparing reported 
practices against those recommended by FM (see Appendix H). Responses were received 
from 14/15 sites contributing samples for analysis one, summarised in Table 51-Table 53. 
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Table 51: Sample numbers and success rate by site (analysis one)   
  
Table 52: Minimum and maximum fixation times at sites participating in analysis one   
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Table 53: Weekend processing at sites participating in analysis one   
 
 
 
 
 
Pathology Survey results  
All sites were using the recommended fixation solution (10% neutral-buffered formalin) and 
9 out of 13 were within the recommended fixation time of 6-72 hours. Numbers are too 
small to permit statistical analyses but it is notable that longer fixation times were observed 
in the lower performing sites (site numbers 11, 42, 72). 3 sites reported shorter than the 
recommended fixation times, although this is thought to have less impact on DNA quality. 5 
sites reported samples received on Friday could remain in fixative over the weekend, thus 
exceeding the maximum recommended time; however this was not observed to associate 
with sequencing success rates. The length of cycle is also an indication of how long samples 
will remain in fixative and exposed to other agents and processes that may impair nucleic 
acid integrity. In all of the 3 low performing sites a routine biopsy cycle, which is typically 
longer than a biopsy specific cycle, was used, although site 72 reported a rapid biopsy 
programme was used for samples received before 11.45am. All but one of the good 
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performing sites reported using a shortened biopsy cycle. No protocol included xylene free 
or microwave processing.  
Exploring sample age  
The impact of sample age was first assessed in analysis one (Graph 14) and suggested a 
higher success rate in younger samples. Based on this finding, the selection criteria for 
analysis two were changed to include more samples estimated to be less than 12 months 
old. A further assessment of the impact of age within analysis two is shown in Graph 15, 
and suggests that the relationship is less clear. Younger samples were selected for analysis 
two however there was a range and high sequencing success was observed in all regardless 
of age. One of the challenges in the assessment of sample age is that it is likely a surrogate 
for other factors e.g. if a site fixation practice changed during this time. As shown in Graph 
16, the sites with low success rates (11, 41, and 72) contributed a high number of older 
samples which likely confounds the assessment of age. In some higher performing sites 
such as 7, 32, and 39, DNA yield and therefore sequencing success appears independent of 
sample age.   
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Graph 14: Success rate by sample age (analysis one: F1)  
 
Graph 15: Success rate by sample age (analysis two: t170)  
 
Graph 16: Success rate by sample age, batch and site (analysis one) 
 
Exploring the impact of sample age on sequencing success rate: Graph 14 suggests that FFPE samples <20 months old are more likely to yield sufficient high quality 
nucleic acids required for targeted next-generation sequencing (tNGS). However the relationship is less clear in Graph 15 which summarises the results of analysis 
two. The samples selected for this analysis were on average younger and overall a higher success rate was observed for this assay. Graph 16 shows that the three 
sites with the highest failure rates contributed a large number of older samples, likely confounding the analysis of sample age.  
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4.3.3 Prevalence data  
The results of analysis one demonstrated 16/115 cases harboured a mutation in an HRD 
gene, equivalent to a prevalence of 14% (95% CI 9-19%). BRCA2 mutations were reported in 
2/115 (2%), but both ATM and CDK12 mutations were more frequent, each occurring in 6%. 
No BRCA1 mutations were detected. Based on the biomarker strategy adopted in the 
evaluation of rucaparib in mCRPC, 8% would be eligible for the BRCA1, BRCA2 or ATM 
mutant group. These findings are consistent with the results of analysis two (as reported in 
May-2018). 12/77 cases were found to have one or more mutations in a HRD gene, 
equivalent to a prevalence of 16% (95% CI 9-23%). BRCA2 mutations were identified in 3% 
and ATM mutations in 10%. When the populations are combined, the estimated HRD 
prevalence is 15% (95% 11-19%); which includes ATM (8%), CDK12 (5%) and BRCA2 (2%). 
BRCA1 mutations are not observed.  
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     Table 54: Summary of HRD prevalence data  
  Analysis One (F1) Analysis Two (t170) Combined 
HRD Gene  n % n % n % 
ATM 7 6% 8 10% 15 8% 
BARD1 0 0% 0 0% 0 0% 
BRCA1 0 0% 0 0% 0 0% 
BRCA2 2 2% 2 3% 4 2% 
BRIP1 0 0% 0 0% 0 0% 
CDK12 7 6% 3 4% 10 5% 
CHEK2 0 0% 1 1% 1 1% 
NBN 0 0% 0 0% 0 0% 
PALB2 0 0% 0 0% 0 0% 
Rad51 0 0% 0 0% 0 0% 
Rad51B 0 0% 0 0% 0 0% 
Rad51C 0 0% 0 0% 0 0% 
Rad51D 0 0% 0 0% 0 0% 
Rad54L 0 0% 0 0% 0 0% 
Total number of mutations 16 14 30 
Number of pts with a mutation 16 12 28 
Total pts sequenced 115 77 192 
Prevalence (%) 
 
14% 16% 15% 
(95% CI 9-19%) (95% CI 9-23%) (95% CI 11-19%) 
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Table 55: Analysis One (F1) sample level prevalence data  
Pt # Gene Event Type Event Detail Position 
1 ATM short-variant 1564_1565delGA chr11:108121755 
2 ATM short-variant 7921C>T chr11:108203621 
3 ATM short-variant 3497_3498insC chr11:108151816 
4 ATM short-variant 3228delA chr11:108143522 
4 ATM copy-number-
alteration 
(loss) 
- - 
5 ATM short-variant 8786+1G>A chr11:108224608 
6 ATM short-variant 7195C>T chr11:108199853 
7 BRCA2 short-variant 2588_2588delA chr13:32911079 
8 BRCA2 short-variant 5722_5723delCT chr13:32914213 
8 CDK12 short-variant 3142C>T chr17:37680973 
10 CDK12 short-variant 2880G>A chr17:37673726 
11 CDK12 short-variant 1025_1026insT chr17:37619349 
12 CDK12 short-variant 4382_4383insG chr17:37687478 
13 CDK12 short-variant 2520delG chr17:37657602 
14 CDK12 short-variant 304_314delTCAGATCGGAG chr17:37618627 
15 CDK12 short-variant 2126delA chr17:37649020 
 
 
Table 56: Analysis Two (t170) sample level prevalence data  
Pt  # Gene Event Type Event Detail 
1 CDK12 short-variant  ENST00000447079.4:c.2670_2673delCCCT 
2 ATM short-variant  ENST00000278616.4:c.323delC 
ATM short-variant  ENST00000278616.4:c.1355delC 
3 BRCA2 short-variant  ENST00000544455.1:c.4936_4939delGAAA 
4 ATM short-variant  ENST00000278616.4:c.3802delG 
5 ATM short-variant  ENST00000278616.4:c.481C>T 
6 CHEK2 short-variant  ENST00000382580.2:c.283C>T 
7 ATM short-variant  ENST00000278616.4:c.7939dupA 
8 BRCA2 short-variant  ENST00000544455.1:c.5303_5304delTT 
9 ATM short-variant  ENST00000278616.4:c.3165T>G 
10 ATM short-variant  ENST00000278616.4:c.4875_4876insCGGA 
11 CDK12 short-variant  ENST00000447079.4:c.366delA 
CDK12 short-variant  ENST00000447079.4:c.452delC 
12 ATM short-variant  ENST00000278616.4:c.972_973insG 
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Comparing approaches adopted in analysis one and two 
The results of the concordance analysis between analysis one and two demonstrated a high 
level of agreement. 20 samples were processed (DNA extraction and library preparation) 
and sequenced by FM and remaining extracted DNA was subsequently analysed by Almac 
who were blind to the prior results. 17/ 20 samples passed DNA QC and were successfully 
sequenced. Results were concordant in 16/17 cases including 7/8 cases with a pathogenic 
HRD aberration as reported in analysis one. The only discordant result was for #7, ATM 
copy number loss, detected in analysis one but not in analysis two.  
 
Table 57: Comparative HRD results (n=20)  
 
 
 
 
  
Key: The only HRD discordant case is highlighted in pink 
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Exploring the impact of the bioinformatic algorithm (Analysis two: t170)  
The RUO results of the t170 assay were refined during the course of this study. All samples 
were sequenced once by Almac in randomised batches, however several updates were 
required to the bioinformatic interpretation of the sequencing data. The first update was 
required to include all mutations predicted to result in frameshift variants resulting in a 
premature stop codon. This type of variant is predicted to be functionally significant. 
Subsequently, two further updates were required to refine the data and impose sufficient 
QC filters to exclude low confidence variant calls and suspected FFPE artefacts. As shown by 
Table 58, updating the bioinformatic interpretation to exclude suspected artefacts had the 
greatest impact on the overall prevalence rate, which as of May-2018, is now in line with 
the estimate obtained by the fully-validated F1 assay.  
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Update:  
Include frameshift 
variants resulting in 
a premature stop 
codon   
Update: 
Application of 
revised QC filters to 
remove low-
confident calls  
Update: Application of 
further revised filters to 
exclude suspected FFPE 
artefacts (significant cause 
of false positives) 
Updates to Bioinformative algorithm  
Table 58: Impact of revised bioinformative algorithm (Analysis two: t170)  
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4.3.4 Germline prevalence  
Preliminary data is available from the ongoing biomarker screening pilot to inform the 
prevalence of germline HRD in men presenting with metastatic castrate-sensitive prostate 
cancer. As of May-2018, 40 patients have undergone germline analysis see Table 59. Two 
pathogenic aberrations have been detected, one well-established germline pathogenic 
duplication in BRCA2 occurring at location 13q13.1 which results in a frameshift, see #8286 
and a second heterozygous CHEK2 mutation, see #25. The germline HRD prevalence is 
therefore currently estimated at 5% of which BRCA2 is 2.5% (95% CI -2 to 7%). No other 
pathogenic mutations were reported in this assay that covers 10 HRD genes of interest; see 
Appendix A7: Figure 43. 
Table 59: Preliminary germline prevalence data  
 
Key: Chr, Chromosome; Ref, Reference; Alt, Alternative; SNV, Single Nucleotide variant; VUS, Variant 
of Unknown Significance; LP, Likely Pathogenic; P, Pathogenic. 
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4.3.5 Prevalence of other genomic aberrations  
The prevalence of other non-HRD aberrations is shown by the results of analysis one as the 
full F1 report was provided for all of the 115 successfully sequenced cases. In contrast, the 
results of analysis two (t170) were limited to the 14 HRD genes of interest so cannot inform 
on the broader genomic profiles.  
In total 1333 mutations were detected of which 24% were reported as likely or known 
pathogenic. 94% of samples (108/115) harboured one or more pathogenic mutation; the 
median number per case was 3 (range 1-11), as shown by Graph 17. When limited to genes 
previously reported to be mutated in prostate cancer in published series e.g. SU2C-PCF39, 
315 pathogenic mutations were detected. 83% (96/115) of samples had a pathogenic 
mutation in one or more of these genes, typical of the ‘long-tail’ previously described33.  
 
Graph 17: Mutations per case highlighting those of clinical significance (Analysis One)  
Each bar represents a patient successfully sequenced as part of analysis one (F1) n=115. The 
median number of aberrations reported per case was 11 (range 2-40), however 76% of all 
reported mutations were variants of unknown significance (VUS) highlighting the “background 
noise” which either represents normal variation or incomplete knowledge of pathogenic 
changes.  
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The most prevalent likely or known pathogenic aberration reported was PTEN loss which 
occurred in 39/115 cases (34%). This was due to copy number loss in 29 cases and insertion, 
deletion or point mutation in the remaining 10. The second most common aberrations 
were TP53 mutations and TMPRSS2 rearrangements, which occurred in 38 (33%) and 37 
(32%) cases respectively. TP53 is a well characterised gene which is frequently mutated in 
multiple cancer types and all mutations identified in this cohort are recognised to be likely 
(n=6) or known (n=32) pathogenic. Within the 47 detected TMPRSS2 rearrangements, 37 
are recognised to be pathogenic and a further 10 are VUS. In contrast with mCRPC, there 
were no detected AR aberrations in this treatment naïve cohort, see Table 60. 
 
Table 60: Summary of prevalence data (analysis one)  
Summary of significant gene/pathway variants  
(n=115) 
n % 
AR AR 0 0% 
TMPRSS2 TMPRSS2 rearrangements 37 32% 
PTEN PTEN (small variant or copy number loss)  39 34% 
TP53 TP53  38 33% 
PIK3  AKT1, AKT3, PIK3C2B, PIK3C2G, PIK3C3, 
PIK3CA, PIK3CB, PIK3CG, PIK3R1, PI3K3R2 
21 18% 
RAF BRAF, RAF1 3 3% 
Wnt APC, CTNNB1, RNF43, ZNRF3 16 14% 
HRD ATM, BARD1, BRCA2, BRCA1, BRIP1, CDK12, 
CHEK2, NBN, RAD50, RAD51, RAD51B, RAD54L   
16 14% 
MSI  MSH2, MSH5, MLH1 3 3% 
Cell cycle  CDKN1B, CDKN2A, CDKN2B, RB1 7 6% 
Chromatin modifier  MLL2, KMT2C, MLL3, KDM5C 12 10% 
Other  SPOP 5 4% 
 
Pathway analysis was undertaken using the genes reportedly aberrant in CPRC as reported 
by the SU2C/PCF collaboration in order to generate exploratory comparative prevalence 
data relevant to this disease setting39. PI3K pathway aberrations were common and 
observed in 18%. As seen in mCRPC, PI3K mutations co-existed with PTEN deficiency in 9%, 
see Figure 37. The Wnt signalling pathway was aberrant in 14%, with pathogenic mutations 
in APC 7% and CTNNB1 in a further 7%. Cell-cycle pathway mutations were observed in 
10%, with RB1 mutations present in 3% and mutations in cyclin-dependent kinases e.g. 
CDKN1B present in a further 3%. 14% of the cohort had a predicted pathogenic mutation in 
one of the 12 HRD genes reported as part of analysis one. In total, 49/115 (43%) had a 
mutation in one or more HRD genes, but 45% of all mutations in HRD genes were reported 
as VUS. Pathogenic SPOP mutations were detected in 5 cases (4%). Pathogenic BRAF 
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mutations were detected in 3 cases; no pathogenic RAF1 mutations were reported. Overall 
3% had evidence of MSI with pathogenic mutations in MSH2 or MSH6, a further 5 VUS were 
detected in MLH1, MSH2 and MSH6. 
4.3.6 Overlap between molecularly-defined groups  
Knowledge of the overlap between molecularly-defined groups is required to determine 
the feasibility of evaluating multiple molecular-directed therapies in one trial platform. 
Using the results from analysis one, the overlap between pathway aberrations and 
frequently mutated genes was explored within this cohort (n=115). The observed overlap is 
presented in two ways: limited to mutations known to be significant and all mutations, 
regardless of current predictions of pathogenicity in anticipation that this will change as 
knowledge is acquired.  
Overlap observed in Analysis One (F1)  
Pathway aberrations were observed to frequently co-exist. Specifically, as shown in Figure 
34 and Figure 35, HRD mutations were observed to overlap with PTEN loss, TMPRSS2 
rearrangements, cell cycle pathway defects, MSI, Wnt pathway defects and aberrations in 
chromatin modifiers. The only finding of mutually exclusivity was with BRAF mutations 
which are rare (3%). 68% of all mutations detected in HRD genes were reported as VUS, 
therefore in all cases, the degree of overlap increases considerably when all mutations are 
included regardless of predicted clinical significance. As shown in Figure 36 overlap is also 
observed between all other pathway aberrations, with the largest overlap seen between 
PTEN loss and PI3K pathway aberrations which co-exist in 9% overall.  
PTEN deficiency has been suggested as a predictive biomarker for AKT-inhibitors287. In 
addition PI3K pathway aberrations may predict sensitivity to PI3K-inhibitors, whilst Wnt 
pathway aberrations have been shown to predict sensitivity to porcupine inhibitors in pre-
clinical studies288. CDK inhibitors have been shown to be active in other tumours with 
evidence of cell-cycle pathway aberrations involving CDKN2A or CCND1 as observed in this 
cohort289. Together with HRD pathway defects, these groups represent the most 
therapeutically significant based on current knowledge. As shown in Figure 37, 67 patients 
have one or more therapeutically relevant mutations, however again these often co-exist. 
Therefore future trial platforms aiming to co-recruit to multiple molecularly-defined 
cohorts would require a hierarchical system to determine allocation.  
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Comparison with publically available datasets  
Through interrogation of publically available datasets, available via cBioPortal, there was 
some evidence that BRAF-RAF1 mutations are mutually exclusive with HRD in prostate 
cancer. However in larger datasets this is limited to a subset of HRD genes and these were 
not consistent. In the MSK-IMPACT cohort BRAF mutations were mutually exclusive with 
mutations in BRCA1, BRIP1, CHEK2, Rad50, Rad51, Rad51B and Rad54L40. In the SU2C 
cohort BRAF mutations were mutually exclusive with BARD1, BRCA1, BRIP1, CHEK2 and 
Rad51 mutations. In the largest cohort (n=1013), only 3 HRD genes were mutually exclusive 
with BRAF (FANCA, NBN and RAD51D); and 8 HRDs mutually exclusive with RAF1 (ATM, 
BARD1, BRCA1, BRCA2, BRIP1, CDK12, Rad51, Rad51D)39. Interestingly, no HRD genes were 
mutually exclusive with BRAF or RAF1 in the MSK-IMPACT pan-cancer cohort (n=10,945). 
Whilst this most likely represents the power of this very large dataset to detect overlap 
between rare aberrations, it may also suggest that this is a prostate specific finding290. 
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Figure 34: Overlap between HRD mutations and other pathway aberrations -1 
Significant mutations All mutations 
Figure 32a Figure 32b 
  
Figure 32c Figure 32d 
  
  
Overlap between HRD (red circles) and other mutations of interest: When limited to mutations of 
known significance 2 out of 3 cancers with MSI also have HRD (Figure 32a) and TMPRSS2 rearrangements 
and HRD co-exist in 2 cases (Figure 32c). HRD is mutually exclusive with known significant TP53 mutations 
(Figure 32c) but 2 cases have co-existing PTEN loss and HRD. When all mutations are included all 
instances of mutual exclusivity are no longer observed (Figure 32d).  
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Figure 35: Overlap between HRD mutations and other pathway aberrations -2 
Significant mutations All mutations 
Figure 33a Figure 33b 
  
Figure 33c Figure 33d 
  
  
 
 
  
Overlap between HRD (red circles) and other mutations of interest: HRD mutations are 
observed to co-exist with PIK3 mutations, Wnt pathway aberrations (Figure 33a) and 
mutations in chromatin modifiers (Figure 33c). HRD mutations are mutually exclusive with 
BRAF mutations, including when mutations of unknown significance are included (Figures 33c 
and 33d).  
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Figure 36: Overlap between non-HRD pathway aberrations  
Significant mutations All mutations 
Figure 34a Figure 34b 
 
 
Figure 34c Figure 34d 
 
 
Figure 34e Figure 34f 
  
 
 
 
 
 
Overlap between other pathway aberrations: PTEN loss and known significant PI3K pathway 
mutations co-exist in 10 (9%) (Figure 34a). TMPRSS2 rearrangements are mutually exclusive with SPOP 
mutations (Figure 34c). TP53 mutations co-exist with BRAF mutations and aberrations in chromatin 
modifiers e.g. MLL2 and MLL3 (Figure 34e). 
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Figure 37: Overlap between therapeutically relevant pathway aberrations 
  
Overlap between therapeutically relevant pathway aberrations: 67 cancers 
harboured potentially therapeutically relevant aberrations and in 42 cases more 
than one was detected. The numbers indicate the number of samples with each 
pathway/gene aberration(s). 
 
The observed degree of overlap means a hierarchical system would be required 
to determine allocation within a trial platform aiming to evaluate multiple 
molecularly-directed treatment strategies. It also limits accrual to each separate 
group in platforms aiming to co-recruit to multiple molecularly directed 
treatment strategies. 
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4.4 Discussion  
This study assessed the feasibility of evaluating molecularly-directed treatments in men 
presenting with metastatic castrate-sensitive prostate cancer guided by sequencing 
routinely available prostate core biopsies, stored as FFPE tumour blocks. Overall, 67% of 
samples were successfully sequenced (192/287); 65% if the 7 samples processed and 
reported at lower confidence in analysis two are included (although these would be 
insufficient to determine trial eligibility). This test performance is comparable with the 
MSK-IMPACT prostate cohort, to date the largest reported series using FFPE samples in 
which a 68% success rate was observed (504/746)40. Although this cohort also included 
some prostatectomy samples which would be expected to have a higher success rate, as 
suggested by the 80% success rate reported by TCGA30. Similar small biopsies are 
sequenced in metastatic lung cancer. The Matrix trial is evaluating biomarker-treatment 
pairings in this setting and in 2016 reported that 70% of biopsy samples submitted are 
suitable for tNGS performed as part of the Stratified Medicine 2 programme (SMP2)291. 
Although consistent with the published experience of others, when considering large-scale 
implementation within a clinical trial the impact of a 33% test failure rate is considerable; 
inflating the number needed to screen, prolonging accrual time, trial duration and cost. 
Where biomarker prevalence is low this may render a trial not feasible. Screen-failures may 
also represent a potential source of bias if those successfully sequenced are systematically 
different to those in whom the test fails. Although limited by the relatively small sample 
size, our data does not suggest this was true in this study.  
The process of formalin-fixation can lead to cross linking of DNA, nucleic acid fragmentation 
and denaturing of proteins and DNA modification, reducing nucleic acid yield and increasing 
the risk of sequencing artefacts292. For this reason, the majority of initial attempts to profile 
PCa cohorts mandated fresh frozen samples, considered the gold-standard for genomic 
research34-36,39. However, for molecular characterisation to be cost-efficient and clinically 
applicable outside of academic healthcare settings it is important to assess if routinely 
available FFPE tissue can be used. We therefore sought to explore potential factors 
influencing test performance. When comparing the results obtained by the two providers 
analysis two (t170) had a decreased failure rate at library construction, suggesting the 
additional macrodissection unique to this extraction protocol may be a useful optimisation 
step to increase tumour purity. However an unexpectedly high degree of inter-site 
199 
 
variability was observed, suggesting that pre-analytical variables were impacting on sample 
suitability.  
A survey of pathology practices confirmed variable fixation times and longer fixation times 
was observed in lower performing sites. Four sites exceeded the maximum time as 
recommended by FM (72 hours), whilst only two sites adhered to the optimum (12-24 
hours) as recommended by Genomic England (GE) 293.  Over fixation is associated with more 
extensive cross linking and as fixation penetration is dependent on tissue volume, shorter 
biopsy specific cycles typically between 3-6 hours are preferred294. However, as tissue 
processing occurs several weeks or months before trial entry is considered, it is beyond the 
scope of clinical trial protocols such as STAMPEDE to impact on standard practice. Within 
the UK, GE  have recognised that the current lack of standardisation of FFPE processing is a 
barrier to optimising NGS protocols and are leading several initiatives aiming to improve 
the suitability of samples for molecular testing. Several pilots are ongoing aiming to validate 
different optimised tumour-specific sample handling techniques295. Our data supports the 
need for this and would suggest that if successful, this could have a considerable impact on 
overall sequencing success rates; out of the 18 sites submitting ≥5 samples the success rate 
varied hugely (0-100%) with 7 sites falling below average (67%).  
Sample age was also explored as a potential factor in sequencing success.  Previous reports 
have been contradictory and limited by small sample size, however in a pilot conducted as 
part of the 100,000 Genomes project, through selecting FFPE samples <6 months old and 
using an optimised DNA extraction protocol it was possible to perform WGS in 80% of 
cases, a significant improvement on the ~30% success rates previously reported296-299. Our 
results show no clear linear relationship between sample age and test performance, 
however considerable site variability and the performance difference between providers 
likely confound this assessment. Firstly, the lower performing sites contributed a larger 
proportion of older samples, meaning that it was not possible to disentangle the two. 
Secondly, younger samples were selected for analysis two which had a slightly improved 
success rate. Interestingly, the preliminary results from the biomarker screening pilot in 
which samples are between 1-4 months old (maximum permitted 8 months) are 
encouraging, with a success rate of over 90% (as of May-2018 40/44 samples). 
The second research question addressed was to determine the prevalence of HRD in 
mCSPC. We hypothesised that this would be greater than observed in M0 prostatectomy 
cohorts but not as frequent as in heavily pre-treated or fatal mCRPC. One of the challenges 
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in comparing HRD prevalence estimates is that different genes may be included in the 
definition. In an attempt to overcome this, Table 61 summarises relevant published data for 
the 14 HRD genes of interest, compiled using cBioPortal (http://www.cbioportal.org) an 
online resource hosted by Memorial Sloan Kettering Cancer Centre (MSK)300-302. Using the 
14-gene HRD definition, the published prevalence estimates obtained in predominantly M0 
populations are 4-24%30,34,38,211; whilst in advanced or fatal mCRPC it is 31-48%31,35,36,39. If 
the narrower biomarker-selection strategy is adopted (requiring pathogenic mutations in 
BRCA1, BRCA2 or ATM), the published estimates are 4-12% in M0 disease and 12-21% in 
mCRPC. The combined results from analysis one and two are between these estimates: the 
HRD prevalence was 15%, BRCA1, BRCA2 and ATM 10%; consistent with the prior 
hypothesis. 
Of the published sequencing studies, the most relevant is MSK-IMPACT, as this contains the 
highest number of mCSPC cases. Although this demographic (New York) would be expected 
to have a higher population of men of Jewish ancestry and this likely explains the higher 
prevalence of BRCA2 mutations (9% vs. 2%)40. It is notable that the highest HRD frequencies 
are observed in the rapid autopsy studies reported by Grasso et al. and Kumar et al 35,36. 
Both studies achieved multi-regional metastatic sampling, sequencing 61 samples obtained 
from 59 patients, and 141 samples obtained from 56 patients respectively.  The frequency 
of HRD has been shown to be highest in metastatic samples, consistent with pro-metastatic 
clones seeding and out-competing other sub-clonal mutations at metastatic sites303,304. This 
would also correlate with the higher frequency of HRD in metastatic cohorts35,39,40. The 
demonstration that prevalence estimates increase when more than one metastatic site is 
sampled supports the concept of branched evolution, leading to multiple sub-clonal 
populations and spatial heterogeneity199. In this study, only 5/286 samples were metastatic 
and no paired primary analysis was performed, so it is not possible to assess if spatial 
heterogeneity is present in de novo metastatic disease.  
Our results add support to others who have suggested that both somatic and germline 
assessments are required to identify HRD PCa40. To date only 2 out of 40 patients screened 
as part of the ongoing pilot has a germline aberration in one of the 10 HRD genes tested; 
5% (95% CI -1-11%), with gBRCA2-m detected in just 2.5% (95% CI -2 to 7%). This is lower 
than has reported in mCRPC; Pritchard et al. who reported 82/692 (12%) of men with 
mCRPC harboured a germline HRD, as defined by a 20 gene panel210. Whilst the PROREPAIR-
B cohort study screened 419 mCRPC patients and mutations in BRCA1, BRCA2 or ATM were 
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reported in 6%209. As germline BRCA1, BRCA2 and ATM mutations are associated with a 
more aggressive disease phenotype and shorter responses to first-line ADT they can be 
expected to be enriched in advanced CRPC. However both studies may have been 
vulnerable to selection bias, especially Pritchard et al. which sampled a population pooled 
from seven clinical trials or precision medicine initiatives, favouring inclusion of younger 
patients recruited at tertiary academic institutions.  
Overall, the most frequently observed aberrations were TP53 (36%), PTEN (34%), PI3K 
pathway (18%) and Wnt pathway (14%). The prevalence of TP53 mutation is comparable 
with other estimates in metastatic cohorts, including in advanced mCRPC consistent with 
this being an early clonal event and supported by previously reported concordance in 
matched archival and metastatic samples40. Others have shown PTEN loss is enriched in 
metastatic disease; consistent with this, we observed a higher frequency than seen in M0 
cohorts. Our estimate is closer to that observed in mCRPC (40-50%); this also suggests PTEN 
loss is an early somatic event33,40. As observed in mCRPC, the most frequent mechanism for 
PTEN loss is copy number loss (25/115; 25%), with base substitutions, indels or 
rearrangements occurring in the remaining (10/115; 9%)39. The frequency of PI3K pathway 
aberrations is also more similar with that observed in mCRPC (~20%) than that observed in 
M0 populations (~7%)30. Wnt pathway aberrations were observed less often than in mCRPC 
(18-23%) but the estimate is comparable with that observed in MSK-IMPACT (15%), which 
has contained the largest number of mCSPC  sequenced to date40.  
We observed a lower prevalence of SPOP mutations (4%) compared with published 
estimates (6-15%)34; this somatic mutation has been shown to be mutually exclusive of ETS-
fusions, however these were present in fewer (41%) than previously reported in other 
cohorts (~50%) therefore cannot explain this. Instead, this finding would support the 
positive prognostic association suggested by data which shows a declining frequency with 
more advanced disease; 12% in M0, 11% in mCRPC (of which half was relapsed metastatic 
disease post radical treatment) and 5% in mCRPC40. As would be expected for a treatment-
naïve population, no AR aberrations were observed. Interestingly this differs with the 
metastatic castrate-sensitive cases sampled as part of MSK-IMPACT which likely reflects 
different prior treatment as half had relapsed metastatic disease post radical treatment and 
all AR-aberrant cases had been exposed to prior ADT, some at this disease presentation 
suggesting they had developed sub-clinical CRPC40. Mutations in the mismatch repair genes 
MSH2 and MSH6 were observed in 3% overall, this is consistent with the prevalence 
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estimated in metastatic castrate-sensitive disease 40. This suggests that this is a rare somatic 
aberration in mCSPC. To date, the highest frequencies of MSI have been in ductal 
adenocarcinoma (4 out of 10 in one small sequenced cohort), and fatal mCRPC sampled at 
autopsy where estimates are as high as 12%227,228.  
A strength of this analysis is that it represents the largest sequenced cohort of de novo 
mCSPC to date and reflects a population of men joining a pragmatic trial with broad 
inclusion criteria, increasing the generalisability of these findings. In contrast to stringent 
sample selection employed in other sequencing studies, we aimed to limit triaging and 
collect representative samples, adding to the validity of the feasibility assessment. Through 
the use of two different sequencing providers, these data illustrate the impact different 
bioinformative pipelines can have on data interpretation. When considering 
implementation within a clinical trial, knowledge of this potential source of variation is 
informative especially if a provider needs to change during the course of recruitment. 
Appreciating the technical challenges of tNGS and the impact of pre-analytical variables is a 
critical part of the feasibility assessment which was strengthened by the comparison 
between providers. This also enabled a greater understanding of how assays are optimised 
to detect different types of genetic variation (e.g. copy number alteration vs. splice 
variants). However in doing so, emphasises that the aim of a centralised molecular 
assessment suitable to guide all potential molecular-directed therapies remains ambitious.  
Several limitations also need to be acknowledged, lack of paired normal tissue means that 
this characterisation is limited to somatic changes, with only limited germline data known 
from the pilot which continues. The tumour biology of PCa is recognised as a potential 
barrier to the implementation of molecularly-selected therapies, particularly due to spatial 
heterogeneity. However, through single site sampling this study cannot explore this 
important issue. Finally, despite including more de novo metastatic patients than any other 
published cohort, the small sample size limits the precision of the prevalence estimates; 
these results need to be replicated in larger cohorts.  
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Table 61: Contextualising prevalence data with published sequenced cohorts  
Summarised from www.cbioportal.org 
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 M0 Mostly M0 Mostly M0 M0   Mixed  mCRPC Fatal mCRPC  Fatal mCRPC 
 
 n=112 n=103 n=57 n=333 n=115 n=77 n=451 n=150 n=59 n=56 
ATM  1.8% 0% 7% 5% 6% 10% 2.2% 5% 8% 9% 
BARD1 0% 1% 0% 0.3% 0% 0% 0.4% 2.7% 1.7% 5% 
BRCA1  1.8% 1% 0% 0.6% 0% 0% 0.9% 0% 0% 5% 
BRCA2  0% 5% 7% 1.5% 2% 3% 6% 8% 10% 11% 
BRIP1 0% 1.9% 0% 1.8% 0% 0% 0.9% 2% 5% 5% 
CDK12 0% 0% 0% 1.5% 6% 4% 6% 4% 5% 7% 
CHEK2 0% 0% 1.8% 3% 0% 1% 0.4% 2% 1.7% 5% 
NBN 0.9% 5% 7% 6% 0% 0% 5% 10% 29% 21% 
PALB2 0% 0% 0% 1.2% 0% 0% 0.4% 0.7% 1.7% 9% 
Rad51 0% 0% 4% 2.1% 0% 0% 0.7% 2% 1.7% 4% 
Rad51B 0% 1.9% 0% 1.5% 0% 0% 0.2% 0.7% 0% 1.8% 
Rad51C 0% 1.9% 0% 0.3% 0% 0% 0.4% 0.7% 1.7% 9% 
Rad51D 0% 1% 0% 1.5% 0% 0% 0 0% 0% 4% 
Rad54L 0% 0% 0% 0.6% 0% 0% 0.2% 0% 0% 7% 
Samples sequenced (n) 112 103 56 333 115 77 501 150 61 141 
HRDm (n) 5/112 12/103 12/56 81/333 16/115 12/77 85/448 47/150 27/59 27/56 
HRD (95% CI) (%) 4 (1-7%) 12 (7-17%) 21 (12-30%) 24 (20-28%) 14 (9-19%) 16 (9-23%) 19 (16-22%) 31 (25-37%) 46 (35-57%) 48 (37-59%) 
BRCA or ATM (n) 4/112 6/103 7/57 22/333 9/115 9/77 42/451 18/150 10/59 12/56 
BRCA or ATM (95% CI (%)) 4(1-7%) 6(2-10%) 12 (8-16%) 7 (5-9%) 8(4-12%) 9(4-13%) 9% (7-11%) 12(8-16%) 17(9-25%) 21(12-30%) 
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Table 62: Contextualising prevalence data  
    Published data 
MSK-IMPACT 
 n=140 
Analysis One 
(F1) 
n=115 
Analysis Two 
(t170) 
n=77 
Pathway Gene     
  
  
  
  
AR 4% 0% - 
PTEN 18% 34% - 
TP53 30% 36% - 
RB1 7% 1% - 
DNA repair 
  
  
  
  
  
  
BRCA2 7% 2% 3% 
BRCA1 1% 0% 0% 
ATM 2% 5% 10% 
FANCA 3% 0% 0% 
CDK12 6% 5% 4% 
MSH2 2% 2% - 
MLH1 1%  - 
PI3K pathway  
  
  
  
PIK3CA 4% 7% - 
PIK3R1 4% 3% - 
AKT1 1% 1% - 
AKT3 0% 1% - 
Wnt pathway 
  
  
APC 14% 7% - 
CTNNB1 6% 7% - 
RNF43 1%  - 
MAPK pathway  
  
  
BRAF 4% 3% - 
HRAS 1%  - 
KRAS 1% 1% - 
Chromatin  
remodelling 
  
  
KMT2A 1%  - 
KMT2C 9% 3% - 
KMT2D 4%  - 
KDM6A 2%  - 
 Others  
  
  
IDH1 0% 1% - 
SPOP 11% 4% - 
FOXA1 10%  - 
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4.5 Conclusion 
Through profiling a sample of men enrolled in the STAMPEDE trial, this study demonstrates 
that it is feasible to use prostate core biopsies stored as FFPE to perform tNGS. However, 
whilst the test failure-rate is comparable with other published examples, it still poises 
challenges to evaluating treatments in low prevalence biomarker-defined groups. HRD is 
present in around 15% (95% CI 11-19%) of metastatic castrate-sensitive tumours which is 
less frequent than observed in mCRPC, but more common than reported in M0 disease. 
When considering the evaluation of PARPi in this setting, the evidence of predictive effect 
needs to be balanced against the prevalence of the biomarker. Currently, BRCA2 mutations 
have the strongest evidence of predictive effect; however our data has shown these are 
rare in the STAMPEDE population (2%).  The trial design will be informed by emerging data 
as to the strength of the predictive effect of HRD, which will in turn influence the 
appropriate target effect size. Our data highlight the many challenges of evaluating multiple 
biomarker-selected questions within one MAMS platform. The mutational prevalence 
remains low and may overlap, reducing the number of eligible patients. Our clinical 
knowledge remains incomplete and the majority of variants are of unknown significance. It 
is hoped that as more treatments are shown to benefit biomarker-selected groups, the 
continued rapid expansion in genomics technology and research will enable trials such as 
STAMPEDE to adapt to evaluate this promising strategy.   
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Chapter 5 Discussion and Future directions of research  
Advances in the understanding of the molecular basis of metastatic prostate cancer may 
explain the clinical heterogeneity observed and provide a biological rationale to move away 
from a uniform approach to management. The results of the STAMPEDE trial have shown 
three additional systemic therapies improve OS when compared with ADT alone; docetaxel, 
celecoxib-ZA and abiraterone. All differ in therapeutic mechanism of action, toxicity and 
cost, such that variable individual patient benefit is anticipated from each approach. In this 
thesis I sought to develop a further understanding of the results of the STAMPEDE trial. I 
aimed to explore how trial data may inform treatment selection and consider how the trial 
may adapt to evaluate biomarker-directed treatment strategies in the future.  
5.1.1 Contextualising the STAMPEDE celecoxib - zoledronic acid results  
I undertook a systematic review and meta-analysis aiming to contextualise the intriguing 
and least well-understood finding of the trial so far, the beneficial effect of celecoxib-ZA in 
men with metastatic castrate-sensitive prostate cancer. The main challenge faced when 
trying to understand this result is the lack of supporting clinical data. Despite extending 
searches to include non-randomised data no studies evaluating the combination of a cox-2 
inhibitor and a bisphosphonate were identified; whilst uncertainty surrounding 
bisphosphonate use in those studies found means the relevance of the available data may 
be limited. This further emphasises that further research is needed if the findings of this 
comparison are to impact practice. Secondly, my findings illustrate the impact the 
cardiovascular toxicity data observed in two adenoma prevention trials had on the 
evaluation of cox-2 inhibitors. The demonstration that celecoxib-ZA acid could be a life-
prolonging, palliative therapy calls into question whether the response to these data was 
proportionate and highlights the need to contextualise efficacy and safety data. Finally, the 
value of adopting a meta-analysis approach is again shown in the recent publication that 
confirms that, contrary to concerns at the time, cardiovascular toxicity is limited to 
rofecoxib and is not a class effect. Taken together, my results add support to the need to 
further evaluate the combination of celecoxib-ZA. 
In the absence of supporting clinical data, the case for future trials is strengthened by work 
showing a potential mechanism for the observed additive, therapeutic effect. It has been 
shown that both celecoxib and ZA have an immunomodulatory role and I suggest a 
hypothesis whereby both treatments act to promote an anti-cancer effect mediated by γ𝛿 T 
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cells. Unfortunately, this hypothesis cannot be explored retrospectively in the samples 
available (which are limited to FFPE prostate core biopsies). This highlights a challenge of 
expectant collection of samples which may often be inappropriate for the hypotheses and 
technologies available at the time of planned analysis. Instead a new trial would be 
required with prospective sampling, to include collection of peripheral blood mononuclear 
cells (PBMCs) to permit analysis of γ𝛿 T cells. Whilst exploratory, the hypothesis proposed 
describes a mechanism that is not specific to PCa therefore evaluation in other solid organ 
cancers with metastatic bone involvement may be considered. Of note, γ𝛿 T cells have 
been shown to exert an anti-cancer effect in lung and breast cancer, providing a rationale 
to consider expanding to these indications if the results of STAMPEDE are confirmed305,306. 
Several ongoing trials of celecoxib with immunomodulatory agents including checkpoint 
inhibitors, vaccines and rintatolimod, a restricted Toll-Like Receptor 3 (TLR3) agonist, may 
also be informative. Many of these trials include translational research that may help 
understand the immunomodulatory role of celecoxib and help define the population in 
which celecoxib-ZA may be of benefit. 
Informing approaches to future research  
Adaptive trial designs, such as that used in the STAMPEDE study, are ideal to evaluate 
therapeutic combinations and address pre-specified biomarker-focused questions. Multiple 
arms enable agents to be assessed alone and in combination, whilst the use of a shared 
control arm permits analyses of proposed predictors of differential response. The 
overlapping putative oncogenic drivers demonstrated in the sequencing analyses 
conducted as part of this work provide a strong rationale to evaluate combination therapies 
in this genetically heterogeneous disease. However, addition treatments can be expected 
to come with increased cost and toxicity and therefore are likely to only be indicated in a 
subset where the risk-benefit and health economic analysis is favourable. For example, 
analyses within the abiraterone comparison may identify a biological subset with a 
differential treatment response which could then be validated within the enzalutamide and 
abiraterone comparison, providing justification for this intensified treatment option. 
Well-designed translational sub-studies conducted in parallel with clinical trials can make 
the most of the clinical data collected as part of the evaluation of the primary outcome, 
whilst also generating and testing hypotheses to explain differential treatment effects. 
Identifying biomarkers predictive of differential treatment effects within the abiraterone 
and docetaxel treated groups is an ongoing research aim of the STRATOSPHERE 
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(STratification for RAtional Treatment-Oncomarker pairings of STAMPEDE Patients starting 
long –term Hormone treatment) consortium. Supported by preliminary data provided by 
me and others, this consortium has been awarded a programme grant from Prostate 
Cancer UK. Having initiated sample retrieval from STAMPEDE sites, I continued to work with 
the trial team in establishing a trial biorepository to support future biomarker studies. 
Focusing on the docetaxel and abiraterone comparisons, we have obtained samples from 
over 1200 patients to date. The STRATOSPHERE protocol outlines the proposed analyses 
focusing on the docetaxel and abiraterone FFPE blocks, germline DNA extracted from saliva 
samples, as well as exploration of resistance mechanisms through sequential ctDNA 
collection. It is hoped that through future adaption prospective validation and evaluation of 
potential therapeutic pairings can be achieved within the STAMPEDE trial platform, for 
example through biomarker-stratified randomisations and testing of biomarker-directed 
therapies through the addition of new research arms. 
5.1.2 PSA kinetics as prognostic biomarkers  
The feasibility and prevalence sequencing study highlights some of the complexities in 
developing and implementing genomic biomarkers, which continue to be costly, logistically 
challenging and reliant on specialist expertise. In comparison, PSA-based biomarkers have 
many advantages; they are readily available, inexpensive and measured using fully 
analytically validated assays, routinely provided in local laboratories. Pragmatically, PSA 
levels are understood by clinicians and men with PCa meaning that PSA based outcomes 
could be relatively easily incorporated into clinical practice and at little extra cost. I sought 
to evaluate two PSA outcomes as additional prognostic biomarkers at two clinically 
meaningful time points such that they may be able to inform the use of different treatment 
strategies in the castrate-sensitive setting307.  
The magnitude of PSA response evaluated in the first 12 weeks of ADT treatment and PSA 
nadir values assessed shortly after completion docetaxel were both shown to associate 
with survival differences. Using established threshold values, the strongest evidence of 
prognostic effect was seen for PSA nadir which remained statistically and clinically 
significant in a multivariable analysis. PSA was also shown to associate with OS, although 
statistical significance is reduced when accounting for absolute PSA, suggesting that future 
prognostic tools should consider evaluating this as well. Consistent with the prior 
hypothesis, the value of PSA based outcomes appears greatest in castrate-sensitive disease, 
compared with castrate-resistant setting.  
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A PSA nadir of >4ng/mL in patients receiving ADT + docetaxel is shown to provide additional 
prognostic information at a clinically relevant time point shortly after completion of 
docetaxel.  Several ongoing trials are evaluating ADT + docetaxel + AR-targeted agents and 
should this intensified approach be shown to be effective, risk-stratification post docetaxel 
will be important in identifying high-risk groups in whom the additional toxicity and cost 
can be justified. Prospective validation of this prognostic biomarker will be important; this 
could be achieved through randomising men shortly after completion of SOC docetaxel 
comparing ADT vs. ADT + AR therapy stratified by PSA nadir. This would permit pre-planned 
subgroup analyses within these proposed risk categories. It may be possible to explore this 
within a further retrospective analysis using STAMPEDE data as a proportion of patients 
allocated to the enzalutamide and abiraterone comparison from Dec-2015 onwards will 
have received SOC docetaxel, permitted by way of protocol amendment. The protocol 
guidance reflected the timelines for the docetaxel-randomised cohort and recommended 
docetaxel was commenced within around 12 weeks after starting ADT. In patients allocated 
to receive abiraterone and enzalutamide, treatment commenced after docetaxel had been 
completed. The PSA nadir value was calculated in the same way and therefore likely reflects 
the PSA response to ADT + docetaxel. Therefore in 2020 when the results of the primary 
efficacy analysis are reported, it may be possible to stratify by PSA nadir category and 
explore this effect further.   
The results of the PSA response analysis are more exploratory. Future work is required to 
validate the optimum threshold value that offers the best discrimination. A larger sample 
size may permit analyses that include both PSA response and absolute PSA. The magnitude 
of PSA response appears prognostic but to influence the clinical decision to give docetaxel it 
is important to determine if patients experiencing a PSA response of ≥99% on ADT alone 
derive the same benefit from docetaxel. The STAMPEDE trial offered a unique opportunity 
to analyse PSA response within a cohort randomised to receive ADT or ADT + docetaxel, but 
unfortunately the data collected as part of the current protocol does not permit this. 
Moving forward, PSA measured close to the time of randomisation could be collected 
however it would be challenging to explore treatment interaction as docetaxel has become 
SOC and use is no longer randomised. Adjustment would be needed for differences in age, 
disease burden, baseline performance status and co-morbidity that currently impact on the 
decision to use docetaxel. Additionally, statistical power to explore this in the STAMPEDE 
cohort would be limited by the small proportion (~10%) within the randomised population 
who are now not planned to receive docetaxel. Retrospective collection of PSA at 
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randomisation from the previously randomised docetaxel cohort within STAMPEDE would 
permit this analysis, and the resource required for this may be considered justified by the 
significant prognostic impact observed in patients receiving ADT alone. 
PSA transcription is AR-dependent and as such it is a measure of a biological process. This 
provided the rationale for the hypothesis that rapid PSA decline could be used as a clinical 
surrogate for a biological subset of exquisitely hormone-sensitive disease. My analyses 
demonstrate that men who experience early disease progression on ADT alone have a 3 
year survival-rate of just 20% and median survival time is considerably reduced in 
comparison to those who reached the landmark (24 weeks post randomisation) progression 
free (17 versus 45 months). A lack of PSA response may reflect poor therapeutic response 
or a pre-existing biological variant. For example, early progression on ADT may represent an 
inherent, aggressive subtype that is inadequately treated by ADT alone. Men experiencing a 
poor PSA response were more likely to have presented with a lower PSA which has been 
associated with a ductal non-PSA secreting subtype308. Sequencing studies have shown a 
higher frequency of MSI associated with ductal carcinoma227. Analyses of pre-treatment 
FFPE blocks using tNGS assays that include assessments of MMR genes and mutational 
burden would enable this hypothesis to be tested. A high PSA nadir was also shown to be 
associated with an increased risk of death: a PSA nadir of >4ng/ml despite docetaxel is 
associated with a 2-fold increase risk of death (HR 2.64; 95% CI 1.64-4.26, p<0.0001) 
compared with a PSA nadir ≤0.2ng/ml. Correlative analysis of this group would enable 
hypotheses to be developed that may explain docetaxel resistance and/or differential 
benefit from abiraterone which is likely to only be cost-effective in those deriving least 
benefit from docetaxel, the current SOC. Developing predictive biomarkers to characterise 
these group at diagnosis would help guide the use of additional treatments aiming to 
identify the optimum treatment strategy for these groups shown by my work to be at high-
risk of poor survival outcomes. 
The clinical utility of PSA nadir and the optimum threshold value requires prospective 
validation. Threshold values are often arbitrarily defined and inadequately interrogated, 
which risks undermining biomarker specificity. However understanding the relationship 
between a continuous biomarker and outcome requires a large trial sufficiently powered to 
assess the interaction, typically estimated to be four times larger than a randomised 
treatment evaluation. The RxPONDER trial (Rx for Positive Node, Endocrine-Responsive 
Breast Cancer; NCT01272037) is an impressive example of this. This NIH sponsored trial will 
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address whether recurrence score (RS), as reported by a gene expression assay using a 
continuous scale 0-100 (Oncotype Dx, Genomic Health, Redwood City) can be used to 
identify breast cancer patients who can safely avoid adjuvant chemotherapy. Patients are 
eligible if RS score is <25 and randomisation is between endocrine therapy, with or without 
chemotherapy. If a significant interaction between RS score and chemotherapy benefit is 
shown, the trial will determine the optimum threshold value for recommending 
chemotherapy using a pre-specified statistical algorithm. Importantly, an additional 
comparative effectiveness analysis will evaluate the benefit of testing e.g. whether the 
resource saving of chemotherapy avoidance justifies the cost of testing. 10,000 women 
have been randomised, costing the NIH $28 billion, in addition to significant insurance 
based funding to support testing, at up to $4000 per test309. The methodology employed by 
RxPONDER has itself has been evaluated in a separate comparative effective analysis. By 
virtue of being able to evaluate the use of a costly test and potential treatment avoidance, 
together with collecting survival, DFS and patient reported outcomes, the expected value of 
the research presents a return of 17-39 times for the public funders of the study309.  
PSA nadir >4ng/ml is proposed as an inclusion criterion for future trials evaluating 
intensified maintenance therapy post-docetaxel in the castrate-sensitive setting. A similar 
strategy has already been explored in a small non-randomised phase II study, albeit not 
using the updated treatment paradigm. The S1014 trial evaluated abiraterone in patients 
experiencing a suboptimal PSA response to ADT (similarly defined as >4ng/ml) assessed 6-
12 months after initiation193. My work would support future trials prospectively evaluating 
PSA nadir as an on treatment prognostic biomarker through randomising to ADT alone or 
intensified treatment e.g. addition of AR-targeted agent following completion of docetaxel. 
This could be assessed within STAMPEDE and may be possible alongside future 
comparisons of treatments that cannot be safety given concurrently with docetaxel. The 
timing of randomisation would move to shortly after completion of docetaxel, as would be 
proposed for any future PARPi evaluation. An enrichment design, limiting recruitment to 
PSA>4ng/ml would be preferable. As shown by our results, this group has the shortest time 
to CRPC progression and death so information could be acquired in the shortest time. 
Results from this work enable this to be modelled and would inform this design. This 
prospective validation could help the translation in clinical practice of the findings of the 
abiraterone comparison, and potentially, if shown to be beneficial, the enzalutamide and 
abiraterone combination.  
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5.1.3 Genomic biomarkers: feasibility and prevalence assessment  
Precision medicine initiatives reliant on characterising molecular predictive biomarkers are 
proving challenging to implement, due in part to incomplete knowledge. My aim was to 
acquire preliminary data to inform the best approach to evaluating treatments such as 
PARPi, hypothesised to benefit a genetic subset of mCSPC. 
The findings of this study show that, whilst routinely available FFPE prostate core biopsy 
samples may be used for tNGS, considerable variability in sample quality is observed and 
test failure rates continue to be a barrier to the cost-efficient evaluation of low-prevalence 
biomarker groups. These data emphasise the importance of obtaining feasibility data in 
clinically representative samples. The variability between sequencing providers also 
illustrates the complexities of sequencing data processing and the impact this can have on 
the biomarker specificity. It is a source of frustration that crucial details of the bioinformatic 
pipeline may not be sufficient well described when clinicians and trialists come to use these 
results to inform clinical decision making. My work highlights the impact different technical 
protocols, analytical processes and data interpretation can have. Indeed, this likely explains 
why regulatory approval of many biomarker-selected treatments is accompanied by a 
specified biomarker and provider. This poses several challenges to trial conduct. The field of 
genomics is in flux; assays, technologies and the knowledge base of germline variants (i.e. 
normal), and somatic variants of potential clinical significance, are all undergoing constant 
refinement. Trial protocols are required to define if the biomarker measurement is to be 
fixed or may evolve; the former defines the population as would be required for regulatory 
submission, but may limit the relevance of the results if assay thresholds and sensitivity 
change. Furthermore, costly equivalence studies are likely required should the biomarker 
provider change during the conduct of a trial. 
Consistent with the prior hypothesis, results demonstrate that the prevalence of HRD is less 
than observed in mCRPC but more frequent than seen in indolent, localised disease. Given 
the challenges of genetic characterisation, I sought to clinically characterise the HRD 
subgroup. Identifying clinical features may be able to supplement genetic data and, much 
like platinum-sensitivity in the context of ovarian cancer could be a useful adjunct in 
identifying patients with this disease subtype. However, unfortunately numbers remain 
small and findings are preliminary at this stage. Interestingly, in contrast to the prior 
hypothesis, the HRD subgroup were no younger in age at presentation of metastatic 
prostate cancer. This would suggest that the majority of HRD mutations are acquired as 
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somatic mutations as opposed to an inherited predisposition, consistent with the low 
frequency of germline HRD aberrations detected in the ongoing biomarker screening pilot.  
Evidence of prognostic effect can inform the design of biomarker-enriched trials and impact 
on the assessment of feasibility, particularly of low-frequency biomarkers. When 
considering biomarker-selected randomisation within a platform trial, this also informs 
whether it is justifiable to share a control arm, with resulting efficiencies. If the biomarker is 
known to be prognostic, separate comparisons are required in order to distinguish 
predictive from prognostic effect, as exemplified by the design of FOCUS-4310. Knowledge of 
prognostic effect can also inform the size of a trial powered to detect in a difference in 
time-to-event outcomes. If the survival time is shorter, the information required for reliable 
analyses (e.g. number of deaths for a trial powered on primary outcome of survival) will be 
accrue sooner and therefore a smaller trial may be required. It is a limitation of this study 
that prognostic impact could not be explored as treatment varied and follow-up was 
insufficient. This is an aim of ongoing translational work being conducted as part of 
STAMPEDE and the association STRATOSPHERE consortium.  
Prevalence data was recognised to be of crucial importance in understanding the scope of 
benefit biomarker-driven therapies could have, and the optimum way in which to evaluate 
these in a trial. We observed the ‘long tail’ of somatic mutations that mostly occur in <10% 
of patients. This represents a challenge in the design of randomised biomarker-driven trials 
and means design approaches originally recommended for rare diseases may become 
relevant. In a recent published framework, Parmar et al. recommend considering extending 
collaborations to broaden recruitment potential and ensuring the experimental and control 
arms are as different as possible. They also suggest considering a more information-heavy 
outcome measure, or finally, reviewing target effect, power and the alpha (type I error 
rate)311. Unique to this setting of biomarker-selected trials is the costs incurred with the 
high screening burden. However, this is not a challenge specific to prostate cancer; in a 
precision initiative led by MD Anderson 6.4% of those screened were paired with a targeted 
drug312. As of July 2017, 5,963 patients have been screened as part of the NCI-MATCH trial, 
but only 18% of patients harboured a mutation and overall the prevalence has been lower 
than anticipated, resulting in only 8 out of 30 treatment arms reaching the minimum 
patient accrual of 35313. Indeed, the denominator of patients undergoing molecular analysis 
is often not captured in precision medicine reports, undermining the assessment of 
feasibility and cost-effectiveness of this approach 314.  
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HRD prostate cancers remain the only genetically-defined subset for which a paired 
treatment strategy has been shown to be beneficial57. There are emerging data to support 
evaluating other biomarker-treatment pairings, but these remain at an early stage and 
predictive biomarkers may be relatively less well defined. For example, the Canadian 
Cancer Trials Group has established the Prostate Cancer Biomarker Enrichment and 
Treatment Selection (NCT03385655) study as a master protocol that facilitates screening 
using cell free DNA, matching participants to a series of spin-off non-randomised phase II 
trials. Only one trial is registered to date, evaluating palbociclib, a CDK4/6 inhibitor in 
mCRPC with CCND1 gain/amplification or RB1 loss (NCT02905318). More often treatment 
and predictive biomarkers are at different development stages, meaning instead trials enrol 
unselected populations with pre-planned biomarker characterisation. Trametinib, a MEK 
1/2 inhibitor, is under evaluation in unselected mCRPC (NCT02881242) due to the lack of a 
predictive biomarker. Instead, mandated pre-treatment and progression metastatic 
sampling, together with ctDNA analysis, will aim to identify molecular correlates of 
treatment sensitivity and resistance. At the time of writing, the only other biomarker-
treatment pairing undergoing randomised evaluation is an AKT-inhibitor (AZD5363); the RE-
AKT trial will randomise 100 men stratified by PTEN loss to receive enzalutamide with 
AZD5463 or placebo (NCT02525068). This follows the demonstration that Ipatasertib (AKT-
inhibitor) and abiraterone prolongs radiological PFS (rPFS) in mCRPC, with the greatest 
treatment effect observed in cases with PTEN loss as determined by IHC; although benefit 
was also seen in those without this proposed predictive biomarker. Therefore, whilst there 
is much enthusiasm for biomarker-directed therapy in prostate cancer, the strength of 
clinical data to support this strategy is limited at this time.  
Well-designed clinical trials are needed to evaluate the numerous putative predictive 
biomarkers and provide evidence of the strength of the predictive effect. In their review, 
Freidlin and Korn propose that clinical trial design should reflect the prior strength of 
evidence315. Very strong evidence that benefit will be limited to the biomarker positive 
subset is required to support an enrichment strategy where enrolment is limited to 
biomarker positive patients. Efficiencies are to be gained, as large treatment effects are 
anticipated, requiring a smaller sample size; although where the biomarker prevalence is 
low the screening burden will remain high. Where there is less certainty, biomarker-
stratified trial designs may be employed, evaluating both biomarker positive and biomarker 
negative groups in parallel or sequentially. Caution is needed in subgroup interpretation 
and protecting against false positive results (Type I error) with this approach. Parallel 
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assessment of biomarker defined subgroups may be undertaken but this reduces the power 
to detect an effect group as a whole, in the case the biomarker is not predictive. Low 
biomarker prevalence may also compromise the power in the biomarker positive subgroup. 
Sequential approaches, such as testing efficacy in the biomarker positive subgroup and 
then in the whole group may be used, however this risks inappropriately recommending 
treatment in the broader group, when in fact the benefit is limited by the subset. The 
Marker sequential test design (MaST) is proposed to mitigate this risk. Treatment efficacy is 
assessed first in the biomarker positive group at a reduced significance level, then, if 
beneficial, assessed in biomarker negative subgroup. Efficacy is only assessed in the whole 
group if no benefit has been seen in the biomarker positive group316. 
As discussed above, putative predictive biomarkers and paired therapies often develop at a 
different pace. Biomarkers of uncertain predictive effect may be tested using a ‘fall-back’ 
design. Recruitment is unselected and the trial is powered to detect a difference in the 
whole group. Pre-planned subgroup analysis of the biomarker positive subset is performed, 
but only if results are negative in the whole population. This is a useful strategy to prevent a 
conclusion being drawn that a treatment is ineffective, when in fact it is beneficial in a 
subset. Pre-specifying this subset is important to avoid the criticisms and type 1 error rate 
of post-hoc analyses. Low biomarker-prevalence will continue to be a challenge however, 
as the power in the biomarker positive subset will remain lower than in the biomarker 
negative group for the majority of biomarkers, leading to longer trials. As such, ongoing 
efforts to provide prevalence data relevant to this disease setting are valuable, enabling 
these scenarios to be modelled and appropriately selected. Two challenges remain with the 
approach suggested by Freidlin et al. Firstly, how should the strength of the biomarker be 
determined? Secondly, given the time and cost of clinical trial design and set-up, how can 
trialists keep up with the pace at which biomarkers are being defined, re-defined and 
evidenced?  One approach is to adopt a pragmatic approach: would randomisation of an 
unselected population be acceptable and therefore feasible?  In answer to the second 
question, adaptive multi-stage protocols that incorporate lack-of-benefit interim analyses 
to determine ongoing accrual, including biomarker subgroup specific rules, are likely to be 
the most efficient. 
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5.1.4 Future work  
The work presented in this thesis highlights many of the challenges relevant to the 
implementation of stratified medicine but also demonstrates the strengths and opportunity 
of conducting translational studies in parallel with clinical trials.  
As the celecoxib-ZA result demonstrates a statistically and clinically significant benefit 
observed within a pre-planned sub-group analysis it should be considered relevant and 
robust. However the impact of this finding is undermined by the lack of a clear mechanistic 
rationale for the combination. My work is speculative as there are no biological samples in 
which to test hypotheses and in retrospect this was a real missed opportunity within a 
study that evaluated celecoxib, ZA and the combination with shared controls. This has 
implications for future evaluate combination therapy which should adopt a MAMS design 
and conduct parallel translational programmes to collect supportive data test hypothesises 
and improve understanding of mechanistic interactions. This in turn can be used to 
rationally identify biologically defined sub-groups with differential treatment response, 
where the toxicities and cost of combination therapy may be justified.  
My work has shown PSA-based outcomes to be pragmatic prognostic biomarkers able to 
improve risk stratification. Adaptive trials such as STAMPEDE can characterise biomarker 
defined sub-sets and through subsequent randomisations, seek to prospectively validate 
these findings within the same overarching protocol. Identifying high risk sub-groups may in 
turn enable new treatment strategies to be evaluated in smaller, quicker trials where 
signals can be sought in groups shown to have the highest unmet clinical need. For 
example, post docetaxel maintenance therapies may be first evaluated in patients with a 
high PSA nadir. Should a FFS benefit be observed at an interim analysis, randomisation 
broadened to include all patients supported by the initial indication of activity. 
Review of the current published data shows that there is currently insufficient evidence to 
support prospective molecularly selected therapeutic selection in mCSPC. My work has 
highlighted many of the challenges, including a relatively high failure rate and the 
importance of assay validation and comparability. Individual putative drivers occur in low 
frequencies but often co-exist. Knowledge as to which are the key oncogenic drivers 
remains incomplete and it is likely that many of those identified are passenger mutations or 
only relevant to sub-clonal populations. The impact of heterogeneity needs to be assessed 
before we can be confident to as to the reliability of directing therapy based on a single 
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core biopsy obtained from a patient with metastatic disease.  Approaches such as ctDNA 
are appealing as they avoid some of these sampling issues. However this strategy is best 
developed in the setting of relapsed mCRPC where yield is likely to be high. It remains 
technically challenging to sample men with mCSPC who are typically reviewed by 
oncologists shortly after starting ADT when the yield of ctDNA will be decreasing rapidly. 
Validating ctDNA approaches in this setting would seem the next priority in advancing 
molecularly targeting therapy in mPCa. Then, as has typically occurred in the past, this 
strategy can be brought forward and evaluated earlier in the disease course if benefit is 
seen. This would justify the likely significant changes in the clinical pathway required e.g. 
ctDNA collection by urologists as soon as a histological diagnosis is made and prior to 
initiation of treatment.  
Whilst data to support a MAMS trial that recruits to molecularly defined cohorts remains 
lacking, it is still possible for trials such as STAMPEDE to acquire data to support a more 
individualised approach to treatment. This can be achieved through parallel translational 
research that aims to further mechanistic understanding and generate and test hypothesis 
to explain differential treatment effects. MAMS trials are ideally designed to support such 
research as the use of shared controls allows several experiments to be conducted to 
explore predictors of response and toxicity. The evaluation of agents alone and in 
combination represents a particular opportunity e.g. analyses within the abiraterone 
comparison could aim to identify a sub-set that derive more benefit from the single agent 
and this this could be validated within the combination abiraterone + enzalutamide. Or 
conversely a population with a poor response could be identified and a hypothesis tested 
that the biology of this sub-group harboured a resistance mechanism that could be 
overcome by the addition of enzalutamide. Importantly, academic trials can seek to explore 
predictor where there is less commercial drive to do so e.g. AR-targeted therapies where 
response rates in unselected populations are sufficient high to de-motivate, but the health 
economic need remains high. Specific to STAMPEDE is the ability to test predictors of 
differential response to abiraterone and docetaxel, both now SOC treatments. This is 
possible using archival diagnostic samples from the randomised comparisons to each, 
including a proportion who were randomised contemporaneously to either. Accepting the 
limitations highlighted of using primary prostate samples, this remains a priority and 
highlights again the ability of un-stratified trials to acquire data to support a more stratified 
approach in the future. Overall the aim should remain the same: we should identify men 
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who are benefiting least from the current treatment strategies in order to focus and 
accelerate research to improve outcomes in those with the highest unmet clinical need. 
 
5.2 Conclusions 
A systematic review was unable to identify any supporting data for the observed beneficial 
effect of celecoxib-ZA. When seeking to understand the STAMPEDE results, an 
immunological hypothesis is proposed by which celecoxib-ZA may interact via promoting γ𝛿 
T cells to exert an anti-cancer effect and modulate the metastatic niche. Two novel 
prognostic biomarkers are proposed, relevant to the updated treatment paradigms; the 
magnitude of PSA response on ADT alone and PSA nadir assessed following docetaxel. 
These assessments are made at clinically meaningful time points and results suggest that 
both are prognostic of overall survival in the STAMPEDE cohort. Further validation is 
required but if confirmed, these may have clinical utility in informing the use of docetaxel 
and subsequent post-docetaxel maintenance therapies. Sequencing data from 192 patients 
with mCSPC was successfully obtained through two industry collaborations. Consistent with 
the prior hypothesis, the prevalence of HRD was observed to be less than reported in 
mCRPC but greater than seen in M0 disease. The evaluation of biomarker-treatment 
pairings continues to be challenged by low biomarker prevalence, compounded by test 
failure rates and a lack of validated intermediate clinical endpoints, which together 
necessitate long clinical trials with a high screening burden. However as shown by the data 
presented, additional analyses within large clinical trial cohorts can provide valuable data 
supporting biomarker development and informing trial design in this disease setting.  
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A1. Summary of study reports ineligible for inclusion in meta-analysis  
A1: Table 63: Summary of ineligible NSCLC trials  
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ar
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Comparison Cox-2 dose 
& duration 
Zhou et al.  
2007
140
 
Metastatic   
1st line 
Abstract 
only (full 
article in 
Chinese) 
China NK 65 
(NK) 
Phase II 
 
SOC chemo +cox-2 
inhibitor 
SOC chemo  
Celecoxib 
400mg BD  
Completed  
 
Insufficient data  
Xiong et 
al. 2007
317
  
Metastatic   
1st line 
Abstract 
only (full 
article in 
Chinese) 
China NK 60 
(NK) 
Phase II  SOC Chemo  + cox-2 
inhibitor 
vs. SOC Chemo 
 
Celecoxib 
400mg BD 
Completed  
 
Insufficient data 
Liu et al.  
2012
318
 
Metastatic   
1st line 
Abstract 
only (full 
article in 
Chinese) 
China NK 46 
(NK) 
Phase II  SOC Chemo  + cox-2 
inhibitor 
vs. SOC Chemo 
Celecoxib 
400mg BD 
 Insufficient data 
 
Pei et al.  
2014
319
 
Metastatic 
1
st   
line 
Abstract 
only 
China 2010 to 
2012 
81 
(NK) 
Phase II  SOC Chemo + Cox-2 
inhibitor  
 vs. SOC Chemo + 
placebo 
Celecoxib 
400mg BD 
  Insufficient data 
Authors contacted, no 
response  
 
Zhou et al.  
2007
140
 
Metastatic   
1st line 
Abstract China NK 65  
(NK) 
Phase II 
 
SOC chemo +cox-2 
inhibitor 
SOC chemo  
Celecoxib 
400mg BD  
 Insufficient data 
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A1: Table 64: Summary of ineligible trials in non-metastatic breast cancer  
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Comparison Cox-2 dose & duration 
Chow et al 
2005 
CAAN trial 
133,320
 
Localised; neo-
adjuvant and  
Adjuvant  
Full Japan & 
Hong Kong 
2002 to 
2003 
41  
(90) 
Phase II/III Exemestane + cox-2 (Group 
A) 
Exemestane (Group B) 
vs Letrozole (Group C) 
Celecoxib 400mg BD for 3 
months pre-surgery and at 
least 2 years in adjuvant 
setting 
Ahmadloo N et 
al 
2009
321
 
Localised;  
neo-adjuvant 
Abstract 
only 
Iran NK 50  
(NK) 
Phase II SOC chemo + cox-2  
SOC chemo + placebo   
 
Celecoxib 100mg BD   
Pierga et al
322
 Localised;  
neo-adjuvant   
Full France  2004 to 
2007 
220 
(NK) 
Phase II  Chemo (docetaxel)  
Vs.  
Chemo (docetaxel) + cox-2 
Celecoxib 400mg BD 
Rosati et 
al.2011
323
 
Localised, adjuvant  Abstract 
only 
Italy  2003 to 
2006 
182 
(NK) 
III Anastrozole + placebo vs. 
Anastrozole + etorcoxib 
Etorcoxib  
Higgins et 
al.2012
135
 
Localised, adjuvant  Abstract 
only  
Multi-
national 
NK 1622 
(NK) 
Phase III, 
factorial 
Exemestane vs. Anastrozole  
2nd randomisation: celecoxib 
vs. placebo  
Celecoxib 400mg BD  
Brandao et 
al.2013
150
 
Localised,  
neo-adjuvant 
Full Holland 2005 to 
2007 
37 
(NK) 
Phase II  Cox-2 vs. placebo Celecoxib 400mg BD 
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A1: Table 65: Summary of ineligible trials in non-metastatic breast cancer -2 
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Comparison Cox-2 dose & duration 
Samuel et 
al.2014
324
 
Localised, 
adjuvant 
Full USA 2004 327 Phase III  
2x2 factorial 
SOC chemo vs. non-standard 
chemo (AC vs. FEC-100)  
With and without addition of cox-
2 inhibitor 
Celecoxib 400mg BD 
 
Aristarco et 
al.2016
325
 
Localised, 
neo-adjuvant 
Full Italy  2004 to 
2009 
125 Phase II  Exemestane  
vs. celecoxib 
vs. Placebo  
Celecoxib 400mg BD 
 
Rea et al.2016 
NEO-EXCEL
326
 
Localised, 
neo-adjuvant 
Abstract  UK & 
Canada 
2016 266 Phase III 
factorial  
Exemestane vs. Letrozole  
 
2
nd
 randomisation:  
Celecoxib vs. placebo 
Celecoxib 400md BD 
 
Giacchetti et 
al.2017
327
 
Locally 
advanced, 
neo-adjuvant 
Full France  2004-
2007 
340 in total; 
220 within 
strata 1 
Phase III HER-
2 stratified  
Strata 1 HER2 negative: 
Chemo vs. chemo + celecoxib  
 
Strata 2 HER2 positive: 
Chemo vs. Chemo + trastuzumab  
Celecoxib 400mg BD  
24 weeks  
241 
 
 
A1: Table 66: Summary of ineligible colorectal cancer trials 
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Comparison Cox-2 dose & 
duration 
Fenwick et 
al.2003
152
 
Metastatic 
undergoing liver 
metastatectomy 
Full UK 2000 
to 
2002 
44 2 Cox-2 inhibitor  
vs. 
Control (placebo) 
Rofecoxib 25mg; 
minimum 
duration of 
therapy 14 days 
  Insufficient 
data 
Debucoquoy et 
al.2009
328
 
Localised,  
neo-adjuvant  
Full Belgium 2003 
to 
2006 
35 (80) 2 RT + chemo + cox-2  
vs. RT + chemo + 
placebo 
Celecoxib 400mg 
BD  
11-13 week 
duration 
 M0 disease  
Midgley et 
al.2010
329
 
Localised, 
 adjuvant  
Full  UK 2002 
to 
2004 
2434 2 Cox-2 inhibitor  
vs. placebo  
Rofecoxib 20mg 
OD 
Recruitment 
halted due to 
withdrawal of 
rofecoxib 
M0 disease 
EORTC 40023 
NCT00085163 
Localised, 
adjuvant 
Registry 
summary 
only 
 
EORTC  NK NK 
(1450)  
3 SOC chemo + cox-2 
inhibitor  
vs. SOC chemo + 
placebo 
Celecoxib 400mg 
BD 
 M0 disease 
Gan et 
al.2015
330
 
Localised,  
neo-adjuvant 
Abstract  2010 
to 
2011 
150 2 3 way randomisation: 
Cox-2 vs. methylpred 
vs. placebo  
Celecoxib 
(8mg/kg) total 10 
days: 5 days 
pre/post op 
 M0 disease 
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A1: Table 67: Summary of ineligible PCa trials  
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Comparison Cox-2 dose & 
duration 
Smith et al.  
2006
96
 
M0 HNPC 
(relapse post 
radical 
therapy) 
Full USA 2002 
to 
2004 
78 (140) 2 Cox-2 inhibitor 
vs. Placebo 
Celecoxib 400mg BD Discontinued 
due to 
external 
safety 
concerns 
PSA outcome 
data only  
Antonarakis et 
al.  2009
151
 
M0 
Neo-adjuvant 
Full USA 2002 
to 
2005 
64  
(60) 
2 Cox-2 inhibitor 
vs. Placebo 
Celecoxib  400mg 
BD, 4-6 weeks prior 
to prostatectomy 
 M0 disease and  
translational 
outcomes only  
Flamiatos et al.  
2011
131
 
M0, 
Neo-adjuvant 
Abstract USA UN 28  
(40) 
2 Cox-2 inhibitor 
vs. Placebo 
Celecoxib 400mg 
BD, minimum 4 
weeks prior to 
prostatectomy 
Discontinued 
due to 
cardiac AE 
and external 
safety data 
M0 disease and  
translational 
outcomes only 
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A2: Exploring concordance for PSA response value 
 
A2: Figure 38: Concordance if lower threshold ≤80% (selected)  
 
 
A2: Figure 39: Concordance if lower threshold 85% 
 
 
A2: Figure 40: Concordance if lower threshold 90%  
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A3: Analysis of PSA response in ADT alone treated group using outcome failure-free 
survival 
 
A3: Table 68: Baseline multivariable FFS model for PSA response analysis 
Characteristic Overall survival 
  Category description n Events 
  
Multivariable  p-value* 
T stage  ≤T2 85 53 0.81 (0.54-1.20) 0.3830 
T3 380 310 1.0 
T4 154 132 1.20 (0.90-1.59)  
Tx 58 50 1.32 (0.89-1.97) 
Nodal stage  N0 228 181 1.0 0.9126 
N+ 387 310 1.07 (0.80-1.43) 
Nx 62 54 1.01 (0.66-1.54) 
Metastatic 
distribution  
Bone only  428 355 3.52 (1.86-6.68) <0.0001 
Distant nodal only  56 38 1.0 
Bone & nodal or 
other  
193 152 3.27 (1.21-2.00) 
Gleason sum score  ≤ 7 148 103 1.0 0.0322 
≥ 8 445 369 1.52 (1.10-2.12) 
Unknown  84 73 1.47 (0.95-2.28) 
Age  ≤55  61 60 2.05 (1.35-3.13) 0.0024 
55-59  96 80 1.55 (1.08-2.24)  
60-64 135 107 1.28 (0.91-1.81) 
65-69* 181 139 1.0 
70-74 124 95 0.85 (0.58-1.26) 
≥ 75 80 64 1.20 (0.80-1.81) 
Performance status   0 495 383 1.0 0.0007 
1 or 2 182 162 1.56 (1.21-2.00) 
Ln (Duration of 
prior ADT)  
na 
 
545 677 0.98 (0.95-1.01) 0.1731 
Ln (week-6 PSA)*** na 545 677 1.28 (1.21-1.37) <0.0001 
*For variable in overall survival model, statistically significant at 5% level shown in bold 
** Median age 65 years  
*** Natural logarithmic transformation  
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A4: Analysis of PSA response in docetaxel-treated population  
 
A4: Table 69: Baseline overall survival model in the docetaxel-treated cohort   
Characteristic  Overall survival 
  Category description n Events 
  
Multivariable  p-value* 
T stage  ≤T2 85 33 1.03 (0.70-1.52)   
  
 0.9911 
 
T3 343 137 1.0 
T4 139 60 1.04 (0.76-1.41) 
Tx 62 32 1.06 (0.69-1.62) 
Nodal stage  N0 208 73 1.0   
  
0.0403 
N+ 366 157 1.50 (1.09-2.06) 
Nx 55 26 1.30 (0.83-2.04) 
Metastatic 
distribution  
Bone only  392 155 1.96 (1.15- 3.34)   
  
0.0101 Distant nodal only  67 17 1.0 
Bone & nodal or other  170 84 2.11 (1.24- 3.57) 
Gleason sum 
score  
≤ 7 112 34 1.0   
  
0.0263 
≥ 8 434 175 1.60 (1.10-2.32) 
Unknown  83 47 1.64(1.04- 2.59) 
Age  ≤55  52 22 0.89 (0.54-1.46)   
  
  
  
  
0.8271 
55-59  86 39 1.05 (0.70-1.58) 
60-64 143 57 0.91 (0.63-1.30) 
65-69* 174 65 1.0 
70-74 120 53 1.09 (0.75-1.58) 
≥ 75 54 20 0.80 (0.48-1.32) 
Performance 
status  
0 467 174 1.0   
0.0031 1 or 2 162 82 1.51 (1.16-1.98) 
Duration of 
prior ADT 
(weeks)  
Continuous  - - 1.06 (1.02-1.10) 0.0014 
Ln week 6 PSA*  Continuous - - 1.14 (1.08-1.21) <0.0001 
*For variable in overall survival model, statistically significant at 5% level shown in bold 
** Median age 65 years  
*** Natural logarithmic transformation  
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A5: Analysis of PSA nadir in docetaxel-treated population using outcome FFS 
 
A5: Table 70: Baseline failure-free survival model for analysis of PSA nadir 
Characteristic Failure free survival 
  Category description n Events  Multivariable  p-value 
T stage  ≤T2 82 56 1.26 (0.94-1.69)   
  
  
0.4269 
T3 336 225 1.0 
T4 135 93 0.96 (0.75-1.23) 
Tx 59 45 1.08 (0.78-1.50) 
Nodal stage  N0 207 145 1.0   
  
0.0624 
N+ 346 225 0.91 (0.74-1.12) 
Nx 58 49 1.35 (0.97-1.87) 
Metastatic 
distribution  
Bone only  390 277 1.53 (1.06- 2.22)   
  
0.0599 
Distant nodal only  66 33 1.0 
Bone & nodal or other  155 109 1.43 (0.95-2.14) 
Gleason sum 
score  
≤ 7 113 67 1.0   
  
0.1961 
≥ 8 423 290 1.27 (0.97-1.66) 
Unknown  75 62 1.21 (0.83-1.76) 
Age  ≤55  53 41 1.06 (0.74-1.51)   
  
  
  
  
<0.0001 
55-59  82 60 1.07 (0.78-1.46) 
60-64 138 98 0.84 (0.64-1.10) 
65-69
a
 168 121 1.0 
70-74 116 74 0.87 (0.65-1.16) 
≥ 75 54 25 0.40 (0.26-0.62) 
Performance 
status 
0 453 303 1.0   
0.1446 1 or 2 159 116 1.18 (0.94-1.47) 
Duration ADT 
prior to 
randomisation  
0 week
b
 29 19   
  
  
  
1.05 (1.02-1.09) 
  
  
  
  
0.0048 
≤2 weeks 77 44 
≤4 weeks 81 51 
≤6 weeks  104 72 
≤8 weeks 105 77 
≤10 weeks 104 70 
≤12 weeks 106 81 
≤14 weeks 5 5 
Presenting 
PSA
c
 
- 611 419 1.08 (1.05-1.11)  <0.0001 
 
  
a 
Median age 65yrs, 
b 
All patients who were yet to start ADT prior to randomisation, commenced within 7 days  
c 
Natural Logarithmic transformation  
*For variable in overall survival model, statistically significant at 5% level shown in bold 
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A6: Targeted Next-generation sequencing methods  
A6: Table 71: F1 Sample Processing   
DNA extraction  
 Pathology review H&E stained slide to ensure sample volume ≥1mm3, nucleated 
cellularity  ≥80% or ≥30,000 cells and 20% nucleated cells tumour derived 
 Macro-dissection only if ≤20% tumour content  
 Preparation of unstained FFPE sections from which DNA can be extracted (typical 
requirement 4x10um sections)  
 DNA extraction by digestion using a proteinase K buffer followed purification 
(Promega Maxwell 16 Tissue LEV DNA kit)  
 Quantification of DNA contraction by Picogreen fluorescence assay  
Library construction  
 Fragmentation of 50-200ng of dsDNA by sonication  
 DNA purification performed through Agencourt AMPure XP, a buffer that selectively 
binds DNA fragments to paramagnetic beads allowing excess primers etc. to be 
washed off 
 Library construction (NEBNExt kits) through addition of end repair and ligation 
(adding of oligonucleotides that can promote amplification) 
 PCR amplification  & purification  
 DNA QC: Threshold >50ng of extracted DNA or 500ng of sequencing library required 
with mean insert size of >400 base pairs 
Hybrid selection & sequencing  
 Solution hybridization: the addition of complementary DNA oligonucleotides 
(referred to as baits) targeting the 287 cancer related exons and 47 introns of and 
3549 polymorphisms (SNP). A minimum of three baits per each target exons and 
introns allocated (Integrated DNA Technology)  
 Captured library isolated and PCR amplified (12 cycles) and quantified by qPCR (Kapa)  
 Sequenced using Illumina HiSeq 2000 
Bioinformatics: sequencing data processing 
 Sequencing data mapped to the reference human genome (BWA aligner v0.5.9) 
 Assessment of read quality made according to pre-defined algorithm that 
incorporates a tissue-specific estimation of whether the mutation would be expected 
(with reference to current published data available via COSMIC).  
 Read quality quantified; reads with mapping quality of <25 and base calls with quality 
≤2 excluded 
 Indel detection in each exon performed through comparison of each read and 
imposing filters to ensure pre-defined QC metrics met e.g. the minimum mutational 
allele frequency required at known mutational hotspots and the neighbouring base 
quality  
 Copy number alteration reported through combining exon coverage with SNPs 
against a process-matched control. Through analysis of the allele frequencies of 
sequenced SNPs tumour purity and copy number is estimated for each segment. 
Focal CNA reported if ≥6 copies reported and homozygous deletion if 0 copies, in 
samples with purity ≥20% 
 Gene fusion detection identified by analysing read pair for which reads map to 
separate chromosomes (chimeric read pairs). Rearrangements annotated according 
to predicted function  
Summarised from published methods (Frampton et al Nature Biotechnology 2016) 
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A6: Table 72: Ilumina TruSight Tumour T170 Panel provided by Almac Diagnostics  
DNA extraction  
 Pathology review of FFPE block and accompanying marked H&E stained slide  
 Macrodissection  
 Dual DNA and RNA extraction using Qiagen AllPrep FFPE Kit: proteinase K containing 
buffer releases RNA and precipitates DNA which can be separated through 
centrifugation enabling separate processing of the RNA containing supernatant and 
DNA-containing pellet.  
 Separately, both RNA and DNA are incubated at 90°c aiming to reverse crosslinking  
 Nucleic acid concentration and purity assessed using spectrophotometric methods  
 Required minimum DNA concentration: 3.3ng/µL  
 Required minimum RNA concentration: 4.7ng/µL 
Library construction  
 Processed using the Illumina TruSight® assay  
 The extracted RNA was denatured, primed with random hexamers and used to 
synthesise complementary DNA(cDNA) 
 Extracted DNA was fragmented using sonication 
 From this point onwards, both cDNA and DNA were processed together  
 Initial library construction achieve through ligation of adaptors (oligonucleotides that 
can promote amplification), purification and then amplification  
Hybrid selection & sequencing 
 Hybridisation: addition of a custom pool of oligonucleotides specific to the targeted 
regions of interest 
 Purification  
 PCR amplification using primers binding regions that flank targeted regions of interest 
 Quantification & QC assessment using fluorometric methods  
 Bead-based normalisation: DNA is bound to normalisation beads and then eluted off 
the beads at a similar concentration, allowing even library quantification required 
prior to loading sequencing machine  
 Sequenced using Illumina NextSeq  
Bioinformatics: sequencing data processing  
 Sequencing data aligned to the Reference Human Genome  
 Analysed using the TST170 application on BaseSpace; this is an online resource 
supporting Illumina products that enables storage and analysis of sequencing data 
using a variety of applications.   
 QC assessment performed as part of BaseSpace application   
 Custom script developed by Almac in conjunction with Clovis’ pre-defined enrolment 
eligibility criteria  applied to processed files outputted via BaseSpace  
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A7: Comparative Targeted Next-generation sequencing gene lists  
 
A7: Figure 41: Foundation One Gene List  
ABL1 BRCA1 CREBBP FANCD2 GID4 KDM5C MUTYH PIK3R1 RUNX1 TET2 
ABL2 BRCA2 CRKL FANCE GLI1 KDM6A MYB PIK3R2 RUNX1T1 TGFBR2 
ACVR1B BRD4 CRLF2 FANCF GNA11 KDR MYC PLCG2 SDHA TMPRSS2 
AKT1 BRIP1 CSF1R FANCG GNA13 KEAP1 MYCL PMS2 SDHB TNFAIP3 
AKT2 BTG1 CTCF FANCL GNAQ KEL MYCN POLD1 SDHC TNFRSF14 
AKT3 BTK CTNNA1 FAS GNAS KIT MYD88 POLE SDHD TOP1 
ALK C11orf30 CTNNB1 FAT1 GPR124 KLHL6 NF1 PPP2R1A SETD2 TOP2A 
AMER1 CARD11 CUL3 FBXW7 GRIN2A KMT2A NF2 PRDM1 SF3B1 TP53 
APC CBFB CYLD FGF10 GRM3 KMT2C NFE2L2 PREX2 SLIT2 TSC1 
AR CBL DAXX FGF14 GSK3B KMT2D NFKBIA PRKAR1A SMAD2 TSC2 
ARAF CCND1 DDR2 FGF19 H3F3A KRAS NKX2-1 PRKCI SMAD3 TSHR 
ARFRP1 CCND2 DICER1 FGF23 HGF LMO1 NOTCH1 PRKDC SMAD4 U2AF1 
ARID1A CCND3 DNMT3A FGF3 HNF1A LRP1B NOTCH2 PRSS8 SMARCA4 VEGFA 
ARID1B CCNE1 DOT1L FGF4 HRAS LYN NOTCH3 PTCH1 SMARCB1 VHL 
ARID2 CD274 EGFR FGF6 HSD3B1 LZTR1 NPM1 PTEN SMO WISP3 
ASXL1 CD79A EP300 FGFR1 HSP90AA1 MAGI2 NRAS PTPN11 SNCAIP WT1 
ATM CD79B EPHA3 FGFR2 IDH1 MAP2K1 NSD1 QKI SOCS1 XPO1 
ATR CDC73 EPHA5 FGFR3 IDH2 MAP2K2 NTRK1 RAC1 SOX10 ZBTB2 
ATRX CDH1 EPHA7 FGFR4 IGF1R MAP2K4 NTRK2 Rad50 SOX2 ZNF217 
AURKA CDK12 EPHB1 FH IGF2 MAP3K1 NTRK3 Rad51 SOX9 ZNF703 
AURKB CDK4 ERBB2 FLCN IKBKE MCL1 NUP93 Rad51B SPEN   
AXIN1 CDK6 ERBB3 FLT1 IKZF1 MDM2 PAK3 Rad51C SPOP   
AXL CDK8 ERBB4 FLT3 IL7R MDM4 PALB2 Rad51D SPTA1   
BAP1 CDKN1A ERG FLT4 INHBA MED12 PARK2 Rad54L SRC   
BARD1 CDKN1B ERRFI1 FOXL2 INPP4B MEF2B PAX5 RAF1 STAG2   
BCL2 CDKN2A ESR1 FOXP1 IRF2 MEN1 PBRM1 RANBP2 STAT3   
BCL2L1 CDKN2B ETV1 FRS2 IRF4 MET PDCD1LG2 RARA STAT4   
BCL2L2 CDKN2C ETV4 FUBP1 IRS2 MITF PDGFRA RB1 STK11   
BCL6 CEBPA ETV5 GABRA6 JAK1 MLH1 PDGFRB RBM10 SUFU   
BCOR CHD2 ETV6 GATA1 JAK2 MPL PDK1 RET SYK   
BCORL1 CHD4 EZH2 GATA2 JAK3 MRE11A PIK3C2B RICTOR TAF1   
BCR CHEK1 FAM46C GATA3 JUN MSH2 PIK3CA RNF43 TBX3   
BLM CHEK2 FANCA GATA4 KAT6A MSH6 PIK3CB ROS1 TERC 
BRAF CIC FANCC GATA6 KDM5A MTOR PIK3CG RPTOR TERT 
      
 
            
Key    
       
  
Present in F1  
       
  
Selected HRD Gene  
       
  
Unique to t170    
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A7: Figure 42: TruSight T170 (t170) Gene List (Almac Diagnostics)  
ABL1 CARD11 EGFR FGF1 FOXL2 MCL1 NOTCH2 PPP2R2A STK11 
AKT1 CCND1 EML4 FGF10 GEN1 MDM2 NOTCH3 PTCH1 TERT 
AKT2 CCND2 EP300 FGF14 GNA11 MDM4 NPM1 PTEN TET2 
AKT3 CCND3 ERBB2 FGF19 GNAQ MET NRAS PTPN11 TFRC 
ALK CCNE1 ERBB3 FGF2 GNAS MLH1 NRG1 Rad51 TMPRSS2 
APC CD79A ERBB4 FGF23 HNF1A MLLT3 NTRK1 Rad51B TP53 
AR CD79B ERCC1 FGF3 HRAS MPL NTRK2 Rad51C TSC1 
ARID1A CDH1 ERCC2 FGF4 IDH1 MRE11A NTRK3 Rad51D TSC2 
ATM CDK12 ERG FGF5 IDH2 MSH2 PALB2 Rad54L VHL 
ATR CDK4 ESR1 FGF6 INPP4B MSH3 PAX3 RAF1 XRCC2 
AXL CDK6 ETS1 FGF7 JAK2 MSH6 PAX7 RB1   
BAP1 CDKN2A ETV1 FGF8 JAK3 MTOR PDGFRA RET   
BARD1 CEBPA ETV4 FGF9 KDR MUTYH PDGFRB RICTOR   
BCL2 CHEK1 ETV5 FGFR1 KIF5B MYC PIK3CA ROS1   
BCL6 CHEK2 EWSR1 FGFR2 KIT MYCL1 PIK3CB RPS6KB1   
BRAF CREBBP EZH2 FGFR3 KMT2A MYCN PIK3CD SLX4   
BRCA1 CSF1R FAM175A FGFR4 KRAS MYD88 PIK3CG SMAD4   
BRCA2 CTNNB1 FANCI FLI1 LAMP1 NBN PIK3R1 SMARCB1   
BRIP1 DDR2 FANCL FLT1 MAP2K1 NF1 PMS2 SMO   
BTK DNMT3A FBXW7 FLT3 MAP2K2 NOTCH1 PPARG SRC   
                  
Key    
      
  
Selected HRD Gene  
      
  
Also present in F1  
      
  
Unique to t170               
 
A7: Figure 43: Color Genomics Gene List (germline analysis)  
APC BRCA1 CHEK2 MLH1 PMS2 SMAD4 
ATM BRCA2 CDKN2A MSH2 POLD1 STK11 
BAP1 BRIP1 EPCAM MUTYH PTEN TP53 
BARD1 CDH1 GREM1 NBN Rad51C   
BMPR1A CDK4 MITF PALB2 Rad51D   
  
    
  
Key      
  
  
Selected HRD Gene            
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A8: Sites contributing samples to each sequencing analysis  
 
A8: Table 73: Sites contributing samples to analysis one (F1)  
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A8: Table 74: Sites contributing samples to analysis two (t170) 
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A9: Treatment allocation for patients sampled in each sequencing analysis  
 
A9: Table 75: Population included in analysis one by research arm 
STAMPEDE Treatment allocation    
Arm A: Control (SOC)  76 (41%) 
Arm B: SOC+ zoledronic acid 8 (4%) 
Arm C: SOC + docetaxel  7 (4%) 
Arm E: SOC + docetaxel + zoledronic acid 6 (3%) 
Arm G: SOC + abiraterone 21 (11%) 
Arm H: SOC+ M1|RT 38 (20%) 
Arm K: SOC + metformin  31 (17%) 
 
A9: Table 76: Population included in analysis two by research arm 
STAMPEDE Treatment allocation  
Arm A: Control (SOC) 32 
Arm H: SOC + Prostate RT  47 
Arm K: SOC + Metformin  21 
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A10: Evidence of pre-analytical variability between sequencing providers 
 
A10: Table 77: Comparative DNA concentration estimates  
# FM assessment 
ng/ul 
Almac assessment  
ng/ul 
Comparison  
(%) 
Almac QC  
1 4.42 0 0.00 Fail 
2 5.079 0 0.00 Fail 
3 4.992 2.7 54.09 Fail 
4 8.652 6.94 80.21 Pass 
5 15.781 15.6 98.85 Pass 
6 11.088 11 99.21 Pass 
7 245.036 248 101.21 Pass 
8 61.254 63.8 104.16 Pass 
9 41.851 45 107.52 Pass 
10 22.935 26.6 115.98 Pass 
11 10.544 12.6 119.50 Pass 
12 49.071 60 122.27 Pass 
13 21.037 26.2 124.54 Pass 
14 24.546 30.6 124.66 Pass 
15 7.467 9.4 125.89 Pass 
16 58.681 74.2 126.45 Pass 
17 49.059 65.8 134.12 Pass 
18 191.494 326 170.24 Pass 
19 18.761 35.6 189.76 Pass 
20 14.077 43.4 308.30 Pass 
Key: QC, quality control; Almac, Almac diagnostics; FM, Foundation Medicine. Green shading 
indicates where results are within 10% 
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Appendix B: Summary of ongoing PARPi trials and other therapies in HRD Prostate cancer 
AB: Table 78: PARPi trials in prostate cancer -1 
Agent Registration 
Acronym  
Phase  Patient 
group 
Biomarker Treatment 
details 
Primary 
outcome 
measures 
Status  
Olaparib NCT01682772 
TOPARP 
II mCRPC Mandatory biopsies 
tNGS  
BRCA1, BRCA2, ATM, + other HRD 
genes 
 ADT + olaparib ORR  TOPARP-A: reported 
TOPARP-B: ongoing  
Olaparib NCT02987543 
PROfound 
III mCRPC (post 
progression 
on abi or 
enza) 
Tumour HRD testing: broader panel 
recruited, powered on subset 
 ADT + olaparib 
 ADT + abi or enza 
rPFS in 
BRCA/ATM 
Recruiting  
Est accrual: 340 
Est report date: Feb 
2021 
Olaparib NCT03012321 II mCRPC  BRCA1/BRCA2/ATM mutations 
eligible for randomisation between 
arms 1-3. Non-BRCA/ATM HRD 
mutant cases eligible for arm  4 
(one or more mutations in 17 HRD 
genes)  
 Arm 1: ADT + abi +pred 
 Arm 2: ADT + olaparib 
 Arm 3: ADT + abi + pred + 
olaparib 
 Arm 4: ADT + olaparib  
PFS at 2 years  Recruiting  
Target accrual: 70 
Est completion date: 
Jan 2022 
 
Olaparib NCT03047135 II High risk 
biochemical 
relapsed  
HRD panel of 20 genes   
Two stage design (similar to 
TOPARP)  to evaluate different 
biomarker enrichment 
 ADT+ olaparib PSA RR Target accrual: 50  
Est report: 2022 
Olaparib NCT02861573 
KEYNOTE-365 
Ib/II mCRPC  unselected  Cohort 1: Pembro + olaparib 
 Cohort 2: Pembro + docetaxel + 
olaparib 
 Cohort 3: Pembro + enza 
Safety and 
PSA response 
(>50%) 
Recruiting 
Target accrual 70 per 
cohort (210) 
Est completion: April 
2020 
Olaparib NCT03434158 
IMANOL 
II mCRPC  PR or SD post docetaxel  
HRD positive (pathogenic mutation 
in any HRD or MMR gene)  
 ADT + Olaparib rPFS Recruiting  
Target accrual: 27  
Est report: Nov 2019 
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AB: Table 79: PARPi trials in prostate cancer -2 
Agent Registration 
Acronym  
Phase  Patient 
group 
Biomarker Treatment 
details 
Primary 
outcome 
measures 
Status  
Rucaparib NCT02952534 
TRITON2 
II mCRPC  3 cohorts:  
A: BRCA1/2 or ATM with 
measurable disease  
B: BRCA1/2 or ATM  
C: non BRCA/ATM HRD (mutation 
in one or more 15 HRD genes)  
 ADT+ rucaparib ORR  
PSA response 
Recruiting 
Target accrual: 160  
Est report date: April 
2020 
Rucaparib NCT02975934 
TRITON3 
III mCRPC 
(bone) 
 
BRCA1/2 or ATM mutant somatic 
or germline on local or centralised 
testing  
 
 ADT + rucaparib 
 ADT + physicians choice 
(docetaxel/abiraterone/ 
enzalutamide) 
 
 
rPFS Recruiting  
Accrual target: 400 
Est report date: Feb 
2022 
Rucaparib   
NCT03413995 
TRIUMPH 
II Metastatic 
hormone-
sensitive  
Pathological germline mutation in 
one or more of 20 HRD on a 
clinically accredited test  
 
 
 Rucaparib alone (ADT not being 
given)   
PSA response Start date: May 2018 
Target accrual: 30  
Est report date: May 
2020  
Rucaparib  NCT03442556 
PLATI-PARP 
II mCRPC  BRCA1/2 or ATM   Carboplatin, Docetaxel & 
Rucaparib 
rPFS Target accrual 20 
Start May 2018  
Completion May 
2024 
Rucaparib  NCT03338790 
CheckMate 
9KD 
II   Unselected but mandatory tumour 
testing – likely subgroup? 
 Nivolumab+ rucaparib  
 Nivolumab, + docetaxel + pred 
 Nivolumab + enza   
ORR  Recruiting  
Completion Feb 2020  
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AB: Table 80: PARPi trials in prostate cancer -3 
Agent Registration 
Acronym  
Phase  Patient 
group 
Biomarker Treatment 
details 
Primary 
outcome 
measures 
Status  
Niraparib NCT02854436 
Galahad 
II mCRPC  Tumour positive for DNA repair 
abnormalities (company assay) 
 ADT + Niraparib  ORR  Recruiting 
Accrual target: 160 
Est report date: Oct 
2019 
Niraparib NCT03431350 Ib/II mCRPC  Cohort  
1A: BM positive (HRD) 
1B: BM negative  
 ADT + Niraparib  
 ADT + Niraparib + anti-PD1 (JNJ-
63723283) 240mg 
 ADT + Niraparib + anti-PD1 
480mg   
  
Safety & ORR  Target accrual: 60  
Started March 2018  
July 2019 
Niraparib NCT02924766 
BEDIVERE 
I/Ib mCRPC unselected  ADT + Niraparib +apalutamide  
 ADT + Niraparib + abi + pred 
MTD & Safety Recruiting 
Target accrual: 60  
Est completion date: 
May 2018 
Talazoparib NCT03148795 II mCRPC HRD as defined by central panel + 
germline testing 
 ADT+Talazoparib ORR Recruiting  
Target accrual: 100  
Est completion 
~2021 
Talazoparib NCT03395197 
TALAPRO-2 
III mCRPC HRD as defined by central panel + 
germline testing: Fresh biopsy 
required if archival tissue not 
sufficient 
 ADT+ Talazoparib + abi or enza 
 ADT + placebo + physicians 
choice of abi or enza 
Safety (part 1) 
rPFS (part 2) 
Recruiting  
Started Dec 2017 
Target accrual: 444 
Est completion: 
March 2024 
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Appendix C: STAMPEDE protocol version 17.0 and associated documents  
 
Link to STAMPEDE Protocol version 17.0 -Describes the Biomarker screening pilot   
http://www.stampedetrial.org/media/1841/01-stampede_protocol_v17_clean.pdf 
  
 
Link to STAMPEDE Sample Handling Manual  
http://www.stampedetrial.org/media/1742/stampede_sample_collection_handling_manu
alv5.pdf 
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Appendix G: Confirmation of Ethical approval  
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Appendix I: Relevant publication  
 PROSPERO International prospective register of systematic reviews
 
Use of Cox-2 inhibitors in the treatment of cancer: a systematic review of the
evidence
Clare Gilson, Sarah Burdett
 
 Citation
Clare Gilson, Sarah Burdett. Use of Cox-2 inhibitors in the treatment of cancer: a systematic review of the evidence.
PROSPERO 2016:CRD42016041743 Available from  
http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42016041743  
Review question(s)
Can the addition of Cox-2 inhibitors improve outcomes in cancer?
Searches
Electronic databases:
MEDLINE 1996-2016 
EMBASE 1996-2016
Cochrane Central Review of Controlled Trials (CENTRAL) 1996-present (via OVID)
Trial registers:
ClinicalTrials.gov
Conference proceedings:
Proceedings of the American Society of Clinical Oncology (ASCO) 2004-2016
Proceedings of the European Society of Medical Oncology (ESMO) 1996-2016
Proceedings of the European Cancer Conference Organization (ECCO) 1996-2016
Searching for trials focusing on six tumour sites/types of interest (Gastrointestinal malignancies, non-small cell lung,
breast, prostate, head and neck, myeloma).
Types of study to be included
Phase II and III randomised controlled trials will be included if they have aimed to evaluate Cox-2 inhibitors alone or
in combination. In order to provide historical context, particularly as many later stage trials were terminated due to
concerns regarding cardiovascular toxicity, non-randomised phase II trials will also be reviewed separately.
Condition or domain being studied
Cancer.
Trials will be reviewed by tumour site focusing on six tumour sites/types of interest:
• Gastrointestinal malignancies (upper and lower gastrointestinal tract, including colorectal and hepatobiliary)
• Non-small cell lung 
• Breast 
                               Page: 1 / 4
• Prostate
• Head and neck 
• Myeloma
Participants/ population
Patients with cancers in whom Cox-2 inhibitors are being evaluated alone or in combination in any disease setting:
including neo-adjuvant (prior to radical surgery or radiotherapy), adjuvant (following radical therapy) and palliative
(i.e. treatment for metastatic disease).
Intervention(s), exposure(s)
Cox-2 inhibitor should be given alone or in combination with additional research treatment or current standard-of-
care.
Comparator(s)/ control
In controlled trials, this group should receive standard-of-care treatment or placebo.
Context
Neo-adjuvant (prior to radical surgery or radiotherapy), adjuvant (following radical therapy) and palliative (i.e.
treatment for metastatic disease).
Outcome(s)
Primary outcomes
Progression-free survival.
Time to progression or death.
Secondary outcomes
Overall survival
Disease-free survival
Response rate
Cardiovascular toxicity
Translational endpoints are of interest although are not amenable to analysis.
Data extraction, (selection and coding)
Data on patient characteristics, interventions and outcomes will be extracted from publications and presentations into
pre-designed forms. Where insufficient data are available from publications, it may be sought directly from
investigators.
Risk of bias (quality) assessment
These will be carried out using the Cochrane Risk of Bias Tool both for individual trials and, if it is possible to
proceed to undertake a meta-analysis, this will be assessed for overall meta-analysis for the primary outcome of
overall survival.
Strategy for data synthesis
If sufficient data is available having undertaken a systemic review, a meta-analysis will performed of time-to-event
outcomes following the extraction of hazard ratio (HR) and associated statistics from the trial reports. Where not
reported, they will be estimated from the Kaplan-Meier curves or other summary statistics using published methods.
Where insufficient data are available, supplementary data may be sought directly from the trial investigators. If
sufficient data is available this will be looked at across all trials and within sub-groups by tumour site. If sufficient
data is available this will be looked at across all trials and within sub-groups by tumour site.
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Analysis of subgroups or subsets
Cancer site focusing on five sites/types of interest.
Setting: Neo-adjuvant, adjuvant, metastatic.
Should sufficient data be available a planned analysis of the metastatic populations across common tumour types will
be performed.
Dissemination plans
The results will be submitted for presentation at an international cancer meeting and for publication in a peer
reviewed journal.
Contact details for further information
Clare Gilson
MRC Clinical Trials Unit at UCL
Aviation House
125 Kingsway
London
WC2B 6NH
c.gilson@ucl.ac.uk
Organisational affiliation of the review
MRC Clinical Trials Unit at UCL
Review team
Dr Clare Gilson, MRC CTU at UCL
Ms Sarah Burdett, MRC CTU at UCL
Anticipated or actual start date
04 July 2016
Anticipated completion date
05 September 2016
Funding sources/sponsors
MRC CTU at UCL
Conflicts of interest
None known
Language
English
Country
England
Subject index terms status
Subject indexing assigned by CRD
Subject index terms
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Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Humans; Neoplasms
Stage of review
Ongoing
Date of registration in PROSPERO
06 July 2016
Date of publication of this revision
06 July 2016
Stage of review at time of this submission Started Completed
Preliminary searches Yes   No 
Piloting of the study selection process   Yes   No 
Formal screening of search results against eligibility criteria   Yes   No 
Data extraction   No   No 
Risk of bias (quality) assessment   No   No 
Data analysis   No   No 
 
PROSPERO
International prospective register of systematic reviews
The information in this record has been provided by the named contact for this review. CRD has accepted this information in good
faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record,
any associated files or external websites.
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Cox-2 inhibitors in the treatment of cancer: search strategy  
Medline Search Strategy Medline non-randomised 
Search strategy  
Central search 
strategy 
Embase search strategy  
1 randomized 
controlled trial (pt) 
2 controlled clinical trial 
(pt) 
3 randomized (ab, ti) 
4 placebo (ab, ti) 
5 clinical trials as 
topic.sh 
6 randomly (ab, ti) 
7 trial (ab, ti) 
8 1 or 2or 3 or 4 or 5 or 
6 or 7 
9 exp neoplasms 
10 cancer in AB or cancer 
in TI 
11 9 or 10 
12 rofecoxib in AB, TI  
13 vioxx in AB, TI 
14 celecoxib in AB, TI 
15 celebrex in AB, TI 
16 etoricoxib in AB, TI 
17 arcoxia in AB, TI 
18 valdecoxib in AB, TI 
19 bextra in AB, TI 
20 etodolac in AB, TI 
21 lodine in AB, TI 
22 meloxicam in AB, TI 
23 mobic in AB, TI 
24 parecoxib in AB, TI 
25 dynastat in AB, TI 
26 lumiracoxib in AB, TI 
27 prexige in AB, TI 
28 12 or 13 or 14 or 15 or 
16 or 17 or 18 or 19 or 
20 or 21 or 22 or 23 or 
24 or 25 or 26 or 27 
29 8 and 11 and 28 
 
1 clinical trials as topic.sh  
2 trial (ab, ti) 
3 1 or 2  
4 exp neoplasms 
5 cancer in AB or cancer 
in TI 
6 4 or 5 
7 rofecoxib in AB, TI  
8 vioxx in AB, TI 
9 celecoxib in AB, TI 
10 celebrex in AB, TI 
11 etoricoxib in AB, TI 
12 arcoxia in AB, TI 
13 valdecoxib in AB, TI 
14 bextra in AB, TI 
15 etodolac in AB, TI 
16 lodine in AB, TI 
17 meloxicam in AB, TI 
18 mobic in AB, TI 
19 parecoxib in AB, TI 
20 dynastat in AB, TI 
21 lumiracoxib in AB, TI 
22 prexige in AB, TI 
23 12 or 13 or 14 or 15 or 
16 or 17 or 18 or 19 or 
20 or 21 or 22 or 23 or 
24 or 25 or 26 or 27 
24 8 and 11 and 28 
 
1 Cancer  
2 Rofecoxib 
3 Vioxx 
4 Celebrex 
5 Etoricoxib 
6 Arcoxia 
7 Valdecoxib  
8 Bextra 
9 Etodolac 
10 Iodine 
11 Mobic 
12 Parecoxib 
13 Lumiracoxib  
14 Prexige 
15 cox-2 
16 Celecoxib 
17 #2 to #16 
(or) 
18 #1 and #17 
1    neoplasm 
2     cancer.ti,ab.  
3     1 or 2  
4     crossover procedure 
5     double blind procedure 
6     randomized controlled 
trial 
7     single blind procedure 
8     random.mp 
9     factorial.mp. 
10     (crossover* or cross 
over* or cross-over*) mp 
11     placebo*mp 
12     (double* adj blind*).mp. 
13     (singl* adj blind).mp.  
14     assign*.mp. 
15     allocat*.mp.  
16     volunteer*.mp. 
17     4 or 5 or 6 or 7 or 8 or 9 
or 10 or 11 or 12 or 13 or 14 
or 15 or 16  
18     rofecoxib.ti,ab. 
19     vioxx.ti,ab. 
20     celecoxib.ti,ab. 
21     celebrex.ti,ab.  
22     etoricoxib.ti,ab. 
23     arcoxia.ti,ab. 
24     valdecoxib.ti,ab. 
25     bextra.ti,ab.  
26     etodolac.ti,ab. 
27     eccoxalac.ti,ab. 
28     etopan.ti,ab.  
29     lodine.ti,ab.  
30     meloxicam.ti,ab. 
31     mobic.ti,ab. 
32     parecoxib.ti,ab.  
33     dynastat.ti,ab.  
34     lumiracoxib.ti,ab. 
35     prexige.ti,ab.  
36     18 or 19 or 20 or 21 or 
22 or 23 or 24 or 25 or 26 or 
27 or 28 or 29 or 30 or 31 or 
32 or 33 or 34 or 35  
 
37     3 and 17 and 36  
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1 GENERAL INFORMATION 
This translational protocol describes a sub-study of STAMPEDE coordinated by the MRC CTU at UCL 
which is a registered trial with the ClinicalTrials.gov Clinical Trials Register, where it is identified as 
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2 SUMMARY  
Prostate cancer is a highly heterogeneous disease with a growing number of treatment options. Yet 
despite increased understanding of tumour biology, prostate cancer management lags behind that 
of other cancers due to the lack of predictive biomarkers.  
 
Integration of clinical and translational research is urgently needed to develop biomarkers able to 
inform treatment selection and provide a rationale for additional targeted strategies.  
 
Systematic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy 
(STAMPEDE) is an ongoing multi-centre randomised controlled trial for men with locally-advanced or 
metastatic prostate cancer. Using a multi-arm, multi-stage (MAMS) platform design STAMPEDE will 
evaluate at least 9 treatment strategies. Analysis of the archival tumour tissue from randomised 
comparisons within STAMPEDE offers a unique opportunity to support biomarker development 
through associated translational sub-studies.  
 
 
 
Figure 1: Treatments evaluated over time in the MAMS STAMPEDE platform  
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3 BACKGROUND 
STAMPEDE is a MAMS trial platform that recruits men with locally-advanced or metastatic prostate 
cancer who are commencing long-term androgen deprivation therapy (ADT) for the first time. The 
trial evaluates whether adding additional treatment strategies to the current 1st line standard-of-
care treatments improves overall survival.  
 
Since opening in 2005, STAMPEDE has recruited over 8000 patients and will evaluate at least 9 
treatment strategies (see figure 1). Each research comparison is compared against a shared control 
arm and is conducted in a number of stages; a Pilot/safety phase, Activity Stages and final Efficacy 
Stage. The primary outcome measure is failure-free survival (FFS) for each Activity Stage with the 
final Efficacy Stage based on overall survival (OS). 
 
The primary results of the “original comparisons” have demonstrated an overall survival benefit 
when docetaxel chemotherapy is added to ADT which has changed practice. The STAMPEDE cohort 
includes men with both metastatic (60%) and locally advanced disease (40%). Overall, the addition of 
docetaxel improved survival by 10 months, from 71 to 80 months (HR 0.78; 0.66-0.93; p=0.006). No 
evidence of heterogeneity was seen in a planned sub-group analysis by metastatic status. Yet 
survival data remains immature in the non-metastatic (M0) sub-group as these men have a better 
prognosis. In M0 disease docetaxel was shown to improve disease control rates and the effect on 
prostate cancer-specific survival remains consistent[1].  
 
In response to the results of STAMPEDE and CHAARTED both of which were included in a 
simultaneously published meta-analysis, UK practice is changing[1]. This is supported by a NHS 
England rapid evidence review which now recommends docetaxel for newly diagnosed hormone-
naïve metastatic prostate cancer[2]. The standard-of-care within the trial has also been updated 
accordingly. 
 
All men joining STAMPEDE have been asked to provide consent for the use of their tissue samples 
obtained at prostate biopsy or following prostate surgery for additional research. Over 2000 patients 
contributed to the randomised comparison of docetaxel (given alone and in combination with 
zoledronic acid). Analysis of archival tissue belonging to this cohort provides a unique opportunity to 
develop prognostic and predictive biomarkers relating to the new standard-of-care treatment. As 
practice has now changed, this randomised comparison will not be replicated and therefore 
represents a valuable translational resource to support biomarker development.  
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4 STUDY AIMS  
The aim of this translational programme of work is to develop biomarkers capable of stratifying men 
at the point at which long-term ADT is started. The following questions are relevant to this 
population:  
 Can prognostic biomarkers stratify locally-advanced prostate cancers and predict benefit 
from adjuvant docetaxel?  
 Can predictive biomarkers identify prostate cancers that benefit less from docetaxel and 
therefore identify in whom alternative treatment strategies should be evaluated? 
 Can biomarkers of DNA repair deficiency hypothesised to predict response to alternative 
treatment strategies have clinical utility in prostate core biopsy tissue? 
 What is the prevalence of ‘targetable’ genetic defects in newly diagnosed metastatic 
disease?  
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5 STUDY DESIGN  
This pilot study will be composed of three analyses each evaluating a biomarker of interest. 
 ANALYSIS 1: CLINICAL VALIDATION OF A PROGNOSTIC BIOMARKER IN NON-5.1
METASTATIC DISEASE 
In collaboration with Professor Richard Kennedy (Queen’s University Belfast/Almac Diagnostics) a 
prognostic signature will be evaluated in non-metastatic (M0) disease. Preliminary work using 
unsupervised clustering has identified two major molecular subsets within M0 disease. A 70-gene 
signature can distinguish these two cohorts and has been shown to be prognostic (Time to 
metastasis HR=6.32; Time to PSA failure HR=3.76). We will aim to validate this prognostic biomarker 
within a sub-set of M0 patients within the randomised docetaxel cohort in STAMPEDE. Through 
comparing samples from both control and docetaxel treated patients the predictive effect of this 
biomarker will be investigated. If shown to be capable of identifying cancers at high risk of relapse, 
this biomarker could inform decisions as to who requires adjuvant docetaxel.  
 
 ANALYSIS OBJECTIVES 5.1.1
 The evaluate the feasibility of using the Prostate Prognostic biomarker as a molecular 
stratifier in the high-risk locally advanced population in STAMPEDE 
 To determine the prevalence of the poor prognostic population as identified by this assay 
 To correlate with clinical outcome data (failure-free survival and overall survival) to 
determine if the poor prognostic group benefit from docetaxel treatment  
 ANALYSIS 2: EVALUATING GENOMIC LOSS-OF-HETEROZYGOSITY (GENOMIC LOH) AS 5.2
A POTENTIAL PREDICTIVE BIOMARKER   
In collaboration with Clovis Oncology, genomic LOH will be assessed as potential predictive 
biomarker of sensitivity to PARP inhibition. Clovis Oncology in partnership with Foundation Medicine 
have developed this assays of genomic scarring, specifically  genome-wide loss of heterozygosity 
(LOH), which is the phenotypic result of homologous recombination deficiency (HRD). Loss of 
heterozygosity occurs when one copy of a heterozygous region of DNA is lost and the other is 
retained. Importantly this can result from alterations in multiple genes, including from those for 
which the mechanism is currently unknown[3].  An assessment of genomic LOH is used to provide a 
HRD score which has been shown to be well correlated with homologous recombination, a major 
pathway of DNA repair[4].  Essentially this provides a functional test of DNA repair capability. This 
has been validated in ovarian cancer within the ARIEL 2 trial and shown to predict response to the 
PARP inhibitor Rucaparib. This project will aim to evaluate the clinical utility of this potential 
predictive biomarker in prostate cancer in order to evaluate a PARP inhibitor in an appropriate 
biomarker defined group.  
 
 ANALYSIS OBJECTIVES 5.2.1
 To determine the feasibility of assessing genomic LOH in prostate core biopsy tissue 
 To determine the prevalence of DNA repair deficiency as determined by high genomic LOH 
in men with newly diagnosed metastatic disease 
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 To correlate with clinical outcome data in order to characterise the biomarker defined 
groups 
 ANALYSIS 3: ASSESSING THE IMMUNE RESPONSE TO DNA DAMAGE USING A GENE-5.3
EXPRESSION SIGNATURE- DNA DAMAGE RESPONSE DEFICIENCY (DDRD) 
Originally developed in a breast cancer cohort, this 44-gene signature predicts response to DNA 
damaging chemotherapy and is associated with docetaxel resistance. Developed by Almac 
diagnostics using unsupervised clustering, this assay predicts loss of the fanconi anaemia pathway 
and detects the immune signal to the presence of abnormal DNA[5]. In addition it provides 
information on over 30,000 genes to support further biomarker development. Preliminary work has 
confirmed this methodology to be feasible in prostate core biopsies with a high success rate of 92% 
in obtaining high quality RNA suitable for analysis.   
 
 ANALYSIS OBJECTIVES 5.3.1
 To determine prevalence of DNA repair deficiency as determined by DDRD in men with 
newly diagnosed metastatic disease.  
 To correlate with clinical outcome data in order to characterise the biomarker defined 
groups and determine the prognostic effect 
 To investigate if DDRD status predicts docetaxel resistance  
 SELECTION CRITERIA 5.4
Samples will be identified from the STAMPEDE cohort selected according to the following criteria:  
 Provided consent for the use of pre-treatment prostate tissue samples in additional 
research 
 Available tissue suitable for biomarker analysis 
 
In addition, three separate cohorts will be selected according to the following criteria for each 
analysis:  
 Analysis 1 will include samples from men with non-metastatic disease randomised between 
control and docetaxel treatment 
 Analysis 2 will include samples from men with newly diagnosed metasatic disease 
randomised to any treatment arm 
 Analysis 3 will include samples from men with newly diagnosed metastatic disease 
randomised to control or docetaxel treatment and who joined the trial from November 2011 
onwards when prostate core biopsies became mandatory  
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6 SAMPLE PROGRESSING  
All samples will be identified from the STAMPEDE trial database and made available to this project 
via the trial biorepository, the Wales Cancer Bank. The samples will be allocated a study specific ID 
for the purposes of this project. Prior to transfer, the samples will be sectioned and reviewed by a 
pathologist in order to mark the dominant Gleason lesion.  
 
For projects 1 and 3 the following samples will be required: 
 Samples from 400 patients (200 docetaxel treated and 200 control). For each patient x4 5um 
slides will be provided with an additional H&E slide on which the dominant Gleason core is 
marked.  
 
For project 2 the following samples will be required:  
 Samples from 100 patients. For each patient 10 unstained slides will be provided (minimum 
1x5mm). 
 
Once analysis is complete any remaining tissue will be returned to the Wales Cancer Bank.  
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7 BIOMARKER ANALYSIS 
 PROSTATE PROGNOSTIC ASSAY  7.1
Archival tissue belonging to 400 patients (200 control and 200 docetaxel treated) will be analysed. 
For each sample the prostate core containing the dominant gleason lesion will be macrodissected 
for RNA extraction using the Roche High Pure RNA Parrafin Kit. Nanodrop spectrophotometric QC 
will be performed on all nucleic acids received or extracted to determine concentration and purity 
and the minimum RNA QC cut off criteria used will be 12.5 ng/µl. Microarray profiling will then be 
performed using Xcel® Array (418 arrays in total – 400 Prostate samples and 18 standard processing 
controls). The total amount of RNA required is 50ng (concentration 12.5 ng/µl). The cohort will be 
separated into molecular subtypes (high and low risk) according to pre-defined cut-offs based on 
preliminary work.  
 GENOMIC LOH 7.2
Archival tissue belonging to 100 patients from all treatment groups within the STAMPEDE trial will 
be analysed. DNA will be extracted and sequenced using Foundation Medicine next generation 
sequencing (NGS) approach, Foundation One®. This analyses a large panel of cancer-related genes 
including BRCA, ATM and other genes involved in DNA repair. Analysis of the sequence data will be 
performed to quantify the extent of loss of heterozygosity across the tumour genome and prostate 
cancer specific cut-offs for high and low genomic LOH defined. An feasibility assessment will be 
undertaken and the prevalance of high genomic LOH  determined in men with treatment naïve de 
novo metastatic disease. 
 DDRD STATUS 7.3
Archival tissue belonging to 400 patients (200 control and 200 docetaxel treated) will be analysed. 
For each sample the prostate core containing the dominant gleason lesion will be macrodissected 
for RNA extraction using the Roche High Pure RNA Parrafin Kit. Nanodrop spectrophotometric QC 
will be performed on all nucleic acids received or extracted to determine concentration and purity 
and the minimum RNA QC cut off criteria used will be 12.5 ng/µl. Microarray profiling will then be 
performed using Xcel® Array (418 arrays in total – 400 Prostate samples and 18 standard processing 
controls). The total amount of RNA required is 50ng (concentration 12.5 ng/µl). DDRD status will be 
determine used pre-defined cut-offs based on preliminary work.  
 SUBSEQUENT ANALYSIS:  7.4
The results of all biomarker analysis will be transferred to the MRC CTU at UCL for correlation with 
clinical data. This will include characterising the biomarker defined subgroups according to current 
prognostic clinical features such as age, PSA, T-stage and Gleason grade. The prevalence of each 
biomarker will be determined and an assessment made as to the feasibility of each approach.  
 
The differential clinical response will be determined for the cohorts tested with the prognostic and 
DDRD assays. This will use available FFS and OS data and will be visualised by Kaplan-Meier curves.  
The results will then be incorporated to predict associations with patient response using univariate 
and multivariate analysis independent of the known prognostic clinical factors.  
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8 STATISTICAL CONSIDERATIONS  
A formal sample size calculation to determine the power to detect a prognostic and predictive effect 
is not possible without knowing the prevalence of each biomarker in this population. This is a key 
aim of the project. The following scenarios illustrate the power this exploratory study will have 
based on an estimated biomarker prevalence of 15-25%. 
 INVESTIGATING THE PROGNOSTIC EFFECT OF BIOMARKER STATUS  8.1
The following assumptions have been made:  
 FFS data known for 70% in Q2 2016  
 Median FFS in M1 patients in control arm is 12 months   
 
Table 1 Minimal detectable difference based on biomarker prevalence of 15% 
NO OF CONTROL 
SAMPLES 
REQUIRED EVENTS IN BM-VE POPULATION 
(ASSUMED TO BE N~150)  
POWER ALPHA MINIMAL DETECTABLE DIFFERENCE  
(HAZARD RATIO) 
200 107  90% 0.05 1.7 
200 118 85% 0.05 1.6 
200 118 80% 0.05 1.55 
 
A Hazard Ration of 1.7 equates to a 5 month difference in FFS i.e. the median FFS in the biomarker 
postiive population of 7 month vs. the biomarker negative population (control) of 12 months. 
 
Table 2 Minimal detectable difference based on biomarker prevalence of 25% 
NO OF CONTROL 
SAMPLES 
REQUIRED EVENTS IN BM-VE POPULATION 
(ASSUMED TO BE N~170)  
POWER ALPHA MINIMAL DETECTABLE DIFFERENCE  
(HAZARD RATIO) 
200 122 80% 0.05 1.75 
200 121 75% 0.05 1.7 
 INVESTIGATING THE PREDICTIVE EFFECT OF BIOMARKER STATUS  8.2
To determine the predictive effect of biomarker status, the effect of treatment is compared between 
biomarker positive patients in the docetaxel and control groups. The hypothesis is that marker 
positive patients may benefit less from docetaxel treatment (i.e. negative predictive biomarker) and 
therefore the analysis needs to be powered to detect a smaller clinical difference in a sub-set of 
patients, estimated to be between 15 and 25% of all those sampled. 
 
The following assumptions have been made:  
 FFS data known for 70% in Q2 2016  
 Median FFS in M1 patients in control arm is 12 months   
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Table 3 Minimal detectable prognostic effect  
NO OF SAMPLES REQUIRED CONTROL EVENTS   POWER ALPHA  MINIMAL DETECTABLE DIFFERENCE  
400 153 90% 0.15 0.76 
400 147 85% 0.15 0.78 
400 149 80% 0.15 0.8 
 
The STAMPEDE data demonstrated a median FFS benefit of docetaxel in the M1 sub-group of 7 
months, equivalent to a 38% improvement (Hazard Ratio = 0.62). If, as hypothesised, biomarker 
positive patients benefit less from docetaxel the effect size will be smaller. Based on the 
assumptions specified above, sampling 400 patients provides 80% power to detect a 20% 
improvement; equivalent to 2.4 months, which has been selected as the minimal clinically significant 
clinical difference we seek to determine.  
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9 FUTURE PROGRAMME OF WORK  
The feasibility and prevalence data generated by this sub-study will be shared with the STAMPEDE 
TMG. It is highly relevant to the ongoing trial development aiming to incorporate biomarker analysis 
within the STAMPEDE trial platform, enabling novel targeted therapeutic strategies to be evaluated 
in biomarker defined sub-groups. In additional it is hoped that through identifying poor prognostic 
groups, alternative treatment strategies can be evaluated in those with the highest unmet need.  
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Dr Clare Gilson 
Clinical Research Fellow 
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Dear Dr Gilson  
 
Study title: Developing prognostic and predictive biomarkers in prostate cancer using 
archival tissue from STAMPEDE participants: a sub-study of STAMPEDE  
REC reference: 16/WM/0188 
IRAS project ID: 203620 
 
The Proportionate Review Sub-committee of the West Midlands - Edgbaston Research Ethics 
Committee reviewed the above application on 20 April 2016. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this favourable opinion letter. The expectation is that this information will be published for all 
studies that receive an ethical opinion but should you wish to provide a substitute contact point, 
wish to make a request to defer, or require further information, please contact the REC Manager 
Adam Garretty, NRESCommittee.WestMidlands-Edgbaston@nhs.net. Under very limited 
circumstances (e.g. for student research which has received an unfavourable opinion), it may be 
possible to grant an exemption to the publication of the study.  
 
 
Ethical opinion 
 
On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting documentation, 
subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
2016.06.28 re-issue: removal of reference to HRA Approval 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given permission 
for the research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for HRA Approval (England)/ NHS permission for research is available in 
the Integrated Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk.  
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database. This should be before the first participant is recruited but no 
later than 6 weeks after recruitment of the first participant. 
  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as part of 
the annual progress reporting process. 
  
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
  
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from the HRA. Guidance on where to register is provided on the HRA website.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
 
Ethical review of research sites 
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The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
“Conditions of the favourable opinion”). 
 
Summary of discussion at the meeting 
 
Social or scientific value; scientific design and conduct of the study 
The sub-committee noted the researchers had sought advice from the Chair of the Edgbaston 
Committee before submitting the application. The sub-committee noted they are familiar with the 
STAMPEDE trial which is a good study with supporting information always laid out well. 
 
Favourable risk benefit ratio; anticipated benefit/risks for research participants (present 
and future) 
The sub-committee noted this is a minimal risk study. 
 
Informed consent process and the adequacy and completeness of participant 
information  
The sub-committee discussed the consent procedure and agreed with the researchers that it is 
not appropriate to go back to participants who may be in a poor state to gain consent to use 
samples as this would cause more distress. 
 
Approved documents 
 
The documents reviewed and approved were: 
 
Document  Version  Date  
Covering letter on headed paper [Cover letter ]      
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [STAMPEDE UCL Insurance certificate]  
    
IRAS Checklist XML [Checklist_30032016]    30 March 2016  
IRAS Checklist XML [Checklist_05042016]    05 April 2016  
Participant information sheet (PIS) [STAMPEDE PIS and ICF by 
version]  
1.0    
REC Application Form [REC_Form_30032016]    30 March 2016  
Research protocol or project proposal [Biomarker development in 
prostate cancer: a sub-study of STAMPEDE Protocol ]  
1.0  18 March 2016  
Summary CV for Chief Investigator (CI) [CV (Clare Gilson, CI)]      
Summary CV for supervisor (student research) [CV (Matt Sydes, 
supervisor)]  
    
 
Membership of the Proportionate Review Sub-Committee 
 
The members of the Sub-Committee who took part in the review are listed on the attached 
sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
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Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
User Feedback 
 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/   
 
HRA Training 
 
We are pleased to welcome researchers and R&D staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/  
 
With the Committee’s best wishes for the success of this project. 
 
16/WM/0188 Please quote this number on all correspondence 
 
Yours sincerely 
 
Mr Paul Hamilton 
Chair 
 
Email: NRESCommittee.WestMidlands-Edgbaston@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the review  
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West Midlands - Edgbaston Research Ethics Committee 
 
Attendance at PRS Sub-Committee of the REC meeting on 20 April 2016 
 
  
Committee Members:  
 
Name  Profession  Present  
Mr Chris Foy  Medical Statistician  Yes  
Mr Paul Hamilton  Retired Local Government Officer  Yes  
Professor John Marriott  Pharmaceutical Chemist/Academic Pharmacist  Yes  
  
Also in attendance:  
 
Name  Position (or reason for attending)  
Mr Adam Garretty  REC Assistant  
 Helen Poole  REC Manager  
 
 
FoundationOne SPECIMEN GUIDELINES
FoundationOne can help you determine next steps for the care of your patients by accurately detecting all classes of 
genomic alterations. Below are Specimen Guidelines to help ensure successful genomic profiling. 
www.FoundationOne.com
Please call +1.888.988.3639  
with questions or to request  
FoundationOne Specimen Kits.
Client.Services@FoundationMedicine.com
1. Place the samples, FoundationOne 
Requisition Form, pathology report, insurance 
information, and any other attachments into 
the FoundationOne Specimen Kit.
2. Place the specimen kit (including samples 
and paperwork) into the provided shipping 
pack and seal the shipping pack.
3. Complete the pre-printed shipping labels  
(if necessary) and apply to shipping pack.
4. Ship sealed shipping pack to:  
Accessioning, Clinical Laboratory 
Foundation Medicine, Inc. 
150 Second Street 
Cambridge, MA 02141
Drop the package at your 
site’s designated FedEx 
pick up location or call 
+1.800.309.0530 to 
request a pick up.
shipping instructions
ONE-I-002-20150925
Resection Small Biopsy Fine Needle Aspiration (Cell Block) Fluid Exfoliative Cytology (Cell block)
Acceptable Samples
sample types
1
Percent tumor nuclei = number of tumor cells divided by total number of all cells with nuclei.* 
* Liver specimens may require additional tumor.
tumor nuclei percentage
3
sample size surface area
2
• FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.
• Tissue should be formalin-fixed, paraffin embedded. Use standard fixation methods to preserve nucleic acid 
integrity. 10% neutral-buffered formalin for 6-72 hours is industry standard. DO NOT use other fixatives (Bouins, 
B5, AZF, Holland’s). 
• Do not decal. When decalcification is required, EDTA is recommended. Do not use strong acids (e.g. hydrochloric 
acid, sulfuric acid, picric acid). 
or
Optimal: 25 mm2
If sending slides, provide 10 
unstained slides cut at 4-5 
microns thick.
Optimal: 30%
Minimal: 5 mm2
For small (<25mm2) or impure 
samples, additional unstained 
slides may be needed to extract 
sufficient DNA for testing.
Minimal: 20%
10 unstained slides (positively 
charged and unbaked at 4-5 
microns thick) + 1 original (not 
recut) H&E Slide.
When feasible, please send the 
block + 1 original (not recut) H&E 
slide.
Has the patient been treated with targeted therapy?
Use recurrence or original resection (most recent material preferred).
Metastasis biopsy or primary tumor acceptable (choose site with highest percent tumor or largest 
tumor focus).
MUST use post-targeted therapy specimen, if available. 
Selecting the Best Specimen from Multiple Options 
NO
YES
For questions, please call Client Services at +1.888.988.3639
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Abstract
The treatment and outcomes for advanced prostate cancer have experienced signiﬁcant progress over recent years. Importantly, the additional beneﬁts of ‘up
front’ chemotherapy (docetaxel) and abiraterone, over and above conventional androgen deprivation, have been separately demonstrated in the multi-arm,
multi-stage (MAMS) STAMPEDE protocol, which continues recruitment to other questions. Alongside this, insights into the underlying molecular biology
and, inevitably, the molecular heterogeneity of prostate cancer are opening the door to new therapeutic approaches. Incorporating this understanding and
testing these hypotheses within STAMPEDE brings new challenges to the MAMS approach, but has the potential to further improve the outlook for this disease.
 2017 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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This overview reﬂects the opinion and experience of the
authors and evidence has been presented accordingly. It is
based upon our own research ﬁndings and clinical trial
experience. It is not a systematic review.Introduction
The last decade has seen major advances in both the
understanding and the treatment of advanced prostate
cancer, with a number of agents gaining approval as stan-
dard of care (SOC) in castrate-resistant disease. More
recently, the additional beneﬁt of using these drugs earlier,
at ﬁrst presentation, has also been shown and is now
considered SOC [1e4]. In parallel, there has been signiﬁcant
progress in understanding prostate cancer biology thatAuthor for correspondence: C. Gilson, MRC Clinical Trials Unit at UCL,
Institute of Clinical Trials & Methodology, 90 High Holborn, 2nd Floor,
London, WC1V 6LJ, UK. Tel: þ44-20-7670-4943.
E-mail address: c.gilson@ucl.ac.uk (C. Gilson).
https://doi.org/10.1016/j.clon.2017.10.004
0936-6555/ 2017 The Royal College of Radiologists. Published by Elsevier Ltd. Th
org/licenses/by/4.0/).promises to further improve outcomes, but by nature
moves away from a ‘one size ﬁts all’ approach. Imple-
menting precision medicine requires the validation of pu-
tative predictive biomarkers within well-designed clinical
trials. Analysis of representative samples obtained as part of
a clinical trial protocol can support many stages of
biomarker discovery, assay development and qualiﬁcation,
as laid out in the Cancer Research UK Biomarker Roadmap
[5]. Knowledge gained through the genomic characterisa-
tion of advanced metastatic prostate cancer provides both
the rationale and the means to progress this research pri-
ority in the ﬁrst-line setting.
It has been shown that around 20% of metastatic
castrate-resistant prostate cancers (mCRPC) have loss-of-
function somatic genomic aberrations or germline de-
ﬁciencies in genes involved in DNA repair, in particular
those involved in the repair of double-stranded DNA breaks
using homologous recombination. The resulting homolo-
gous recombination deﬁciency (HRD) supports synthetic
lethality as a therapeutic approach in prostate cancer.
Importantly, the poly(ADP-ribose) polymerase (PARP) in-
hibitor, olaparib, has been shown to beneﬁt this group,is is an open access article under the CC BY license (http://creativecommons.
C. Gilson et al. / Clinical Oncology 29 (2017) 778e786 779providing the proof-of-concept for this precision approach
[6,7].
However, the greatest absolute beneﬁt of effective ther-
apies may be observed when used early, at the initiation of
long-term androgen-deprivation therapy (ADT) [1e4].
Furthermore, prostate cancers exhibit signiﬁcant intra-
tumoural genetic heterogeneity, which increases in
advanced disease in response to multiple lines of therapy
[8,9]. Mechanistically, DNA repair-deﬁcient cancers can be
expected to acquire and tolerate somatic mutations at a
greater rate, which may thwart targeted precision medicine
approaches due to the increasing likelihood of acquired
secondary resistance and risk of sampling bias due to the
spatial genetic heterogeneity observed in metastatic pros-
tate cancer [10,11]. Together, this provides the rationale to
evaluate precision medicine approaches earlier, with the
aim of achieving the greatest impact on patient outcome.
Approval from Cancer Research UK and independent
scientiﬁc peer-review has been obtained to evaluate ruca-
parib within the STAMPEDE trial platform. Here we set out
the considerations and challenges faced when incorpo-
rating biomarker stratiﬁcation within an adaptive trial
platform, which will be the ﬁrst example of a biomarker-
directed treatment strategy in this disease setting.STAMPEDE
STAMPEDE (Systemic Therapy in Advancing or Metasta-
tic Prostate Cancer: Evaluation of Drug Efﬁcacy) is a well-
established randomised controlled trial that recruits men
with high-risk locally advanced or metastatic prostate
cancer who are commencing long-term ADT for the ﬁrstTr
ia
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Fig 1. Arms of the STAMPEDEtime, termed hormone-naive prostate cancer (HNPC) [12].
The trial uses a multi-arm multi-stage (MAMS) platform
design: multi-arm because many treatment approaches can
be tested simultaneously; multi-stage because pre-
speciﬁed interim analyses can be used to stop recruitment
early to arms showing insufﬁcient evidence of activity [13].
Data from all stages are included in the ﬁnal analysis of
efﬁcacy, powered on the primary outcome, overall survival.
The trial opened in 2005 with ﬁve ‘original comparisons’
evaluating the efﬁcacy of adding docetaxel, zoledronic acid
and celecoxib, given alone or in combination, to the then
SOC, ADT prostate radiotherapy. Since then a number of
new research arms have been added to undertake rando-
mised comparisons of: abiraterone; prostate radiotherapy
for patients with newly diagnosed metastatic disease
(M1jRT); enzalutamide given in combination with abir-
aterone; metformin, an anti-diabetic medication; and, most
recently, transdermal oestradiol, a proposed alternative
form of ADT (see Figure 1).Comparisons: Reported, Unreported and
Ongoing
The results of the ‘original comparisons’ and the ‘abir-
aterone comparison’ have been reported, with both doce-
taxel and abiraterone shown to signiﬁcantly improve
survival [2,3]. The addition of docetaxel improved median
survival from 71 months to 81 months; hazard ratio 0.78
(95% conﬁdence interval 0.66e0.93); P¼ 0.006. The
strength of evidence is most clearly apparent within the
metastatic subgroup where the beneﬁt is also reﬂected in
the results of the CHAARTED trial. Both trials contributed toLSOC+tE2
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C. Gilson et al. / Clinical Oncology 29 (2017) 778e786780the STOpCaP meta-analysis; aggregate data from 3206 pa-
tients with metastatic HNPC showed that docetaxel
improved 4 year survival by 9% (hazard ratio 0.77; 95%
conﬁdence interval 0.68e0.87; P< 0.0001) [14]. These data
have been practice changing [15]. The results of the ‘abir-
aterone comparison’ also show improved outcome; 3 year
survival improved from 76% to 83%; hazard ratio 0.63 (95%
conﬁdence interval 0.52e0.76) [3]. Opportunistic data ac-
quired through the overlapping randomised population
accrued between 2011 and 2014 were presented at ESMO
2017 and suggest superior progression-free survival with
abiraterone but a comparable survival outcome [16]. The
‘M1jRT comparison’ and ‘enzalutamide and abiraterone
comparison’ continue in follow-up, with survival results
expected in the next 1e3 years. Recruitment is ongoing to
two comparisons evaluating metformin and transdermal
oestradiol as re-purposed anti-cancer therapies, both pro-
posed to mitigate the adverse cardiovascular and metabolic
effects of long-term androgen suppression [17,18]. STAM-
PEDE is investigating whether adding metformin to the
current SOC for non-diabetic men can improve all-cause
survival, and whether transdermal oestradiol, shown to
offer superior cardiovascular, quality-of-life and bone
health outcome, is non-inferior based on survival [19e21].Safety
AcƟvity
Eﬃcacy
Safety
AcƟvity
Eﬃcacy
Key SOC= standard of care
Fig 2. Future STAMPEDE randomisation schema.
Table 1
Considerations for biomarker-enriched trial designs
Framework for incorporating biomarker stratiﬁcation
in a platform trial
1. Can the biomarker of interest be reliably measured
using a validated assay?Rationale to Incorporate Biomarker
Selection within STAMPEDE
The ‘rucaparib comparison’ will be embedded into
STAMPEDE by way of a protocol amendment as the most
efﬁcient route to address this question in this disease
setting (see Figure 2). Through further adaptation, we avoid
establishing a competing biomarker-selected trial within an
overlapping population, which could risk impacting on
accrual and potentially generalisability of results through
depletion of biomarker-deﬁned groups hypothesised to
have both prognostic and predictive effects. Through
incorporation we can determine and control the impact on
the ongoing comparisons and continue to answer impor-
tant research questions for both biomarker-positive and
-negative patients through an inclusive trial platform. This
is key to sustaining efﬁcient accrual to all comparisons and
conducting cost-effective evaluation of new agents, partic-
ularly for those targeted at low-frequency biomarkers.2. What is test-performance in clinically available
samples representative of the population of interest?
3. Is the biomarker prognostic necessitating a separate control
in order to distinguish a prognostic from a predictive effect?
4. What is the biomarker prevalence in the population
of interest?
5. What is the strength of evidence of a predictive effect,
i.e. the speciﬁcity of the biomarker?
6. What is the strength of evidence to support the rationale
and clinical efﬁcacy of the targeted therapy in the
biomarker-deﬁned group?
7. What is the overlap between this biomarker-deﬁned
group and others of interest?
8. What are the implications for other overlapping
accruing comparisons?Biomarker Stratiﬁcation: Considerations
When planning biomarker-enriched clinical trials
requiring prospective biomarker characterisation there are
several aspects that require consideration to inform the trial
design and feasibility of implementation (summarised in
Table 1).
Biomarker Measurement
The reliable identiﬁcation of the biomarker-positive
population of interest requires an analytically validatedassay shown to perform to an acceptable standard in
clinically available samples [22]. In the case of the STAM-
PEDE trial population, these are typically small, prostate
core biopsies stored as formalin-ﬁxed, parafﬁn-embedded
tumour blocks. Preliminary data have highlighted the
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tween sites’ ﬁxation protocols in the ability to extract
sufﬁciently high-quality DNA required for analysis. This
has been recognised by others; Genomic England have
reported that the quality of routinely obtained cancer
samples may often be suboptimal for molecular analysis
and are leading several initiatives aiming to improve
sample quality and inform the most suitable methods for
sample collection and storage [23]. The clinical utility of
the method of biomarker measurement should be assessed
in representative clinical samples to estimate the test-
failure rate. This in turn informs the numbers needed to
screen, a crucial parameter in deﬁning the cost, accrual
time and, therefore, feasibility of implementation. The
impact of a high test failure rate is greatest when aiming to
evaluate low-prevalence biomarkers when this can render
a trial infeasible.
To be workable within a clinical trial screening window
the biomarker assessment must be available within a
reasonable timeframe. Several factors will affect turn-
around around times, including pathology department
resources, shipping distances, the capacity of the
biomarker provider and the need to batch for cost-
efﬁciency. The risk of a long turnaround time is that
randomisation and, therefore, treatment, is delayed. The
effect of this will probably be greatest in trials recruiting
patients with progressive disease where a participant’s
clinical status may change, making them ineligible during
the time taken to complete screening. However, in all
disease settings, the time required to undertake
biomarker analysis should not risk disadvantaging pa-
tients’ access to treatment. In trial platforms where mul-
tiple randomisations are possible, biomarker analysis
should be completed in such time that patients remain
eligible for all possible randomisations. This is relevant for
STAMPEDE, which will continue to randomise to non-
biomarker selected comparisons.
Prognostic Importance
Aberrations in BRCA and other HRD genes are negatively
prognostic in prostate cancer and, therefore, patients allo-
cated to the research arm of the ‘rucaparib comparison’ will
only be evaluated against comparable biomarker-positive
controls [24e27]. Evidence of a prognostic effect can
inform the design of biomarker-enriched trials and affect
the assessment of feasibility, particularly of low-frequency
biomarkers. When considering a biomarker-selected ran-
domisation within a platform trial, knowledge of a prog-
nostic effect informs whether it is justiﬁable to share a
control arm, with resulting efﬁciencies (namely fewer
control arm patients). If the biomarker is known to be
prognostic, separate comparisons are required in order to
distinguish a predictive from a prognostic effect, as exem-
pliﬁed by the design of FOCUS-4 [28]. Knowledge of a
prognostic effect can also inform the size of a trial powered
to detect a difference in time-to-event outcomes. If the
survival time is shorter, the information required for reli-
able analyses (e.g. number of deaths for a trial powered onthe primary outcome of survival) will be accrued sooner
and, therefore, a smaller trial may be required.
However, the acquisition of robust prognostic informa-
tion for emerging biomarker-deﬁned groups can be chal-
lenging. Retrospective retrieval of archival samples is
vulnerable to bias, with the risk that those patients who
have subsequently progressed and enrolled onmCPRC trials
requiring archival tissue analysis are under-represented.
Additionally, it has been suggested that the quality of the
DNA extracted from formalin-ﬁxed parafﬁn-embedded
samples declines with sample age; this has been sup-
ported by the experience of the STAMPEDE group to date. It
is hoped that through data sharing, for example through
contribution to genetic consortia, it will be possible to
inform clinical trial design and target research efforts in
poor prognostic genetic subpopulations, aiming to improve
outcome in those patients with the greatest unmet clinical
need.
Biomarker Prevalence
The duration of recruitment to the ‘rucaparib compari-
son’ will depend on the frequency of DNA repair defects in
men eligible for STAMPEDE. Evidence from mCRPC cohorts
and primary localised prostate cancer has that shown DNA
repair defects are more common in metastatic disease
[8,29e32]. Around 20% of mCRPC cohorts (range 7e27%)
have detectable mutations in one or more of 14 genes
involved in homologous recombination, including BRCA1,
BRCA2, ATM, BARD1, CHEK2, PALB2, RAD51 [6,7,9,33e40].
The vast majority of the prostate cancer cohorts proﬁled to
date have either consisted of men with advanced, heavily
pre-treated CRPC or localised prostate cancer suitable for
radical prostatectomy. Therefore, knowledge of the genomic
landscape of men presenting with high-risk locally
advanced or metastatic prostate cancer (i.e. eligible for
STAMPEDE) is currently very limited. Furthermore, all
sequenced mCRPC series to date involve patients partici-
pating in trials, precision medicine initiatives or autopsy
programmes at tertiary academic centres and are, therefore,
vulnerable to selection bias (see Table 2) [6,7,9,34,36,37].
Eligibility to the ‘rucaparib comparison’ will be limited to
metastatic HNPC with a detectable pathogenic mutation in
one or more of 14 HRD-related genes and the trial design
has been developed based on an estimated biomarker
prevalence of 10e15%. A feasibility assessment is planned 1
year after the activation of recruitment; accumulating
prevalence data acquired in the screened populationwill be
reviewed and adjustments to the target screening accrual
numbers made accordingly.
The frequency of the biomarker of interest in the target
population is crucial in developing the best approach to
therapeutic evaluation within a biomarker-enriched trial.
Trials restricting enrolment to low-prevalent biomarker
groups risk being very costly, given the numbers needed to
screen; additionally, the high screen failure rates can deter
patients and investigators, negatively impacting on accrual.
This contributes to the rationale for incorporating both
biomarker-selected and -unselected randomisations within
Table 2
DNA repair deﬁciency in prostate cancer: summary of prevalence data
Ref Cohort details M0 (n) M1 (n) % BRCAm % HRD*
[30] HNPC suitable for prostatectomy 112 - 1% 4%
[31] Low/intermediate risk HNPC 333 - 4% 13%
[29] Mixed HNPC 55 2 0% 11%
[32] Mixed cohort, predominantly M0 181 37 0 0
[8] Mixed cohort, both HNPC and mCRPC 25 20 12% 20%
[29] Mixed, fatal mCRPC sampled at rapid
autopsy and HNPC suitable for
prostatectomy
11 50 2% 7%
[34] Selected due to unusual clinical course,
suspected predisposition, e.g. family history
or atypical histology
29 13 16%
(10% gBRCA)
27%
(24% gHRD)
[36] Fatal mCPRC sampled at rapid autopsy 54 7% 16%
[6] mCRPC trial participants at academic centres - 150 14% 23%
[7] mCRPC in an unselected PARPi trial - 50 14% 27%
[37] Cohorts participating in clinical trials, rapid
autopsy programmes or precision medicine
initiatives at academic centres
692 6.2% (gBRCA) 11.2% (gHRD)
[35] Sporadic mCRPC eligible for abiraterone +/-
PARPi
- 80 25%
[33] Sporadic mCRPC eligible for PROREPAIR-B
(prospective cohort study)
- 419 4.2% (gBRCA) 9.1% (gHRD)
BRCAm ¼ BRCA mutant, CNA ¼ copy number alteration, gBRCA ¼ germline BRCA mutation, gHRD ¼ germline HRD mutation, HNPC ¼
hormone-naïve prostate cancer, M0 ¼ non-metastatic prostate cancer, M1 ¼ metastatic prostate cancer, tNGS ¼ targeted next generation
sequencing, mCRPC ¼ metastatic castrate resistant prostate cancer, PARPi ¼ PARP inhibitor, WES ¼ whole exome sequencing.
*Homologous recombination deﬁciency deﬁned as pathogenic aberration in one or more: BRCA1, BRCA2, ATM, BARD1, BRIP, CDK12,
CHEK2, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L.
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prevalence biomarker groups.
Evidence of a Predictive Effect
Eligibility for the ‘rucaparib comparison’ will be
restricted to the biomarker-positive population based on
the evidence of a predictive effect demonstrated for PARP
inhibition in mCRPC. Justiﬁcation of biomarker enrichment
requires evaluating the strength of evidence of a predictive
effect; this also informs the effect size [41]. In the scenario
that the evidence of a predictive effect is judged insufﬁcient
to limit treatment to only biomarker-positive patients, it
may be preferable to enrol an unselected population and,
through prospective biomarker assessment, stratify by
biomarker status to enable pre-planned subgroup analyses.
If, however, there is good evidence of a predictive effect,
such that enrichment can be justiﬁed, randomisation may
be limited to the biomarker population. One approach to
the challenge of deﬁning the level of evidence required is to
adopt a pragmatic approach: would randomisation of an
unselected population be acceptable and, therefore,
feasible? Here, evaluation within an adaptive MAMS trial
platform is advantageous as it is possible to initially ran-
domise the population with the strongest evidence of a
predictive effect and then subsequently activate random-
isation in a broader group should sufﬁcient activity be
shown. Early stopping rules could be used in this scenario,
but the value of being able to test the speciﬁcity of the
marker is high: it may be that the research treatment couldoffer a broader beneﬁt, which risks being missed if an
enrichment design is adopted and not subsequently
evaluated.
The magnitude of the targeted treatment effect is also
dependent on the evidence of a predictive effect; where
there is strong evidence of a predictive effect in a
biomarker-deﬁned group, the treatment effect may be
expected to be greater than for a non-targeted therapy in
an unselected population. The vast majority of data
demonstrating the efﬁcacy of PARP inhibition have been
acquired in the setting of ovarian or breast cancer and the
strongest evidence of a predictive effect has been shown
for inactivating mutations in BRCA1 and BRCA2 [42e45].
Preliminary evidence of an anti-tumour effect has been
shown for mCRPC, with defects in several homologous
recombination genes, including BRCA2, ATM and CHEK2
[7]. However, as ATM and CHEK2 mutations have not been
described in other BRCA-associated cancers to date, here
the evidence of a predictive effect is judged to be less,
limited to prostate cancer and pre-clinical data [7,40]. A
balance is required in order to evaluate the treatment in
the broadest patient group hypothesised to beneﬁt, while
accepting that where there is less evidence of a predictive
effect, it may be appropriate to target a smaller treatment
effect, thus requiring a larger randomised population. It
should be considered whether to include a pre-planned
subgroup analysis in the group(s) with the strongest evi-
dence of a predictive effect; a step-down approach to
analysis may be taken, as shown by other PARP trials
[44,46].
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Only through pairing the biomarker-deﬁned population
with an effective therapeutic strategy can precision medi-
cine approaches improve outcome. However, biomarker-
treatment pairings may fail to translate to patient beneﬁt
due to an incomplete understanding of the biology of the
biomarker or the interaction between the biomarker and
the therapy [47]. Metastatic prostate cancer has been
shown to be associated with multiple genetic aberrations,
but in order to realise the therapeutic potential of this, it is
necessary to distinguish mutations of signiﬁcance. Ulti-
mately, the highest level of evidence supporting an identi-
ﬁed genetic alteration as an oncogenic driver and, therefore,
a valuable therapeutic target, requires prospective evalua-
tion within a clinical trial, including demonstration that
biomarker-negative cohorts do not beneﬁt from the tar-
geted therapy [48]. Such evidence needs to be tumour site-
speciﬁc due to the concept of epistasis, the geneegene in-
teractions proposed to explain the observed attenuated
biological consequences of speciﬁc genetic aberrations ac-
cording to tumour type. Examples of this include the
differing impact of a BRAF V600E mutation, predictive of
sensitivity to vemurafenib in melanoma and dabrafenib in
non-small cell lung cancer, but not in the context of colo-
rectal cancer. The latter is proposed to be due to the feed-
back of epidermal growth factor receptor, thus emphasising
that driver classiﬁcation requires contextual knowledge of
other mutations present [49,50].
One of the most well-described and seemingly per-
plexing challenges to the implementation of precision
medicine approaches is intratumoural heterogeneity [51].
This can be considered as either spatial, the variation be-
tween different sites of disease, or temporal, the variation
at different time points, for example pre- and post-
treatment [52]. The key challenge to implementing preci-
sion medicine in metastatic prostate cancer is spatial
heterogeneity, as this has the potential to introduce sam-
pling bias [51]. Evidence from multi-regional sampling of
cases of mCRPC obtained at rapid autopsy and sequential
sampling shows metastatic spread to be polyclonal and
polyphyletic, with evidence of metastatic-to-metastatic
spread and both spatial and temporal heterogeneity [10].
This provides a powerful rationale to evaluate precision
approaches in the ﬁrst-line treatment of metastatic HNPC
at the point closest to the sampling of the primary tumour.
However, evidence of spatial heterogeneity will continue
to motivate the investigation of alternative approaches to
biomarker assessment, such as circulating tumour DNA.
Such approaches are particularly relevant to this disease
setting, given the predominance of bone metastatic
involvement, which remains challenging to sample
adequately to allow genetic analyses [53].Overlapping Biomarkers of Interest
In order for a trial platform such as STAMPEDE to eval-
uate multiple biomarkeretherapeutic pairings, knowledgeof the overlap between predictive biomarkers is required.
This requires systematic proﬁling of a representative pop-
ulation; ongoing work being conducted as part of STAM-
PEDE aims to inform this. Genomic characterisation of
clinical trial cohorts has been invaluable in other disease
settings, such as those conducted as part of the S-CORT
programme associated with FOCUS-4, which have informed
biomarker prevalence, prognostic impact and overlap
[54,55]. If, for example, all cases of HRD prostate cancers
overlap with a second biomarker of interest, then the
feasibility of accruing to both comparisons would be
dependent on the prevalence of both biomarkers or
expanding accrual internationally. Greater understanding of
the genetic proﬁle of high-risk or metastatic prostate cancer
will be crucial in identifying and designing future potential
comparisons to be assessed in STAMPEDE.What Next for STAMPEDE?
In preparation for activating randomisation to the
‘rucaparib comparison’, a biomarker-screening pilot will
start in late 2017. This will aim to establish the necessary
processes to obtain rapid, prospective sequencing data prior
to randomisation in order to determine eligibility.
Following the pilot phase, biomarker screening will be
activated in all participating centres when randomisation
opens in early 2018. The development of this, the ﬁrst
biomarker-selected comparison, has highlighted the
requirement for preliminary biomarker-focused research to
inform the implementation of such approaches. The
STAMPEDE protocol has included participant consent for
the collection and analysis of archived tumour samples. As
more outcome data become available there are a growing
number of opportunities to support biomarker develop-
ment through correlative analysis. Funded by Prostate
Cancer UK, the STRATOSPHere consortium (STratiﬁcation
for RAtional Treatment-Oncomarker pairings of STAMPEDE
Patients starting long-term Hormone treatment) aims to
undertake a co-ordinated, multi-centre approach to gener-
ating preliminary data to accelerate the introduction of
biomarker-selected comparisons with STAMPEDE.
One such future comparison in development aims to
evaluate the addition of a checkpoint inhibitor in men with
metastatic HNPC. Recognising that there are currently
insufﬁcient data to support the use of a predictive
biomarker-enrichment strategy, an alternative approach to
biomarker development is suggested. As part of the
STRATOSPHere consortium, a parallel translational pro-
gramme would aim to prospectively collect and character-
ise the randomised population. Then, if supported by
external data, prospective enrichment may subsequently be
implemented as part of the multi-stage design. Alterna-
tively, it may be possible to power a subgroup analysis by
biomarker status, based on the prevalence data acquired.
Finally, in order to accelerate biomarker validation it will be
important to establish the necessary infrastructure that al-
lows clinical and molecular characterisation and endorses
data sharing.
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The management of men with high-risk prostate cancer
has lagged behind other tumour types where molecular
characteristics routinely inform therapeutic choice.
Knowledge gained from the genomic characterisation of
CRPC cohorts, together with the evidence of the therapeutic
relevance of DNA repair defects, provides the rationale to
investigate a precision approach to treatment. Through
further adaptation, STAMPEDE will evaluate the addition of
a PARP inhibitor in this, the disease setting in which the
greatest impact of outcome has been shown to date. The
implementation of precision medicine approaches in low-
frequency biomarker groups is challenging, but incorpo-
rating both biomarker-selected and -unselected random-
isations within a single platform offers further efﬁciencies
to the MAMS approach and ensures that the trial platform
remains inclusive and attractive to patients, investigators
and funders. Correlative translational analyses using
STAMPEDE data offer unparalleled opportunity for
biomarker development, which can continue to inform the
trial design and generate the required preliminary data as
laid out in the framework presented in this review. Through
this latest adaption, we aim to ensure STAMPEDE remains
innovative and continues to accelerate the acquisition of
knowledge that will improve outcomes for men affected by
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